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 Scope of this thesis 
 
 
Immunotherapy aims to re-engage and revitalize the immune system in the fight against cancer. Our 
immune system is a highly organized multi-cellular system designed to protect us from invading 
pathogens and malignantly transformed cells. As such, the immune system acts with enormous 
specificity and great sensitivity, in concert with regulatory mechanisms, to avoid destructive self-
reactivity. The notion of the immunogenic aspects of cancer, together with the attractive modes of 
action of the immune system, has initiated the development of treatments that rely on immune cells.  
Owing to their unique immune stimulatory properties, dendritic cells (DC) have become an essential 
target for anti-cancer immunotherapy. We, and others, have explored DC-based therapy to induce 
tumor-specific immune responses in metastatic melanoma patients. However, research in the past 
four decades has shown that the relationship between the immune system and human cancer is 
complex, highly dynamic and dependent on the individuals’ characteristics.  
 
Given this complexity, it is crucial to understand the processes that precede the failure or success of 
therapy-induced immune responses. This thesis focuses on the evaluation of DC-based therapy and 
the development of novel tools to monitor therapy-induced immune responses. Such monitoring 
tools would allow further optimizing therapy parameters and identifying probable responding 
patients early during treatment. Functional multimodal in vivo imaging is a powerful candidate to 
fulfil this task as it addresses critical steps in ensuing immune responses. 
 
The first section is focused on clinical studies and describes three single-arm proof-of-principle 
studies investigating different vaccination parameters. Chapter 1 provides a ‘roadmap’ for optimizing 
the efficacy of DC-based strategies. In Chapter 2, we studied the targeting of tumor-specific CD4+ T 
cells by including MHC Class II binding epitopes for loading ex vivo generated DC. In Chapter 3, we 
investigate immune responses to mRNA transfected DC presenting a multitude of (un-)defined 
epitopes, in metastatic melanoma patients and patients with locoregional lymph node metastases. 
Chapter 4 describes the immunological and clinical responses to vaccination with plasmacytoid DC, a 
naturally circulating subset with high capacity to produce type 1 interferons.  
 
In the second section, we discuss the first step in the successful induction of anti-cancer immune 
responses; correct delivery of DC to the relevant sites. Chapter 5 introduces this section by reviewing 
strategies to maximize the migration of vaccinated DC to lymph nodes. Next, we demonstrate in 
Chapter 6 by scintigraphic imaging that even limited numbers of DC that reach the lymph nodes are 
capable of inducing tumor-specific immune responses. Chapter 7 concludes this section by providing 
an ex vivo model using 19F-MRI and in vivo experimental data, in order to speed up the optimization 
of intradermal delivery of DC.  
 
The last section is devoted to the monitoring of the mainstay of immunotherapy; vaccine-specific 
effector immune cells. Chapter 8 emphasizes that the concept of optimizing DC-based strategies by 
small proof-of-principle studies warrants intensive immune monitoring. Chapter 9 highlights the 
contribution of functional in vivo imaging for real time assessment of parameters such as cell 
localization, numbers and viability. In Chapter 10, we investigate the patterns of humoral responses 
to keyhole limpet hemocyanin (KLH), as a surrogate marker, in response to varying vaccination 
parameters by developing a novel quantitative KLH-specific ELISA. The diversity and quality of tumor-
1
 specific CD8+ T cell responses after vaccination are evaluated in skin-test infiltrating lymphocyte 
cultures. We show in Chapter 11 that this bioassay accurately identifies long-term survivors after 
completing of vaccination. Chapter 12 demonstrates that already during the course of DC-based 
therapy, vaccine-specific immune responses in vaccinated lymph nodes can be assessed 
quantitatively using 18F-FLT PET/CT; showing for the first time in human how functional in vivo 
imaging can aid physicians in individualized decision-making, by early discrimination of responding 
patients. The General Discussion, Chapter 13, provides an overview of the role of imaging modalities 
in the monitoring of therapy-induced anti-cancer immune responses and a visionary view on further 
development.  
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Abstract 
Dendritic cells (DC) are the directors of the immune system, capable of inducing tumour antigen-
specific T- and B cell responses. As such, they are currently applied in clinical studies in cancer 
patients. Early small clinical trials showed promising results, with frequent induction of anti-cancer 
immune reactivity and clinical responses. In recent years, additional trials have been carried out in 
melanoma patients, and although immunological responses are often reported, objective clinical 
responses remain anecdotal with objective response rates not exceeding 5-10%. Thus, DC 
vaccination research has now entered a stage in between ‘proof of principle’ and ‘proof of efficacy’ 
trials. Crucial questions to answer at this moment are why the clinical responses remain scarce and 
what can be done to improve the efficacy of vaccination. The answers to these questions probably lie 
in the preparation and administration of the DC vaccines. Predominantly, cytokine-matured DC are 
used in clinical studies, while from preclinical studies it is evident that DC that are activated by 
pathogen-associated molecules are much more potent T cell activators. For sake of easy accessibility 
monocyte-derived DC are often used, but are these cells also the most potent type of DC? Other yet 
unsettled issues include the optimal antigen-loading strategy and route of administration. In 
addition, trials are needed to investigate the value of manipulating tolerizing mechanisms, such as 
depletion of regulatory T cells or blockade of the inhibitory T cell molecule CTLA-4. These issues need 
to be addressed in well-designed comparative clinical studies with biological endpoints in order to 
determine the optimal vaccine characteristics. DC vaccination can then be put to the ultimate test of 
randomized clinical trials.  Here, we review the immunobiology of DC with emphasis on the different 
aspects that are most relevant for the induction of anti-tumour responses in vivo. The different 
variables in preparing and administering DC vaccines are discussed in this context and the 
immunological and clinical results of studies with DC vaccines in melanoma patients are summarized. 
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1. Introduction 
Melanoma is one of the more immunogenic cancer types and many strategies to enhance specific or 
non-specific immunity in melanoma patients have been explored in clinical studies (1). Dendritic cells 
(DC) are crucial as the sentinels of the immune system. It has been proposed that when the tumour 
reaches a certain size and causes damage to the surrounding tissues with release of products by the 
microenvironment, local DC are activated and subsequently the immune system is alerted (2). It then 
depends on the size of the tumour and its immunomodulatory characteristics, whether the immune 
system is able to eradicate the cancer. Often malignant growth is a slow and silent process that fails 
to provide a ‘danger signal’ necessary for the activation of the immune system. The goal of DC 
vaccination is to mend this inattention of the immune system by providing it with ex vivo ‘educated’ 
DC; appropriately activated and loaded with tumour antigen. The underlying principle is that DC are 
the most potent antigen presenting cells of the immune system that play a central role in the 
induction-phase of antigen-specific immunity. DC acquire and process antigen and migrate to the 
lymphoid organs where they present the antigen to the specific arm of the immune system, resulting 
in the induction of primary T- and B cell responses. Because of these unique qualities they represent 
an interesting tool in cancer immunotherapy. The possibility to generate DC in large amounts for 
clinical use has accelerated research in this field, and immunological and clinical responses have been 
reported in melanoma patients after vaccination with DC (Table 1-2) (3-5). Several years ago it was 
already estimated that more than thousand cancer patients had received some form of DC-based 
vaccination (6). In contrast to other systemic therapies in cancer treatment, it is not possible to pool 
these patients in a meta-analysis. This is due to the enormous diversity in terms of vaccine 
preparation and administration and immunomonitoring. Although much progress has been made in 
several of these areas over the past years, there seems still room for significant improvement before 
an optimal DC vaccine is to put to the ultimate test of large scale clinical studies.  
 
2. DC subsets 
Two distinct categories of DC exist: plasmacytoid DC and conventional or ‘myeloid’ DC (7). 
Plasmacytoid DC are circulating cells with a plasmacytoid morphology that are capable of producing 
large amounts of type I interferons upon activation by microbial stimuli (8). In addition, they can 
differentiate into DC that are capable of activating naïve T cells against allo-antigens (9) and 
exogenous antigens (10). In the context of cancer, plasmacytoid DC have been implicated in the 
induction of both immunity and tolerance, and their potential role in vaccination strategies in cancer 
patients still has to be determined (11).  Conventional DC or ‘myeloid’ DC (12) can be further divided 
into migratory DC, which actively sample the peripheral tissues and migrate to draining lymph node 
to present antigens to T cells, and lymphoid-tissue-resident DC which captivate local (foreign and 
self-) antigens and present it to local T cells (13). Examples of lymphoid-tissue-resident DC are splenic 
and thymic DC. Migratory DC derived from both CD34+ precursor cells and monocytes. Monocytes 
can differentiate into DC upon transendothelial migration (14).  The presence of GM-CSF, in addition 
to other pro-inflammatory cytokines, can differentiate both CD34+ precursor cells and monocytes 
into DC. Recently, it was proposed to recognize a third distinct group of conventional DC, 
‘inflammatory’ DC: cells that are not present in the steady state, but that appear under the influence 
of inflammation or infection (13).    
 
3. DC subsets in clinical trials 
Monocyte-derived DC have been used in most vaccination studies because of the relative ease with 
which large quantities of cells can be obtained. Usually, one leukapheresis is enough to obtain 
approximately 100-150×106 cells. Yields are much lower with CD34+ selection and repeated 
leukaphereses are often necessary to obtain enough cells (15).  The same accounts for circulating 
blood DC, which can be obtained from peripheral blood after in vivo Flt-3L expansion and negative 
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selection ex vivo (16).  Banchereau and collegues have reported impressive immunological and 
clinical results using Flt3-Ligand expanded CD34+ DC (15). In other studies with CD34+ DC, using 
different maturation and vaccination regimes, clinical responses were observed less frequently (17, 
18). The same variable outcomes are seen in studies with monocyte-derived DC (Table 1 and 2, and 
section on clinical results). These differences may well be more related to the differences in culture 
and maturation protocols, than to the differences in DC subsets. Due to the fragmented nature of the 
available data and the absence of direct comparative studies, it is not possible at this moment to 
draw any firm conclusion on the most optimal DC subset to be used in clinical trials. In recent years, 
evidence is accumulating that considerable cross-talk takes place between the different DC subsets 
(7), and that perhaps it is beneficial even to combine different subsets of DCs, as has been done in 
the above mentioned studies (15). 
 
4. Maturation 
The term ‘maturation’ refers to the phenotypical and functional reaction of DC upon encountering 
danger signals. Maturation can be induced by pro-inflammatory cytokines such as IL-1 or IL-6, by 
interaction with T cells and by interaction with pathogens. DC can detect pathogens through pattern 
recognition receptors such as Toll-like receptors (TLR)(19). The TLR family consists of several 
receptors that recognize molecular patterns of pathogens, for example bacterial lipopolysaccharide 
(through TLR4) and single stranded viral RNA (through TLR7) (20). In the past 10 years, the term 
‘mature’ DC has generally been used to describe T (helper 1) cell stimulatory DC. Immature DC were 
considered to be primarily involved in the recognition and uptake of antigen. Upon receiving 
maturation signals these immature DC would then change their chemokine receptor repertoire and 
upregulate their co-stimulatory molecules, thus acquiring the phenotype of mature DC that are 
capable of migration to the lymph nodes and activation of T cells. In the absence of maturation 
signals, DC would not upregulate their co-stimulatory molecules and would thus remain anergy- or 
tolerance-inducing antigen-presenting cells. Although this concept may not be entirely wrong, recent 
findings show that this is probably an oversimplification (for a comprehensive review on this topic 
see reference (21)). For instance, in the steady state, that is in the absence of ‘danger’, immature DC 
have been shown to be capable of circulating through the tissues and lymphoid organs, encountering 
and capturing both self-antigens and innocuous environmental antigens (22). It is suggested that 
through this mechanism immature DC play a critical role in the continuous induction of peripheral 
tolerance, thereby preventing both auto-immunity and hyperreactivity (23). In addition, although the 
expression of co-stimulatory molecules is one of the phenotypic markers of mature DC, the induction 
of a tolerogenic immune response depends on the presence of these molecules as well (24). In a 
chimeric murine model it was shown that although cytokine-matured DC demonstrated upregulation 
of co-stimulatory molecules and induction of T cell proliferation, the activated T cells did not fully 
develop into IFN-producing effector cells (25). Only when the DC were activated through Toll-like 
receptors (TLRs), also referred to as ‘licensed’ DC (26), the induced antigen-specific T cells were able 
to fully develop into effector cells. The ‘licensing’ of DC is not only restricted to pathogen-derived 
signals, since activation by bystanding T helper cells may also suffice (27, 28).  Another level of 
complexity is added by the timing and duration of the maturation signal. For example, murine bone 
marrow-derived DC that are exposed to lipopolysaccharide for 48 hours have the same expression of 
costimulatory molecules CD80, CD86 and CD40 as compared to DC that are exposed to 
lipopolysaccharide for 8 hours and also have a comparable migratory capacity and allostimulatory 
potential. However, the former exhibit a decreased IL-12 production potential correlating with low 
antigen-specific T cell responses after vaccination in mice (29, 30). In addition, both the timing of the 
activation signal and the exposure to antigen are of crucial importance for optimal antigen 
presentation: only the simultaneous presence of apoptotic cells and TLR ligands to DC resulted in 
efficient antigen-presentation and subsequent T cell activation (31). 
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Table 1. Results of published DC-vaccination trials with non-matured DC in metastatic melanoma 
DC culture method Antigens Ag-loading 
method 
Route No. pts Clinical response Immunologic
al response 
1
  
Ref 
IL-4/GM-CSF/FCS moDC tyrosinase, gp100, 
MART-1, MAGE-1, 
MAGE-3 or lysate 
peptides/ 
lysate 
in 16 2 CR, 2 PR  not tested 49 
IL-4/GM-CSF/FCS moDC MAGE-3A.2, tyrosinase, 
gp100, MART-1 or 
lysate 
peptides/ 
lysate 
in 33 3 PR, 1MR, 6 SD  13 93 
IL-4/GM-CSF moDC MART-1, gp100 MHC-I 
peptides 
iv 10  1 PR 1 85 
IL-4/GM-CSF moDC autologous peptides autologous 
peptides 
id 22 1 CR, 1 PR  not tested 96 
IL-4/GM-CSF moDC lysate lysate id 14 1 PR, 1 SD 4 91 
IL-4/GM-CSF moDC MART-1, gp100, 
tyrosinase 
MHC-I 
peptides 
iv 16 1 CR, 2 PR, 2 MR  5 76 
IL-4/GM-CSF moDC MART-1 MHC-I 
peptides 
id 4 1 CR2, 1 SD2, 1 MR  4 86 
IL-4/GM-CSF/FCS moDC lysate lysate in/sc  4 1 PR, 1 CR 3 94 
IL-4/GM-CSF moDC gp100/tyrosinase MHC-1 
peptides 
iv/id 9 - - 52 
Results of published DC-vaccination trials in which non-matured DC were used, only melanoma patients with distant 
metastases and evaluable disease are included. Abbreviations: IL, interleukin; GM-CSF, granulocyte macrophage-colony 
stimulating factor; FCS, fetal calf serum; moDC, monocyte-derived DC; sc, subcutaneous; in, intranodal; id, intradermal; 
iv, intraveneous; CR, complete response; PR, partial response; MR, mixed response; SD, stable disease (≥ 4 months). 
1
Immunological response is defined as any evidence of melanoma peptide or tumor-specific T cell response after 
vaccination by one or more test methods; the number of patients with an immune reponse are given.
  
2
After DC-vaccination these patients received treatment with an anti-CTLA4 blocking antibody. 
 
With respect to the type of TLR ligands, it has been shown that combinations of different TLR ligands 
can have a synergistic effect on the immunogenic potential of DC in vitro (32) and in vivo (33). For 
example, a combination of triggering via TLR3 and TLR 7 leads to a ten- to hundred-fold higher IL-12 
production, when compared to DC that have been activated by one of the respective TLRs alone (32). 
In concordance with these data, Querec et al. recently showed that broad immunity that was 
induced by a Yellow fever vaccine was dependent on triggering multiple TLRs simultaneously (notably 
TLR 2,7,8,9) (34). In terms of IL-12 production, it appears that monocyte-derived DC activation via 
TLR3 and 7 leads to the most potent Th1 T cell responses (32, 35, 36). However, migratory capacity is 
somewhat hampered in these cells as compared to cytokine-matured DC, which can be restored by 
co-culturing the DC in PGE2 (36). If DC with similar expression of co-stimulatory molecules can exert 
entirely different functions, what then determines the nature of the induced T cell response? The 
ability of DC to produce IL-12, TNF- and IL-6 is thought to be important for the induction of robust T 
cell responses and to bypass suppressor T cell-induced tolerance (37-39). In addition, several factors 
such as IL-10, vitamin-D3 and cortico-steroids can skew the DC into a more suppressive T cell type of 
inducer (40). However, it still remains poorly understood which mechanisms truly determine the 
nature of the T cell response as instructed by the DC.  Taken together, these findings show that the 
process of maturation is highly complex and that different maturation stimuli do not lead to one 
common ‘mature DC’, but that there are in fact a lot of different types of mature DC that exert 
different functions ranging from the induction of strong Th1-type responses to the induction of 
tolerance. These data also show that the maturation stage of DC cannot be fully characterized by the 
expression of costimulatory molecules and surface-MHC. When reporting clinical DC vaccination 
trials it is therefore of crucial importance that the phenotypic and functional characteristics of the DC 
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are carefully described. Thus far, T cells have been the primary target of DC vaccination protocols. In 
the last few years more evidence is accumulating that also DC-induced activation of natural killer 
(NK) cells (41) and natural killer T (NKT) cells (42) can eradicate cancer. NKT cells and DC activate 
each other communally. DC activate NKT cells by presentation of exogenous (microbial) and 
endogenous glycolipid antigens, thereby inducing IFN release and CD40-ligand upregulation by the 
NKT cells (43, 44) Reciprocally, NKT cells activate DC via CD40-CD40L interaction. This in turn causes 
the DC to produce IL-12, which further activates the NKT cells (reviewed in (42)). Because glycolipid 
antigens induce both NKT and DC activation in this manner, they offer an interesting target in cancer 
immunotherapy. The synthetically produced, marin sponge-derived glycolipid -galactosylceramide 
(GalCer) has been studied in murine and human studies. A single injection of GalCer combined 
with a model antigen induced strong CD4+ and CD8+ T cell responses, through activation of DC in a 
TLR-independent but NKT cell-dependent manner (45). The results were confirmed using tumour 
vaccines instead of a model antigen (46, 47). Thus far, one phase I dose-escalation study with clinical-
grade GalCer (KRN7000) has been carried out in 24 patients with solid tumours, in which no clinical 
responses were observed (48). 
 
5. Maturation of DC in clinical trials  
In early clinical trials only immature DC were used (49, 50). Some of these DC might have been ‘semi-
mature’ due to the addition of fetal calf serum in the culture medium (49, 51). Although objective 
clinical remissions were observed in these studies, there is now strong evidence that immature DC 
should no longer be used in clinical practice. In a comparative study in metastatic melanoma patients 
cytokine-matured, peptide-pulsed DC were superior to immature DC, with no immune induction 
against the control protein keyhole limpet hemocyanine (KLH) in the latter arm of the study, while all 
patients that were vaccinated with cytokine-matured DC showed a strong T cell and B cell response 
against KLH (52). In addition, only in patients vaccinated with mature DC, delayed type 
hypersensitivity (DTH) responses against the vaccine were observed. Using immature DC in 
vaccination protocols in cancer patients might in fact be hazardous due to the induction of tolerance 
instead of immunity (23, 53, 54). Several maturation methods have been applied with maturation 
being defined by a high expression of mature DC-specific surface markers (which is a rather limited 
description a discussed in the previous paragraph). Most widely used is a cytokine cocktail that 
includes TNF, with any of the following cytokines in any combination: IL-1, IL-6, PGE2, or the 
supernatant of activated autologous monocytes, (Monocytes Conditioned Medium) (55-59).  There is 
some evidence that culturing DC with IL-15 may lead to a type of mature DC that induces stronger 
Th1 effector type of immune responses (60), however no comparative studies have been reported 
yet. Lastly, CD40-ligation has been used as a method of activation of DC in a clinical setting (61, 62).  
None of these different maturation methods has shown to be clearly superior, which is mainly due to 
the fact that there are no direct comparative studies, neither in animal models nor in cancer patients. 
It is important to realize that to date no trial has been published in which TLR-matured, truly Th1-
polarized DC were used in cancer patients. In vitro data are promising (63), but clinical results with 
TLR-matured DC are eagerly awaited.  
 
6. Antigen-processing and presentation 
Intracellular endogenous antigens usually are presented in MHC class I, whereas exogenous antigens 
are usually presented in class II by antigen-presenting cells (Figure 1a) (64). Of crucial importance for 
DC-based vaccines in cancer immunotherapy is the finding that internalized antigens from exogenous 
sources, such as apoptotic or necrotic tumour cells (65, 66) are also presented in MHC class I to 
cytotoxic T cells, a process referred to as cross presentation (Figure 1a) (67, 68). Thus, tumour 
antigens derived from necrotic or apoptotic tumour cells can be presented by the DC to both CD4+  
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Table 2. Results of published DC-vaccination trials with matured DC. 
DC culture method Antigens Ag-loading method Route No. pts Clinical 
response 
Immune 
response  
Ref 
IL-4/GM-CSF/MCM/ TNF-
/ moDC 
MAGE-3 MHC I peptides sc, id, iv 13 6 MR 9 56 
IL-4/GM-CSF/IL-1b/   IL-
6/TNF-/PGE2 moDC 
MAGE-3, MAGE-1, 
tyrosinase, MAGE-4, 
MAGE-10, gp100, 
MART-1 
MHC I+II peptides sc 19 1 CR, 4 SD  12  57 
IL-4/GM-CSF/MCM/ TNF-
  moDC 
MAGE-3 MHCI peptides sc, iv 8 1 SD 8  59 
GM-CSF/Calcium-
ionophore/IL-2/IL-12 
moDC 
MART-1, gp100, 
tyrosinase, 
MHC I peptides in, id, iv 27 3 PR 13 78 
IL-4/GM-CSF/MCM/ TNF-
+PGE2 moDC 
gp100, tyrosinase MHC I peptides id, iv 10 1 PR, 1 MR, 3 SD 2 52 
Flt3L/GM-CSF/TNF 
CD34+ DC 
MART-1, MAGE-3, 
gp100, tyrosinase 
MHC I peptides sc 18 4 CR1, 4 PR, 3 SD 17 15, 82, 83 
IL-4/GM-CSF/TNF/IL-3/ 
IL-6/SCF CD34+ DC 
MART-1, gp100, 
tyrosinase, MAGE-1, 
MAGE-3 
MHC I peptides iv 14 1 PR, 6 SD  1 18 
Flt3L/GM-CSF/TNF/ 
IFN CD34+ DC 
MART-1, MAGE-3, 
gp100, tyrosinase 
MHC I peptides sc 20 1 SD 7 17 
IL-4/GM-CSF/TNF-/ 
CD40L moDC 
Allogeneic lysate Allogeneic lysate sc 20 1 CR, 1 PR 2  61 
IL-4/GM-CSF/IL-1/  
IL-6/TNF-/PGE2 moDC 
Autologous tumor 
RNA 
RNA-electroporation id or in 21 1 MR 9 110, 111 
IL-4/GM-CSF/TNF moDC 
± sc IL-2 
Allogeneic lysate lysate id 15  6 SD  9 99 
IFN/IL-3/polyI:C moDC NA17, MAGE-3 MHCI +II peptides sc, id 4 1 SD 1  84 
IL-4/GM-CSF/IL-1/IL-6/ 
TNF-/PGE2 moDC 
MAGE-1, MAGE-3, 
tyrosinase, gp100, 
MART-1 
MHCI +II peptides sc 53  2 PR, 8 SD2 Not given 87 
GM-CSF/IL-13 moDC Allogeneic lysate Allogeneic lysate in, sc, id 10 1 SD 3 98 
GM-CSF/IL-13/ 
Ribomunyl/IFNg 
MART-1, ± NA17 MHCI+II peptides il then in 14 2 SD 5 133 
Results of published DC-vaccination trials in which DC were used that had received some form of maturation signals, only 
melanoma patients with distant metastases and evaluable disease are included. Abbreviations: IL, interleukin; GM-CSF, 
granulocyte macrophage-colony stimulating factor; MCM, monocyte-conditioned medium; TNF, tumor necrosis factor 
alpha; PGE2, PGE2; moDC, monocyte-derived DC; Flt3L, Flt3-Ligand; SCF, stem cell factor; IFN, interferon; sc, subcutaneous; 
in, intranodal; id, intradermal; iv, intraveneous; il, intralymfatic; CR, complete response; PR, partial response; MR, mixed 
response; SD, stable disease (≥ 4 months). 
1 
In a follow-up report, all complete responders were still free of disease with a median of 5 years. 
2 
This is a multi-instutional, randomized phase III trial. In the other treatment-arm 55 patients were treated with DTIC, in 
which 3 PR and 10 SD were seen. No differences in overall or progression-free survival were observed. 
 
(in MHC class II) and CD8+ T cells (in MHC class I), which implies that a broad effector and memory 
immune response can be induced against tumour antigens.Apoptosis is a physiological ‘silent’ 
immunologic event, pertaining millions of cells per second. However, with regard to the 
immunogenicity of apoptotic cancer cells the data are less clear (69-73). Recently it was shown in a 
murine model that chemotherapy-induced apoptosis results in cross-presentation and T cell 
activation, thereby preventing tumour outgrowth in a prophylactic setting (74). The same authors 
show in another study that apoptotic tumour cells induce immune responses in a TLR-4 dependent 
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manner via secretion of HMBG1 (75). The importance of these findings is that apoptosis of cancer 
cells may be an immunologic event without the need of an extra ‘danger signal’, and that this can be 
accomplished by the administration of cytotoxic drugs or radiotherapy. 
 
7. DC Antigen-loading in clinical trials 
In most clinical DC vaccination studies synthetic MHC class I-binding peptides have been used (15, 17, 
18, 49, 52, 56, 76-86), with class II-binding peptides being added in some (Figure 1b) (57, 87). There is 
convincing preclinical evidence that targeting both cytotoxic T cells and T helper cells is of crucial 
importance for the induction of a strong and sustained anti-tumour T cell response (88, 89). 
However, no clinical trial has yet been performed in which MHC class I antigen-loaded DC are 
compared to the combination of both MHC class I and II antigen-loaded DC. Instead of HLA-binding 
peptides, whole antigenic proteins can be used. The DC processes the protein into peptides, which 
has the advantage that multiple epitopes are presented in both MHC class I and II and that there is 
no HLA-restriction. Unfortunately, little recombinant proteins are clinically grade available (90). 
Autologous (49, 91-96) or allogeneic (61, 97-99) tumour cell lysates have also been applied as a 
source of antigens. This has several advantages: the antigen expression by the tumour does not need 
to be defined and a wide array of both MHC class I and II epitopes are presented including tumour-
unique antigens. Possible drawbacks include the presentation of auto-antigens, the requirement of a 
sufficient volume of tumour tissue and difficulties in monitoring tumour-specific T cell responses 
since the antigens relevant to T cell responses are not known. Palucka et al. partly circumvented the 
latter problem by using large peptide libraries to pinpoint the dominant T cell responses in advanced 
melanoma patients after vaccination with allogeneic tumour lysate-loaded DC (61). Transfection of 
DC with RNA concerns a novel antigen-loading technique (100), with either tumour-derived RNA 
(101, 102) or synthetic RNA encoding specific melanoma-associated antigens being used (103). A 
benefit of this technique lies in the presentation of several MHC class I epitopes and sometimes also 
MHC class II epitopes, depending on the presence of an endosomal targeting sequence (104). Also, it 
may lead to a more prolonged presentation of the antigen as compared to peptide-loading which 
appears to be short-lived (105). Potential drawbacks of RNA transfection include a variable 
expression and a low yield of viable cells after transfection, especially with respect to the most 
widely used technique of RNA electroporation. However, several studies have shown that this 
technique is feasible and results in highly efficient DC-transfection (103, 106-109). Furthermore, anti-
tumour T cell responses and clinical responses have been reported in patients vaccinated with DC 
electroporated with tumour-derived RNA (110, 111). In a study with 33 metastatic melanoma 
patients vaccination with autologous tumour lysate-loaded DC resulted in a slightly higher response 
rate compared to peptide-pulsed DC, (3 versus no partial remissions, respectively) (93). Equal 
immunogenicity was demonstrated for peptide- and RNA-pulsed DC in colorectal cancer patients 
(112).  However, immature DC were used in both studies. Mature DC have not been used in clinical 
studies comparing different antigen-loading techniques. Therefore at this moment the optimal 
method for antigen loading is unknown. Antigens that target DC in vivo would obviate the need for 
laborious ex vivo culturing protocols (113). Although this appears to be feasible through DC specific 
molecules such as the C-type lectins DC-SIGN (114) and DEC-205 (115) using model antigens, it will 
probably take some years before this can be applied in clinical experiments in cancer patients. In 
addition, a DC maturation stimulus should be applied in vivo.  Another approach concerns the 
targeting of intratumoural DC by delivering danger signals in situ, which can be combined with 
chemokine treatment in order to increase the number of intratumoural DC (116). In addition, local 
tumour-destructing therapies can induce antigen-release in situ, for example by using radiotherapy 
(117), chemotherapy (118) or radiofrequency ablation (119). The immunogenicity of these methods 
may then be further enhanced by the local delivery of DC activating signals (120, 121).  
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Figure 1. Antigens can be processed by the DC through three major pathways. (A) Exogenous antigens will be internalized by 
the DC and enter the endocytic pathway in which they are targeted to lysosome-related MHCclass II-rich compartments. In 
these compartments the antigens are degraded and loaded onto MHC class II molecules. During maturation of the DC the 
MHC-peptide complexes are released to the surface, thus making the cell ready for antigen presentation to CD4
+
 T helper 
cells (route 1 in the Figure). Intracellular endogenous antigens, such as unstable self-proteins or viral proteins, are cleaved 
into peptides in the proteasome and subsequently translocated into the lumen of the endoplasmatic reticulum (ER) by 
transporters associated with antigen processing (TAP), where stable MHC class I-peptide complexes are assembled. Upon 
binding of the peptide, the complex is released from the endoplasmatic reticulum and transferred to the cell surface (route 
2 in the Figure), where it is presented to CD8
+
 cytotoxic T cells. Lastly, DC have the unique capacity to present exogenous 
antigens, such as necrotic or apoptotic tumour cells, in MHC class I to cytotoxic T cells, a process referred to as cross 
presentation (route 3 in the Figure). (B) Melanoma antigens can be loaded onto the DC for antigen presentation either by 
transfection with DNA or RNA encoding melanoma antigens, or pulsing with tumour lysate, antigenic proteins or peptides. 
 
8. Migration 
DC are the sentinels of the immune system and therefore need efficient migratory capacity. In 
peripheral tissues they continuously sample the environment for antigens. After antigen uptake DC 
must migrate to the secondary lymphoid organs, in particular the lymph nodes for presentation of 
the antigens to the adaptive arm of the immune system. The lymph node homing chemokine 
receptor CCR7 is essential for DC migration to the lymph nodes (122, 123). CCR7 guides the DC 
towards and through the lymphatic vessels to the lymph nodes in response to chemotactic gradients 
of its ligands CCL19 and CCL21 that are expressed by lymphatic vessels and lymph node-residing cells 
(Figure 2a) (124). Expression of CCR7 is upregulated upon DC maturation, resulting in an enhanced 
migratory capacity of matured DC as compared to immature DC (73). In addition, inflammatory 
signals such as PGE2 are needed to further sensitize CCR7 to its ligands (125, 126). These findings are 
of importance for DC-based vaccination, since they show that it may be beneficial to culture DC in 
the presence of PGE2 in order to get a good migratory capacity after vaccination, even though PGE2 
has been described to skew DC under some circumstances towards a Th2 type of immune response 
(40). Interestingly, in a murine model DC migration could be increased up to ten-fold after 
pretreatment of the injection site with TNF or unloaded DC, due to the upregulation of CCR7-ligand 
CCL21 in lymphatic endothelial cells, resulting in a superior magnitude and quality of the T cell 
response (123).  
 
9. Route of DC administration in clinical trials 
For the effective induction of immunity it is obligatory for the DC to interact with T cells, which takes 
place in the peripheral lymphoid organs: mainly in the lymph nodes but to some extent also in the 
spleen. Recent evidence suggests that also the bone marrow may be a site for primary immune 
responses (127). As different routes lead to different sites of accumulation of the vaccinated DC, 
these issues are of importance when considering the route of delivery of the DC (Figure 2b). Murine 
models have shown that after intravenous injection the majority of DC accumulate in the spleen and 
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to a lesser extent in the lungs, kidneys and liver, while hardly any DC end up in peripheral lymph 
nodes (128). In vivo studies in cancer patients have shown that after intradermal injection 
approximately 2-4% of the DC migrate to draining lymph nodes (129). There is now convincing 
evidence from several independent human studies that migration after subcutaneous injection is 
much lower compared with intradermal injection (84, 129-131). Intranodal injection results in a 
much higher amount of DC accumulating in lymph nodes, not only in the injected node, but also in 
subsequent draining nodes (129). Migration to these subsequent nodes via the physiological pathway 
through lymph vessels can be as much as 80%. However, the magnitude of DC migration that is 
observed after intranodal injection is more variable than after intradermal vaccination (129). 
Intranodal injections are usually administered under ultrasound guidance. Supposedly, this would 
result in an assured accurate delivery, which was the reason for some studies to prefer this route of 
administration (54). However, using paramagnetic beads-labeled DC that can be tracked in patients 
after injection by MR imaging, we recently found that intranodal injection is complicated by 
inaccurate delivery: in a considerable proportion of patients the DC were misinjected, in the 
perinodal fat (132). Inaccurate injection correlated with absent migration to remote lymph nodes. 
These results explain the variability in migratory outcome after intranodal administration and 
underscore the importance of accurate delivery (133). Recently, Lesimple and colleagues showed 
that intralymphatic delivery into a lymph vessel in the dorsum of the foot is also feasible (134). 
Migration of administered cells however, is only a surrogate endpoint. The true value of the different 
routes of delivery can only be determined with immune response or even clinical response as an 
endpoint. One study in melanoma patients found a small benefit in peptide-specific T cell responses 
after intranodal injection as compared to intradermal or intravenous injection (78). Another study in 
advanced melanoma patients showed no benefit for intranodal vaccination as compared to 
intradermal vaccination: of 22 evaluable patients a positive DTH reaction against the vaccine was 
detected in 7/10 intradermal vaccinated patients and in 3/12 intranodal vaccinated patients (135). 
Fong et al compared vaccination with DC enriched from peripheral blood mononuclear cells injected 
via three different routes in advanced prostate cancer patients: intradermal, intravenous and 
intralymphatic injection via a canule in a lymphatic channel in the dorsum of the foot (136). Antigen-
specific T cell responses were observed regardless of the route of delivery, although IFNγ production 
after antigen stimulation in vitro was only demonstrated in the intradermally and intralymphaticly 
vaccinated patients. However, the intravenous route gave rise to a more pronounced antibody 
response. In an important study performed by the same group intravenous injection of DC was 
shown to be essential for immune responses against visceral melanoma metastases, whereas for 
subcutaneous vaccination this was true for non-visceral metastases (137). These findings indicate 
that the combination of different routes of administration may be beneficial to target different 
tumour locations in the entire body (138). In conclusion, to date no specific route of administration 
has unequivocally been shown to be superior in terms of induction of immune or clinical responses.  
 
10. Tolerance  
The immune system has several pathways to tune down immune responses In order to prevent 
autoimmunity or excessively long or vigorous inflammatory reactions. These many pathways include 
antigen-presentation by tolerizing DC (as discussed above), the suppressive activity of so-called 
regulatory T cells (Treg) and tolerance induction via inhibitory molecules on T cells. According to 
current insights there are two major distinct populations of Treg: naturally occurring CD4+/CD25+ 
Treg which at the time they leave the thymus already have a suppressive potential, and induced Treg 
that are ‘conventional’ CD4+ or CD8+ T cells but transformed into cells with an immunosuppressive 
function under the influence of tolerizing conditions (139, 140). Treg can affect immune responses at 
the level of antigen-presentation and during the effector phase of T cells at the site of inflammation 
or tumour growth (139). 
15
Part 1, Chapter 1 
 
Figure 2. Routes of DC administration in clinical trials. (A) DC that reside in the periphery migrate to draining lymph nodes 
through afferent lymphatic vessels following chemotactic gradients of CCL19and CCL21. These chemokines are expressed 
by lymphatic endothelial cells and lymph node-residing cells. Blood DC enter the lymph nodes through high endothelial 
venules (HEV). After interaction with DC, the T cells leave the lymph node through efferent lymphatic vessels and 
disseminate throughout the body via the circulation. (B) Several routes of administration are used in clinical DC vaccination 
trials: intradermal, subcutaneous, intratumoural, intralymphatic, intranodal and intraveneous. 
 
Treg function is controlled by cytokines,  cross-talk with antigen-presenting cells, but also by direct 
interaction with pathogens via TLRs (141). The mechanisms by which Treg exert their suppressive 
function are not completely elucidated, but it may happen in a cell-cell contact dependent manner 
via camp as second messenger (142) as well as through cytokines such as IL-10 or TGF (140). The 
clinical importance of Treg in cancer has been demonstrated by Curiel et al. (143). A high number of 
Treg in tumours of ovarian cancer patients correlated with  poor survival. In other tumor types, these 
data have been confirmed (144-146). Furthermore, depletion of naturally occurring Treg by anti-
CD25 or anti-GITR monoclonal antibodies in murine models resulted in enhanced therapeutic efficacy 
of a cancer vaccine (147, 148). Since T effector cells also upregulate CD25 upon activation (the -
chain of the IL-2 receptor), a potential drawback of targeting Tregs via CD25 may be the depletion of 
newly activated T effector cells along with the Tregs (148). It may therefore be a meticulous task to 
find the optimal dosing and timing of anti-CD25 treatment to deplete Tregs via anti-CD25 antibodies 
without affecting the activate T cell population. Another important pathway through which tolerance 
or anergy may be induced involves inhibitory molecules on the T cells, such as cytotoxic T 
lymphocyte-associated antigen-4 (CTLA-4) or programmed death-1 receptor (PD-1) (149). The ligands 
of CTLA-4 are the DC co-stimulatory molecules CD80 and CD86. Binding of these costimulatory 
molecules to the inhibitory molecule CTLA-4 instead of the activating T cell molecule CD28, results in 
suppression of T cell activation and proliferation. Activated T cells express CTLA-4. Since the affinity 
of CTLA-4 for CD80 and CD86 is higher than that of CD28, eventually the tolerogenic pathway 
prevails, thereby terminating immune reactions (149, 150).  PD-1 is another inhibitory T cell surface 
molecule that upon binding to its ligands PD-L1 and PD-L2 induces anergy or tolerance (149). 
Interestingly, PD-L1 and 2 are expressed by several types of cancer, which may allow the tumour to 
escape from immune surveillance (151, 152). This phenomenon can be reversed in mice by 
treatment with an anti-PD-L1 antibody (152, 153). Although this has been confirmed in vitro for the 
human situation, studies using PD-L1 blockade in cancer patients have not been reported yet (154). 
 
11. Breaking tolerance in melanoma patients  
Several new drugs have entered the clinic that target immunosuppressive mechanisms and may 
therefore be relevant in combination with anti-cancer vaccines. Treg can be efficiently depleted in 
prostate cancer patients with denileukin diftitox, a compund that consists of a diphteria toxin 
coupled to IL-2, resulting in enhanced antigen-specific T cell responses after DC vaccination (155). 
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Denileukin diftitox as a single agent has shown promising immunological and clinical results in phase I 
and II studies in ovarian cancer (Barnet ASCO 2006). In melanoma however, thus far the data are 
conflicting, with one study failing to show any efficient Treg (156), while another preliminary study 
showed tumour regression in two patients (Chesney ASCO 2006). Mahnke et al. found enhanced 
antigenic immune responses after peptide vaccination and a significant reduction in Treg frequencies 
in melanoma patients after denileukin diftitox (157). The combination of DC vaccination with 
denileukin diftitox has not yet been reported in melanoma patients. This also holds true for the 
combination with anti-CD25 antibodies, despite the fact that these are commonly used in transplant 
patients. The recent unexpected results with the anti-CD28 monoclonal antibody TGN1412-trial again 
demonstrated the enormous potency of drugs that manipulate the co-stimulatory pathways (158, 
159). Blockade of CTLA-4 has been shown to induce durable objective responses in metastatic 
melanoma patients, at the cost of autoimmune side effects (160-163).  Anti-CTLA-4 treatment in 
melanoma patients did not result in depletion or decreased suppressive activity of Treg (which highly 
express CTLA-4), suggesting that the anti-tumour efficacy of the treatment is caused by an increased 
T cell activation and not by inhibition or depletion of Treg (164). Since treatment with anti-CTLA-4 is 
antigen is non-specific, the combination with a vaccine could potentially direct the T cell response in 
a more specific manner, thereby diminishing autoimmune side effects. There is anecdotal 
information that anti-CTLA4 treatment after DC vaccination may indeed enhance DC vaccine-induced 
T cell responses (163), however clinical trials that are specifically designed to answer this question 
are lacking. 
 
12. Clinical results of DC vaccination studies in melanoma  
Proof of principle studies were performed in the late nineties, showing the feasibility and the 
potential efficacy of DC vaccination in cancer patients (49, 50, 56). Since then numerous small studies 
have been performed, especially in melanoma patients (Table 1 and 2). Given the enormous 
variations in culturing protocols and frequency, dose and route of administration, it is not possible to 
pool all these data in a meta-analysis. Nevertheless, some general observations can be made. 
Objective response rates in these selected patients do not exceed 5-10%, with disease stabilization 
and mixed responses being observed more often. As discussed above, there is convincing evidence 
from preclinical and clinical studies that immature DC are not proper T cell activators, and could even 
induce tolerance. Strikingly however, this does not translate into a dramatic difference in clinical 
outcome when studies with immature DC are compared with studies in which matured DC have been 
used (Table 1 and 2). Perhaps this hints at the relatively low immunogenicity of the mature DC 
vaccines that are currently applied: using cytokines to mature the DC without activation by Toll-like 
receptor triggers. In a recent phase III multi-institutional, randomized controlled trial the standard 
chemotherapy regimen for patients with metastatic melanoma, DTIC, was compared with cytokine-
matured DC vaccination and no difference in survival was observed after inclusion of all patients, 
upon which the study was discontinued (87). How can this disappointing result be explained? As 
reported by the authors themselves, the DC displayed a variable maturation status and the 
subcutaneous route of administration that was used is inferior. In addition, not all patients received 
the anticipated numbers of DC. Others have pointed at the enormous complexity of performing a 
multi-center study with patient-specific vaccines and the difficulties in establishing a standardized 
vaccine product as a possible explanation of the negative outcome of this study (90). Together these 
factors may explain why no clinical benefit was found for the DC vaccine. In a subgroup-analysis a 
correlation was found between response to DC vaccination and HLA-type, with a favorable outcome 
for the HLA-2+/HLA-B44- haplotype. Although this trial could be interpreted as a negative trial for DC 
vaccination, in our view equality with the standard therapy for the last 30 years is perhaps not a bad 
starting point, given the the fact that there are many parameters regarding DC vaccination that can 
still be optimized, as we have discussed above.  
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13. Immunological results of DC vaccination studies in melanoma  
Successful development of DC vaccines in cancer patients much depends on obtaining biological 
information that correlates with clinical efficacy. A clear correlation between immunological 
response and clinical outcome has been observed in some studies (15, 165), but not in all (93). 
Monitoring immune responses in DC vaccination trials is difficult and laborious, since very low 
frequencies of high-affinity melanoma antigen-specific T cells in peripheral blood may be sufficient 
for tumour rejection. These frequencies can be as low as 1 in 40.000 T cells (166). These low 
responses are often not detected by the most frequently used techniques such as Elispot-analysis 
and direct tetramer-staining of peripheral blood lymphocytes. In order to detect these low 
frequencies Coulie et al. stimulated blood lymphocyte cultures from peptide-vaccinated melanoma 
patients in vitro with melanoma antigens, followed by cloning of the antigen-specific cells and T-cell 
receptor sequence analysis of the clones (166). We took another approach by analyzing T cell 
responses in vaccinated patients from biopsies of delayed type hypersensitivity reactions (DTH) that 
were performed with the peptide-loaded DC vaccine (165, 167). In these DTH biopsies we found 
evidence for functional antigen-specific T cell responses after vaccination. Moreover, the presence of 
these specific T cells was significantly correlated with a prolonged progression-free survival in 
metastatic melanoma patients (165). These data suggest that the success or failure of tumour-
specific T cels to migrate towards the DTH site reflects the potency of the T cells at the site of 
disease. In a provocative study Lonchay et al. showed that although frequencies of vaccine-specific T 
cell may be higher after vaccinations, this does not necessarily mean that these cells are the true 
effector cells that actually cause the tumour regression (168). They found that other tumour-specific 
T cells that were already present prior to vaccination were much more expanded after vaccination 
than the vaccine-specific T cells. The current hypothesis is that vaccine-specific T cells ignite a certain 
‘spark’ in the tumour, causing the non-active tumour-residing specific T cells to become active and 
proliferative. Thus, the expanded specific T cell frequencies that are observed upon DC vaccination 
and correlate with an improved clinical outcome may cause tumour regression either in a direct or in 
an indirect manner. 
 
14. Study design and clinical endpoints in DC vaccination 
The study design and clinical endpoints that should be used in therapeutic cancer vaccine studies, 
were recently defined in a consensus process by the Cancer Vaccine Clinical Trial Working Group, 
representing academia and pharmaceutical and biotechnology industries with participation from the 
US Food and Drug Administration (169), There are several differences between cytostatic drugs and 
therapeutic vaccines that should be taken into account when designing and evaluating clinical cancer 
vaccine trials. Firstly, conventional RECIST criteria may not always be the most appropriate endpoint 
to decide which DC vaccine will be the most optimal vaccine to be tested in large clinical trials. 
Because vaccine-induced immune responses will take some time before they become clinically 
apparent, initial minor progression could be accepTable. (169). In fact, adequate immune induction 
could theoretically first induce enlargement of tumour lesions through T cell infiltration and local 
inflammation. For these reasons, it may be proper to deviate from standard RECIST criteria, provided 
that the new criteria are pre-defined and clearly described, as proposed before (4). Whether 
functional in vivo imaging has a role in the monitoring of clinical responses in cancer vaccine trials 
remains to be determined. It has been shown that upon DC vaccination regional non-tumourous 
lymph nodes become FDG-positive on positron emission tomography-scanning, reflecting immune 
activation rather than tumour progression (170).  A second major difference between conventional 
cytostatic therapy and DC vaccination is that the highest dose is not necessarily the most effective 
one. And because DC vaccines have an almost negligible toxicity, conventional dose-escalating phase 
I trials with toxicity as the primary endpoint would not result in the selection of the optimal dose to 
be used in further clinical testing. This problem has been circumvented by performing dose-
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escalation studies with immune response as the primary endpoint rather than toxicity (see for 
example (15)). Another difference is that in patients with advanced disease, the patient group in 
which normally phase I trials are performed, immunotherapy will probably have little chances of 
being successful because of immunosuppressive mechanisms at the tumour site. For these reasons, 
the conventional phase I-II-III trial paradigm that is applied in the field of cytostatic therapy, may not 
be the most optimal trial design for DC vaccination. The Cancer Vaccine Clinical Trial Working Group 
concensus recently proposed a two-step development in clinical trial design in cancer vaccination: 
proof of principle trials and efficacy trials (169). The following criteria were proposed for proof-of-
principle trials. They should include a minimum of 20 or more patients in a homogenous, well-
defined population. The disease should not be rapidly progressive in order to allow the vaccines 
adequate time to induce immunological activity. Study objectives should include determination of 
dose and schedule and demonstration of immunological activity as proof-of-principle. Immunological 
activity is demonstrated if determined in 2 separate, established and reproducible assays at 2 
consecutive follow-up time points after the baseline assessment. Efficacy trials then formally 
establish clinical benefit, either directly or through a surrogate endpoint. In contrast with the field of 
conventional cytostatic therapies, it is promoted that these trials are randomized. We believe that 
these guidelines are of great practical use and could help the field forward. And although in some 
instances it may be sufficient to include smaller numbers of patients (for example in trials 
investigating DC migration in vivo), we believe that adherence to these guidelines should be 
encouraged. 
 
15. DC Companies 
The preparation of a standard high-quality DC vaccine that meets Good Manufacturing 
Practice/Good Laboratory Practice (GMP/GLP), and clinical grade criteria is a laborious and costly 
process. Dedicated GMP/GLP cleanrooms are needed. Culturing a DC vaccine for one patient takes at 
least two persons two to three full working days. Even more costly are the culture media and 
cytokines that need to be toxin-free, clinical grade materials. Together with the fact that the vaccines 
are patient-specific, ‘tailor-made’, these issues gave rise to the long-held believe that companies 
would not be interested in DC vaccination. However, at the moment several companies are trying to 
get approval from official regulatory authorities (171). One company-made DC vaccine is Sipuleucel-
T, which is made of antigen-presenting cells that are collected by two density centrifugation steps, 
pulsed with recombinant prostatic acid phosphatase fused to GM-CSF (172). A placebo-controlled 
phase III trial in hormone-refractory metastatic cancer patients was not able to show improvement in 
time to progression, the primary endpoint, although overall survival was prolonged from 21.4 to 25.9 
months (173). Initially an FDA Advisory Committee recommended to approve Sipuleucel-T, but the 
FDA decided to await further proof of efficacy. This should come from an ongoing phase III trial with 
overall survival as primary endpoint of which the first interim analysis is planned in 2008 (171, 174). 
Other firms are seeking approval by the European and US regulatory authorities for vaccines targeted 
at lymphoma, sarcoma, glioblastoma and acute myelogenous leukaemia (171). 
 
16. Combination therapies 
There is a need to test combinations with more cytotoxic therapies, given the low frequency of 
clinical responses in patients with advanced disease upon DC vaccination alone. Although initially 
chemotherapy was believed to be detrimental to T cell-directed immunotherapy because most 
chemotherapy regimens have a myelosuppressive effect, now more evidence is accumulating that 
some forms of chemotherapy may not harm T cell responses (175) and may in fact have a synergistic 
effect together with immunotherapeutic approaches (reviewed in (176)) (75, 118). It is tempting to 
speculate on the possibility of tumour debulking by chemotherapy, combined with immune 
surveillance and immune memory induction by vaccination therapy to prevent relapses. The same 
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applies to radiotherapy (177) and targeted therapy (178). Another interesting approach involves in 
situ tumor destruction by cryo- or radiofrequency ablation in combination with immune activation, 
including injection of DC (119-121, 179). However, clinical data are lacking, trials combining 
chemotherapy and DC vaccination are in progress. As discussed above, also combination therapy 
with anti-CTLA4 and DC vaccination may have a synergistic effect. It is currently under study whether 
DC vaccination can enhance the graft-versus-tumour effect of stem cell transplantation and donor 
lymphocyte infusions in haematological malignancies (180). Adoptive T cell transfer following non-
myeloablative but lymphodepleting chemotherapy showed impressive clinical results in advanced 
melanoma patients (181, 182). Adoptive T cell transfer generates a high, but short peek of antigen-
specific T cells, whereas DC vaccination induces T cell responses more gradually that endure longer 
(183), providing a rationale to combine the two treatment modalities. In preclinical models DC 
vaccination indeed boosted and sustained anti-tumour T cell responses after adoptive T cell transfer 
(183, 184). Trials in the near future will have to answer the question whether DC vaccination can add 
to the efficacy of these other anti-cancer treatment modalities.  
 
17. Conclusion and future prospects 
DC vaccination has shown to be feasible and safe. Immunological responses are frequently observed. 
Clinical responses have been reported, but the incidence is low. Exciting new insights arise from 
preclinical studies, some of which are currently being applied in clinical studies. For example, 
depletion of suppressor T cells combined with DC vaccination may enhance the immunogenicity of 
the vaccine, as has been shown in prostate cancer patients (155). Also blockade of the inhibitory T 
cell molecule CTLA-4 by monoclonal antibodies could enhance the immunogenicity of DC vaccines 
(162). Combination treatment with chemotherapy, radiotherapy or other tumour ablative 
treatments needs to be further investigated. Trials with TLR-ligand activated DC are eagerly awaited. 
Although these novel treatment strategies are now entering clinical studies, the pace of in vitro and 
animal research is inevitably faster than that of clinical research. For this reason a lot of crucial 
questions regarding the optimal DC vaccine for clinical use remain unanswered to date. These 
questions concern the optimal methods for culture, maturation and antigen-loading, route of 
administration, subsets of DC and effects of suppressor T cell-depletion or blockade of other 
inhibitory pathways. Significant progress is only to be expected from well-designed, properly 
conducted and comparative studies with biological endpoints.  
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Abstract  
To determine the relevance of targeting antigen-specific CD4+ T helper cells in anti-cancer 
immunotherapy, we investigated the immunological and clinical responses to vaccination with 
dendritic cells (DC) pulsed with either MHC Class I (MHC-I) restricted epitopes alone or both MHC 
Class I and II (MHC-I/II) restricted epitopes. 
We enrolled thirty-three stage III and IV HLA-A*02:01 positive melanoma patients in this study, 29 
patients were evaluable for immunological response. Patients received intranodal vaccinations with 
cytokine-matured DC loaded with keyhole limpet hemocyanin and MHC-I alone or MHC-I/II restricted 
tumor associated antigens (TAA) of tyrosinase and gp100, depending on their HLA-DR4 status.  
In 4/15 patients vaccinated with MHC-I/II loaded DC and 1/14 patients vaccinated with MHC-I loaded 
DC, we detected TAA-specific CD8+ T cells with maintained IFN production in skin-test infiltrating 
lymphocyte (SKIL) cultures and circulating TAA-specific CD8+ T cells. If TAA-specific CD4+ T cell 
responses were detected in SKIL cultures, it coincided with TAA-specific CD8+ T cell responses. In 
3/13 patients tested, we detected TAA-specific CD4+CD25+FoxP3- T cells with high proliferative 
capacity and IFNproduction, indicating that these were not regulatory T cells. Vaccination with 
MHC-I/II loaded DC resulted in improved clinical outcome compared to matched control patients 
treated with DTIC, median OS 15.0 versus 8.3 months (p=0.089) and median PFS 5.0 versus 2.8 
months (p=0.0089) . In conclusion, co-activating TAA-specific CD4+ T helper cells with DC pulsed with 
both MHC Class I and II restricted epitopes augments TAA-specific CD8+ T cell responses, contributing 
to improved clinical responses.  
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Introduction  
Dendritic cells (DC) are considered the most effective antigen-presenting cells to activate naïve T cells 
(1). Immunotherapy exploiting ex vivo generated autologous DC pulsed with tumor peptides has 
shown proof of principle (2). We and others have shown that tumor-specific immune responses can 
be induced in both stage III and IV melanoma patients (2). Nevertheless, further optimization is 
warranted before this approach is accepted for clinical practice (3).  
The role of CD8+ cytotoxic T cells (CTL) in the eradication of tumor cells that express tumor associated 
antigens (TAA) in the context of MHC class I (MHC-I), has clearly been established (4). For melanoma, 
many HLA-A*01, A*02 and A*03 restricted epitopes derived from gp100, tyrosinase, MAGE-3 or 
MART-1 have been identified (5). The majority of clinical studies have been performed with MHC-I 
peptide-pulsed DC (6-11). A potential disadvantage of this method is that exclusively CD8+ cytotoxic T 
cells are targeted, without involving CD4+ T helper cells in the induction of anti-tumor responses.  
The role of T helper cells has recently been better characterized. It has been shown that the 
presentation of tumor peptides in both MHC class I and II (MHC-I/II) induces high-affinity T cells 
reactive to multiple MHC-I/II epitopes (12). Subsequent direct activation of APC by T helper cells 
leads to stimulation of precursor CTL to become effector CTL (13). Several studies have shown a 
critical role for T helper cells in the maintenance of long-term protective immunity (14, 15).  
Furthermore, T helper cells themselves can also have a direct anti-tumor effect (13). This effect may 
be particularly relevant to melanoma, since melanoma cells often constitutively express MHC-II 
molecules (16), which are not down-regulated during progression (17). Recently, MHC-II epitopes 
derived from gp100 and tyrosinase have been made available for use in clinical trials (18-20). To 
determine the additional value of co-activating CD4+ T helper cells we investigated the 
immunological and clinical responses after vaccination with DC either pulsed with MHC-I or MHC-I/II 
restricted epitopes of g100 and tyrosinase. 
 
Materials and methods 
Patient population 
Melanoma patients with regional lymph node metastases (American Joint Committee on Cancer 
criteria stage III) scheduled for radical lymph node dissection (RLND) or with distant metastases (AJCC 
stage IV) were included. Additional eligibility criteria included HLA-A*02:01 genotype, known HLA-
DR4 status, expression of melanoma-associated antigens gp100 and tyrosinase, WHO performance 
status 0 or 1, lactate dehydrogenase within 2x upper limit of normal (reference value 450 U/L). 
Patients with symptomatic brain metastases, serious concomitant disease or a history of second 
malignancy were excluded. The trial was registered at ClinicalTrials.gov, identifier NCT00243529 and 
approved by the local Institutional Review Board. Written informed consent was obtained from all 
patients.  
 
Study protocol 
Patients received the vaccine intranodally (i.n.) injected in a clinically tumor-free lymph node under 
ultrasound guidance. All administered vaccines consisted of autologous mature monocyte-derived 
DC pulsed with gp100 and tyrosinase peptides and keyhole limpet hemocyanin (KLH) protein. 
Patients were assigned to two different groups, depending on their HLA-DR4 genotype. Patients with 
HLA-DR4 genotype were vaccinated with DC loaded with MHC-I/II peptides (group A), patients 
without HLA-DR4 genotype were vaccinated DC loaded with MHC-I peptides only (group B). Patients 
were evaluable for immunological response, as they completed at least one cycle of three 
vaccinations with a biweekly interval, followed by delayed type hypersensitivity skin test (21). All 
seven patients with regional lymph node metastases received one extra vaccination 2 days prior to 
scheduled RLND for additional imaging studies (Aarntzen et al, Clin Cancer Res. 2012) and started 
thereafter with the standard schedule of 3 biweekly vaccinations. Patients without progression after 
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the first vaccination cycle were eligible for a maximum of two maintenance cycles at 6-month 
intervals. All vaccinations were administered between February 2002 and February 2009. The 
primary study endpoint was vaccine-specific immune response; secondary endpoints included the 
clinical response (progression-free survival and overall survival on intention to treat bases, calculated 
from the time of apheresis to event) and toxicity.  
 
 
Supplementary Figure 1. CONSORT flow chart. 
 
DC preparation and characterization 
DC were generated from peripheral blood mononuclear cells (PBMC) prepared from leukapheresis 
products as described previously (8). Part of the PBMC was used to generate monocyte-conditioned 
medium (MCM). Plastic-adherent monocytes were cultured in X-VIVO-15™ medium (BioWhittaker, 
Walkersville, Maryland) supplemented with 2% pooled human serum (HS) (Bloodbank Rivierenland, 
Nijmegen, The Netherlands), IL-4 (500 U/ml) and GM-CSF (800 U/ml) (both CellGenix, Freiburg, 
Germany). Immature DC were pulsed at day 3 with Keyhole limpet hemocyanin (KLH, 10 g/ml; 
Calbiochem, San Diego, CA). Two days prior the harvesting, cells were matured with autologous 
MCM with prostaglandin E2 john, Puurs, Belgium) and 10 ng/ml of 
recombinant tumor necrosis factor alpha (provided by dr. G. Adolf, Bender Wien, Vienna, Austria). 
This protocol gave rise to mature DC (22). Patients received at maximum 15×106 DCs per injection.  
 
Peptide-pulsing of DC 
DC were pulsed with the MHC-I-restricted peptides gp100:154-162 (KTWGQYWQV) (23) and 
gp100:280-288 (YLEPGPVTA) (24) and tyrosinase:369-377 (YMDGTMSQV); MHC-II-restricted peptides 
gp100:44-59 (WNRQLYPEWTEAQRLD) (25) and tyrosinase:448-462 (DYSYLQDSDPDSFQD) (26). 
Peptide pulsing was performed as described previously (8), and cells were suspended in 0.1 ml for 
injection. 
 
Assessed for eligibility (n = 33)
Patients assigned (n = 33)
Started allocated intervention  (n = 16)
patient IV-A-02 did not meet inclusion 
criteria
Allocated to vaccination with MHC Class 
I/II loaded DC (n = 17)
Completed allocated intervention (n = 15), 
patient IV-A-08 did not complete 
intervention due to rapid progressive
Started allocated intervention (n = 16)
Completed allocated intervention (n = 14), 
patients IV-B-07 and IV-B-13 did not 
complete intervention due to rapid 
progressive disease 
Allocated to vaccination with MHC Class I 
loaded DC (n = 16)                             
Supplementary Figure 1. CONSORT flowchart
analyzed for immunological responses
Group A Group B
analyzed for clinical responses
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Flow cytometry 
The following FITC-conjugated mAbs were used: anti-HLA-Class-I (W6/32), and anti-HLA-DR/DP 
(Q5/13); and PE-conjugated mAbs: anti-CD14, anti-CD83, anti-CD28 (Beckman Coulter, Mijdrecht, 
The Netherlands), and anti-CD80, anti-CD8, anti-CD86, anti-CD45RA, anti-CD62L (BD Biosciences, San 
Diego, CA). Directly labelled mAbs against CD4, CD8, CD25, CD127, CTLA-4 (BD Pharmingen) and 
FoxP3 (eBiosciece, San Diego, CA, USA), all according to the manufacturer’s protocol, were used to 
characterize T cells. Regulatory T cells were defined as CD4+FoxP3+CD25highCD127low cells. The 
FACSCalibur™ flow cytometer equipped with CellQuest software (BD Biosciences) was used. 
 
Evaluation of immunological responses 
Peripheral blood sampling was performed prior to and after each vaccination and at every follow-up 
visit thereafter, for the evaluation of KLH-specific responses and tetramer staining. Delayed type 
hypersensitivity skin-test procedures were performed at the completion of each cycle of 3 biweekly 
vaccinations, up to a total 3 cycles at a 6 month interval in case of no progression. For evaluation of 
the immunological responses we compared the maximum vaccine-induced responses per individual, 
as this most accurately reflects the competence of an individual to mount an immune response 
(Aarntzen et al, Cancer Res. 2012 ). 
 
KLH-specific proliferation 
PBMC were isolated from heparinized blood by Ficoll-Paque density centrifugation, stimulated with 
KLH (4 µg/2×105 PBMC) in X-VIVO with 2% HS. After 3 days, cells were incubated with 3H-thymidine 
for 8 hours, incorporation was measured with a -counter. Experiments were performed in triplicate.  
 
KLH-specific antibodies 
Antibodies against KLH were measured in the serum of vaccinated patients using enzyme-linked 
immunosorbent assays (ELISA) (21). Microtiter plates were coated with KLH and different 
concentrations of patient serum were allowed to bind. After washing, patient antibodies were 
detected with mouse-anti-human IgG, IgA or IgM antibodies labeled with horseradish peroxidase; 
3,3’-5,5-tetramethyl-benzidine was used as a substrate. An isotype-specific calibration curve for the 
KLH response was included in each plate, the detection limit was determined at >20mg/l (27). 
 
Skin-test infiltrating lymphocyte (SKIL) analyses 
Skin tests were performed as described before (21) and at Labtube.tv [internet], available from 
www.labtube.tv/playvideo.aspx?vid+131825. Briefly, 2–10×106 DC pulsed with the indicated peptides 
were injected intradermally at different sites. After 48 hours, punch biopsies (6 mm) were taken, half 
of the biopsy was manually cut and cultured in RPMI-1640 containing 7% HS and IL-2 (100 U/ml).  
No SKIL cultures were obtained prior to therapy since we previously demonstrated that, although 
induration might be present, no vaccine-specific T cells were detected prior to DC-based vaccination 
(28). 
 
Tetramer staining 
SKIL cultures and PBMC were stained with tetrameric-MHC complexes containing the MHC-I epitopes 
gp100:154-168, gp100:280-288 or tyrosinase:369-377 (Sanquin, Amsterdam, The Netherlands) or 
MHC-II epitopes gp100:44-59 and tyrosinase:448-462 (provided by William Kwok, Benaroya Research 
Institute, Seattle, WA) as described previously (21). In addition, PBMCs were restimulated for 8 days 
with DR4-binding gp100 or tyrosinase peptides and stained with tetrameric-MHC complexes 
containing MHC-II epitopes gp100:44-59 and tyrosinase:448-462. Tetrameric-MHC complexes 
recognizing HIV were used as correction for background binding. Tetramer positivity was defined as 
at least two-fold increase in the double positive population.  
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Antigen and tumor recognition 
SKIL cultures were challenged with T2 cells pulsed with the indicated peptides or control antigen 
G250; or an allogenic HLA-A*02:01-positive, HLA-DR4 negative, gp100-positive and tyrosinase-
positive tumor cell line (MEL624), which was stimulated with IFN (400 U/L) for 48 hours prior to 
stimulation. Cytokines were measured in supernatants after 16 hours by the cytometric bead array 
(Th1/Th2 Cytokine CBA 1; BD Pharmingen). Positive and specific cytokine production was defined as a 
two-fold increase compared to stimulation with the cell lines pulsed with an irrelevant peptide.  
 
Cytotoxic activity  
Cytotoxic activity of SKILs was measured using the chromium release assay as described previously 
(29). Briefly, T2 or MEL624 cells were incubated with 100 Ci Na2[
51Cr]O4 (Amersham, Bucks, UK) and, 
after washing, added to lymphocytes (1×105 cells) and unlabeled K562 cells (1×104 cells) in triplicate 
wells of a round bottom microtiter plate (E/T ratio 10/1). After 4 hours, supernatants were harvested 
and radioactivity was measured. The specific percentage of cytotoxicity was defined by the following 
formula:  
 
                        
                                                     
                                                
        
 
Matched controls  
Matched controls were identified from records of metastatic melanoma patients from the Radboud 
University Nijmegen Medical Centre (Nijmegen, The Netherlands), The Netherlands Cancer Institute 
– Antoni van Leeuwenhoek Hospital (Amsterdam, The Netherlands) and University Hospital Essen 
(Essen, Germany) who had received first-line dacarbazine (DTIC) chemotherapy at 850–1000 mg/m2 
i.v. at 3 weekly intervals, between March 2000 and March 2010. All matched controls were HLA-
A*02:01 positive and were required to have received at least 3 infusions, a therapy time-frame that 
is consistent with one cycle of vaccinations. 
Control patients were matched to study subjects, in ratio 1:3, primarily for M substage at baseline 
according to AJCC criteria, number of distant metastases, number of metastatic sites, localization of 
distant metastases and baseline serum LDH. These criteria currently represent the most important 
prognostic factors for survival (30). In case of more than three matches for one study subject, 
demographic criteria (age, gender) and systemic salvage treatment after progression on DTIC were 
used to select the closest match. 
 
Statistical analysis 
Differences between the groups were evaluated using an unpaired non-parametric t-test (Mann-
Whitney U). Differences between pre- and post-vaccination were evaluated by a Wilcoxon’s signed-
ranks test, p-values are two-tailed. Kaplan-Meier probability estimates of PFS and OS were 
calculated, statistical differences between groups were determined by a log-rank test. Statistical 
significance was defined as p<0.05.  SPSS19.0 was used for all analyses.  
 
Results 
Patient and vaccine characteristics 
A total of 33 patients were enrolled (Supplementary Figure 1, available online). Three patients were 
considered as non-evaluable for immunological response, since they did not complete 3 vaccinations 
and DTH skin test because of rapid progressive disease. One patient did not meet eligibility criteria. 
Thus, a total of 29 stage III (n=7) and IV (n=22) melanoma patients completed at least one cycle of 
vaccinations. Group A (vaccination with MHC-I/II loaded DC) consisted of 15 patients (4 stage III and 
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11 stage IV), and group B (vaccination with MHC-I loaded DC) of 14 patients (3 stage III and 11 stage 
IV. Patient and treatment characteristics are summarized in Table 1. 
The genotype of the ex vivo generated DC was determined by flow cytometry and in both groups the 
vaccine met the standard release criteria , with respect to expression of MHC-Class I and II, co-
stimulatory molecules, CD83 and CCR7 (Supplementary Figure 2).  
 
 
Table 1. Patient and treatment characteristics 
 sex age 
(yrs) 
AJCC 
stage 
N 
stage 
M        
stage 
LDH
a
 
(U/L) 
number 
of mets 
localization of mets prior 
systemic 
treatment 
IV-A-01 m 69 IV N1b M1a 384 >10 LN, skin Cx 
IV-A-03 m 57 IV Nx M1b n.a. n.a. LN, lung no 
IV-A-04 m 51 IV Nx M1c 417 6 liver no 
IV-A-05 m 37 IV Nx M1a 253 3 skin Ix
b 
IV-A-06 m 66 IV Nx M1c 345 6 adrenal gland, intestine no 
IV-A-07 m 38 IV N1b M1b 315 6 LN, skin, lung no 
IV-A-08 m 55 IV N3 M1c 652 3 LN no 
IV-A-09 f 44 IIIa N1a M0 319  2 LN no 
IV-A-10 f 54 IV Nx M1c 432 2 liver, lung no 
IV-A-11 m 64 IV Nx M1b 361 3 lung Ix 
b 
IV-A-12 m 41 IV N3 M1c 334 4 liver, LN, skin Cx, Ix
c 
IV-A-13 f 55 IV Nx M1c 532 6 liver, LN, lung no 
IV-A-14 m 22 IIIb/c N1b M0 267  1 LN no 
IV-A-15 f 70 IIIb/c N1b M0 318  1 LN no 
IV-A-16 m 56 IIIc N3 M0 346  9 LN no 
IV-A-17 m 59 IV N2c M1c 459 6 LN, lung, intestine no 
IV-B-01 m 48 IIIb/c N2b M0 298 3 LN no 
IV-B-02 f 57 IIIb/c N1b M0 403 1 LN no 
IV-B-03 m 54 IV N2b M1a 456 6 skin no 
IV-B-04 f 65 IV Nx M1b 469 2 lung no 
IV-B-05 m 50 IV N3 M1c 1834 >10 liver, LN, lung, bone, skin no 
IV-B-06 m 50 IV N3 M1c 735 6 liver, LN no 
IV-B-07 f 42 IV Nx M1c 487 >10 LN, lung, bone, skin Cx 
IV-B-08 m 43 IV N2b M1c 324 5 LN, lung, skin, bladder no 
IV-B-09 m 65 IV N1b M1c 449 6 liver, bone, skin no 
IV-B-10 f 37 IV N1b M1b 334 6 LN, lung, skin  no 
IV-B-11 m 65 IV Nx M1c 640 >10 liver, LN, lung Cx 
IV-B-12 f 38 IV Nx M1b 387 >10 lung, skin no 
IV-B-13 m 30 IV N3 M1c 464 3 
 
LN, bone Cx 
IV-B-14 f 20 IV N2a M1b 293 5 LN, lung, skin no 
IV-B-15 m 69 IV N2b M1c 788 6 LN, lung, skin, adrenal gland no 
IV-B-16 f 46 IIIb N2b M0 292  3 LN no 
Abbreviations: LN, lymph nodes; Cx, chemotherapy; Ix, immunotherapy; n.a., not available; mets, metastases; 
a
ULN = 450 
U/L; 
b
 IFN adjuvant; 
c
 MAGE-A3 peptide vaccination 
 
No grade 3 or 4 toxicities were observed (Table 2). In group A, 4 patients experienced grade 1 and 4 
patients experienced grade 2 flu-like symptoms; 3 patients had grade 2 injection site reaction 
consisting of induration and redness. One patient developed vitiligo during the course of vaccination. 
In group B, 7 patients developed grade 1 flu-like symptoms and 6 patients had grade 1 injection site 
reactions. No grade 2 toxicities were observed in group B.  
 
Immunological response to the control antigen KLH 
To test the capacity of the patients in this study to generate an immune response we loaded the DC 
with the control antigen KLH. Most patients showed increased T cell proliferation upon stimulation 
with KLH, to comparable extent in both groups (Supplementary Figure 3, available online). Anti-KLH 
IgG antibodies were detected in 10 out of 15 patients tested in group A and 7 out of 14 patients in 
group B, to comparable levels. Anti-KLH IgA and IgM antibodies were detected in a minority of 
patients (Supplementary Figure 3, available online).  
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Table 2. Toxicity and clinical outcome.  
 
number of 
vaccinations 
flu-like  
symptoms 
(CTC grade) 
injection site  
reaction 
(CTC grade) 
other immune  
related side 
effects 
(CTC grade) 
Best  
response 
 
PFS  
(months) 
Salvage 
 systemic 
treatment  
OS  
(months) 
 
  
IV-A-01 9 2 2 vitiligo MR 39 no  119+ 
IV-A-03 6 0 0 no SD 12 CIx 16 
IV-A-04 3 1 0 no SD 5 Cx 19 
IV-A-05 6 0 0 no SD 12 Cx 20 
IV-A-06 3 1 0 no PD 2 Cx 14 
IV-A-07 3 1 0 no SD 4 Cx 9 
IV-A-08 1 0 0 no PD 1 Cx 5 
IV-A-09 9 2 0 no NED 36 no 86+ 
IV-A-10 6 1 0 no SD 14 unknown 51 
IV-A-11 3 0 0 no SD 7 no 14 
IV-A-12 3 0 0 no PD 1 no 14 
IV-A-13 3 0 0 no SD 5 Cx 20 
IV-A-14 9 2 2 no NED 83+ n.a. 83+ 
IV-A-15 3 0 0 no NED 5 no 6 
IV-A-16 9 2 2 no NED 40 no 41 
IV-A-17 3 0 0 no PD 2 no 7 
IV-B-01 9 0 1 no NED 19 Cx 22 
IV-B-02 9 1 1 no NED 18 no 23 
IV-B-03 3 0 0 no PD 2 CIx 7 
IV-B-04 3 1 0 no PD 2 CIx 16 
IV-B-05 3 1 0 no PD 2 Cx 3 
IV-B-06 3 0 0 no PD 2 Cx 7 
IV-B-07 3 0 0 no PD 1 no 3 
IV-B-08 3 1 0 no PD 4 Cx 7 
IV-B-09 3 0 1 no PD 2 Cx 6 
IV-B-10 3 0 0 no SD 6 Cx 12 
IV-B-11 3 0 1 no SD 5 no 9 
IV-B-12 3 0 0 no PD 2 no 4 
IV-B-13 3 1 0 no PD 3 no 3 
IV-B-14 3 0 1 no SD 8 no 46 
IV-B-15 3 1 0 no PD 2 no 3 
IV-B-16 9 1 1 no NED 69+ n.a. 69+ 
 
Abbreviations: MR, mixed response; SD, stable disease; PD, progressive disease; NED, no evidence of disease; Cx, 
chemotherapy; CIx, chemoimmunotherapy; n.a., not available 
 
Tumor-specific CD8+ T cell responses in skin test infiltrating lymphocyte (SKIL) cultures 
In group A, 7 out of 14 patients tested showed tetramer-positive CD8+ T cells against at least 1 
epitope and 3 patients had tetramer-positive CD8+ T cells against multiple epitopes present in SKIL 
cultures. In group B this was 6 and 5 out of 14 patients, respectively (Figure 1). 
In order to test the functionality of TAA-specific CD8+ T cells, we measured cytokine production upon 
in vitro challenge with either peptide pulsed T2 cells or a gp100 and tyrosinase expressing HLA-
A*02:01positive melanoma cell line (Figure 1). In 4 out of 11 patients tested in group A, we observed 
increased levels of IFN production upon challenge with the melanoma cell line, indicative of 
development of high affinity CTL which maintain tumor reactivity in a suppressive microenvironment. 
In contrast, in group B, antigen-specific IFN production was measured in 6 out of 6 patients tested, 
but only one patient maintained IFN production upon encounter of the melanoma cell line, 
suggesting that most T cells developed peptide specificity but cannot recognize naturally processed 
tumor antigen. In two patients, IV-A-05 and IV-A-07, the cytokine production was dominated by IL-5 
(Figure 1).  
 
Tumor-specific CD4+ T cell responses in SKIL cultures 
Similarly, we analyzed SKIL cultures for the presence of TAA-specific CD4+ T cells in group A. In 4 out 
of 10 patients tested with cytokine bead assays, we observed specific IFN production to stimulation; 
in 3 patients (A-01, A-06 and A-16) to both gp100 and tyrosinase and 2 patients (A-09 and A-10) to 
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one TAA. Interestingly, in 4 out of 6 patients with a CD4+ T cell response in either peripheral blood or 
in SKIL cultures, concurrent TAA-specific CD8+ T cells were detected.  
 
 
 
Figure 1. Tumor specific immune responses upon vaccination with MHC-I or MHC-I/II loaded dendritic cell vaccination. (A) 
Tetramer screening for vaccine induced CD4
+
 T cell responses in peripheral blood. (B) Tetramer screening for vaccine 
induced CD8
+
 T cell responses in peripheral blood. (C) The production of IFN in SKIL cultures upon stimulation with gp100 
(open light grey bars) or tyrosinase (hatched light grey bars). (D) Tetramer screening for vaccine induced CD8
+
 T cell 
responses in SKIL cultures (open bars represent percentages of tetramerspecific T cell populations that did not meet the 
predefined criteria for positivity, but positive IFN production was measured upon stimulation with their cognate antigen). 
To test their functionality, TAA-specific CD8
+
 T cells were challenged with specific epitopes presented by T2 cell line (E) or 
with naturally processed gp100 and tyrosinase presented by an allogeneic tumor cell line Mel 624 (F), cytokine production 
was measured (pg/ml). Figure explanation: n.a., not available; dashed line is cut-off value for positivity as defined in 
Materials and Methods, light grey bars represent IFN production upon challenge, dark grey bars represent IL-5 production 
upon challenge and dotted grey bars represent IL-2 production upon challenge, the Y-axis is not scaled; bar heights are for 
visualization only, actual cytokine-concentrations (pg/ml) are denoted on top of the bars.  
  
Tumor-specific responses in peripheral blood 
We detected TAA-specific CD8+ T cells in 2 out of 12 patients tested in group A and none in group B 
(Figure 1). In 3 out of 13 patients tested in group A, we detected tetramer-positive CD4+ T cells. In all 
three patients, TAA-specific CD4+ T cells were characterized as CD25+FoxP3- with maintained capacity 
to proliferate and produce IFN (Figure 2).  
 
Clinical responses 
Clinical responses are summarized in Table 2. The median PFS of stage III patients was 37 months 
(range 5 – 76), however their number is too limited to draw meaningful conclusions on the clinical 
response. For patients with distant metastatic disease we retrospectively compared survival data to 
carefully matched controls (Supplementary Table 1, available online). The median PFS in group A was  
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significantly improved compared to controls, with 5.0 months versus 2.8 months (p=0.0089), Hazard 
Ratio (HR) 0.39 (95%CI 0.19 – 0.79) (Figure 3A). There was no significant difference in median PFS 
between patients vaccinated in group B versus matched controls; 2.0 months versus 2.5 months (p = 
0.891), HR 1.05 (95%CI 0.52 – 2.14).  
With regard to overall survival, patients in group A showed increased 1-year survival rates as 
compared to matched controls, 80% versus 36%. Median OS was improved, 15.0 months compared 
to 8.3 months for matched historic controls (p=0.089), HR 0.57 (95%CI 0.30 – 1.09). In comparison, 
patients in group B did not show improved 1-year survival rates nor median OS over DTIC; 27% 
versus 36% and 7.0 months versus 7.9 months (p=0.202), HR 1.32 (95%CI 0.64 – 2.71).  
In group A, the presence of vaccine-specific CD4+ T cell responses in peripheral blood or SKIL cultures 
was not significantly associated with OS: HR 0.21 (95%CI 0.03 – 1.70, p=0.144). In group A and B, the 
presence of vaccine-specific CD8+ T cell responses in peripheral blood or SKIL cultures was not 
associated with OS: HR 0.65 (95%CI 0.19 – 2.29, p=0.507) and HR 1.16 (95%CI 0.30 – 4.50, p=0.834).    
 
 
Figure 2. Vaccine-induced CD4
+
 T cells are not regulatory T cells. In 3 patients, TAA-specific CD4
+
 T cells were detected in 
peripheral blood, recognizing 1 or more MHC Class II epitopes (Table 3). A flowcytometric analysis was performed to further 
characterize these cells. In all patients, the tetramer-positive cells were CD25
+
FoxP3
-
, maintained their proliferative capacity 
(Table 3) and produced marked levels of IFN upon restimulation. 
 
Discussion 
The efficacy of DC-based vaccination in cancer patients has significantly improved over the past 
decade, as several vaccine parameters have been optimized. We initiated the current study to 
compare immunological responses to DC pulsed with MHC-I restricted melanoma epitopes alone or 
MHC-I/II restricted epitopes. Upon vaccination with MHC-I/II loaded DC we detected highly 
functional vaccine-specific CD8+ T cells. These cells maintained their IFN production even in a 
suppressive milieu of an IL-10 producing melanoma cell-line. Interestingly, only in patients vaccinated 
with MHC-I/II loaded DC we found circulating TAA-specific CD8+ T cells. The induction of regulatory 
CD4+ T cells is of particular concern in immunotherapies targeting MHC-II restricted antigens (31, 32). 
We demonstrated in all patients that TAA-specific CD4+ T cells were FoxP3 negative which is in line 
with the high proliferative capacity and production of significant levels of IFN. Furthermore, in most 
patients we detected concomitant TAA-specific CD8+ T cell responses. These findings strongly 
support the hypothesis that co-activating TAA-specific CD4+ T helper cells augments the induction 
and proliferation of TAA-specific CD8+ T cells. 
Figure 2. Vaccine-induced TAA-specific CD4+ T cells are not regulatory T cells
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Our findings are in line with previous reports on vaccination with MHC-I/II loaded DC (33-36), but 
direct comparison is hampered by the large variation in study protocols. This is the first paper that 
evaluates the immunological responses upon vaccination with MHC-I/II loaded DC in direct 
comparison to MHC-I loaded DC.  
 
 
Figure 3. Improved clinical responses upon vaccination with MHC Class I and II loaded DC. In patients with distant metastatic 
or irresectable melanoma (stage IV), vaccination with MHC/I-II loaded DC resulted in significantly improved PFS compared 
to controls (A). Vaccination with MHC-I loaded DC only did not improve PFS (B). Median OS was improved for vaccination 
with MHC-I/II loaded DC compared to DTIC chemotherapy (C). Accordingly, one year survival rates improved upon 
vaccination with MHC-I/II loaded DC. Vaccination with MHC- loaded DC did not result in improved OS (D). 
 
However, our findings are in contrast to previously published trials on peptide vaccination in 
melanoma patients (37-39). In a recent randomized multicentre trial Slingluff et al. report on 167 
stage IIB to IV melanoma patients vaccinated with either MHC-I or MHC-I/II restricted peptides, with 
or without cyclophosphamide pretreatment (37). In this trial, the inclusion of melanoma-associated 
helper peptides paradoxically decreased CD8+ T cell responses. The discrepancy with our findings 
might be explained by the intradermal/subcutaneous delivery of peptides, since it might target 
different DC subsets, compared to direct delivery of antigen-loaded DC into lymph nodes. To our 
opinion, controlling antigen presentation is crucial since the induction of CD4+ T cells with improved 
functionality depends on density and potency of peptide-MHC complexes (40, 41).  
 
Supplementary Figure 2. Vaccine characteristics. 
The expression of surface markers, measured by 
flow cytometry on mature DCs for the first 
vaccination, is shown. Data are represented as 
percentage of cells (mean with SD) expressing 
the surface marker. Analyses was performed 
with one-way ANOVA with post-hoc (Dunn’s 
Multiple     Comparison Test) comparison of 2 
groups per surface marker. Abbreviations: n.s. 
denotes not significant. 
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Supplementary Figure 3. KLH specific responses. KLH-specific T-cell proliferation was analyzed before vaccination and after 
each DC vaccination (A), maximum responses are depicted.  KLH-specific IgG (B), IgA (C) and IgM (D) antibodies were 
quantitatively measured in sera after each DC vaccination during the treatment course, maximum responses are depicted. 
Per isotype, each dot represents 1 patient. Horizontal lines represent averages per group. Abbreviations: n.s. denotes not 
significant. 
 
Although in a previous vaccination study in 108 melanoma patients no benefit was found for HLA-
DR4 expression (42), we cannot exclude that this haplotype forms a possible confounding bias in our 
study when interpreting the clinical data. In order to obtain more insight in the clinical efficacy of our 
DC vaccination, we compared the clinical outcome to carefully selected control patients treated with 
standard DTIC chemotherapy. Comparison with control patients is based on the assumption that the 
observed historical control response rate is equal to the true control response rate (43). In this 
respect, survival rates of our matched controls treated with DTIC chemotherapy is comparable to the 
survival rates reported in recent large randomized trials using DTIC as comparative arm (44, 45). The 
observed clinical responses are in line with the trend in the differences in the immunological 
responses. Only patients who received MHC-I/II loaded DC showed increased PFS and 1-year overall 
survival as compared to matched control patients. Strikingly, the presence of circulating TAA-specific 
CD4+ or CD8+ T cells or IFN production upon challenge with naturally processed antigens was clearly 
linked to a more beneficial clinical course of disease (Figure 1 and Table 1). It is tempting to speculate 
that part of the clinical response is related to action of the CD4+ T helper cell at the tumor site itself. 
CD4+ T helper cells have been demonstrated to play an important role in assisting infiltration of the 
tumor by CTLs and can exert a direct cytotoxic effect themselves as well ((46, 47). In 2006, a 
randomized trial comparing MHC-I/II loaded DC vaccination to DTIC chemotherapy was reported 
(42). This study failed to demonstrate improved clinical outcome to DC-based vaccination. As 
discussed previously (48), the exploited DC-based vaccine in this study was far from optimized. Due 
to the subcutaneous delivery and low number of injected DC, it is questionable how many antigen-
loaded DC were available for immune induction. Furthermore, injected DC mostly had a low mature 
genotype and lacked a non-specific T helper antigen, so their immune stimulatory capacity is 
suboptimal (48). Our study suggests that optimized DC-based vaccination harbors more potential 
than has been concluded from this study. The importance of antigen-specific CD4+ T cell stimulus by 
the same antigen-presenting cell that present tumor-antigen in MHC Class I to CD8+ T cells, has been 
Supplementary Figure 3. KLH-specific responses
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demonstrated in previous studies (49, 50). Optimal CD4+ T cell help might mediated by CD40-CD40L 
interaction and cytokines like IL-2. These studies support our findings of superior immune responses 
in patients vaccinated with DC loaded with tumor-antigen in both MHC Class I and II. Finally, the 
current vaccination protocol might be further improved by overcoming the disadvantages of peptide-
pulsing of DC; e.g. the dissociation of peptides from MHC complexes and the lack of post-
translational modification by the use of mRNA-electroporation (51, 52). This method has shown to 
result in mature and migratory DCs expressing the encoded antigens in situ (52).  
In conclusion, our results show that targeting CD4+ T helper cells with DC pulsed with both MHC Class 
I and II restricted epitopes enhances vaccine-specific immunological responses.  
Supplementary Table 1. Matched controls. 
  
control group A control group B 
  
n=33 % n=33 % 
      sex male 20 61 21 64 
 
female 13 39 12 36 
      age median (range) 57 (31 - 77) 57 (31 - 74) 
      M stage M1a 5 15 3 9 
 
M1b 9 27 12 36 
 
M1c 19 58 18 55 
      nr of mets <5 3 9 3 9 
 
>5 19 58 20 61 
 
n.a. 11 33 10 30 
      nr of organs 1 10 30 12 36 
 
>1 23 70 21 64 
      LDH at baseline <ULN 18 55 14 42 
 
>ULN 9 27 11 33 
 
n.a. 6 18 8 24 
      prior systemic immunotherapya 9 27 9 27 
treatmentb chemotherapy  0 0 0 0 
 
none 16 48 16 48 
 
n.a. 8 24 8 24 
      salvage systemic immunotherapy 7 21 9 27 
treatmentb chemotherapy 3 9 2 6 
 
chemoimmunotherapy 1 3 1 3 
 
none 17 52 16 48 
 
n.a. 5 15 5 15 
a
 in adjuvant setting; 
b
 multiple entries possible 
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Abstract  
Electroporation of dendritic cells (DC) with mRNA encoding tumor associated antigens (TAA) has 
multiple advantages over peptide loading. We investigated the immunological and clinical responses 
to vaccination with mRNA-electroporated DC in stage III and IV melanoma patients. Twenty-six stage 
III HLA*02:01 melanoma patients scheduled for radical lymph node dissection (stage III) and 19 
melanoma patients with irresectable locoregional or distant metastatic disease (referred to as stage 
IV) were included. Monocyte-derived DC, electroporated with mRNA encoding gp100 and tyrosinase, 
were pulsed with keyhole limpet hemocyanin (KLH) and administered intranodally. TAA-specific T cell 
responses were monitored in blood and skin-test infiltrating lymphocyte (SKIL) cultures. Comparable 
numbers of vaccine-induced CD8+ and/or CD4+ TAA-specific T cell responses were detected in SKIL 
cultures; 17/26 stage III patients and 11/19 stage IV patients. Strikingly, in this population, TAA-
specific CD8+ T cells that recognize multiple epitopes and produce elevated levels of IFN upon 
antigenic challenge in vitro, were significantly more often observed in stage III patients; 15/17 versus 
3/11 stage IV patients, p=0.0033. In stage IV patients, one mixed and one partial response were 
documented. The presence or absence of IFN-producing TAA-specific CD8+ T cells in stage IV 
patients was associated with marked difference in median OS of 24.1 months versus 11.0 months, 
respectively. Vaccination with mRNA-electroporated DC induces a broad repertoire of IFN producing 
TAA-specific CD8+ and CD4+ T cell responses, particularly in stage III melanoma patients.  
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Introduction 
Dendritic cells (DC) are the most effective antigen-presenting cells (APC) of the immune system, 
highly capable of stimulating naïve T cells. Immunotherapy with ex vivo-generated autologous DC 
pulsed with tumor peptides has provided proof of concept in clinical trials (1). We, and others, have 
demonstrated that tumor-specific immune responses can be induced in both stage III and IV 
melanoma patients (1-5). Since objective clinical responses are observed in a minority of patients, 
further optimization of DC based immunotherapy is warranted. To date, the majority of clinical 
studies on DC based vaccinations have been performed with MHC class I restricted peptide-pulsed 
monocyte derived DC in patients with measurable distant metastatic disease. However, there are at 
least several theoretical disadvantages 
against these protocols, which might be 
improved to induce more effective and 
sustained immunological responses. 
First, the exploitation of MHC class I 
restricted peptide epitopes target CD8+ 
cytotoxic T cells (CTL) only, without 
involving CD4+ T helper cells to enhance 
and sustain anti-tumor CTL responses.  
Secondly, pulsing DC with peptide 
epitopes implicates the use of a given 
HLA type, with defined tumor 
associated antigens (TAA). Moreover, 
peptide-loaded DC expose the antigen 
only for a short period of time (6), since 
the peptides may readily dissociate 
from the MHC molecules (7). 
Importantly, peptide loading does not 
account for post-transcriptional 
modifications of peptide epitopes (8;9). 
One strategy to circumvent most of 
these disadvantages of peptide pulsing 
is electroporation with synthetic mRNA 
encoding TAA, resulting in endogenous synthesis of the complete TAA. It has been shown previously 
that electroporation of DC with mRNA is effective and safe (7;10;11). DCs retain their phenotype and 
maturation potential upon electroporation, as well as their migratory capacities (10;12). 
Electroporated DC express TAA antigens, encoded by the electroporated mRNA and induce specific 
CD8+ T cell responses in melanoma patients (10). Importantly, since mRNA lacks the potential to 
integrate into the host genome, it obviates safety concerns associated with gene therapy trials. It is 
now widely recognized that high tumorload in end-stage cancer patients often induces local, or even 
systemic, immune suppression by the secretion of suppressive cytokines and attraction of regulatory 
T cells (13-15). This suppressive tumor microenvironment will hamper the effective anti-tumor 
responses. Melanoma patients with locoregional lymph node metastases are at high risk of relapse 
and currently no standard adjuvant treatment is available which results in overall survival benefit 
(16). Given the minimal burden of tumor; we hypothesized that vaccination of patients adjuvant to 
therapeutic radical lymph node dissection might enhance vaccine efficacy. In this study we 
investigated in detail the immunological responses to intranodal vaccination with monocyte-derived 
DC electroporated with mRNA encoding gp100 and tyrosinase in 2 cohorts of melanoma patients; 
with distant metastatic or irresectable locoregional disease following radical regional lymph node 
dissection.  
Translational relevance 
Electroporation of dendritic cells (DC) with mRNA 
encoding tumor associated antigens (TAA) has 
multiple advantages over the conventional peptide 
loading. The presentation of multiple naturally 
processed epitopes in both MHC Class I and II should 
broaden the repertoire of responding lymphocytes. 
We studied in detail the immunological response to 
vaccination with mRNA-electroporated DC in 2 
cohorts of melanoma patients: as palliative treatment 
for distant or irresectable locoregional metastatic 
disease and as adjuvant treatment following radical 
dissection of regional lymph nodes. A wide spectrum 
of tumor-specific IFN producing CD8
+
 T cells was 
detected, in particular in patients vaccinated in the 
adjuvant setting. Furthermore, vaccine-induced CD4
+
 
T cells were shown to be FoxP3 negative. In 
conclusion, vaccination with mRNA-electroporated DC 
successfully enhances anti-tumor cytotoxic T cell 
responses and appears to be a promising adjuvant 
treatment for stage III melanoma patients.  
48
Part 1, Chapter 3 
 
Patients and methods 
Patient population 
Melanoma patients with locoregional resectable disease (further referred to as stage III), before or 
within 2 months after radical dissection of regional lymph node metastases, and patients with 
irresectable locoregional or distant metastatic disease (further referred to as stage IV) were included. 
Additional inclusion criteria were HLA*02:01 phenotype, melanoma expressing the melanoma-
associated antigens gp100 and tyrosinase, and WHO performance status 0 or 1. Patients with brain 
metastases, serious concomitant disease or a history of a second malignancy were excluded. The 
study was approved by our Institutional Review Board, and written informed consent was obtained 
from all patients. Clinical trial registration number is NCT00243529.  
 
Supplementary Figure 1. CONSORT flowchart. 
 
Study protocol 
Patients received a DC vaccine intranodally, injected into a clinically tumor-free lymph node under 
ultrasound guidance. The DC vaccine consisted of autologous mature monocyte-derived DC 
electroporated with mRNA encoding for gp100 and tyrosinase protein, and pulsed with keyhole 
limped hemocyan (KLH) protein. Patients received three vaccinations with a biweekly interval. Ten 
patients received an extra vaccination 1 or 2 days before the radical lymph node dissection for 
additional imaging studies (see Chapter 7). One to two weeks after the last vaccination a skin test 
was performed. In absence of disease progression or recurrence, patients received a maximum of 
two maintenance series at 6-month intervals, each consisting of three biweekly intranodal 
vaccinations (Supplementary Figure 1). All vaccinations were administered between May 2006 and 
May 2010. Patients were considered evaluable when they had completed the first vaccination cycle. 
Vaccine-specific immune response was the primary endpoint, clinical response was a secondary 
endpoint in stage IV patients. Progression-free and overall survival were calculated from the time 
from apheresis to recurrence (for stage III patients) or progression (for stage IV patients), or death. 
 
Patients assigned (n=48)
Evaluable (n=45)
Did not complete 1st cycle due to rapid 
disease progression (n=3)
Evaluable for immunological 
and clinical response (n=43)
Evaluable for immunological response 
only (n=2)
- Symptomatic brain metastases 
during vaccination (n=1)
- No target lesion at baseline (n=1)
Stage III (n=27) Stage IV (n=16)
Completed 1st vaccination cycle (n=27)
Received extra vaccination for imaging 
study (n=10)
Completed 1st vaccination cycle (n=16)
Received extra vaccination for imaging 
study (n=1)
Completed 2nd vaccination cycle (n=24) Completed 2nd vaccination cycle (n=2)
Completed 3rd vaccination cycle (n=21) Completed 3rd vaccination cycle (n=0)
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DC preparation and characterization 
DC were generated from peripheral blood mononuclear cells (PBMC) prepared from leukapheresis 
products as described previously (17). After leukapheresis, part of the PBMC was used for the 
generation of monocyte-conditioned medium (MCM) (18). Plastic-adherent monocytes or monocytes 
isolated by centrifugal elutriation were cultured for 5-7 days in X-VIVO 15TM medium (BioWhittaker, 
Walkersville, Maryland) supplemented with 2% pooled human serum (HS) (Bloodbank Rivierenland, 
Nijmegen, The Nethterlands), IL-4 (500 U/ml) and GM-CSF (800 U/ml) (both from Cellgenix, Freiburg, 
Germany). Immature DCs were pulsed at day 3 with Keyhole limpet hemocyanin (KLH, 10 g/ml; 
Calbiochem, San Diego, CA). Two days prior the harvesting, cells were matured with autologous 
MCM, prostaglandin E2 (10 µg/ml; Pharmacia & Upjohn, Puurs, Belgium) and recombinant tumor 
necrosis factor alpha (10 ng/ml; provided by dr. G. Adolf, Bender Wien, Vienna, Austria) (19). This 
protocol gave rise to a mature phenotype meeting the release criteria described previously (20): low 
expression of CD14, high expression of MHC class I, MHC class II, CD83, CD80, CD86, and CCR7, and 
expression of gp100 and tyrosinase after electroporation with mRNA (Supplementary Figure 2). 
Harvested DCs were tested by FACS analysis as described below.  
 
 
Supplementary Figure 2. Vaccine characteristics of first cycle of all patients. (A) Expression of HLA-ABC, HLA-DR/DP, HLA-DQ, 
CD80, CD86, CD83, and CCR7 was analyzed by flow cytometry. (B) Tumor antigen expression by DCs 2-4 hrs after 
electroporation with mRNA encoding gp100 and tyrosinase. Data are shown as percentage of positive DCs used for the first 
vaccination. The graphs represent mean ± SD of all patients. 
 
Plasmids and in vitro mRNA transcription 
Plasmids have been sent to CureVac GmbH (Tübingen, Germany) for the production of documented 
GMP grade gp100 and tyrosinase RNA for ex vivo use in clinical DC vaccination. The documented 
gp100 and tyrosinase mRNA was produced from the plasmids pGEM4Z/hgp100/A64 and 
pGEM4Z/tyrosinase/A64 (provided by Kris Thielemans, Free University Brussels, Belgium) according 
to GMP guidelines. CureVac mRNA contains a 5’ cap and 3’ poly A-tail that leads to high RNA stability 
and increased protein expression in transfected cells. The mRNA is purified by PUREmessengerTM 
technology. This chromatography method efficiently eradicates traces of DNA and proteins. The 
mRNA production process is performed in clean room facilities and is documented by in-process 
controls. RNA quality was verified by agarose gel electrophoresis, RNA concentration was measured 
spectrophotometrically, and RNA was stored at -80ºC in small aliquots.  
 
Electroporation of DC 
Mature DCs were electroporated as described previously (10). Briefly, DC were washed twice in PBS 
and once in OptiMEM without phenol red (Invitrogen, Breda, The Netherlands). Twenty micrograms 
of RNA encoding either gp100 or tyrosinase were transferred to a 4 mm cuvette (Bio-Rad, Hercules, 
CA) and 8×106 cells were added in 200 µl OptiMEM and incubated for 3’ before being pulsed in a 
Genepulser Xcell (Bio-Rad) by an exponential decay pulse of 300 V, 150 F, as described before(10). 
Immediately after electroporation, cells were washed and were transferred to warm (37ºC) X-VIVO 
15TM without phenol red (Cambrex Bio Science, Verviers, Belgium) supplemented with 5% HS and left 
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for at least 2 hours at 37ºC, before further manipulation. The first vaccination was given with fresh 
DC 4 hours after electroporation. DC for subsequent vaccinations were frozen 2 hours after 
electroporation, thawed at the day of vaccination and incubated for 2 more hours at 37C before 
injection. Electroporation efficiency was analyzed by intracellular staining and flow cytometric 
analysis for each separate TAA, electroporated DC were mixed before vaccination.  
 
 
Supplementary Figure 3. Detection of tumor-specific T cells in SKIL cultures does not require challenge with defined epitopes. 
Tetramer analysis of SKILs cultured from biopsies of DTH reactions to DCs pulsed with tumor peptides (upper plots) or DCs 
electroporated with mRNA encoding tumor proteins (lower plots) of patients II-E-09 (A), II-E-03 (B), and II-E-10 (C). This 
figure shows that sampling DTH biopsy cultures with tetramers yields similar results when the patient is challenged with 
intradermal injections with DC pulsed with defined epitopes or DC electroporated with mRNA encoding the full tumor 
antigen. 
 
Flow cytometric analysis 
The following FITC-conjugated mAbs were used: anti-HLA class I (W6/32), and anti-HLA DR/DP 
(Q5/13); and PE-conjugated mAbs: anti-CD80 (BD Biosciences, Mountain View, CA), anti-CD14, anti-
CD83 (Beckman Coulter, Mijdrecht, The Netherlands), and anti-CD83 (BD Pharmingen, San Diego, 
CA). For intracellular staining of the TAA the following mAb were used: NKI/beteb (IgG2b) (purified 
antibody) against gp100, T311 (IgG2a) (Cell Marque Corp., Rocklin, CA) against tyrosinase. For 
intracellular staining cells were fixed for 4’ on ice in 4% (w/v) paraformaldehyde (Merck, Darmstadt, 
Germany) in PBS, permeabilized in PBS/2%BSA/0.02% azide/0.5% saponin (Sigma-Aldrich) 
(PBA/saponin), and stained with mAb diluted in PBA/saponin/2%HS, followed by staining with 
allophycocyanin-labeled goat-anti-mouse (BD PharMingen). Flow cytometry was performed with 
FACSCaliburTM flow cytometer equipped with CellQuest software (BD Biosciences). 
Flow cytometric analysis of T cells was performed using directly labelled mAbs against CD4, CD8, 
CD25, CD127, CTLA-4 (BD Pharmingen) and FoxP3 (eBiosciece, San Diego, CA, USA), all according to 
the manufacturer’s protocol. Tregs were defined as CD4+FoxP3+CD25highCD127low cells; percentage of 
Tregs was defined as the number of CD4+FoxP3+CD25highCD127low cells divided by the total number of 
CD4+ cells x100. 
 
KLH-specific proliferation 
KLH-specific cellular responses were measured before and after vaccination by proliferation assay. 
Peripheral blood mononuclear cells (PBMC) were isolated from heparinised blood by Ficoll-Paque 
density centrifugation. PBMC were stimulated with KLH (4 µg/2×105 PBMC) in medium with 10% 
human AB serum. After 3 days, cells were pulsed with 3H-thymidine for 8 hours, and incorporation 
was measured with a betacounter. Experiments were performed in triplicate.  
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KLH-specific antibody production 
KLH-specific antibodies were measured in the sera of patients before and after vaccination. 
Microtiter plates (96 wells) were coated overnight at 4ºC with KLH (25 µg/ml in PBS). Different 
concentrations of patient serum (range 1:100 to 1:50,000) were added for 60’ at room temperature. 
After extensive washing, patient antibodies were detected with mouse anti-human IgG, IgA, or IgM 
antibodies labelled with horseradish peroxidase (Invitrogen, San Diego, CA).  3,3’ 5,5-tetramethyl-
benzidine was used as a substrate and plates were measured with a microtiter plate reader at 450 
nm. For quantification, an isotype-specific calibration curve for the KLH response was included in 
each microtiter plate. 
 
Skin-test infiltrating lymphocyte (SKIL) cultures 
0.2 - 1 x 106 DC pulsed with the gp100 and/or tyrosinase peptides and DC electroporated with gp100 
and/or tyrosinase mRNA each were injected i.d. in the skin of the back of the patient at four or six 
different sites(21). The maximum diameter of induration was measured after 48 hours. From each 
site induration was measured and punch biopsies (6 mm) were obtained. Half of the biopsy was 
cryopreserved and the other part was manually cut and cultured in RPMI 1640 containing 7% HS and 
IL-2 (100 U/ml). Every 7 days, half of the medium was replaced by fresh medium containing HS and 
IL-2. After 2 to 4 weeks of culturing, SKILs were tested. In general, similar results were obtained per 
patient, regardless of the method of antigen-presentation (Supplementary Figure 3).  
 
 
Figure 1. KLH-specific immune responses before and after DC vaccination. (A) KLH-specific T cell proliferation was analysed 
before the first vaccination and after each DC vaccination during the first vaccination cycle in PBMC of stage III (filled 
circles) and stage IV (open circles) melanoma patients. Per time point each dot represents one patient. Proliferative 
response to KLH is given as proliferation index (proliferation with KLH/proliferation w/o KLH). * p <0.05; NS, not significant. 
(B) KLH-specific IgG, IgA, and IgM antibodies were quantitatively measured after the first vaccination cycle in sera of 
vaccinated patients. Numbers indicate the number of patients without proliferative (A) or humoral (B) KLH-response. 
 
Tetramer staining 
SKILs and freshly isolated PBMC were stained with tetrameric-MHC complexes containing the HLA-
A2-binding epitopes gp100:154-168, gp100:280-288 or tyrosinase:369-377 (Sanquin, Amsterdam, 
The Netherlands) or HLA-DR4-binding epitopes gp100:44-59 and tyrosinase:448-462 (provided by 
William Kwok, Benaroya Research Institute, Seattle, WA) as described previously(19). In addition, 
PBMCs of patients with tetramer positive CD4+ T cells were restimulated for 8 days with DR4-binding 
gp100 or tyrosinase peptides and stained with tetrameric-MHC complexes containing class II 
epitopes gp100:44-59 and tyrosinase:448-462. Tetrameric-MHC complexes recognizing HIV were 
used as controls; at least a two-fold increase of the double-positive population compared to control 
was regarded to be positive. 
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Antigen and tumor recognition 
Antigen recognition was determined by the production of cytokines and cytotoxic activity of SKILs in 
response to T2 pulsed with the indicated peptides or BLM (a melanoma cell line expressing 
HLA*02:01 but no endogenous expression of gp100 and tyrosinase), transfected with control antigen 
G250, with gp100 or tyrosinase, or an allogenic HLA*02:01-positive, gp100-positive, and tyrosinase-
positive tumor cell line (MEL624) were measured. Cytokine production was measured in 
supernatants after 16 hours of co-culture by a cytrometric bead array (Th1/Th2 Cytokine CBA 1; BD 
PharMingen). Positive and specific cytokine production was defined as a two-fold increase compared 
to stimulation with the cell lines pulsed with an irrelevant peptide. 
 
Statistical analysis 
Differences between the groups were evaluated using the Fisher’s exact test or one-way ANOVA. 
Statistical significance was defined as p<0.05.  GraphPad Prism 5.0 was used for all analyses. 
 
 
Figure 2. Tumor antigen-specific CD8
+
 T cell responses in peripheral blood. An example of tetramer analysis of PBMCs from 
patient II-E-08 is shown. Cells were stained with tetramers encompassing the HLA*02-specific gp100:154-168, gp100:280-
288, tyrosinase:369-377 peptide or an irrelevant peptide and with anti-CD8 mAb. The irrelevant control peptide stained 
0.01% of the PBMCs. 
 
Results 
Patient characteristics 
A total of 48 HLA*02:01 positive melanoma patients were enrolled (Supplementary Figure 1), of 
which 3 patients (IV-D-13, IV-D-12, IV-D-07) were regarded as non-evaluable, since they did not 
complete the first cycle due to rapid progressive disease. Two stage IV patients were only evaluable 
for immunologic response; patient IV-C-05 had no measurable disease at baseline and patient IV-D-
15 had proven brain metastasis after the second vaccination but completed the first cycle. Twenty-six 
stage III and 19 stage IV patients were included. Twenty-three stage III patients received 1 cycle of 
maintenance vaccinations and 20 patients completed the full three cycles. Three stage IV patients 
received 1 cycle of maintenance vaccinations; one patient completed the full three vaccination 
cycles. No unexpected or severe adverse events were observed. Patient characteristics are 
summarized in Table 1.  
 
Vaccine characteristics 
Phenotypic and functional release criteria were defined for DC vaccines to ensure minimal quality 
criteria and the usage of mature DC in clinical vaccination protocols (22). The phenotype of the ex 
vivo-generated DC was determined by flow cytometry and all produced vaccines met the standard 
release criteria, with respect to expression of MHC class I and II, and co-stimulatory molecules, CD83 
and CCR7 (Supplementary Figure 2). Furthermore, we confirmed the intracellular expression of 
tumor associated antigens gp100 and tyrosinase after electroporation by flow cytometry 
(Supplementary Figure 2). Patients received on average 12×106 DC per vaccination with a maximum 
of 15×106 DC per vaccination. 
gp100:154-163 gp100:280-288 tyrosinase:369-377
CD8
te
tr
am
er
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Immunological response to KLH 
For immunomonitoring purposes all DC have been loaded with the control antigen KLH. PBMC, 
isolated after each vaccination, showed increased proliferation upon stimulation with KLH after 
vaccination in almost all patients in the first cycle (Figure 1a). One patient first developed a 
proliferative response to KLH in the second cycle. Anti-KLH antibodies were detected in 9 out of 17 
stage IV patients tested, and 15 out of 26 stage III patients tested (Figure 1b). These data 
demonstrate that the vaccine effectively induced de novo immune responses. 
Table 1. Patient characteristics. 
Patient Sex  Age  
(yrs) 
Origin of 
primary 
tumor 
Stage 
on 
entry 
Site of metastatic disease LDH 
(U/l) 
gp100c tyroc HLA-DR4 
status  
 
# of DC per vaccination  
(x 106) 
 
# of  
vacc 
previous 
systemic 
treatment 
salvage systemic    
treatment 
Stage IV 
  
 
      
mean min max     
II-E-01 m 54 skin M1c LN 542   ++  +  - 8,8 6 13 3 no DTIC 
IV-C-01 f 60 skin M1b lung, LN 343  +++  +++  + 10,7 9 12 3 no DTIC 
IV-C-02 f 48 skin M1c liver, lung, skin 318  +++  ++  + 11,0 8 14 3 no TMZ 
IV-C-05 f 31 skin M1c lung, skin, breast 301   +++  +  + 14,0 9 15 12 no no 
IV-C-06 m 57 skin M1c lung, bladder, skin 412  ++  -  + 12,3 11 15 3 no no 
IV-C-09 f 48 skin M1b lung, skin, LN 402  +++  -  + 12,0 10 15 3 DTIC no 
IV-C-13 f 47 skin M1c skin, LN 531  +  +  + 12,3 9 15 3 DTIC no 
IV-D-01 m 75 skin M1c liver, lung, bladder 334   +++  +++  - 11,5 11 12 3 DTIC no 
IV-D-02 m 69 skin M1c liver, lung, bone, adrenal 502   +  ++  - 10,0 7 12 3 no no 
IV-D-03 f 42 eye M1c liver, lung 344   +++  +  - 7,3 6 9 3 DTIC TMZ 
IV-D-04 m 59 
skin 
M1c lung, bladder, LN 381   +++  ++  - 
9,7 8 12 3 
no DTIC, TMZ, 
AZD6244 
IV-D-06 f 61 skin M1a LN 459a  +   +  - 11,5 5 15 6 no no 
IV-D-09 m 50 skin M1a LN 431   +++   +++  - 15,0 15 15 3 no DTIC 
IV-D-11 m 44 mucosa N3 LN, maxillary sinus 351   +++   ++  -  14,2 12 15 12 no no 
IV-D-15 m 58 skin M1c lung, bone, LN 523  +++  +++  -  14,7 14 15 3 no DTIC 
IV-D-17 m 66 skin M1c lung, adrenal, intracardial 387  +++  +++  -  15,0 15 15 3 no no 
IV-D-18 m 57 skin  M1a  skin, LN 369  +++  +++  -  13,0 11 15 6 no DTIC, AZD6244 
IV-D-20 m 62 skin M1c liver, LN, adrenal 390   +++  +  - 15,0 15 15 3 no DTIC 
IV-D-21 f 30 skin M1c liver, lung, LN, skin 421   +++   +++  - 9,3 5 15 3 no DTIC 
Stage III 
  
 
      
      
II-E-02 m 38 skin N3 LN 368   +++  ++  - 11,3 6 15 12 n.a. no 
II-E-03 m 45 skin N1a LN 351  +++  ++  + 13,9 10 15 12 n.a.  
II-E-04 m 41 skin N2a LN 392   +++  +  - 6,8 3 11 12 n.a.  
II-E-05 f 49 skin N2a LN 279   -   ++   - 11,2 6 15 12 n.a. DTIC 
II-E-06 m 48 skin N2a LN 356   +++  ++  - 12,6 10 15 12 n.a. no 
II-E-07 f 59 skin N3 LN 422   +  n.a.  - 14,1 12 15 12 n.a.  
II-E-08 m 56 skin N3 LN 598a  ++  ++  - 12,0 9 15 3 n.a. DTIC 
II-E-09 m 26 skin N3 LN 352  +++  +++  - 13,5 10 15 12 n.a. unknown 
II-E-10 f 34 skin N1a LN 348  +++  +++  - 14,5 13 15 12 n.a.  
II-E-11 m 47 skin N1a LN 299  +++  ++  - 13,8 10 15 12 n.a.  
IV-C-03 m 37 skin N1a LN 393  +++  +++  + 12,2 8 15 12 n.a. DTIC 
IV-C-04 m 45 skin N3 LN 408  +  +  + 9,0 8 10 7 n.a. no 
IV-C-07 m 35 skin N1a LN 335  +++  +++  + 13,0 9 15 12 n.a.  
IV-C-08 m 35 skin N1a LN 390  ++  ++  + 14,2 8 15 12 n.a.  
IV-C-10 f 36 skin N1a LN 361  +++  ++  + 13,1 9 15 12 n.a.  
IV-C-11 m 50 no primary N1b LN 379  +  +  + 14,0 11 15 12 n.a.  
IV-C-12 f 38 no primary N1b LN 360  +++  +++  + 13,7 11 15 3 n.a. DTIC 
IV-C-14 f 54 skin N1b LN 458  +++  +  + 12,2 7 15 12 n.a.  
IV-D-05 m 48 skin N3 LN 388   ++  ++  -  7,0 6 8 6 n.a. DTIC 
IV-D-08 f 54 skin N2b LN 416  +++  +  -  15,0 15 15 6 n.a. no 
IV-D-10 f 37 skin N1a LN 342   ++  ++  -  11,6 10 15 12 n.a. no 
IV-D-14 m 63 skin Nxb LN 348  +++  +  -  13,3 10 15 12 n.a.  
IV-D-16 m 31 skin N2b LN 517a  +++  +++  -  12,1 8 15 12 n.a.  
IV-D-19 m 62 skin N1b LN 280  +++  +  -  10,8 7 15 12 n.a. ITx 
IV-D-22 m 23 skin N1b LN 394  ++  -  -  13,3 12 15 3 n.a. DTIC, anti-CTLA4 
IV-D-24 m 65 skin N2a LN 350  ++  ++  -  14,2 12 15 12 n.a. no 
a 
LDH normalized after RLND 
b
 Patients stopped because of burden of skin test 
c
 gp100 and tyrosinase expression on the primary tumor was analyzed by immunohistochemistry. Intensity of positive cells 
were scored centrally and semi-quantitatively by a pathologist. Intensity was scored as low (+), intermediate (++), or high 
(+++). 
Abbreviations: f=female, m=male, nr= number, LN=lymph node, n.a.=not applicable. 
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Tumor-associated antigen specific responses in blood 
To investigate TAA-specific immune responses, PBMC were screened with tetrameric-MHC 
complexes before and after each cycle of 3 vaccinations at the time point of SKIL test. TAA-specific 
CD8+ T cells were only found in freshly isolated PBMC from 3 stage III and 3 stage IV patients after 
vaccination (Figure 2 and Table 2). Since it has been described that melanoma patients can already 
have a substantial number of TAA-specific T cells circulating in their blood, we analysed the presence 
of TAA-specific T cells in PBMC isolated prior to vaccination. Three out of these 6 patients had no 
detectable TAA-specific CD8+ T cells circulating before vaccination, suggesting that TAA-specific CD8+ 
T cells were newly induced, or at least enhanced, by the DC vaccinations in these patients, in 
concordance with previous reports (23).  
Evidence is emerging that CD4+ T cells needs to be antigen-specific in order to potentiate the CD8+ 
immune response. Therefore we analysed the presence of TAA-specific CD4+ T cells in PBMCs of all 
15 DR4+ patients. Four patients were positive after vaccination (patients IV-C-01, IV-C-02, IV-C-03, IV-
C-08; Figure 3 and Table 2). Tetramer analysis of PBMCs restimulated in vitro with DR4-binding 
peptides confirmed the presence of TAA-specific CD4+ T cells (Figure 3). TAA-specific CD4+ T cells 
were detectable before vaccination in only one patient (IV-C-03), but only after in vitro restimulation 
of PBMCs with DR4-binding peptides, suggesting that tumor-specific CD4+ T cells were induced, or at 
least enhanced, by DC vaccinations in these patients. We identified concurrent TAA-specific CD8+ T 
cells in SKIL cultures in 3 of the 4 patients with tumor-specific CD4+ T cells in their blood (patients IV-
C-01, IV-C-02, IV-C-03; Table 2). To exclude that the TAA-specific CD4+ T cells have a suppressor 
phenotype, we tested their FoxP3 expression, all were negative (Figure 3). 
 
Figure 3. Tumor antigen-specific CD4
+
 T 
cell responses in peripheral blood. An 
example of tetramer analysis of PBMCs of 
patient IV-C-02 after the first cycle of DC 
vaccination is shown. (A) Freshy isolated 
PBMCs were stained directly after 
isolation with tetramers encompassing 
the HLA-DR4-specific gp100:44-59 
peptide, tyrosinase:448-462 peptide, or 
an irrelevant peptide and with anti-CD4 
mAb. (B) Tetramer analysis of PBMC after 
8 days of in vitro restimulation with DR4-
binding gp100 or tyrosinase peptides. 
Note that before restimulation (A), only 
gp100-specific CD4
+
 T cells are found, 
whereas after restimulation (B) both 
gp100- and tyrosinase-specific CD4
+
 T 
cells are detectable. (C) The in vitro 
stimulated population of gp100- or 
tyrosinase-specific CD4
+
 PBMC of patient 
IV-C-02 was further characterized for 
FoxP3 expression. TAA-specific CD4
+
 T 
cells did not express FoxP3. 
 
  
TAA-specific responses in skin-test infiltrating lymphocyte (SKIL) cultures 
Previously we showed that the presence of TAA-specific T cells in SKIL cultures positively correlates 
with clinical outcome in stage IV melanoma patients (22). Skin tests were performed after each cycle 
of vaccinations. Since performing skin tests and taking biopsies puts a great burden to the patient, 
and previously we observed in a series of patients who underwent pre-vaccination skin test analysis 
that none of the patients had detectable levels of TAA-specific T cells prior to vaccination, we choose 
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not to perform pre-vaccination skin-tests, but rather perform in-depth analysis on the post-
vaccination samples. Tetramer positive CD8+ SKILs were detected in 17 stage III patients and in 11 
stage IV patients (p=0.7574 Fischer’s exact test). In 8 stage III patients and in 2 stage IV patients, CD8+ 
SKILs were specific for all 3 tested epitopes (Table 2, Figure 4). Six stage III and 3 stage IV patients had 
TAA-specific CD8+ T cells against 2 of the 3 epitopes tested, while CD8+ T cells of the other patients 
recognized one epitope.  
 
 
Figure 4. Tumor antigen-specific CD8
+
 T cell responses in post-treatment SKIL cultures. The presence and functionality of 
TAA-specific T cells were tested in lymphocytes cultured form skin-test biopsies (SKILs). (A) An example is shown of 
tetramer analysis of SKILs from patient II-E-07, cultured from a DTH reaction to DC pulsed with tumor peptides. Cells were 
stained with tetramers encompassing the gp100:154 peptide, gp100:280, tyrosinase or an irrelevant peptide (control) and 
with anti-CD8 mAb. The irrelevant control peptide stained 0.07% of the T cells. The biopsy contains gp100- and tyrosinase-
specific CD8
+
 T cells. (B) IFN production by the same T cells after stimulation with T2 cells loaded with gp100:154-168 
peptide and gp100:280-288 or tyrosinase:369-377 peptide (peptide stimulation), BLM cells expressing gp100- or tyrosinase 
protein (protein stimulation), or Mel624 cells expressing both gp100 and tyrosinase (tumor stimulation). (C) Example of 
functional responses of SKILs of patient IV-C-14, cultured from a biopsy of a DTH reaction to DC electroporated with 
tyrosinase mRNA, showing recognition of tyrosinase epitopes when presented by HLA-A2.1 positive tyrosinase-transfected 
BLM cells or endogenously tyrosinase expressing Mel624 cells, by the specific and elevated production of IFN, although it 
does not recognize the specific epitopes used in previous vaccination studies. This indicates that a broad repertoire of TAA-
specific T cells can be stimulated by vaccination with mRNA-transfected DC.  
 
Merely the presence of TAA-specific CD8+ T cells is not necessary sufficient for effective anti-tumor 
responses. Therefore we tested whether the vaccine-induced TAA-specific CD8+ T cells were 
‘functional’ in terms of selective IFN production upon coculture with peptide-, or protein-loaded 
target cells or tumor cells (Table 2, Figure 4). Strikingly, although we detected tetramer-specific CD8+ 
T cells in both stage III and IV melanoma patients to similar extend, we found increased IFN 
production only in 3 out of 11 stage IV melanoma patients. In contrast, in stage III patients with no 
measurable disease, we found IFN production in 15 out of 17 patients with tetramer-positive CD8+ 
SKIL cultures, (p=0.0033 Fisher’s exact test).  
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Interestingly, SKILs of three patients (IV-C-02, IV-C-10, IV-C-14) that did not produce cytokines upon 
co-culture with the HLA*02:01 binding peptides, produced IFN upon co-culture with the respective 
tumor protein, indicating that T cells recognized different epitopes. SKILs derived from three 
additional patients (II-E-04, II-E-05, IV-C-12) that produced IFN upon stimulation with only one of the 
HLA*02:01 binding peptides, produced IFN upon co-culture with gp100-expressing cell lines or 
tyrosinase-expressing cell lines (Table 2, Figure 4), suggesting that TAA-specific T cells with another 
specificity than the epitopes used for peptide stimulation and tetramer staining were induced by the 
DC vaccine.  
 
Clinical outcome in stage III patients 
One patient had progressive disease within 4 months after start of vaccinations. As of June 2011, 15 
out of 26 patients progressed at 3 to 37 months after the start of vaccination. Twelve of 26 patients 
are in ongoing remission for up to 45 months. The median progression free survival (PFS) is 34.3 
months, and the median overall survival has not yet been reached. Extended follow-up is necessary 
to draw conclusions on the potency of vaccination with mRNA electroporated dendritic cells as an 
adjuvant therapy in melanoma patients.  
 
Figure 5. Partial reponse 
after three i.n. vaccinations 
with mRNA-transfected DC. 
(A) Patient IV-D-11 
presented with a 
irresectable primary 
melanoma from nasal 
mucosa with extension into 
the nasal septum, maxillary 
and ethmoid sinus, and 
bilateral lymphadenopathy 
of level 1, 2 and 5. (B) Three 
intranodal vaccinations with 
mRNA-transfected DC 
induce a partial response, 
allowing resection of the 
primary tumor. (C) Patient is 
in ongoing remission. 
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Table 2. Immunological and clinical responses 
Patient Flu like 
symptoms 
Injection  
site 
reaction 
TAA specific T cells in blood, 
pre-vaccination a 
TAA specific T cells  in blood, 
post- vaccination a 
TAA specific T cells  in SKIL cultures  Clinical 
responseg 
PFS 
  
OS  
 
   CD4+ CD8+ CD4+  CD8+  CD8+      
 
CTC grade CTC grade tetramer+ tetramer+ tetramer+ tetramer+ tetramer+ a peptide 
b protein b tumor b  (months) (months) 
Stage IV            
  
II-E-01 1 0 n.a. - n.a. - - - - - PD 3 11 
IV-C-01 0 0 - - ++ - +++ - - - SD 6 14 
IV-C-02 1 0 - - ++ - + - ++ + MR 5 10 
IV-C-05 1 1 - - - + ++ - - - SD 16d 49d 
IV-C-06 0 0 - - - - - - - - PD 1 3 
IV-C-09 1 2 - - - - - - - - PD 3 15 
IV-C-13 0 0 - - - - - - - - PD 1 5 
IV-D-01 0 0 n.a. - n.a. - ++ - - - PD 3 5 
IV-D-02 1 0 n.a. - n.a. - + - - - PD 2 5 
IV-D-03 0 0 n.a. - n.a. + - - - - SD 6 26 
IV-D-04 1 1 n.a. - n.a. - - - - - PD 3 22 
IV-D-06 2 1 n.a. + n.a. + + + + - SD 16 24 
IV-D-09 1 0 n.a. - n.a. - - - - - SD 7 14 
IV-D-11 1 1 n.a. - n.a. - +++ + + + PR 8 52+ 
IV-D-15 0 0 n.a. - n.a. - + - - - PD 1e 8e 
IV-D-17 0 0 n.a. - n.a. - - - - - PD 2 2 
IV-D-18 2 1 n.a. - n.a. - + - - - SD 10 22 
IV-D-20 0 0 n.a. - n.a. - ++ - - - PD 4 21 
IV-D-21 1 0 n.a. - n.a. - + - - - PD 1 7 
Stage III      
   
    
  
II-E-02 0 0 n.a. - n.a. - - - - - NED 34 54+ 
II-E-03 2 1 - - - - +++ +++ ++ + NED 53+ 53+ 
II-E-04 1 1 n.a. - n.a. - ++ + ++ - NED 52+ 52+ 
II-E-05 1 1 n.a. - n.a. - + + ++ - NED 37 52+ 
II-E-06 2 0 n.a. - n.a. - +++ +++ ++ + NED 14 17 
II-E-07 2 1 n.a. - n.a. - +++ ++ ++ + NED 51+ 51+ 
II-E-08 1 0 n.a. + n.a. + +++ +++ ++ + NED 9 50+ 
II-E-09 0 1 n.a. - n.a. + +++ ++ ++ + NED 24 25 
II-E-10 1 1 n.a. - n.a. - +++ + + - NED 48+ 48+ 
II-E-11 2 1 n.a. - n.a. - ++ - - - NED 47+ 47+ 
IV-C-03 2 1 -
f - + - ++ + + + NED 21 30 
IV-C-04 1 0 - - - - - - - - NED 8 22 
IV-C-07 1 1 - - - - +++ ++ + + NED 46+ 46+ 
IV-C-08 2 1 - - + - - - - - NED 40+ 40+ 
IV-C-10 2 1 - - - - +++ - ++ - NED 37+ 37+ 
IV-C-11 1 1 - - - - - - - - NED 36+ 36+ 
IV-C-12 1 1 - + - + + + ++ + NED 8 16 
IV-C-14 1 0 - - - - -c - + + NED 15 28+ 
IV-D-05 1 1 n.a. - n.a. - ++ ++ + + NED 8 16 
IV-D-08 2 1 n.a. - n.a. - - - - - NED 10 12 
IV-D-10 0 1 n.a. - n.a. - ++ +++ - - NED 23 28 
IV-D-14 0 0 n.a. - n.a. - + + - - NED 51+ 51+ 
IV-D-16 0 1 n.a. - n.a. - - - - - NED 50+ 50+ 
IV-D-19 1 1 n.a. - n.a. - ++ + + - NED 26 48+ 
IV-D-22 0 0 n.a. - n.a. - - - - - PD 3 47+ 
IV-D-24 0 0 n.a. - n.a. - - - - - NED 36+ 36+ 
Abbreviations: n.a. = not applicable; n.t.= not tested; SKIL= Skin-test Infiltrating Lymphocytes; PFS= Progression free 
survival; OS= Overall survival 
a
 Tetramer staining of freshly isolated PBMC or SKILs. - no recognition, + one epitope recognized, ++ two epitopes 
recognized, +++ three epitopes recognized.  
b
 Antigen recognition of SKILs after stimulation with T2 cells loaded with HLA-A2.1-binding gp100 or tyrosinase peptides 
(peptide recognition), BLM transfected with gp100 or tyrosinase protein (protein recognition) or the gp100 and 
tyrosinase-expressing tumor cell line Mel624 (tumor recognition) as analyzed by
 
IFNγ production. Responses were scored 
as the best immunological response after 1-3 cycles of DC vaccinations. 
c
 Patient IV-C-14 had functional T cells without recognizing the tested epitopes (see Figure 4). 
d
 not evaluable for clinical response because no target lesion at start of vaccination. 
e 
not evaluable for clinical response because of symptomatic brain metastases during 1st cycle 
f 
gp100-specific CD4+ T cells were found after in vitro restimulation with DR4-binding peptides 
g 
SD = stable disease, PD= progressive disease, NED=no evidence of disease, PR= partial response, MR= mixed response 
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Clinical responses in stage IV patients 
All stage IV patients were evaluated for clinical response at 3-month intervals with CT scan. Five 
patients had stable disease up to 15 months and one patient (IV-C-02) showed a mixed response. 
One patient (IV-D-11) with irresectable primary melanoma of the nasal mucosa with bilateral lymph 
node metastases in the neck region and metastases in the maxillary sinus, showed a partial response 
of the primary tumor after three vaccinations, allowing resection of the primary tumor. The lymph 
node metastases and sinus metastases completely regressed upon further vaccination and this 
patient is in ongoing complete remission for 52+ months (Figure 5). DR4 expression was not 
correlated with survival (data not shown) in the vaccinated patients.  
We observed a trend towards improved PFS in patients with TAA-specific T cells in their blood or SKIL 
cultures compared to patients without TAA-specific responses, with 8.1 month versus 2.8 months, 
respectively (p= 0.062). Similarly, patients with TAA-specific T cells showed improved OS compared 
to patients without TAA-specific T cells, 24.1 months versus 11.0 respectively (p = 0.101). 
 
Discussion 
Early clinical trials have shown that vaccination with DC loaded with tumor peptides is feasible, safe 
and can induce tumor-specific immune responses in advanced cancer patients (1;5;24). Although 
these results are promising, further improvement is warranted before its use can be accepted in 
clinical practice. In the present study we show that DC presenting multiple naturally processed 
epitopes following mRNA electroporation, enhance tumor-specific CD8+ and CD4+ T cell responses in 
melanoma patients. Importantly, both the presence of TAA-specific CD8+ T cells and their capacity to 
produce IFN upon encounter of their cognate antigen was significantly increased in stage III patients 
treated in the adjuvant setting. 
Long-lasting T cell receptor stimulation of several hours by fully matured DCs is necessary to activate 
naïve T cells to proliferate and differentiate into effector cells (25;26). The generated DCs highly and 
sustainably expressed gp100 and tyrosinase after electroporation with mRNA. In vitro, DCs were able 
to activate gp100-specific CTL up to 48 hours after electroporation. Previously, we demonstrated 
that gp100 and tyrosinase protein can be detected inside lymph nodes up to 24 hours after 
intranodal injection of mRNA electroporated DC (10). In this study, TAA-specific T cells were induced 
in the majority of patients which clearly demonstrates that electroporated DC are indeed potent 
inducers of tumor-specific T cells.  
We detected TAA-specific CD8+ T cells in peripheral blood of only 6 of the 45 patients. This is an 
underestimation, likely due to the low frequencies of these cells in the circulation and the 
observation that substantially more TAA-specific CD8+ T cells were detected in SKIL cultures. Still, the 
number of TAA-specific T cells measured in this study might be underestimated because we screened 
with HLA*02:01 binding tetramers only. Indeed, in six patients SKILs produced IFN upon co-culture 
with the protein gp100 and/or tyrosinase, while no IFN production was detected upon co-culture 
with the corresponding HLA*02-binding peptide(s), supporting the notion that T cells with a broader 
specificity than the HLA*02:01 epitopes were induced. Recently, Bonehill et al. reported on the use 
of monocyte-derived DC electroporated with mRNA encoding multiple tumor antigens, CD40 ligand, 
active TLR4 and CD70 (TriMix-DC) (27). Although they monitored tumor-specific T cells by using 
autologous EBV-transformed B cells transfected with tumor antigens as target cells, comparable 
frequencies of gp100 and tyrosinase-specific CD8+ T cells were found.  
In 4 out of 10 patients tested, mRNA-electroporated DC induced concomitant TAA-specific CD4+ T 
cells. The observation that these cells did not express FoxP3, suggest that these cells were T helper 
cells and not regulatory T cells. Initially, the main function of CD4+ T helper 1 cells was thought to be 
the production of cytokines providing growth and differentiation signals to precursor CTL to become 
effector CTL (28). However, CD4+ T cells have also been demonstrate to participate in the elimination 
of tumor and the maintenance of long-term protective immunity (29-31). In addition, activated T 
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helper cells can stimulate precursor CTLs by reciprocal activation of APCs, for instance via CD40-
CD40L interactions (32). Recently it was shown that CD4+ T cells enhance the recruitment of CD8+ T 
cells to the lymph nodes(33) and tumor(34-36). Moreover, a direct antitumor effect of T helper cells 
has been demonstrated (37-39). This may be of particular relevance for the antitumor response 
against melanoma since this tumor type frequently expresses class II molecules constitutively 
(40;41). Indeed, CD4+ T cell responses have been identified in peripheral blood from melanoma 
patients who remained disease-free after treatment for multiple relapses (39). 
Our data suggests a trend towards improved overall survival, when compared to recently reported 
survival data in comparative arms from large randomized prospective studies on immunotherapy 
with anti-CTLA4 antibodies in irresectable metastatic melanoma patients (42;43). It is tempting to 
speculate that the observed clinical responses result from vaccine-induced immune responses. 
Indeed, stage IV melanoma patients with TAA-specific T cell responses showed increased clinical 
outcome after vaccination with mRNA-loaded DC when compared to patients with no vaccine-
enhanced TAA-specific T cell responses. These data confirm and extend our previous findings that the 
presence of tumor-specific T cells in SKIL cultures identifies a subgroup of patients that might benefit 
from immunotherapy (21). Moreover, these studies demonstrate that sustained disease control can 
be achieved in increasing numbers of patients, but objective anti-tumor responses might take several 
months to years to develop (44;45). The, generally, delayed response patterns in immunotherapy 
and the high response rates to novel targeted therapies in melanoma, obviously warrants future 
studies that combine both modalities to achieve durable tumor control. Such studies should 
implement SKIL culture analyses pre- and post-intervention in both active and comparative arms in 
order to elucidate the dynamics and nature of the induced immune responses.  
The higher tumor burden in stage IV as compared to stage III melanoma patients may hamper the 
induction of effective immune responses but instead favour local immune suppression. The present 
study demonstrates that robust immunological responses are more frequently induced in patients 
with no evidence of disease compared to patients with macroscopic tumor burden. Based on the 
association of tumor-specific T cells and improved clinical outcome, this suggests that DC based 
vaccination is a promising adjuvant treatment for stage III melanoma patients. However, extended 
follow-up is warranted to draw conclusions on the clinical efficacy of DC based vaccination in this 
stage of disease.  
In summary, the advantages of vaccination with DC electroporated with mRNA encoding TAA include 
lack of HLA-restriction, presentation of multiple TAA epitopes to both CD8+ and CD4+ T cells, and the 
subsequent induction of a large repertoire of TAA-specific T cells. We demonstrate that vaccination 
of melanoma patients with mRNA-electroporated DC induces robust tumor-specific CD4+ and CD8+ T 
cell responses, in particular in stage III melanoma patients treated adjuvant to radical lymph node 
dissection. 
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Abstract 
Vaccination against cancer exploiting dendritic cells (DCs) has for more than a decade been based on 
DCs generated ex vivo from monocytes or CD34+ progenitors. Here, we report on the first clinical 
study of therapeutic vaccination against cancer exploiting activated naturally occurring plasmacytoid 
DCs (pDCs). Fifteen metastatic melanoma patients received intranodal injections of pDCs activated ex 
vivo and loaded with tumor-associated peptides. In vivo imaging demonstrated that administered 
pDCs migrated and distributed over multiple lymph nodes. Several patients mounted anti-vaccine 
CD4+ and CD8+ T cell responses. Despite the limited number of administered pDCs, an IFN signature 
was observed after each vaccination. Finally, patients that received the pDC-vaccine not only had a 
significant difference in the median survival (22 months) compared to patients that received 
standard DTIC chemotherapy (7.6 months), but also had a significant increase in the overall survival. 
These results indicate that vaccination with activated natural pDCs is feasible with minimal toxicity 
and that in patients with metastatic melanoma it induces immune responses and improve survival 
rate.  
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Introduction 
Dendritic cells (DCs) constitute a family of antigen-presenting cells defined by their morphology, 
phenotype and unique capacity to process exogenously encountered antigens and to present them 
to naive T cells. Following infection or inflammation, DCs undergo a complex process of maturation 
and migrate to lymph nodes to present antigens and activate T cells. This decisive role in inducing 
immunity was the rationale for DC based immunotherapy, in which DCs loaded with tumor antigens 
were injected into cancer patients to stimulate T cells to eradicate tumors (1-3). So far, most DC-
based vaccination studies were conducted in patients with metastatic melanoma because of the 
immunogenicity of this tumor and the characterization of antigens such as gp100 and tyrosinase (4, 
5). Although numerous vaccination studies demonstrated the immunogenicity of tumor antigen-
loaded DCs, the number of objective clinical responses has been limited, hampering its 
implementation as a novel form of standard treatment (6). Because of the limited number of 
naturally circulating DCs, virtually all vaccination studies have used DCs differentiated ex vivo from 
monocytes or CD34+ progenitors. Recently we proposed that these 'artificial' DCs may be less 
effective than their natural counterparts that circulate in the blood (7). Two major subsets of natural 
circulating DCs can be found; plasmacytoid DCs (pDCs) and myeloid DCs.  
Plasmacytoid DCs are the major producers of type I interferon (IFN), which is of major importance in 
combatting viral infections. Freshly isolated pDCs have been associated with tolerance or Th2 
responses (8, 9), but several groups have now demonstrated that human pDCs produced large 
amounts of type I IFNs and induced Th1 responses (8, 10). Human pDCs induced strong allogeneic T 
cell responses (11), and primed CD4+ and CD8+ T cells against viruses or tumor antigens (12, 13). 
Preclinical studies showed that antigen-loaded pDCs protected against Leishmania major (14), and 
induced anti-tumor responses that inhibited tumor growth (15, 16). Recently, Takagi et al 
demonstrated that pDCs were crucial for the initiation of inflammation and T cell immunity (17). 
Together, these findings prompted us to test the capacity of activated human pDCs to elicit anti-
tumor immune responses in patients.  
In this first-in-human study, we report on vaccinating metastatic melanoma patients, with 
autologous activated pDCs loaded with tumor-associated peptides. Despite their low abundance in 
peripheral blood, we succeeded in isolating sufficient numbers (0.3-3 million per vaccination) of 
highly purified cells to carry out this study. We used the inactivated thick-borne encephalitis virus 
vaccine as a natural TLR agonist to activate pDCs and used these antigens as an immunomonitoring 
tool. We demonstrate that these activated pDCs induced antigen-specific CD4+ and CD8+ T cell 
responses associated with a significantly enhanced overall survival. 
 
Material and Methods 
Patient characteristics 
Sixteen distant metastatic melanoma patients (according to the 2001 American Joint Committee on 
Cancer staging system) (18) were enrolled in this feasibility study. One patient did not complete the 
scheduled vaccinations and monitoring due to rapid progression of disease. Fifteen of the patients 
were considered evaluable. Eligibility criteria included measurable target lesions, HLA-A2.1 
phenotype, histologically documented metastatic melanoma expressing gp100 (compulsory) and 
tyrosinase (non compulsory), no active infection or immune suppressive conditions, serum LDH 
concentration within normal limits (< 450 U/l) and WHO performance status 0 or 1. Primary endpoint 
was toxicity related to vaccination and immunological response. Informed consent was obtained 
from all patients and the study was approved by the local medical ethics committee.  
 
CliniMACS pDC isolation and immunization schedule 
Patients were vaccinated with autologous pDCs loaded with HLA-A2.1-binding tumor peptides 
derived from the melanoma-associated antigens gp100 and tyrosinase. The following HLA-A2.1-
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restricted peptides were used: gp100-derived peptides gp100:154-162 (KTWGQYWQV) and 
gp100:280-288 (YLEPGPVTA) and tyrosinase-derived peptide tyrosinase:369-377 (YMNGTMSQV). The 
clinical study was designed as a feasibility study. The first patient received 0.3x106 pDCs per 
vaccination, patients 2 and 3 received 1.0x106 pDCs per vaccination, and patients 4 and 5 received 
3x106 pDCs per injection. Considering the yield from pDC isolation, this is the maximum feasible 
dose, and was also given to patients 6 to 15. Three intranodal injections were given once every two 
weeks followed by a DTH challenge. In the absence of disease progression, patients were eligible for 
a maximum of two maintenance cycles consisting of three biweekly vaccinations and a DTH 
challenge, each with a 6 month interval.  
Plasmacytoid DCs were directly isolated from aphaeresis products using the fully closed 
immunomagnetic CliniMACS isolation system (Miltenyi Biotec, Bergisch-Gladbach, Germany). GMP-
grade magnetic bead-coupled BDCA4 antibodies were used, following the manufacturer’s guidelines. 
This procedure resulted in clinically applicable purified pDCs, which had an average purity of 75% and 
a yield between 13x106 and 33x106 (Supplementary Figure S1). Following aphaeresis and CliniMACS 
isolation, pDCs were cultured overnight at a concentration of 106 cells/ml in X-VIVO-15 (Cambrex, 
Belgium) containing 2% pooled human serum (HS) (Sanquin, Nijmegen, The Netherlands), 
supplemented with 10 ng/ml recombinant human interleukin-3 (rhIL-3) (Cellgenix, Freiburg, 
Germany). For the first vaccination, these pDCs were subsequently activated for 6 hours by addition 
of FSME-IMMUN® (1:10 v/v) (Baxter AG). During the last 3 hours of activation, pDCs were loaded 
with the melanoma-associated peptides gp100:154, gp100:280 and tyrosinase (19). For subsequent 
vaccinations and DTH skin tests, overnight IL-3 cultured pDCs were activated for 3 hours by addition 
of FSME-IMMUN® (1:10 v/v). Thereafter, these 3-hour activated pDCs were frozen in X-vivo 15 
medium containing 10% DMSO. The peptide-loaded pDCs were administered intranodally in a 
clinically tumor-free lymphnode region under ultrasound guidance (20).  
 
 
Figure 1 Schematic overview of the pDC culture protocol and vaccination strategy. 
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Phenotype 
The purity of pDCs after CliniMACS isolation and the phenotype of the pDCs were determined by flow 
cytometry. The following primary monoclonal antibodies (mAbs) and the appropriate isotype 
controls were used: anti-CD45-FITC, anti-BDCA2-PE and anti-CD123-APC (all Miltenyi Biotec); anti-
HLA-ABC-PE (W6/32), anti-HLA-DR/DP-FITC (Q5/13), anti-CD80-PE and CD86-PE (all BD Bioscience 
Pharmingen, San Diego, CA, USA); anti-CD83 (Beckman Coulter, Mijdrecht, the Netherlands) and anti-
CCR7 (R&D Systems); followed by goat-anti-mouse PE.  
 
Cytokine detection 
Supernatants were collected from pDC cultures either directly after 6 h of stimulation or after 6 h of 
stimulation followed by a washing step and subsequent reconstitution of cells in fresh medium for an 
additional 12 hours, and IFNα production was analyzed with murine monoclonal capture and HRP-
conjugated anti-IFNα antibodies (BenderMed Systems, Vienna, Austria) using standard ELISA 
procedures. To analyze the T helper cell profile, supernatants were collected after 2 days of pDC-PBL 
coculture. Cytokine production (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12 (p70), TNF, TNFβ, IFN) in 
the supernatant was analyzed with a human Th1/Th2 Multiplex kit (BenderMed System) according to 
the manufacturer’s instructions.  
 
111In-oxinate labeling and scintigraphic imaging 
Six-hour FSME-activated pDCs were labeled with 5 MBq 111In-oxinate (GE Healthcare, Eindhoven, The 
Netherlands) in 0.1 M Tris-HCl (pH 7.0) for 15 minutes at room temperature as described previously 
(21, 22). Cells were washed three times with PBS/1%HSA, and the labelling efficiency was calculated 
as the percentage of the activity that remained associated with the cell pellet. 111In-labeled pDCs 
(3×106; 4 MBq) in 200 µl saline were injected under ultrasound guidance directly into a clinically 
tumor-free lymph node. In vivo planar scintigraphic images (256  256 matrix, 174 and 247 keV 111In 
photopeaks with 15% energy window) of the injection depot and corresponding lymph node basin 
were acquired with a gamma camera (Siemens ECAM, Hoffman Estates, IL) equipped with medium 
energy collimators, 15 minutes, 24 hours and 48 hours after injection. Migration was quantified by 
region-of-interest analysis of the individual nodes visualized on the images and expressed as the 
fraction of 111In-labeled DC that had migrated from the injection depot to following lymph nodes 
after 15 minutes, 24 hours and 48 hours. 
 
Immunomonitoring of patients 
 Blood samples were obtained before the start of the vaccination regimen and after each individual 
vaccination. Each sample was tested for the presence of FSME-specific T cells by proliferation and 3H-
thymidine incorporation, and for the presence of FSME-specific antibodies in the serum using an 
ELISA specific for Tick-Borne Encephalitis IgG (Serion/Virio, Würzburg, Germany). Four days after the 
third vaccination, a DTH skin test was performed as described previously (23). moDCs pulsed with 
gp100 or tyrosinase peptides (1x106) and pDCs pulsed with gp100 or tyrosinase peptides (0.2x106) 
were injected intradermally in the skin of the back of the patient at 4 different sites. The maximum 
diameter of induration was measured after 48 hours. Punch biopsies (6 mm) were obtained from all 
DTH sites. Half of the biopsy was cryopreserved and the other half was manually cut and cultured in 
RPMI 1640 (Gibco-BRL Life Technologies) containing 7% HS and IL-2 (100 U/ml, Proleukin®, Chiron, 
the Netherlands). Every 7 days, half of the medium was replaced by fresh medium containing HS and 
IL-2. After 2 to 5 weeks of culturing, T cells were tested for specificity against gp100 and tyrosinase 
(19). DTH-derived cells were stained with tetrameric-MHC complexes containing the gp100:154-167, 
gp100:280-288 or tyrosinase:369-376 peptide (Sanquin, Amsterdam, The Netherlands) combined 
with CD8 staining as described previously (23). All samples were tested with HIV:77–85 HLA-A2.1-
tetramers recognizing the irrelevant HIV-peptide (SLYNTVATL) for background staining.  
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Mixed lymphocyte-peptide cultures 
Blood frequencies of anti-vaccine CD8+ T cells were estimated using mixed lymphocyte-peptide 
cultures (MLPCs) as described previously (24). Briefly, PBMCs isolated before and after one cycle of 
three pDC injections, were thawed and divided in three groups incubated for 1 h at room 
temperature in Iscove’s medium (Life Technologies, Carlsbad, CA, USA) with 1% HS and 2 µM of the 
peptides tyrosinase:369 (YMDGTMSQV), wild-type gp100:154
 (KTWGQYWQV), or wild-type 
gp100:280 (YLEPGPVVTA). These pulsed cells were then washed, pooled, and distributed at 2 x 105 
cells/0.2 ml in round-bottom microwells in Iscove’s with 10% HS, L-arginine (116 mg/l), L-asparagine 
(36 mg/l), L-glutamine (216 mg/l), 1-methyl-L-tryptophan (100 µM),  IL-2 (20 U/ml), and IL-7 (10 
ng/ml). On day 7, 50% of the medium was replaced by fresh medium containing IL-2 and peptides at 
4 µM. Tetramer labeling was performed on day 14 as described previously (24). Anti-gp100:154 T cell 
clones were derived that represented either the spontaneous anti-gp100 T cells present prior to 
vaccination in patients 2, 5, 6, 10 and 11, or the pDC-induced anti-gp100 T cells present after 
vaccination in patients 1, 4, 8 and 12. Tetramer-positive CD8+ T cells were sorted at 1 cell/well and 
restimulated weekly with irradiated HLA-A2+ EBV-transformed B cells pulsed with the gp100:154 
peptide at 2 µM and irradiated allogeneic PBMC as feeder cells, in medium supplemented with IL-2 
and IL-7. Established T cell clones were stained with the relevant tetramer and their functional avidity 
was evaluated by testing their production of IFN after stimulation with HLA-A2+ EBV-B cells pulsed 
with various concentrations (from 10 pM up to 10 µM) of the gp100:154 peptide.      
 
RNA isolation and qPCR 
To determine mRNA expression of IFN and IFN-stimulated genes (ISGs) blood was drawn from one 
patient during one cycle of 3 vaccinations before each vaccination and at 4 and 24 hours after each 
vaccination using PAXgene tubes. RNA isolation was performed using PAXgene blood RNA kit 
according to the manufacturer’s instructions (Qiagen). RNA isolations from PBMCs from healthy 
volunteers were done using the ZR RNA isolation kit (Zymo Research) according to manufacturer’s 
instructions. RNA was treated with DNase I (amplification grade; Invitrogen) and reverse-transcribed 
into cDNA by using random hexamers and Moloney murine leukemia virus reverse transcriptase 
(Invitrogen). To exclude genomic DNA contamination we included a “-RT” control in which the 
reverse transcriptase was replaced with RNase-free water. The “-RT” control was taken along in the 
qPCR analysis, and was used as a cut-off value. cDNA was stored at -20°C until further use. mRNA 
levels for the genes of interest were determined by quantitative PCR (qPCR) with a Biorad CFX 
apparatus (Biorad) with SYBR Green (Applied Biosystems). Analysis was done using Biorad CFX-1.6 
software, and expression levels were determined relative to PBGD expression. Primer sequences are 
available on request and were from the Primer Bank database (25). 
 
Matched controls  
Matched controls were identified from records of metastatic melanoma patients from the Radboud 
University Nijmegen Medical Centre (Nijmegen, The Netherlands), The Netherlands Cancer Institute 
– Antoni van Leeuwenhoek Hospital (Amsterdam, The Netherlands) and University Hospital Essen 
(Essen, Germany) who had received first-line dacarbazine (DTIC) chemotherapy at 850–1000 mg/m2 
i.v. at 3 weekly intervals, between March 2000 and March 2010. All matched controls were HLA-
A*02:01 positive and were required to have received at least 3 infusions, a therapy time-frame that 
is consistent with one cycle of vaccinations. 
Controls were matched to study subjects, in ratio 1:3, primarily for M substage at baseline according 
to AJCC criteria, number of distant metastases, number of metastatic sites, localization of distant 
metastases and baseline serum LDH. These criteria currently represent the most important 
prognostic factors for survival (26). In case of more than three matches for one study subject, 
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demographic criteria (age, gender) and systemic salvage treatment after progression on DTIC were 
used to select the closest match. 
 
Statistical analysis 
Significant differences from controls were determined according to paired student t-test or by one-
way ANOVA analysis followed by the Tukey’s post-hoc test. Differences between the groups were 
evaluated using an unpaired t-test. Differences between pre- and post-vaccination were evaluated 
with a Wilcoxon signed-rank test. Kaplan-Meier probability estimates of PFS and OS were calculated, 
statistical differences between the survival of the groups were determined with a log-rank test. 
Statistical significance was defined as p<0.05. SPSS19.0 was used for survival analyses. 
 
 
Figure 2. Activated pDCs are mature and migrate to distinct lymph nodes in vivo. (A) Expression levels of the surface 
molecules CD80, CD83, CD86, MHC class I and MHC class II on pDCs after 6 hours of activation with the FSME-vaccine. 
Surface receptor expression levels of all molecules of the pDC vaccines depicted in the percentage of positive cells (left 
graph) and mean fluorescence intensity (right graph) after 6 hours of activation with the FSME-vaccine (n=15). (B) IFNα 
production by pDCs after 6 hours of cultivation/activation with rhIL-3 or FSME-vaccine or after 6 hours of activation 
followed by a washing step and reconstitution of pDCs in fresh medium for an additional 12 hours (n=9; *: P<0.05, ***: 
P<0.001). (C) Tracking of pDC migration in vivo. Migration and biodistribution of 
111
In-labeled pDCs visualized by 
scintigraphical imaging. Forty-eight hours after administration, 11% (Pt 01), 3% (Pt 02) and 42% (Pt 03) of injected pDCs 
were distributed over up to 4 distant lymph nodes away from the injection depot. 
 
Results 
Vaccination of metastatic melanoma patients with activated pDCs is safe with minimal side effects 
It is of utmost importance that pDCs administered to cancer patients have an immunostimulatory 
phenotype (19). Previously we demonstrated that the commonly used preventive FSME-vaccine 
induced both IFNα secretion and a mature pDC phenotype (27). Thus FSME could be used as a 
clinically applicable natural TLR agonist. In this first-in human study we vaccinated 15 patients with 
increasing pDC numbers, ranging from 0.3 to 3 million per vaccination, with three vaccinations at bi-
weekly intervals. Patient characteristics are shown in Table 1. The expression of CD80, CD83, CD86, 
MHC class I and II upon FSME-induced activation indicated that the generated pDCs were highly 
mature and capable of providing costimulatory signals needed for optimal T cell activation (Figure 
2A). Furthermore, pDC activation for 6 hours led to the secretion of high levels of type I IFN (Figure 
2B). Additionally, we also washed 6 hour activated pDCs and reconstituted the cells in fresh medium. 
Thereafter, pDCs were maintained for an additional 12 hours to demonstrate that pDCs have a 
sustained ability to secrete IFNα (Figure 2B). Thus, all patients received purified and activated 
peptide-loaded pDCs that met the predefined release criteria with the ability to secrete type I IFN in 
70
Part 1, Chapter 4 
 
vivo (6).  Furthermore, the vaccines were well tolerated and no signs of severe toxicity (common 
toxicity criteria grade 3-4) were observed. Six vaccinated patients developed grade 1 flu-like 
symptoms and one patient reported grade 2 non-treatment related pain resulting from progressive 
subcutaneous metastasis. In none of the vaccinated patients did we detect antibodies to the murine 
antibody used during the isolation procedure (data not shown). We conclude that it is feasible and 
safe to administer activated and tumor-peptide loaded pDCs to patients. 
 
 
Figure 3. Vaccination with activated pDCs induces an IFN signature. (A) The graphs show the IFNα and IFNβ gene expression 
levels in the blood relative to PBGD expression at indicated times after each vaccination. (B) The graphs show the mRNA 
expression of indicated ISGs determined as in (A). Healthy indicates steady state expression levels of indicated genes in 8 
healthy individuals. n.a.: not analyzed, n.d.: not detected (* p<0.05; ** p<0.01; *** p<0.001). 
 
Migration of activated pDCs in vivo 
For effective immunization, injected DCs have to migrate into the T cell areas of draining lymph 
nodes to present antigens to naive T cells. Because of the limited amount of pDCs available, we 
opted for intranodal injection to maximize the number of pDCs in the lymph node. In three patients 
we examined the migration in vivo of activated pDCs labelled with 111In (21, 28). Forty-eight hours 
after intranodal injection a significant proportion of 111In-labeled pDCs remained at the injection site 
and distinct amounts were detected in distant lymph nodes (Figure 2C). These results demonstrated 
that the pDCs injected in a single lymph node distributed into downstream nodes.  
 
Vaccination with activated pDC induce an IFN signature in vivo 
To verify whether activated pDCs secreted significant quantities of type I IFNs in vivo, we investigated 
in one patient the IFN signatures in great detail (multiple time points / three vaccinations). We 
measured in blood mononuclear cells the expression of type I IFNs genes and of five IFN-induced 
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genes in blood mononuclear cells one hour before and four and 24 hours after vaccination, and 
compared these expression levels to those of healthy individuals. Transcription of both IFNα and 
IFNβ genes was clearly induced four hours after vaccination and decreased 20 hours later (Figure 3A), 
indicating a temporal systemic induction of type I IFNs. As expected, we observed increases in the 
expression of the IFN-induced genes RIG-I, PKR, OAS-1, OAS-2 and IRF-7 after four hours and further 
increases after 24 hours (Figure 3B). These results demonstrate that after each vaccination even 
small numbers of injected pDCs induced a systemic type I IFN signature. 
 
Plasmacytoid DC vaccination leads to CD4+ T cell proliferation and antibody production 
We next analyzed the ability of activated pDCs to prime T cell responses to the FSME antigens, which 
served as an internal control for the tumor-associated antigenic peptides. After 3 pDC vaccinations, 
FSME-stimulated T cell proliferation increased in 9 out of 14 tested patients (Figure 4A, Table 1). 
Cytokine production experiments carried out in 6 patients showed higher levels of IFNγ, IL-10 and IL-
5 after vaccinations  than before (Figure 4B, and data not shown).  
Furthermore, we followed the levels of serum anti-FSME antibodies after each vaccination. Twelve 
out of the 15 tested patients significantly increased their anti-FSME IgG titers sstarting after the 
second vaccination (Figure 4C, Table 1). One patient (pt 14) already had anti-FSME antibodies prior to 
vaccination.  
In only one of the 15 patients neither T cells nor antibodies to FSME were detected. Thus the 
majority of patients developed de novo proliferative and humoral FSME-specific immune responses 
upon vaccination, indicative of a functional immune system that can be primed by activated and 
antigen-loaded pDCs. 
 
 
 
Figure 4. Activated pDCs induce de novo FSME-specific cellular and humoral immune response in vivo.  (A) Proliferation of 
anti-FSME blood T cells collected before and after three vaccinations with tumor-peptide loaded pDCs. Proliferation of T 
cells was measured by 
3
H-Thymidine incorporation and depicted as proliferation in counts per minute (log scale). (B) 
Cytokine production pre- (white bars) and post-vaccination (black bars); IFNγ, IL-10 and IL-5 production by T cells stimulated 
overnight by FSME-activated pDCs (log scale). The graphs show the cytokine production of T cells from 6 patients. (C) FSME-
specific IgG detected in the serum of patients before and after the first, second and third vaccination. The dotted line 
represents the threshold (28 Units) for positivity. (ns, not significant; *** p<0.001). 
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Figure 5. Activated pDCs induce tumor-antigen specific CD8
+
 T cell responses in patients. (A) Proportions of blood CD3
+
 CD8
+
 
T cells before and after 1 cycle of vaccination. (B) pDC vaccine-related CD8
+
 T cell responses are detected in the blood after 
MLPCs. The graphs show the blood frequencies of gp100154, gp100280 and tyrosinase tetramer
+
 CD8
+
 T cells before and after 
1 cycle of vaccination on a log scale. (C) Functional avidities of anti-gp100154 CD8
+
 T cell clones derived from selected 
patients before (7 clones) or after (8 clones) one cycle of vaccination. The graph shows the concentrations of antigenic 
peptide, pulsed on HLA-A2
+
 cells, required to obtain 50% of maximal IFN-g production by each of the T cell clones on a log 
scale. (D) pDC vaccine-related CD8
+
 T cell responses are detected in biopsies taken from DTH skin tests. Two weeks after the 
third pDC injection, a DTH skin test was performed by injecting intradermally pDCs and moDCs loaded with either the gp100 
or the tyrosinase peptides. Biopsies taken 2 days later were cultured for 3-4 weeks in low dose IL-2, and proliferating T cells 
were stained with specific tetramers. FACS plots from patients 01 (after one vaccination cycle) and 13 (after two vaccination 
cycles)show DTH-infiltrating lymphocytes stained by gp100154 tetramers. (ns, not significant; ** p<0.01). 
 
Activated pDCs induce tumor antigen-specific CD8+ T cell responses in vivo 
We used tetramers to detect the presence of tumor antigen-specific CD8+ T cells in blood, and in 
biopsies taken from skin delayed-type hypersensitivity (DTH) reactions as described previously (23). 
In blood, the proportions of total CD8+ T cells did not change following vaccination (Figure 5A), and 
ex vivo tetramer staining was negative both before and after vaccination (data not shown). We 
resorted to an in vitro restimulation of blood mononuclear cells in limiting dilution conditions over 
two weeks with the 3 antigenic peptides, before screening all microcultures for the presence of CD8+ 
tetramer+ cells. This procedure allows estimating the frequencies of blood CD8+ T cells that recognize 
a given antigen and proliferate in vitro in response to this antigen. As shown in Figure 5B, 7 out of 15 
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patients showed a significant increase (≥5-fold) of the frequency of gp100154-specific CD8
+ T cells in 
(Figure 5B). To evaluate the affinity of these anti-vaccine T cells, we derived anti-gp100154 T cell 
clones from pre- and -postvaccination PBMC and measured IFNg production after stimulation with 
various concentrations of peptide. The concentration of peptide that stimulates a half-maximal 
cytokine production reflects the functional avidity of the T cells. As shown in Figure 5C, 2 out of the 8 
post-vaccination clones had a higher (>10-fold) functional avidity than that of all the other pre- or 
post-vaccination clones, suggesting the efficacy of pDCs at priming high affinity T cells.  
In the skin, we observed in 10 out of the 15 patients positive DTH responses with indurations of up to 
22 mm at the sites of intradermal injection of 0.2 x 106 peptide-loaded activated pDCs 
(Supplementary Table S1). Furthermore we detected anti-gp100:154 CD8+ T cells in one DTH biopsy 
obtained after one cycle of vaccination (pt 1) and in one obtained after two cycles (pt 13) (Figure 5D). 
T cells obtained from biopsies of DTH reactions to unloaded pDCs did not proliferate demonstrating 
the specificity of this response. We conclude that vaccination with small numbers of peptide-loaded 
and activated pDCs can induce tumor-specific CD8+ T cell responses in metastatic melanoma patients. 
 
Plasmacytoid DC vaccination enhances the overall survival of late stage melanoma patients 
Two patients (pt 13 and 14) showed durable stable disease and were eligible for two additional cycles 
consisting of three pDC vaccinations. Patient 14 developed a mixed response with regression of lung 
metastases and progression of a nodal metastasis. Patient 10 had a documented progression but 
achieved complete remission after surgery and subsequently received maintenance treatment. We 
compared the clinical outcome of these 15 patients to that of carefully matched historical control 
patients (n=72) who received standard DTIC (Dacarbazine) chemotherapy as a first line treatment 
(Supplementary Table S2). The median progression-free survival in the pDC group was 4.0 months 
versus 2.1 months in the control group (not significant; Figure 6A). Although the initial endpoint of 
this study was safety and feasibility, the median overall survival showed a remarkable improvement 
compared to matched control patients: 22.0 months (95%CI 1.8 – 42.2) versus 7.6 months (95%CI 5.8 
– 9.4), p=0.001. Furthermore, based on a log-rank test, patients vaccinated with pDCs also showed a 
significant overall survival, p=0.001. Seven out of the 15 patients were alive, even 2 years after the 
start of treatment, compared to 6 out of 72 patients treated with standard chemotherapy (Figure 
6B).  
 
Table 1 Patient characteristics & clinical and immunological responses after pDC vaccination 
                                                                      Anti FSME response Anti tumor response  
Pt Sex/ 
age 
Prior 
therapy 
Stage  Site of metastases Injected  
pDCs 
T cella Abb CD8+     
T cell 
Clinical 
responsec 
PFSd OSe Salvage 
treatmentg 
01 M / 43 S M1b Lung, skin 0,3*106 ++ ++ + PD < 4 10 RT 
02 F / 45 - M1b Lymph nodes, lung 1*106 + ++ - PD < 4 3 CT 
03 M / 62 - M1c Liver, lung 1*106 ++ ++ + SD 6 36+ CT, IT1,2 
04 M / 35 - M1c Liver, lymph nodes, 
esophagus, omentum 
3*106 - ++ + SD 5 27 CT, IT1,3 
05 F / 53 S M1c Liver, lung, skin, spleen 3*106 - ++ + PD < 4 5 RT 
06 M / 59 S M1b Lung, skin 3*106 n.a. - - PD < 4 6 RT 
07 M / 43 - M1c Lymph nodes, skin, testis 3*106 + ++ - PD 4 5 None 
08 F / 51 - M1b Lung 3*106 + ++ + PD < 4 13 None 
09 M / 36 - M1b Lung, skin 3*106 + + + SD 5 23 CT, IT3,4  
10 M / 52 S M1a Lymph nodes 3*106 - - - SD 7 28+ S 
11 M / 66 - M1c Liver, lymph nodes, lung 3*106 - ++ - PD < 4 12 CT 
12 F / 39 S M1b Lung 3*106 ++ ++ + SD 5 27+ RT, CT, IT1 
13 F / 56 S M1b Lung 3*106 ++ ++ + SD 15 26+ CT, IT1 
14 M / 69 S M1c Lung, skin, adrenal gland 3*106 + ++ - MR 14+ 24+ None 
15 M / 67 S, RT, CT M1b Lymph nodes, lung, skin 3*106 ++ - - PD < 4 24+ IT1 
a – No T cell response; + Stimulation index >1<2; ++ SI ≥2<10. 
b – No Ab or < 15 U/ml; +/- Ab titer < 28 U/ml; + Ab titer > 28 <100 U/ml; ++ Ab titer >100 U/ml 
c PD, progressive disease; SD, stable disease; MR, mixed response. 
d Progression free survival (PFS) in months. 
e Overall survival (OS) in months 
g RT, radiotherapy; CT, chemotherapy; S, surgery; IT, immunotherapy 
1 anti-CTLA4 antibody,2 Akt inhibitor,3 Ifosfamide-pazopanib,4 MEK inhibitor (AZD6244) 
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Discussion 
After almost 15 years of DC based immunotherapy, the clinical efficacy of the ex vivo generated 
monocyte- or CD34+ progenitor derived-DCs is disappointing. Therefore, properly activated naturally 
occurring dendritic cells might represent the next generation of anti-cancer cellular therapy to induce 
tumor-specific immunological responses and improved clinical efficacy. In this first clinical study with 
plasmacytoid DCs in metastatic melanoma patients, with activated pDCs injected into lymph nodes, 
we noted a significant increase in overall survival. In these patients we observed: 1) distribution of 
injected pDCs over multiple lymph nodes, 2) enhanced systemic secretion of type I IFNs, 3) de novo T 
and B cell responses to control antigen, and 4) induction of tumor antigen specific CD8+ T cells, 
including some with high functional avidity.  
Plasmacytoid DCs are known to sense viral or self nucleic acids and to become activated to produce 
type I IFN at sites of inflammation. These IFNs initiate protective immunity through maturation of 
resident myeloid DCs and subsequent activation of infiltrating T cells and NK cells. By contrast, non-
activated pDCs promote T regulatory cell-mediated immunosuppression (29), and the presence of 
pDCs in tumors has been correlated with poor clinical outcome (30, 31). We hypothesized that 
properly activated pDCs, because of their IFN production, might stimulate myeloid DCs and enhance 
their ability to cross-prime CD8+ T cells, thereby inducing more efficient anti-tumor T cell responses 
when compared to in vitro generated DCs. This notion is supported by two independent studies 
demonstrating in mice that type I IFNs were critical for the induction of anti-tumor immune 
responses (32, 33). Therefore, to warrant clinical efficacy, pDCs should secrete type I IFN at the time 
of administration. Since previous studies showed that pDCs produced IFN within 12 hours after 
activation and then became refractory to further stimulation (34-36), isolated pDCs were maintained 
overnight in IL-3 and subsequently activated for 6 hours with FSME. Our approach resulted in 
clinically applicable pDCs with a stimulatory phenotype and secretion of type I IFNs in vivo. 
Accordingly, we now demonstrate that vaccination with such pDCs indeed induced an IFN signature 
based on the upregulated IFN-induced genes in the blood after  vaccination, validating our approach. 
For an optimal immune response the injected pDCs should migrate to neighboring lymph nodes and 
then to T cell areas. The observed migratory behavior and distribution over multiple lymph nodes of 
the injected pDCs might be linked to the expression of CCR7 (Supplementary Figure S2), the homing 
receptor for the chemokines CCL19 and CCL21 that are expressed by high endothelial venules and 
stromal cells in the T cell areas (29, 37, 38). The pDC migratory behavior is in agreement with 
previous studies, where although the majority of injected DCs reside at the injection depot (22, 28, 
39, 40), a substantial fraction of the pDCs migrated to subsequent lymph nodes. It is important to 
consider that the microenvironment influences cell migration (41). Therefore, a high number of pDCs 
at the injection site might affect the microenvironment. For example, pDC-derived IFNs could drive 
expression of chemokines resulting in the recruitment of immune cells, thereby circumventing the 
need for active migration of the pDCs themselves. Unfortunately, the clinical protocol did not allow 
lymph node resections, to further substantiate this important aspect. 
We used FSME as natural TLR agonist to activate pDCs. As FSME comprises a total inactivated virus 
we reasoned that during activation pDCs will process FSME-derived antigens and present antigenic 
peptides on HLA molecules. Indeed, we observed cellular as well as humoral responses against FSME 
in almost all patients. Therefore, commonly used vaccines are potentially interesting, to serve both 
as a TLR agonist and as a control antigen. In addition, it cannot be excluded that anti-FSME Th1 
responses contribute to the expansion of CD8+ tumor specific T cells. 
We previously demonstrated that the presence of anti-vaccine CD8+ T cells at sites of vaccine-
induced skin DTH reactions was correlated with favorable clinical outcome (23, 42). Several clinical 
studies in cancer patients have reported anti-vaccine T cell responses in the blood, but only in a 
minority of patients or after prolonged in vitro restimulation with antigen (43-46). Here, we observed 
the specific induction of tumor specific CD8+ T cells, which indicates that even small numbers of pDCs 
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can evoke antigen-specific immune responses. To verify if this tumor specific T cell response 
contributed to long-term tumor control, we compared the clinical outcome of our patients to that of 
carefully selected historical controls treated with standard DTIC chemotherapy. Although it must be 
emphasized that this study was not designed to evaluate clinical outcome, several interesting 
observations were made. First, progression-free survival in vaccinated patients was similar to that of 
the matched control patients, matching progression-free survival reported in literature (47-49). 
Remarkably, the 1-year and 2-year survival rates were 60% and 45% after pDC vaccination compared 
to 30% and less than 10% of the matched control patients respectively. To exclude that this 
discrepancy in survival might partially be influenced by subsequent salvage treatments, we carefully 
matched the total number of different treatments and the types of salvage treatments for both 
control group and the vaccinated patients (Supplementary Table S1). Secondly, we detected tumor-
specific CD8+ T cells almost in all patients with a long overall survival. Therefore, we hypothesize that 
the improved overall survival is related to the priming or restimulation of anti-tumor CD8+ T cells, 
which would be in line with our previous findings (23). Thirdly, given the low numbers of cytotoxic T 
cells that we detected, as compared to number reported in trials with monocyte- or CD34+ 
progenitor-derived DCs, it is tempting to speculate that other immune cells from the innate arm play 
an important role in assisting cytotoxic T cells. Therefore it would be extremely interesting to study 
the immune cell repertoire within resected lymph nodes in more detail. Comparable patterns, no 
effect on progression free survival but significantly extended overall survival, were recently described 
for other immunotherapies, especially anti-CTLA4 blockade (48). These findings support the notion 
that immunotherapy may act indirectly, rather than having a direct cytotoxic anti-tumor effect.  
The remarkable extended 2-year overall survival by a significant number (7 out of 15) of patients, 
urge for a randomized phase II clinical trial to confirm the potential of natural pDCs as an anti-cancer 
vaccine. 
 
 
Figure 6. pDC vaccination improves overall survival. Clinical outcome to pDC vaccination was compared to a group of 
carefully matched historical control patients who received Dacarbazine as first line treatment. (A) Progression-free survival 
for pDC vaccination was 4.0 months versus 2.1 months in the control group. Median overall survival data showed a 
remarkable improvement compared to matched control patients; 22.0 months versus 7.6 months. (B) Overall survival of 
pDC vaccinated patients was significantly improved compared to matched controls. Statistical significance between the 
survival of the groups was determined by a log-rank test, p=0,001. 
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Abstract 
The success of dendritic cell (DC) based immunotherapy to induce cellular immunity against tumors is 
highly dependent on accurate delivery and trafficking of the DC to T cell-rich areas of secondary 
lymphoid tissues. This article aims to provide an overview on DC migration in vivo and how migration 
to peripheral lymph nodes might be improved to optimize DC therapy. We focused on DC migration 
in preclinical models and human skin explants and on clinical vaccination trials studying migration of 
in vitro generated DC.DC migration requires an intricate interplay between the cell and its 
environment. To maximize migration for cellular therapy, it is important to optimize the generation 
of migratory DC as well as treatment strategies. 
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1. DC cancer immunotherapy 
Immunotherapy in patients with cancer aims to activate the immune system to eradicate the tumor 
and to induce specific and long lasting immunity to protect against recurrent disease. Since the 
discovery of dendritic cells as antigen presenting cells with the unique capacity to induce naive 
antigen-specific T cells, many experimental immune therapies are now based on the vaccination of 
cancer patients with ex vivo generated autologous DC loaded with tumor antigens. Although 
immunological responses are observed in most studies, clinical responses are limited to a minority of 
patients. Opportunities for improvement of clinical outcome lie in a number of variables, such as DC 
subsets and culture methods used for the generation of DC, antigen loading, route of administration, 
dose and frequency and others (1). One important aspect of cell based immune therapy is accurate 
delivery of the vaccine. DC must closely encounter and interact with T cells to exert their action. 
Therefore DC must reach the secondary lymphoid tissues, and enter the T cell-rich areas. It has now 
been generally accepted that the site at which T cell priming occurs significantly influences the 
homing characteristics of the effector cells. For example, subcutaneous (s.c.), but not intravenous 
(i.v.), injection of DC in a mouse melanoma model induced protective immunity against 
subcutaneously growing tumors (2-4). In contrast, metastatic-like lung lesions were controlled by i.v. 
immunization and only partially by s.c. immunization (4). Similarly, only DC from mesenteric lymph 
nodes (5) and Peyer’s patches  (6) induced the expression of the gut-homing integrin 47 on T cells. 
It is therefore not only essential to generate DC with high immunostimulatory capacity but research 
should also focus on maximizing migratory capacities and vaccine delivery. In this review we will 
discuss how endogenous DCs migrate and how this can be exploited to improve DC immunotherapy. 
 
2. In vivo migration of DC for therapy 
For the delivery of DC three different options for administration can be distinguished: in peripheral 
tissue, such as skin (intradermal (i.d.) or s.c.) and mucosa, into the lymphatic system (intralymphatic 
(i.l.) or intranodal (i.n.)), and intravenous administration (i.v.). Vaccine delivery and distribution after 
injection has been studied in several clinical trials. In these trials DC generated from blood-derived 
monocytes or CD34+ progenitor cells were radio-labeled with 111Indium or 99mTechnetium and the 
distribution after injection was imaged and quantified by scintigraphic imaging of the patients. This 
approach showed that after i.v. injection DC are found in liver, lung, spleen and bone marrow (7; 8). 
In mice, DC reach the liver and spleen after a short accumulation in the lungs, and in some studies 
very low amounts of DC were detected in mesenteric and mediastinal nodes (2; 9). This is consistent 
with the finding that myeloid DC in the peripheral blood do not enter lymph nodes via the high 
endothelial venules, but first migrate to peripheral tissues and subsequently to draining lymph nodes 
via the afferent lymphatics (10). To target peripheral lymph nodes DC can be injected into the skin or 
directly into the skin-draining lymphatics or lymph node. In mice, subcutaneous (s.c.) injection is 
effective in both targeting DC to draining lymph nodes and inducing immune responses (2-4; 9; 11; 
12). However, significantly more DC reached the draining lymph nodes after intradermal (i.d.) 
injection compared with s.c. injection (13). In human, no (7; 14; 15) or little (16; 17) migration of DC 
to skin-draining lymph nodes was found after s.c. injection of DC. Intradermal injection is more 
effective although the number of DC that reach the regional lymph nodes did not exceed 4% (7; 14-
20). Best results have been accomplished with DC administered directly into the nasal submucosa. In 
this clinical study, DC showed rapid migration to the regional lymph nodes (21), however, whether 
this also leads to (systemic) immunity is not known. Alternatively, ex vivo generated DC can also be 
injected directly into lymph nodes or lymphatic vessels draining the skin, as a result of which all cells 
will be targeted to the draining lymph nodes (8; 18; 19; 22). Initial analyses showed that intranodal 
(i.n.) injection is not always successful, even when it is performed under ultrasound guidance by a 
highly experienced radiologist (22). Intralymphatic (i.l.) injection is an even more challenging 
technique that requires a highly skilled surgeon and hospital admission. Importantly, despite the fact 
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that most of the injected cells reach one or in most cases multiple lymph nodes, DC still need to 
migrate into the T cell-rich areas. Thus to conclude, for large-scale clinical trials i.d. and i.v. 
administration of DC are preferred, while they are simple and robust, although one important 
drawback is the low efficiency in targeting DC to peripheral lymph nodes. Inefficient delivery of ex 
vivo generated DC to T cell rich areas in secondary lymphoid organs may contribute to the limited 
clinical responses to DC based immunotherapy. Maximizing the migration of DC for cellular therapy 
might enhance these responses.  
 
3. What can be learned from endogenous DC migration?  
In the human body DC continuously migrate from the periphery into lymphatic tissues to orchestrate 
the immune system both in the presence and the absence of ‘danger’ signals. In an effort to 
maximize the migration of DC for cellular therapy it is indispensable to know how DC migration is 
initiated and what factors are essential for the cell to move towards the draining lymph node and 
enter the T cell-rich areas. 
 
3.1 Emigration of DC from peripheral tissues towards lymph nodes 
In a steady state, immature myeloid DC mainly reside in peripheral tissues where they continuously 
sample the environment for ‘danger’ signals. When they sense such signals the DC rapidly become 
activated, mature and emigrate from the tissue. Langerhans cells (LC) migrate from the epidermis to 
the draining lymph node upon application of proinflammatory mediators on the skin, such as contact 
allergens (23; 24) or toll-like receptor (TLR) ligands like CpG (25) and lipopolysaccharide (LPS) (26; 
27). Critical factors are the local production of tumor necrosis factor  (TNF) and interleukin (IL)-1 
and of prostaglandin E2 (PGE2). Indeed, direct injection of TNF (28-30) or IL-1 (31; 32) into the 
dermis of mice or human skin explants induces the emigration of LC (reviewed in (33)). Similarly, 
neutralizing antibodies to TNF and IL-1 inhibit the spontaneous migration of DC from skin explants 
in mice and human (34). Interestingly, TNF effects were neutralized by anti-IL-1 and vice versa (32; 
34; 35), demonstrating that both cytokines are required for the initiation of DC migration. That the 
emigration upon proinflammatory stimuli is very rapid is illustrated by the fact that lung DC and LC 
migrate within 2 hours to draining lymph nodes after viral inoculation (36) or upon the application of 
the proinflammatory cytokines, respectively (30; 32). Importantly, TNF effects were dose 
dependent: low concentrations (50 U/ml) of TNF augmented LC migration, whereas high doses 
(5000 U/ml) of the same cytokine inhibited LC migration in human skin explant (34). 
Proinflammatory mediators exert their effects on different levels: while they act directly on the DC 
by inducing DC maturation and initiation of DC migration to the draining lymph nodes, they also 
stimulate the local environment to produce factors, such as chemokines that promote emigration of 
DC and recruitment of circulating immune cells. Furthermore, LPS, IL-1, and TNF also induce the 
production of PGE2 (37), which has proven to be required for DC migration and increases the 
responsiveness of monocyte-derived DC of the lymph node homing receptor, CCR7 (38-41). When 
applying DC therapy, we may benefit from these effects by stimulating the migration of injected DC 
in situ. By applying proinflammatory stimuli to the site where ex vivo generated DC will be injected, 
the local environment will be conditioned such that the emigration of the injected cells is favored. 
Indeed, Martín-Fontecha et al. (42) described that in mice conditioning of the injection site increased 
the migration of subcutaneously injected BM-DC up to 10-fold. The footpath of mice was pretreated 
by injection of TNF or IL-1 or with DC, respectively 8 or 24 hours before vaccination. As a result 5- to 
10 fold more fluorescently-labeled DCs were recovered from the draining lymph nodes. Accordingly, 
the T cell responses were up to 10 fold enhanced. The authors hypothesized that local inflammation 
induced by the injection of DC or pro-inflammatory cytokines conditioned the environment to 
promote rapid migration of DC towards the lymph nodes. To support this, they showed that the 
85
Part 2, Chapter 5 
 
lymph node chemokine CCL21 is up-regulated in the local lymphatics. These data show that 
conditioning of the skin has potential in increasing DC migration to lymph nodes after i.d. or s.c. 
injection. Skin conditioning prior to vaccination with mature DC has not yet been described in 
humans, but is a promising opportunity to improve DC migration. When proinflammatory mediators 
act directly on the DC, DC migration to the draining lymph nodes is likely initiated by the induction of 
DC maturation. With the use of radio-labels it was shown that immature, monocyte-derived DC are 
not able to migrate to subsequent lymph nodes upon injection in patients. Stimulating the 
maturation of immature DC after i.d. injections may improve migration and circumvents the need for 
in vitro maturation. Prins et al. showed that the combination of Imiquimod (containing TLR7 ligand) 
and s.c. injection of immature DC dramatically increased both the persistence and the trafficking of 
DC into the draining lymph nodes of mice (43). In mice, migration of immature DC was enhanced 
from 1.8 to 6.5% when cells were injected into skin that was pretreated with Imiquimod. 
Importantly, although migration of mature DC injected in untreated skin was higher (10%), the CTL 
responses induced after injection of immature DC in pretreated skin were superior to those induced 
by mature DC alone (20). In follow-up studies, Nair et al. injected immature DC intradermally in 
human skin pretreated with Imiquimod. Application of Imiquimod onto the injection site every other 
day for three times before injection of immature DC increased migration of DC compared to 
immature DC alone. Again the percentage of migrating cells did not exceed that of injections with 
mature DC (20). Application of Imiquimod before injection of immature DC for cellular therapy seems 
therefore a valid alternative to circumvent ex vivo maturation of DC, but not for amplifying the 
percentage of migrating DC. Its effect may increase after optimization of the timing and dose of 
Imiquimod, for example to apply the agent not before but after the injection of the immature cells, 
so that Imiquimod can directly stimulate the injected DC. Interestingly, it has been described that DC 
that migrate into the lymph nodes are not uniquely responsible for the activation of specific T cells. 
They can transfer antigen to resident DC and thereby spread antigens to a larger pool of DC to 
increase priming efficiency  (44; 45). This would mean that, when antigen loading is sufficient, only a 
small number of cells need to reach the draining lymph node. How antigens are being transferred to 
lymphoid DC and what the requirements are for the maturation state of the immigrating DC to 
induce effective T cell responses is yet unknown. Addressing these questions may renew the insights 
on the type of DC and method of antigen-loading that are most appropriate for DC immunotherapy. 
 
3.2 DC phenotype 
Homing to specific tissues is controlled by the combined expression of different chemokine receptor 
and specific adhesion molecule receptors. After stimulation with proinflammatory stimuli, DC 
maturation is initiated and many molecules that are important for their change in function are either 
up- or down-regulated. Not only must DC change from an endocytic sentinel into a professional 
antigen presenting cell, but it also needs to detach from its local environment, migrate through 
surrounding tissues, enter the lymphatics and subsequent the draining lymph node and in particular 
penetrate the T cell area. To emigrate from the periphery towards the draining lymph nodes, DC 
rapidly change their repertoire of chemokine receptor and adhesion molecules and the expression of 
many other migration related proteins, such as matrix metalloproteases and cytoskeletal proteins. In 
this section an overview will be presented of chemokine receptors, adhesion molecules and MMP 
that were found essential in lymph node homing of endogenous DC. 
 
3.2.1 Chemokine receptors 
The dominant mediator in the mobilization of DC to lymph nodes via lymphatics is CCR7 (46-48). 
Constitutive expression of ligands CCL19 and CCL21 is found at the luminal site of high endothelial 
venules and in the T cell rich areas of secondary lymphoid tissues, such as tonsil, spleen and lymph 
nodes (49). CCL21 is also expressed on lymphatic vessels in the peripheral tissues and its expression 
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is increased during inflammation (42). The expression of CCR7 is essential for both the entry of DC 
into lymphatic vessels at peripheral sites and the entry into T cell rich areas of lymphoid tissues in 
both steady state and under inflammatory conditions (48). Besides CCR7 several other chemokine 
receptors play a role in DC homing from the periphery to draining lymph nodes but appear less 
important. Lung myeloid DCs are dependent on CCR5 and its ligand CCL5 for migration and 
maturation, since these events are significantly impaired in CCL5-/- and CCR5-/- mice. However, this 
effect seems to be mediated via CCR7 as in these mice the failure of DC to migrate to draining lymph 
nodes is associated with impaired up-regulation of CCR7 (36). Similarly, emigration of skin-DC (50) 
and lung-DC (51) to the draining LN was only partially blocked in CCR8-deficient mice. Migration of 
plasmacytoid DC matured with CpG for 24 hour from peripheral blood into the lymph nodes was 
described to depend on the CXCR3 ligand CXCL9 (10). But also pDC express high levels of CCR7 and 
gain responsiveness to CCR7 upon maturation (10; 52), suggesting that CCR7 is also important in 
lymph node homing of pDC. Overall, it appears that CCR7 is the main receptor for lymph node 
homing and that targeting from the periphery to the lymph node is promoted by additional 
chemokine receptors. For cellular therapy, chemokine-mediated migration of DC may be enhanced in 
two ways, by manipulating the local chemokine expression or by manipulating the expression of 
chemokine receptors by the DC itself. As described in the previous section, conditioning of the skin 
injection site, increased the expression of CCL21 on the local lymphatics (42). Inducing the expression 
of chemokines, such as CCL21, on (local) lymphatics before or together with the DC injection may 
improve the recruitment of CCR7-expressing cells to afferent lymphatics and eventually the draining 
lymph nodes. The chemokine receptor expression profile of DC is dependent on DC culture and 
maturation methods. The addition of PGE2 as maturation stimulus enhances CCR7 expression and its 
activation, and drives effective migration of monocyte-derived DC towards CCR7 ligands CCL19 and 
21 (38-40; 53). Another approach could be to introduce the expression of chemokine receptors in the 
ex vivo generated DC, which will be discussed below.  
 
3.2.2 Adhesion molecules 
Adhesion molecules play a pivotal role in successive steps in the process of migration. Therefore, 
their expression profile is tightly controlled. A switch in adhesion molecule expression profile is 
required to allow detachment of resident DC from existing interactions and to enable migration 
through the lymphatic system and into the lymph node. Thus far, no extensive analysis of the 
molecules implicated in transendothelial migration of DC into the lymphatic system has been carried 
out (54), but a variety of adhesion molecules is involved in the emigration of DC through the 
extracellular matrix (ECM) and in emigration of LC from skin. In mice LC, 6 and 4 integrins are 
oppositely regulated during migration to lymph nodes. 6 integrin is up-regulated and contributes to 
migration of LC (55). When the interaction between 6 and laminin was blocked, the emigration of 
LC from the epidermis was completely abrogated, although the cells had lost their cellular processes 
and seemed to have detached from neighboring keratinocytes. By contrast, blocking of 4 integrin 
had no effect on LC migration (55). In addition, ICAM-1 and LFA-1 (L2) were found to play a 
significant role in contact hypersensitivity-induced migration of LC to regional lymph nodes (56). Also 
non-integrins are regulated during DC migration and maturation. In mice CD44 is described as an 
adhesion molecule that binds to ECM-compound hyaluronic acid, which is expressed on the leading 
edge of migrating cells. Migrating and lymph node LC and DC express different CD44 splicing variants 
(57). CD44 can also bind the matrix metalloprotease MMP9 to the cells surface and mediate 
degredation of extracellular matrix (58). Blocking of CD44 inhibited the migration of LC from the 
epidermis. Furthermore, it prevented binding of both activated LC and DC to the T cell rich areas of 
lymph nodes (57). Another example of adhesion molecules regulated during DC migration are the 
syndecans (SDC), a family of transmembrane proteoglycans. In human skin explants, SDC1 and 4 (59) 
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have been implicated in the migration of LC. SDC1 was down-regulated and SDC4 was strongly up-
regulated during LC emigration and within the first hours of LPS-induced DC maturation (59). 
Blocking SDC4 decreased DC motility. Thus, SDC1 may be involved in stable adhesive interactions 
with the ECM, whereas SDC4 seems involved in trafficking through the ECM. Lymph node homing 
from the peripheral blood is dependent on L-selectin, and is required for efficient rolling and 
attachment on HEV. L-selectin is expressed on a subset of circulating leukocytes, such as naive T cells 
(60) and pDC (61), but not on DC of the myeloid lineage. Next to L-selectin, pDC depend on the 
inducible endothelial adhesion molecule E-selectin to enter lymph nodes (10). CD44, which is a ligand 
for E-selectin, may therefore also play a role in pDC migration. In addition to chemokine 
responsiveness, manipulation of the expression of adhesion molecules on ex vivo generated DC may 
improve the migratory capacities of the cellular vaccine. 
 
3.2.3 Matrix metalloproteases 
To move through the physical obstacles, such as basement membranes and ECM, they express and 
secrete matrix metalloproteases (MMP). Upon triggering with IL-1 and TNF, murine LC increase 
the expression of MMP9, (57; 62). Human immature monocyte derived-DC secrete MMP1, 2, 3 and 9 
(63; 64), and their inhibitors (TIMP1 and 2) (63; 64), which are down-regulated upon stimulation with 
TNF (64). The importance of MMP in DC migration through tissues is demonstrated in MMP9-
deficient mouse, where DC migration through tracheal epithelial tight junctions was impaired (65). 
Furthermore, in human skin explants antibodies against MMP2 and 9 and inhibitors of MMP 
markedly reduced the migration of human LC and dermal DC (66; 67). Also, up-regulation of genes 
encoding matrix metalloproteinases (MMP), such as MMP1, 10 and 12 correlated with enhanced 
migratory capacity of DC measured in Matrigel (68). Thus, MMP are essential for effective migration 
through extracellular matrix. In brief, DC need to express appropriate chemokine receptors, adhesion 
molecules, and other migration-related proteins in addition to high T cell stimulatory capacities. To 
achieve maximal DC migration after injection, we need to exploit this information for the 
development of better DC or DC vaccination protocols.  
 
4. Generating DC with migratory capacities 
The characteristics of DC that are cultured in vitro are determined by the source and subset of the DC 
but even more by the culture and maturation procedures. Thus the migratory capacities can be 
manipulated by choosing the right subsets and culture conditions or by introducing migration-related 
proteins. 
 
4.1 Dendritic cell subsets  
The isolation of DC and DC precursors for cellular therapy DC or DC precursors is dependent on the 
availability of these cells and is therefore constrained to the peripheral blood leukocytes. From the 
circulation, monocytes and CD34+ progenitor cells can be isolated that can be differentiated into DC, 
but also myeloid and plasmacytoid DC (precursors) that already have DC phenotype. The method of 
isolation and the subsequent culture methods can influence the final characteristics of the DC. For 
example, isolation of cells by immunoselection via subset-specific membrane markers may 
preactivate the cells. Monocytes that are immunoselected via the novel monocyte specific molecule 
CD300e, differentiate into DC that show greater migration towards CCL21 compared with CD14-
immunoselected DC (69). Currently, most clinical trials use DC generated from monocytes or CD34+ 
progenitor cells, as high numbers can be obtained from the peripheral blood after leukopheresis. A 
drawback is the relatively long necessity of in vitro culturing to generate fully differentiated DC of 
more than one week. Recently, also peripheral blood plasmacytoid DC are considered for 
immunotherapy, since pDC not only can directly induce antigen-specific CD8+ T cell immune 
responses (70; 71), but are also thought to enhance the priming ability of myeloid DC (71). Another 
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interesting aspect is that they can enter the lymph nodes directly from the blood (10). pDC isolated 
from blood already have DC phenotype and only require additional activation to induce DC 
maturation, which makes them potential candidates for cellular therapy, despite their low frequency 
in the blood. 
 
4.2 Ex vivo culture of monocyte derived DC 
The phenotype of ex vivo differentiated DC depends greatly on the culture conditions. Generally, 
monocytes are differentiated into DC in the presence of IL-4 and GM-CSF. Different cytokine 
cocktails, using cytokines such as IL-15, IL-13, IFN, IFN and TNF, have been used for DC 
differentiation and function. Monocytes cultured with IFN instead of IL-4 differentiate into 
immature DC with high expression of MMP9 and enhanced migration through ECM in response to 
CCL3 and CCL5. However, IFN-DC migrated similarly towards the lymph node chemokine CCL21 
compared to LPS-matured DC (72). Perhaps even more important than the differentiation conditions 
is the maturation procedure of the DC. In current clinical trials exploiting DC for cellular therapy, 
monocyte-derived DC are generally matured with cytokine cocktail containing PGE2, which was first 
described by Jonuleit et al., based on inflammation induced monocyte-derived cytokines TNF, IL-1, 
IL-6 and PGE2. PGE2 greatly enhanced the migratory capacities by increasing the CCR7 responsiveness 
(38-40; 53) and inducing high-speed migration (41). The effect of different maturation stimuli on the 
migratory capacities of DC is broadly studied. According to the hypothesis of Luft et al. mature DC 
can be either migratory or cytokine-secreting (73). Maturation with TLR-ligands or with strong and 
sustained CD40 signaling induce DC with high IL-12p70 secretion and low migratory capacities (68; 
73-76), whereas DC matured with PGE2 containing cocktails show a migratory-type functional profile 
but produce little or no IL-12p70 (38; 77). Recently, galectin-1 was described as a new DC maturation 
factor resulting in up-regulation of genes related to cell migration through ECM (tenascin, MMP1, -10 
and -12) and better chemotactic migration through Matrigel compared to LPS-matured DC, but also 
these cells did not produce IL-12p70 (68). The addition of IFN enhances the IL-12p70 production by 
DC, but at the same time negatively influences DC migratory capacities both in vitro  (76; 78; 79), and 
in vivo (80). So indeed, upon maturation DCs seem to differentiate toward either a migratory or a 
cytokine producing phenotype, while in fact both are important. For DC therapy, the lack of 
production of Th1 inducing cytokines, such as IL-12p70, by DC matured with PGE2 containing 
cocktails, is regarded as a major drawback. However, primary IL-12p70 production occurs during the 
first 24 hours of DC maturation and may not be relevant for DC therapy, since ex vivo generated DC 
are generally exposed to maturation stimuli for 24 to 48 hours. Recently, we observed that although 
PGE2 inhibits the primary production of IL-12p70 upon DC maturation with TLR-ligands, it does not 
prevent IL-12p70 production upon DC-T cell contact  (76). Thus, by stimulating DC with a combination 
of maturation stimuli that both promote cytokine-secretion and PGE2, DC can be generated that have 
the ability to migrate to draining lymph nodes and to secrete IL-12p70 locally. 
 
4.3 Manipulation of DC expression profiles  
When specific DC characteristics cannot be attained via culture of maturation methods, phenotypic 
features of DC necessary for migration or T cell stimulation can also be achieved by manipulation of 
the cell by transducing the desired gene of gene transcript into the ex vivo generated cells. For 
example the homing of DC can be manipulated by transfection with specific homing receptors. 
Transduction of the CCR7 gene by RGD fiber-mutant adenovirus vector generated DC with strong 
chemotactic activity for CCL19 and a mature phenotype. Importantly, CCR7-DC injected i.d. into mice 
did accumulate in draining lymph nodes about 5.5 fold as efficient as the control vector-applied DC  
(81). DC that normally only enter lymph nodes via the lymphatics can be manipulated to enter lymph 
nodes via the peripheral blood by transfecting the appropriate receptors. Robert et al. retrovirally-
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transduced murine DC with a chimeric E/L-selectin, providing them with the ability to extravasate 
directly from blood by binding to peripheral node addressin (PNAd), an adhesion molecule present 
on the lymph node vascular endothelium (60). As ethical and regulatory restrictions hamper the use 
of retrovirally-transduced DC in human, alternatives are being developed. To avoid the introduction 
of foreign DNA into patients, cells can now be transduced with mRNA encoding the molecules of 
interest. Already, transfection with mRNA encoding for tumor antigens is now being employed in 
clinical trials for the antigen-loading of DC, circumventing the use of HLA-restricted peptides. 
Recently, Dörrie et al. elegantly showed that human monocyte derived DC electroporated with E/L 
selectin-encoding mRNA indeed gained the capacity to role by binding to sialyl-Lewisx, creating the 
potential to extravasate through the HEV into the lymph node. Thus mRNA transfection opens many 
opportunities to manipulate DC to express proteins essential for either migration of immune 
activation, which may lead to the creation of DC with both migratory and immune stimulatory 
capacities.  
 
5. Expert Opinion 
DC migration requires an intricate interplay between the cell and its environment. To maximize 
migration for cellular therapy, it is important to take into account all the different variables and 
realize that the route of administration may have great influence on the homing of the activated T 
cells and therefore the clinical outcome, and that for example, DC for intravenous injection will need 
different characteristics than when injected into the skin. In mice it was demonstrated that in DC 
immunotherapy the spleen is essential for the clearance of lung metastasis, but not subcutaneously 
growing tumors. In contrast, peripheral lymph nodes were essential for the rejection of 
subcutaneously growing tumors and not lung metastasis (4). Similarly, only DC from mesenteric 
lymph nodes could induce gut-homing T cells  (5). Thus, to induce systemic immunity, both the 
spleen and lymph nodes should be targeted during immunotherapy. This can be achieved by 
combining intravenous injections with intradermal or intranodal injection in the case of cutaneous 
tumors or with intraperitoneal injections in the case of intestinal tumors. Alternatively, DC can be 
injected that enter the peripheral lymph nodes directly from the blood, like pDC or ex vivo generated 
DC in which the required receptors for blood-lymph node homing are introduced. Identification of 
the factors that determine the homing of T cells might make it possible to create DC that can instruct 
T cells to home to specific tissues regardless of the route of administration. 
When the choice is for i.d. injection, DC migration can be stimulated by manipulating either the 
injection site or the DC itself. Conditioning of the skin injection site can act in two ways: Induce the 
local production of factors that promote the emigration of DC, such as chemokines, or directly 
stimulate the DC to migrate. An important factor in this is the timing. If pretreatment of the skin is to 
early, the stimulatory effect may have faded away, or induce inflammatory conditions that retain DC 
rather than stimulate emigration. Focusing only on conditioning of the site of injection might not be 
sufficient. It is important to consider that emigration of resident DC is interrelated with DC 
maturation. In the first hours after the initiation of migration to the draining lymph nodes DC rapidly 
change the expression levels of chemokine receptors, adhesion molecules and other migration-
related MMP and TIMP that are important for trafficking through the ECM and via lymphatics. For 
immunotherapy, DC are generally cultured with maturation stimuli for 24 to 48 hours prior to 
injection. These cells have excellent migratory capacities in in vitro assays, but their capability to 
migrate through barriers such as ECM, and lymphatic or blood endothelium, has been poorly studied.  
Intradermal injection of immature instead of mature DC in combination with conditioning of the skin 
with TLR-ligands, such as Imiquimod, is an interesting approach and should be further developed. 
Important is to realize that also here timing is crucial. Delivery of the maturation stimuli 
simultaneously with the immature DC or perhaps just prior to injection may ensure a direct effect of 
the stimuli on the DC. Alternatively, preactivated but not yet fully mature DC could be injected in the 
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skin, possibly combined with local conditioning of the injection site. Whatever route of 
administration of DC subsets is selected, to improve the proficiency of the cells, they can be 
endowed with molecules that improve lymph node homing, and DC can be provided with T cell 
stimulatory molecules, like IL-12 or costimulatory molecules. 
Now RNA transfection of DC has proven safe and effective this should be exploited to manipulate 
and control DC function including migratory and costimulatory properties. Similary, proteins that 
compromise the immunostimulatory and migratory capacities of DC may be silenced using small 
interfering RNA (siRNA). That this may indeed be effective was recently demonstrated by.Kang et al. 
(83) who demonstrated that by silencing pro-apoptotic proteins the survival of DC was significantly 
increased and lead to an enhanced T cell response upon vaccination in mice. At the same time, 
Dannull et al. (84) showed that the ability of DC to stimulate anti-tumor immunity could be enhanced 
by down-modulating the immunoproteasome with siRNA.  
In conclusion, optimal DC migration for cellular therapy against tumors, may be attained by creating 
both a stimulatory environment and generating of DC with a high migratory capacity and immune 
activation potential. Maximizing DC trafficking, homing to lymph nodes and T cell activation to a level 
that is adequate to induce a competent immune response against the tumor and long-lasting 
protection against recurrence disease is essential for the development of DC immune therapy into a 
valid treatment. Exploiting RNA and or siRNA to enhance DC function will certainly contribute to the 
next generation of DC vaccines. 
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Abstract 
Success of immunotherapy with dendritic cells (DC) to treat cancer is dependent on effective 
migration to lymph nodes and subsequent activation of antigen-specific T cells. In this study, we 
investigated the fate of DC after intradermal or intranodal administration and the consequences for 
the immune activating potential of DC vaccines in melanoma patients. DC were intradermally or 
intranodally administered to 25 patients with metastatic melanoma scheduled for regional lymph 
node resection. To track DC in vivo with scintigraphic imaging and in lymph nodes by 
immunohistochemistry, cells were labeled with both 111In and superparamagnetic iron oxide. After 
intradermal injection maximally 4% of the DC reached the draining lymph nodes. When correctly 
delivered, all DC were delivered to one or more lymph nodes after intranodal injection. Independent 
of the route of administration, large numbers of DC remained at the injection site, lost viability and 
were cleared by infiltrating CD163+ macrophages within 48 hours. Interestingly, 8710% of surviving 
DC preferentially migrated into the T cell areas, where they induced antigen-specific T cell responses. 
Even though more DC reached the T cell areas, intranodal injection of DC induced similar antigen-
specific immune responses as intradermal injection. Efficient immune responses were already 
induced with less than 5105 DC migrating into the T cell areas. 
Monocyte-derived DCs have high immune activating potential, irrespective of the route of 
vaccination. Limited numbers of DC in the draining lymph nodes are required to induce antigen-
specific immunological responses. 
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Introduction 
In cancer patients the immune system has not been able to establish an effective immune response 
against the tumor. Immunotherapy aims at educating the immune system to generate effective 
tumor-specific immune responses. Dendritic cells (DC) are specialized antigen presenting cells that 
can induce de novo anti-tumor responses and are excellent candidates for cell-based 
immunotherapy. While many DC-based clinical studies for the treatment of cancer have shown the 
feasibility and safety of DC vaccinations (reviewed in 1,2), clinical efficacy of the therapy still needs to 
be improved (3). One important factor that determines the outcome of DC therapy is the delivery of 
the vaccine to immune-reactive sites, such as lymph nodes, and more specifically to the T cell-rich 
area, the paracortex. To exert their action DC must closely encounter and interact with T cells. In 
addition, it has now been generally accepted that the site at which T cell priming occurs significantly 
influences the homing characteristics of the effector cells (4-8). Therefore, the route of 
administration may be of crucial importance. Currently, for treatment of solid tumors intradermal or 
subcutaneous administration of DC is most frequently used (91 clinical trials), followed by 
intravenous (47 trials) and intranodal (9 trials) injection (reported on www.mmri.mater.org.au). 
Scintigraphic imaging of cancer patients  injected with DC labeled with 111In or 99mTc demonstrated 
that only after  intradermal (i.d.) or subcutaneous (9-16) intranodal (i.n.) (9,11,17) and intralymphatic 
(11,18) injection DC migrated to the draining lymph node regions. More substantial evidence was 
obtained in our previous study where DC were labeled with both 111In and paramagnetic iron oxide 
particles (SPIO), which is a suitable contrast agent for magnetic resonance imaging (17). We 
demonstrated that after i.n. injection DC were indeed present in the injected node and had migrated 
to nearby lymph nodes. However, these images do not show how many cells actually reach the T cell 
area and provide no information on the phenotype and quality of the injected cells and whether the 
label is still present in the administered cells. SPIO-labeled DC can be easily visualized in resected 
lymph nodes and allow detailed analysis of the fate and local immune effects of the injected DC in 
the targeted lymph nodes. We demonstrate that, although the majority of non-migrating DC at the 
injection site are phagocytosed by macrophages, part of the SPIO-labeled cells migrate into the T cell 
areas, exhibit a DC phenotype, and activate specific T cells. Since immune responses in both groups 
of patients were comparable, there was no advantage of i.n. injection over i.d. administration. 
 
Materials and methods  
Patients 
Eligibility criteria included stage III and IV melanoma according to AJCC criteria (19), HLA-A2.1 
phenotype, and melanoma expressing the melanocyte-associated antigens gp100 and tyrosinase. 
The study was approved by our Institutional Review Board, and written informed consent was 
obtained from all patients.  
 
Treatment schedule 
At day -7 peripheral blood mononuclear cells were obtained by leukapheresis for DC-culturing. DC 
loaded with both KLH and tumor associated antigen peptides were injected either i.n. into a lymph 
node of the region that was to be resected or i.d. in close vicinity of this lymph node region. On day 
0, patients received either an i.n. injection of 111In-labeled DC (7.5106) mixed with SPIO-labeled DC 
(7.5106, total volume 100 μl) directly into a lymph node, or an i.d. injection of DC labeled with both 
111In and SPIO (15106, total volume 100 μl). I.n. injections were performed under ultrasound 
guidance by an experienced radiologist. Scintigraphic imaging of the lymph node region was 
performed 30 minutes after i.n. injection and 24, 48, and/or 48 hours after i.n. or i.d. injection, 
before dissection of the regional lymph nodes. Two patients received an i.n. injection in both the left 
and right lymph node region. Radiolabeled lymph nodes were dissected from the surgical specimen 
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under guidance of a gamma probe (Europrobe®, Eurorad, Strasbourg, France) and then fixed in 
Unifix® (Klinipath; Duiven, The Netherlands). The lymph nodes were embedded in paraffin and 
processed for histology and immunohistochemistry. Patients received three more vaccinations at 
days 14, 28 and 42.  
 
DC culture and labeling  
DC were generated from adherent peripheral blood mononuclear cells by culturing in the presence of 
interleukin-4 (500 U/ml) and granulocyte-monocyte colony stimulating factor (800 U/ml) (both 
Cellgenix, Freiburg, Germany). On day 4 the immature DC were loaded with the control antigen 
keyhole limpet hemocyanin (KLH, 10 μg/ml, Calbiochem, Darmstadt, Germany) and labeled with SPIO 
by adding 100 µg Ferumoxide/ml (Endorem®, Laboratoire Guerbet, Aulnay-sous-Bois, France) three 
days after the onset of DC culturing (17). On day 5, DC were matured with autologous monocyte-
conditioned medium supplemented with prostaglandin E2 (10 g/ml, Pharmacia & Upjohn, Puurs, 
Belgium) and 10 ng/ml recombinant tumor necrosis factor- (Cellgenix, Freiburg, Germany) for 48 
hours, as described previously (20,21). DC were pulsed with the melanoma peptides gp100:154-167, 
gp100:280-288, tyrosinase:369-376 as described previously (9). Mature DC were labeled with 111In-
oxine (Covidien, Petten, The Netherlands) in 0.1 M Tris-HCl (pH 7.0) for 15 minutes at room 
temperature as described previously (9,20) resulting in 4 MBq activity per 7.5106 cells. 
 
Scintigraphic imaging 
In vivo and ex vivo planar scintigraphic images (256256 matrix, 174 and 247 keV 111In photopeaks 
with 15% energy window) of the injection depot and corresponding lymph node basin were acquired 
with a gamma camera (Siemens ECAM, Hoffman Estates, IL) equipped with medium energy 
collimators, at day 0 and day 2). Migration was quantified by region of interest analysis of the 
individual nodes visualized on the images and expressed as the relative fraction of 111In-labeled DC 
that had migrated from the injection depot to successive lymph nodes after 2 days.  
 
Iron-staining and immunohistochemistry of histopathological sections 
Sections (5 µm) of the resected radiolabeled lymph nodes were stained stained with hematoxilin and 
eosin (HE) or with Prussian blue to detect SPIO-labeled cells. Slides were stained with 2% potassium 
hexacyanoferrate (II)-trihydrate in 0.2 M HCl for 15 minutes and counterstained with 0.05% nuclear 
fast red in 5% aluminum sulphate. Immunohistochemical stainings were performed on paraffin-
embedded tissue sections using monoclonal antibodies. Paraffin sections were de-waxed and 
rehydrated. All reactions were performed at room temperature, unless stated otherwise. 
Endogenous peroxidase activity was blocked by incubation in phosphate-buffered saline (PBS) 
containing 3% H2O2 for 30 min. After rinsing with PBS, antigen retrieval consisted of microwave 
boiling in either 10 mM sodium citrate buffer (pH 6.0) or 10 mM EDTA/1 mM Tris buffer (pH 8.0 or 
9.0) for 10 min, depending on the primary antibody. After boiling, the slides were allowed to cool 
down for at least 2 h. After rinsing with PBS, slides were pretreated with 20% normal horse serum for 
10 minutes to reduce nonspecific staining. All sera and antibodies were dissolved in PBS with 1% BSA. 
Subsequently, slides were incubated in a humidity chamber with the primary antibody at 4° C for 16–
20h. The following primary monoclonal antibodies were used: CD4, CD8 (both from Beckman 
Coulter, Mijdrecht, The Netherlands) CD25, CD69, CD83 and CD163 (Novocastra, Newcastle upon 
Tyne, UK). The ABC (avidin–biotin complex, Vector, Burlingame, USA) method was used for 
visualization with 3, 3'-diaminobenzide hydrochloride solution (DAB). Staining of the DAB substrate 
was intensified with a 0.5% copper sulfate solution. Slides were counterstained with hematoxylin 
solution or nuclear fast red. Sections were analyzed by microscopy (Zeiss Axioskop 2 plus, Zeiss, 
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Sliedrecht, The Nehterlands or Leica DMLB microscope, Lieca, , Wetzlar, Germany) using ProgRes 
Capture Pro (Jenoptik, Jena, Germany) or Leica IM500 (Leica) software. 
 
Humoral responses to KLH 
Antibodies against KLH were measured in the serum of vaccinated patients by enzyme-linked 
immunosorbent assays (ELISA) (22). Microtiter plates (96 wells) were coated overnight at 4C with 
KLH (25 μg/ml in PBS per well). After washing the plates, different concentrations of patient serum 
(range 1 in 100 to 1 in 500,000) were added for 1 hour at room temperature. After extensive 
washing, specific Ab (total IgG, IgG1, IgG2, and IgG4) labeled with horseradish peroxidase were 
allowed to bind for 1 hour at room temperature. Peroxidase activity was revealed using 3,3’ 5,5-
tetramethyl-benzidine as substrate and measured in a microtiter plate reader at 450nm.  
 
Proliferation assay 
Cellular responses against KLH were measured in a proliferation assay. Briefly, peripheral blood 
mononuclear cells (PBMC) isolated from blood samples taken before each DC vaccination were 
plated in a 96-well tissue culture microplate with or without KLH. After 4 days of culture, 1 μCi/well 
of tritiated thymidine was added for 8 hours, and incorporation of tritiated thymidine was measured 
in a -counter.  
 
Isolation of lymph node DC and T cells 
Cell suspensions were made from resected radiolabeled lymph nodes from 3 patients. Lymph node 
tissue was cut into small fragments in Hanks Balanced salts solution medium (HBBS, GIBCO), with 50 
g/ml collagenase type 1A , 10 μg/ml DNAse and 1 μg/ml trypsin inhibitor (Sigma Chemical Co., St. 
Louis, MO). The fragments were incubated for 30 minutes at 37C. For the isolation of DC-T cell 
rosettes, the large fragments were left to settle down and the supernatant was transferred to a fresh 
tube. SPIO-containing DCs were isolated with the use of a Dynal MPC® magnet. Cells were washed 
with RPMI supplemented with 7% human serum. The isolated SPIO-DC were spun onto microscope 
slides and stained with HE. From 2 patients lymph node cells were cultured 4 to 6 weeks in RPMI/7% 
human serum and 200 IU/ml of IL-2. KLH-specific T cell proliferation was measured in a proliferation 
assay. Fresh autologous PBMC were loaded with KLH overnight, irradiated and used as stimulator 
cells for lymph node T cells (ratio 1:1). After 4 days of culture, 1 μCi/well of tritiated thymidine was 
added for 8 hours, and incorporation of tritiated thymidine was measured in a -counter.  
 
Delayed Type Hypersensitivity  
One to two weeks after the four DC vaccinations a delayed type hypersensitivity (DTH) skin test was 
performed. Briefly, DC pulsed with peptides and DC pulsed with peptides plus KLH (2x105 DC each) 
were injected i.d. in the skin of the back of the patients at four different sites. The diameter (in 
millimeters) of induration was measured after 48 hours, and punch biopsies (6 mm) were obtained 
under local anesthesia. Biopsies were cut in half, one part was frozen directly in liquid nitrogen for 
immunohistochemistry and the other part was cut in small pieces and cultured in RPMI/7% HS 
supplemented with IL-2 (100 U/ml). Every 7 days, half of the medium was replaced by fresh IL-2-
containg RPMI/7%HS. After 2 to 4 weeks of culturing, T cells were tested for antigen recognition or 
tested for tetramer binding. For tetramer binding PBMC of T cells were incubated with 
allophycocyanin-labeled tetrameric-MHC complexes containing the gp100:154-167, gp100:280-288 
or tyrosinase:369-376 peptide (Sanquin, Amsterdam, The Netherlands) for 1 h, washed and analyzed 
by flowcytometry. 
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Antigen recognition assay 
Antigen recognition was determined by the production of cytokines by DTH-derived cells in response 
to T2 cells pulsed with the indicated peptides or BLM (a melanoma cell line expressing HLA-A2.1 and 
no endogenous expression of gp100 and tyrosinase), transfected with control antigen G250, or with 
gp100 or an allogenic HLA-A2.1-positive, gp100-positive, and tyrosinase-positive tumor cell line 
(MEL624) were measured. Cytokine production was measured in supernatants after 16 hours of 
coculture by the cytometric bead array (Th1/Th2 Cytokine CBA 1; BD Pharmingen).  
 
Statistics 
Data were analyzed using unpaired student t-test, p-values <0.05 were considered to be statistically 
significant.  
 
 
 
 
Figure 1.  DC migration to nearby lymph nodes after vaccination in melanoma patients. Percentage of cells redistributed to 
nearby lymph nodes after i.d. (A) and i.n. (B) injection of 
111
In- and SPIO-labeled DC, imaged by scintigraphy of the lymph 
node region. Each symbol represents one injection of 1510
6
 cells (open symbols: i.d., closed symbols: i.n.). The line 
indicates the mean redistribution. Migration of radiolabeled DC was measured 30 minutes and/or 24-48 hours after 
injection. 
 
Results 
Biodistribution of 111In/SPIO-DC after i.d. and i.n. vaccination 
To study the distribution of the dendritic cell vaccine after i.d. and i.n injection in patients with 
metastatic melanoma, DC were labeled with 111In and SPIO for the first vaccination and injected in 
(the vicinity of) a lymph node region 24-72 hours before scheduled lymph node resection. Delivery of 
the DC to skin-draining lymph nodes after i.d. (n=12) and i.n. injection (13 patients) was monitored 
by scintigraphic imaging of the lymph node region (Supplementary table 1). After i.d. administration 
never more than 4% migration was observed (Figure 1A, mean 1.11.1%). In contrast, the percentage 
of cells reaching nearby lymph nodes after i.n. administration was highly variable and ranged from 0 
to 56% (Figure  1B, mean 10.617.5%). In 5 patients distribution to more than one lymph node had 
already taken place within the first 30 minutes after injection, indicating that DC had spread via the 
lymphatics system during injection. Migration to subsequent lymph nodes increased in the next 24-
72 h. In 6 patients DC remained localized at the injection site, suggesting that either DC had not 
(detectably) migrated, or that DC were not correctly injected into a lymph node. For 5 patients the 
latter was indeed confirmed with magnetic resonance imaging as previously described 17. In the 
resected lymph node basin from the sixth patient an 111In-positive lymph node was isolated, 
demonstrating that injection was correct but that the cells had not migrated to nearby lymph nodes. 
Taken together, while maximally 4% of the DC reached the draining lymph nodes after i.d. injection, 
all DC were delivered to one or more lymph nodes after i.n. injection, when correctly delivered. 
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Figure 2. Most 
111
In/SPIO-DC 
remain at site of injection. 
Melanoma patients received i.d. 
or i.n. injections of 
111
In- and 
SPIO labeled DC 48 hours before 
surgery. Resected lymph nodes 
and skin biopsies were analyzed 
for the presence of SPIO-labeled 
cells by Prussian blue staining. 
(A) Injection site in the dermis 
after i.d. vaccination (two 
patients) (50). (B) Injection site 
in the lymph node after i.n. 
vaccination (two patients) (50). 
Bar, 500 m. 
 
 
 
 
 
Numerous 111In/SPIO-DC die at the injection site and are phagocytosed by macrophages  
Because the presence of 111In/SPIO-DC inside lymph nodes does not necessarily imply that DC 
actually reach the T cell area, we analyzed the dissected radiolabeled lymph nodes by 
immunohistochemistry to visualize 111In/SPIO-DC. Lymph nodes were obtained from 8 and 9 patients 
that received i.d. or i.n injections, respectively. In addition, biopsies from the i.d. injection site were 
obtained and analyzed in the same way. Although single 111In/SPIO-DC were present in the sinuses 
and paracortex of draining lymph nodes, a large depot of SPIO+ cells was found at the site of 
injection, as was expected from the scintigraphs. This was not only observed after i.d. vaccination 
(Figure  2A), but also after i.n. injection (Figure  2B). In lymph nodes from patients where immediate 
redistribution of the DC after injection was observed, 111In/SPIO-DC also accumulated in the sinuses 
of subsequent nodes (not shown). To verify whether the SPIO+ cells at the i.d. or i.n. injection site 
were indeed DC and not phagocytes that have taken up label, lymph node sections were stained for 
the DC marker CD83, and for the macrophage marker CD163 23. This revealed that in the dermis only 
part of the SPIO+ cells in the injection site expressed CD83 (Figure  3A). In the CD83 negative areas, all 
SPIO+ cells were positive for the macrophage marker CD163 (Figure 3A-C). Staining with hematoxylin-
eosin revealed that in areas with the most CD83+ 111In/SPIO-DC cells were enlarged and exhibited 
pale pink nuclei, typical for necrotic cells (Figure 3D right panel). At the same time the SPIO+ cells in 
the CD163+ area appeared viable, exhibiting regular hematoxilin staining of the nuclei (Figure  3D left 
panel), suggesting that macrophages had infiltrated the injection site and had phagocytosed dead 
111In/SPIO-DC. Comparable results were found after i.n. injection (Figure  3E-I). Most of the SPIO+ cells 
at the site of injection still expressed CD83 at 24 h (1 patient), but numerous small macrophages 
containing no or little SPIO were present in-between enlarged SPIO+ cells (Figure  3E). In lymph nodes 
resected after 48 hours, CD83 expression was rare and mainly found in the centre of the depot, while 
macrophages were present throughout the injection site (Figure  3F-H). Like in i.d. injection sites, 
necrotic cells were found at sites where CD83 expression was most abundant, whereas in areas with 
only CD83- SPIO+ macrophages cells seemed viable (Figure  3I). Thus, the majority of the 111In/SPIO-
DC remained at the injection site and had lost viability, while macrophages infiltrated the depot and 
phagocytosed dead 111In/SPIO-DC. 
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Figure 3.  Expression of DC and macrophage markers on SPIO
+
 cells in the injection depot. (A-I). Paraffin-embedded sections 
of i.d. (A-D) and i.n. (E-I) injection sites were stained with HE or with antibodies for CD83 and CD163. (A) Overview of CD83 
(left panel)and CD163 (right panel) expression in injection site 48 hours after i.d. injection of 111In/SPIO-DC (50). (E,F) 
Overview of CD83 (left panel) and CD163 (right panel) expression in injection site in lymph nodes resected 24 h (E) or 48 h 
(F) after injection of 
111
In/SPIO-DC (100). (B-D, G-I) Higher magnifications (400) of indicated areas in C and H, stained for 
CD83 (B and G), CD163 (C and H), or with HE (D and I) (400). Bar, 100 m. In HE stainings SPIO is visible as brown granula. 
In immunostainings SPIO was visualized by Prussian blue staining and nuclei were stained with nuclear fast red. 
 
111In/SPIO-DC migrate into the T cell areas and activate antigen-specific T cells.  
Although most 111In/SPIO-DC were trapped at the site of injection, single SPIO+ cells were found 
scattered in draining lymph nodes both after i.d. injection and in the injected and subsequent nodes 
after i.n. injection. We evaluated the CD83 expression and location within the lymph node of these 
SPIO+ cells. After i.d. injection SPIO+ cells can only reach the draining lymph nodes by active migration 
via the afferent lymphatics. Indeed, SPIO+ cells were predominantly found in the T cell areas (939%) 
and sometimes in the subcapsular sinuses (Figure  4A, left panels). Of all SPIO+ cells in the paracortex 
8513% were CD83+ DC (Figure  4B), indicating that mainly viable 111In/SPIO-DC and only few SPIO+ 
macrophages had migrated to the draining lymph nodes and into the T cell areas. After i.n. injection 
more SPIO+ cells were dispersed over lymph nodes than after injection in the dermis. SPIO+ cells were 
present in high numbers both in the sinuses and the paracortex. We estimated the total number of 
SPIO+ cells in the paracortex in single lymph node sections after i.n. injection to be 10-30 fold higher 
than after i.d. administration. However, also many SPIO+ macrophages were present both in the 
injected node and in nearby lymph nodes. Analysis of the paracortex of all lymph nodes revealed that 
5421% of all SPIO+ cells in the paracortex were DC. Within each section the ratio between 
111In/SPIO-DC and SPIO+ macrophages was variable and correlated with the distance from the depot. 
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In close vicinity of the injection depot 5% SPIO+ cells were CD83+ 111In/SPIO-DC, whereas at more 
distant sites virtually all of the SPIO+ cells expressed CD83 (not shown). Quantitative analysis of the 
total number of SPIO+ cells was only possible in sections of lymph nodes where DC had migrated to. 
Quantification of CD83+ and CD163+ expression revealed that only 3526% of all SPIO+ cells were 
CD83+ DC (Figure  4A, right panels, and 4C). Interestingly, 8710% of these CD83+ 111In/SPIO-DC were 
found in the T cell area, indicating that 111in/SPIO-DC that do survive preferentially migrate into the 
paracortex. 
 
Figure 4.  
111
In/SPIO-DC preferentially 
migrate into the T cell area. Immuno-
histochemistry of paraffin-embedded 
sections of lymph nodes to which DC had 
migrated after i.d. and i.n. injection. A. T 
cell area of lymph nodes after i.d. (left 
panels) and i.n. (right panels) stained for 
CD83 and CD163 (200). B-C. Graphs 
representing the percentage of SPIO
+
 cells 
expressing CD83 or CD163 in the 
paracortex and sinuses of draining lymph 
nodes after i.d. injection (B) and of lymph 
nodes after i.n. injection that do not 
contain injection depots (C). Bar, 100 m. 
 
 
 
 
 
 
 
 
 
 
 
DCs in T cell area are fully functional and activate T cells 
We next analyzed whether 111in/SPIO-DC that had migrated into the paracortex of the (draining) 
lymph nodes were still functional and able to interact with resident T cells. SPIO+ DC in the T cell area 
colocalized with both CD4+ and CD8+ T cells (Figure  5A). Interestingly, the staining for CD8 was most 
prominent at the interface between the T cell and the SPIO-positive cells (Figure  5B, second panel). 
This explicit localized expression of CD8 molecules suggests that the T cells are actively engaged with 
the DC in a way that stimulated redistribution of the CD8 molecules and likely the formation of an 
immunological synapse. Activation of T cells surrounding the injected DC was further supported by 
the expression of the early T cell activation marker CD69 and the activation marker CD25 (Figure  5B). 
Of the SPIO+ cells in the T cell area 6522% were in the immediate proximity of CD69+ cells (8 lymph 
nodes from 6 patients). Similarly, 6413% of the SPIO+ cells in the paracortex were surrounded by 
CD25+ T cells (10 lymph nodes from 6 patients). To further investigate the immune-activating 
potential of the migrated 111In/SPIO-DC, they were isolated from a lymph node cell suspension by a 
magnet. We found that some of these DC were still forming rosettes with T cells (Figure  5C). In 
addition, we could demonstrate that T cells cultured from lymph node suspensions of two i.n. 
vaccinated patients showed KLH-specific proliferation (Figure  5D). Thus, 111In/SPIO-DC interacted 
with T cells and induced antigen-specific T cell responses within 48 hours after vaccination. 
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Figure 5. 
111
In/SPIO-DC interact with lymph node T cells and activate KLH-specific T cells. (A) T cell area after i.n. injection 
stained for CD83, CD163, CD4 and CD8 (630x). Bar, 20 m. (B) T cell area of lymph node after i.n. injection stained for CD8 
(2nd panel shows a detail of the first panel), CD69 (3rd panel) and CD25 (last panel) (original magnification: 630x). Bar, 20 
m. Iron oxide was visualized by Prussian blue staining. Nuclei were stained with hematoxilin (A, E right panels) or nuclear 
fast red (D, E left panels). (C) Rosette of a SPIO-labeled DC with T cells magnetically isolated from a lymph node of a patient 
after i.n. injection. Bar, 20 m. (D) KLH-specific proliferation of lymph node-derived T cells from two patients after one i.n. 
DC injection. T cells were cocultured with irradiated, autologous PBMC loaded with (black bars) or without KLH (white bars). 
Proliferation was measured in a tritiated-thymidin incorporation assay. 
 
 
 
 
Figure 6. Immune activation by DC vaccination. Immunological response against KLH in the peripheral blood of patients 
before and after DC vaccination. PBMC and serum were isolated from blood from vaccinated patients at day 30, 44 and 56, 
respectively after 2, 3 and 4 vaccinations. Symbols represent individual patients (open circles: i.d. vaccination, closed circles: 
i.n. vaccination). The line indicates the mean. (A) Antibody response against KLH. Graphs shows the OD450 values of total 
IgG directed to KLH in serum of individual patients diluted 1 in 200. (B) KLH-induced proliferation of PBMC of melanoma 
patients before and after DC vaccination. Each symbol represents one patient (open symbols: i.d. injections, closed 
symbols: i.n. injections). The line indicates the mean.  
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Systemic immune responses after i.d. and i.n. vaccination with DC are comparable despite difference 
in number of DC in T cell area 
To test whether the differences in 111In/SPIO-DC distribution after vaccination by different routes of 
administration had any effect on the strength of immune activation, we compared the immune 
responses elicited in patients that received multiple injections. To monitor the capacity of vaccinated 
DC to initiate an immune response, DC were not only pulsed with TAA peptides, but also loaded with 
the foreign protein KLH. We observed that most patients (i.n. 11/13, i.d. 10/11) developed an IgG 
antibody response against KLH after DC vaccination, with serum levels increasing after each 
vaccination (Figure 6A). Levels of KLH specific IgG antibody were comparable after i.n. and i.d. 
vaccination. In addition, KLH-specific proliferation of CD4+ T cells was induced in all i.n. and i.d. 
injected patients (Figure 6B). Thus, despite the difference in the number of DC that reach the skin 
draining lymph nodes, there was no effect on the strength of the immune response against KLH after 
i.n. or i.d. injection. Next we compared the capacity of i.d. and i.n. injected DC to induce specific CD8+ 
T cell responses against the tumor associated peptides used for loading. Tumor associated antigen 
responses were tested by staining T cells with HLA-A2.1 tetramers encompassing gp100:154, 
gp100:280 or tyrosinase:369 peptides.  In one patient in each group we could already detect 
tetramer-specific T cells in PBMC freshly isolated after four vaccinations. Because the frequency of 
peptide-specific T cell in the blood is very low and often undetectable, DTH responses were induced 
by injecting peptide-loaded DC intradermally. We have shown previously that sampling of DTH sites 
is a very powerful approach to detect vaccine-related T cells (24). No significant differences were 
found in the number of patients with tetramer+ and IFN-γ-producing T cells isolated from DTH 
reactions. TAA-tetramer-positive T cells were found in 4 out of 11 patients after i.d. vaccination and 
in 6 out of 11 patients after i.n. vaccination (Supplementary Table 1). The functionality of these T 
cells was tested by coculturing with T2 cells loaded with TAA-peptides and measuring the IFN-γ-
production. Both after i.d. (4/10 patients) and after i.n. (4/8 patients) T cells from DTH biopsies 
produced IFN-γ in cocultures with peptide loaded target cells (Supplementary Table 1). Thus, despite 
the limited number of DC migrating to subsequent lymph nodes, immulological responses were 
found in most patients and no significant differences were found in the immunological responses 
after i.n. and i.d. DC vaccination.  
 
Discussion 
Previously, we have demonstrated that DC can be tracked in vivo both by scintigraphic imaging and 
MRI (9,17). In this study we monitored the migration of DC into the T cell area, paracortex, of the 
lymph node at microscopical level. Although in vivo imaging provided us with much information on 
the distribution of the DC vaccine after injection, the limitation is that lymph nodes can only be 
generally qualified as positive for the cell tracking label. Here we exploit immunohistochemistry to 
show that many DC remained at the site of injection where they died and were cleared by 
macrophages. Nevertheless, small numbers of labeled DC did reach the lymph node and migrated 
into the T cell area, where they interacted with T cells and induced immune responses against KLH 
and TAA. Importantly, despite the fact that more DC reached the T cell areas after i.n. injection, DCs 
were equally well capable of inducing immune responses. In vivo tracking of ex vivo generated cells is 
an important read-out for evaluation of cellular therapy. Our results explicate that in vivo tracking of 
therapeutic cells primarily tracks the cell label and may need to be confirmed with 
immunohistochemical studies. For example, whereas quantification of migrated DC after i.d. 
injection proved to be quite accurate (approximately 85% of the migrated cells were indeed DC), 
quantification of the number of viable therapeutic cells that had actually migrated after i.n. injection 
was not possible, because the migrated cells as well as the depot were present within the same 
lymph nodes. Therefore, not only viable DC, but also non-viable DC and phagocytes that have taken 
up the tracking agent were imaged. Moreover, migration may be overestimated because therapeutic 
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cells and phagocytes containing the tracking label cannot be distinguished by in vivo imaging. Thus, 
depending on the method of administration and the nature of the vaccine, immunohistochemical 
analysis of target organs will still be decisive for quantitative and qualitative evaluation of the 
efficacy of cellular therapy. Intradermal administration of DC vaccines is not only attractive for 
imaging purposes, it is also easier to perform and less time consuming and less expensive than i.n. 
injection, which needs to be performed under ultrasound guidance by an experienced radiologist. 
We found that after i.d. injection never more than 4% of DC migrated to the draining lymph node, 
while up to 56% of the DC redistributed to distinct lymph nodes after i.n. injection. Despite these 
major differences in migrating DC, immunological responses were comparable after both i.n. and i.d. 
DC injection. Up till now, the minimal amount of DC that is needed to induce an efficient immune 
response in humans is unknown. From our data we can calculate that after i.d. injection less than 
5105 DC reach the T cell area (in the case of maximal migration of 4%, of which 84% accounts for 
viable DC after injection of 15106 DC). Apparently this low number of DC is sufficient to induce de 
novo immune responses. It is interesting that after 4 vaccinations immune responses after i.n. 
injection of DC were not significantly higher than after i.d. injection, even though at least 10-30 fold 
more SPIO+ cells reach the paracortex with each vaccination. Important difference is that after 
intradermal injection only few macrophages migrate from the injection site into the lymph nodes, 
whereas after intranodal injection all macrophages are already inside.  The presence of macrophages 
that have phagocytosed 111In/SPIO-DC in the paracortex (ca. 50% of SPIO+ cells after i.n. injection 
versus 13% after i.d. injection) may have a negative effect on the immune response, for instance by 
the secretion of anti-inflammatory cytokines. CD163 was found to be exclusively expressed by anti-
inflammatory (m2) and not by pro-inflammatory macrophage (m1) subsets cultured from 
monocytes (25). These m2 macrophages can induce regulatory T cells via the expression of 
membrane bound tumor growth factor (TGF)- (26). Thus, the presence of large numbers of 
CD163+SPIO+ macrophages may dampen the immune response induced by the 111In/SPIO-DC.  
Although we detected anti-KLH immune responses in most patients, TAA-specific immune response 
were observed less frequently. One of the reasons may be the absence of MHC class II-restricted 
peptides. Also, the threshold for the activation of T cells specific for TAA tyrosinase and gp100 is 
likely higher than for the immunogenic foreign antigen KLH. Most importantly, the binding of 
exogenous-loaded TAA-peptides to DC is not stable and peptides may therefore be presented by less 
cells at lower densities and for a shorter period of time (27). An alternative way of antigen delivery 
would be loading of DC with antigens that need to be intracellularly processed. The use of antigens 
requiring processing results in prolonged antigen presentation (27), thereby increasing the time span 
during which the DC can activate specific T cells. Furthermore, DC may amplify the response by the 
transfer of antigen to resident DC, in addition to presenting processed antigen to T cells themselves 
(28,29). Increasing antigen presentation, immune-stimulatory potential and migratory capacities of 
DC for immunotherapy may greatly enhance the efficacy of DC therapy (reviewed in 30). At present, 
we are comparing peptide-loaded DC with DC loaded with mRNA encoding for TAA. Initial findings 
demonstrate that when DC electroporated with TAA-mRNA are injected into a lymph node, TAA-
protein expression was detectable up till 24 hours after injection (Schuurhuis et al. submitted). 
Simultaneously, our research focuses on the generation of DC with high immune-stimulatory capacity 
(31) and on maximizing migratory capacities and vaccine delivery. In addition, it will be worthwhile to 
investigate whether the injection of no more than 5106 DC directly into a lymph node will already 
be sufficient to induce immunological responses, as this will greatly reduce the need for large-scale 
production of DC and may make the use of DC that circulate in small numbers in the peripheral blood 
feasible. Optimizing both the generation of high migratory and immune-stimulatory DC and 
improving application and treatment strategies will be necessary to enhance the number of 
responding patients and advance experimental DC immune therapy into a standard treatment.  
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Abstract  
Anti-cancer dendritic cell (DC) vaccines require the DC to relocate to lymph nodes (LN) to trigger 
immune responses. However, these migration rates are typically very poor. Improving the targeting 
of ex vivo generated DC to LN might increase vaccine efficacy and reduce costs. We investigated DC 
migration in vivo in humans in different conditions. HLA-A*02:01 melanoma patients were 
vaccinated with mature DC loaded with tyrosinase and gp100 peptides together with keyhole limpet 
hemocyanin (KLH) (NCT00243594). For this study, patients received an additional intradermal (i.d.) 
vaccination with 111In-labeled mature DC. The injection site was pretreated with nonloaded, activated 
DC, TNF or Imiquimod; GM-CSF was co-injected or smaller numbers of DC were injected. Migration 
was measured by scintigraphy and compared to an intra-patient control vaccination. In an ex vivo 
tissue model, we measured CCL21-directed migration of 19F-labeled DC over a period of up to 12 
hours using 19F MRI to supplement our patient data. Pretreatment of the injection site induced local 
inflammatory reactions but did not improve migration rates. Both in vitro and in vivo, reduction of 
cell numbers to 5×106 or less cells per injection improved migration. Furthermore, scintigraphy is 
insufficient to study migration of such small numbers of 111In-labeled DC in vivo. 
Reduction of cell density, not pretreatment of the injection site, is crucial for improved migration of 
DC to lymph nodes in vivo. 
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Introduction  
Cellular therapy in cancer patients aims to activate the immune system in a highly specific response 
against the tumor. In most studies, autologous antigen-presenting cells, principally dendritic cells 
(DC), are activated and loaded with tumor antigen ex vivo (1). To trigger an effective immune 
response, the DC need to relocate to immune reactive sites, such as lymph nodes (LN) upon injection 
back into the patient. Different routes are used to administer the DC to the patients, of which 
intradermal (i.d.) injection is the most frequently used (2). The biodistribution of DC after vaccination 
has been studied in humans, primarily using 111In or 99mTc-labeled DC and scintigraphy (2). However, 
even though about 20 clinical trials have been carried out with DC delivered intradermally, the 
number of cells that reach a LN has never reproducibly exceeded 4% of the total cells injected (2). 
Why migration of mature DC from the vaccination site is so poor is still unknown. Several reasons 
have been suggested, for example the lack of an inflammatory microenvironment which would 
promote emigration of immune cells to afferent lymphatic vessels. In a mouse model, the migration 
of bone marrow derived DC into the draining lymph node could be dramatically increased by 
pretreating the injection site (3, 4). Prior to the vaccination the skin was injected with either an extra 
dose of DC, pro-inflammatory cytokines (TNF or IL-1) or Toll-like receptor ligands before injection 
of the vaccine-DC. This pretreatment of the skin resulted in a five to ten-fold increase in the number 
of DC in the draining lymph node that correlated with a similar increase in T cell activation. Other 
parameters of DC delivery might also contribute to more efficient emigration of DC from the skin to 
the draining LN, e.g. the frequency of delivery, the infrastructure in terms of vascular and lymphatic 
networks at site of transplant and the local availability of oxygen and nutrients (5-7).Thus 
conditioning the injection site, and perhaps indirectly the draining lymph nodes, may stimulate the 
emigration of DC from the skin and directly improve the clinical efficacy of DC-based therapy. Given 
this multitude of parameters, in vitro cell migration assays are warranted, as they allow high-
throughput screening of influences of single parameters or combinations of parameters. The 
common in vitro cell migration assays that do exist, such as those based on microscopy or plate-
based migration assays, have some major drawbacks: these techniques typically only work with small 
numbers of cells or non-opaque samples and thus do not replicate clinical conditions. Furthermore, 
most techniques assess migration in two-dimensional setting, whereas in vivo migration requires 
motility in 3D. Thus, studying cell migration in a sensitive and quantitative manner for clinical 
application is extremely challenging, and not readily feasible with current technology (2). 
In this study, we investigated DC migration in vivo in humans after pretreatment of the injection site, 
using nonloaded but activated DC, TNF or Imiquimod (a synthetic TLR7/8 ligand), to induce a local 
inflammatory microenvironment; or co-injection with GM-CSF to enhance DC survival. We tracked 
111In-labeled vaccine-DC over a period of 48 hours by planar scintigraphy and compared migration to 
the LN to a standardized control vaccination in the same patient. Furthermore, we modified an in 
vitro assay that closely reflects in vivo vaccination conditions to measure human DC migration in a 
standardized manner in tissue samples (8). By using this model, we measured CCL21 directed 
migration of 19F-labeled vaccine-DC over a period of up to 12 hours using 19F MRI. We show that 
reduction of cell density, not pretreatment, at the injection site is crucial for improved DC migration 
in vivo. In particular, we found that cell numbers greater than 1 million reduced migration both in 
vitro and in vivo. However, current clinical imaging modalities for clinical in vivo tracking of DC are 
insufficient to study migration of reduced numbers of DC in human studies.  
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Materials and Methods 
DC vaccination in melanoma patients  
In this study, stage III and IV melanoma patients (according to American Joint Committee on Cancer 
criteria) who were scheduled for regional lymph node dissection with either curative or palliative 
intention were included. Additional inclusion criteria included HLA*A02:01 phenotype, melanoma 
expressing the melanoma-associated antigens gp100 and tyrosinase, and WHO performance status 0 
or 1. Patients with brain metastases, serious concomitant disease, or a history of a second 
malignancy were excluded (see Supplementary Table 1 for details). The study was approved by the 
Regional Review Board, and written informed consent was obtained from all patients. Clinical trial 
registration number is NCT00243594.  
Patients received a DC vaccine via intradermal or intranodal injection, either with or without 
systemically administered IL-2. Intranodal vaccination was conducted in a clinically tumor-free lymph 
node under ultrasound guidance. Intradermal vaccination was conducted at 5 to 10 cm distal from a 
(preferably inguinal) clinically tumor-free lymph node, by clinicians with extensive experience with 
the procedure (W.J. Lesterhuis, E.H.J.G. Aarntzen, C.J.A. Punt). Because the first vaccination was 
administered 1-2 day before regional lymph node dissection, presumably a significant benefit to the 
patient could not be expected. For this reason, the first vaccination always consisted of an injection 
of 111In-labeled, but not peptide-pulsed and not keyhole limpet hemocyanin (KLH)-loaded DCs on the 
side of the lymph node dissection, and an injection of peptide-pulsed DCs on the contralateral side. 
The latter vaccine could be 111In-labeled or not. The DC vaccine consisted of autologous mature DCs 
pulsed with gp100 and tyrosinase peptides and KLH. Patients received 1 cycle consisting of 4 DC 
vaccinations administered at a biweekly interval. IL-2 was administered by subcutaneous injections 
(at 9 MIU) once daily for 1 week starting 3 days after each DC vaccination. Twenty-four to 48 hours 
after the first vaccination, a radical lymph node dissection was conducted. One to 2 weeks after the 
fourth vaccination, a DTH test was conducted (9). All patients who remained free of disease 
progression after the first vaccination cycle were eligible for 2 maintenance cycles, each at 6-month 
intervals and each consisting of 3 biweekly intranodal vaccinations without IL-2. Patients were 
considered evaluable when they had completed the first vaccination cycle. Vaccine-specific immune 
response was the primary endpoint, as reported in previous publication (10).  
 
DC preparation and characterization 
KLH-loaded DCs were generated from peripheral blood mononuclear cells (PBMC) and matured with 
autologous monocyte-conditioned medium containing prostaglandin E2 (10 mg/mL; Pharmacia & 
Upjohn) and recombinant TNF (10 ng/mL; provided by Dr. G. Adolf, Bender Wien GmbH), as 
described (29, 30). This procedure gave rise to mature DCs meeting the release criteria (29) and 
detailed vaccine phenotype is reported in previous publication (10). 
 
Peptide pulsing 
DCs were pulsed with the HLA class I gp100-derived peptides gp100:154–162 and gp100:280–288 
and the tyrosinase-derived peptide tyrosinase: 369–377 (31–33). Peptide pulsing was conducted as 
described (13), and cells were resuspended in 0.1 mL for injection.  
 
111In-labeling and scintigraphy 
For 111In labeling, 111In-oxine (Covidien, Petten, The Netherlands) in 0.1 M Tris-HCl (pH 7.0) was added 
to mature DC for 15 min at room temperature as described previously (11). This results in 5 µCi per 
15×106 cells. Cells were washed three times with PBS. Radiolabeling efficiency was determined by 
measuring activity in both the cell pellet and the washing buffer. 
For this study, patients received an extra injection prior to scheduled RLND as mentioned above, or 
during the course of vaccination with increasing numbers of DC resuspended in 100 l of injection 
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liquid and distributed over one or multiple injection sites, as indicated. At 24 hours and 48 hours 
post-injection, migration of DC was imaged by planar scintigraphy (256  256 matrix, 174 and 247 
keV 111In photopeaks with 15% energy window) of the injection depot and corresponding LN basin 
with a gamma camera (Siemens ECAM, Hoffman Estates, Ill) equipped with medium energy 
collimators). Migration was quantified by region of interest (ROI) analysis of the individual nodes 
visualized on the images and expressed as the relative fraction of 111In-labeled DC that had migrated 
from the injection depot to draining LN.  
 
19F-labeling and MR imaging in vitro 
For 19F labeling, the label particles were prepared using perfluoro-[15]-crown-5 ether (C10F20O5) 
(Exfluor Research Corp., Round Rock, TX, USA ) and PLGA (Resomer RG 502 H, lactide: glycolide molar 
ratio 48:52 to 52:48; Boehringer Ingelheim, Ingelheim am Rhein, Germany) as described (12). 10 mg 
per 106 cells of particles was added to the DC culture at day 3. Upon harvesting (day 8), cells were 
washed three times in PBS to remove excess particles. 
For the migration assay, the technique was adapted from (8) to replace the gel scaffold with a tissue 
sample, in this case bovine muscle. DC were injected as a bolus in the center of a 2 ml Eppendorf 
tube filled with a single piece of tissue, leaving about 1cm above the tissue as space for medium (see 
Figure 3a). The region below the cells formed the control layer to account for nonspecific motion, 
and the region above was the migration region through the use of a chemokine gradient consiting of 
0.2g recombinant human CCL21 (R&D Systems, Minneapolis, MN, USA). 
1H and 19F images were acquired on a 7T horizontal bore MR-system with a 1H/19F volume coil. 1H 2D 
spin echo images were taken for localization and nine 19F chemical shift spectroscopic imaging (CSI) 
was done every hour for up to 9 hours, to measure cell migration. Proton images were acquired with 
TR/TE=1000/22 ms and 0.125×0.125×1 mm3 resolution. A 0.94×0.94×10 mm3 matrix size with 
TR/TE=400/2.94ms was used for CSI. The sample was sealed and not moved for the duration of the 
imaging experiment. Temperature was maintained at 37 oC using regulated warm air flows. 
 
Histology 
Sections (5 µm) of the resected skin from the injection sites were stained with hematoxilin. The 
staining protocol was done as in (13). Similar sections were cut from the tissue used for the ex vivo 
migration assay. These were stained with hematoxilin and an antibody against carbonic anhydrase 
9(CAIX; Novus Biologicals)..  
 
Statistical analyses 
All comparisons were performed using a two-tailed unpaired t-test with the intradermal migration 
after 48 hours without pretreatment as comparator.  
 
Results  
DC migration to LN is poor after intradermal vaccination 
In current and previous studies (10, 14), migration of DC to skin-draining lymph nodes after i.d. 
injection (n=18) was monitored by labeling the DC vaccine with 111In and subsequent scintigraphy of 
injected region (14, 15). Figure 1A shows the percentage of migrating DC after i.d. injection of 15×106 
DC at 24 or 48 hrs post-injection. The average migration achieved was 1.2% after 24 hours and 1.4% 
after 48 hrs, indicating that most of the migration occurred within 24 hrs after injection. Migration 
rates never exceeded 4% of the total cells injected. Figure 1B shows representative scintigraphs, with 
the arrow indicating a pretreated site. 
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Figure 1. Pretreatment of the skin does not improve DC migration.Migration of DC to skin-draining lymph nodes (n=18) was 
monitored after intradermal injection with 15×10
6
 
111
In-labeled DC vaccine and planar scintigraphy of injected region. (A) 
The percentage of migrating DC at 24 or 48 hrs post-injection, or after different pretreatments, never exceeded 4% of the 
total cells injected. Statistical analyses using a two-tailed unpaired t-test showed no significant differences between the 
experimental conditions or migration at 48 hours after intradermal migration without pretreatment. (B) For each 
pretreatment condition, TNF(n=3), GM-CSF (n=3), Imiquimod (n=4) or unloaded but activated DC 6 hours (n=3) or 24 
hours (n=3) prior to vaccination, the individual images are shown. Upon GM-CSF addition, the induration and migration at 
the site of injection was markedly larger than after injection of DC alone, suggesting random migration into surrounding 
dermis. Red arrows indicate the pretreated site. 
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The induction of local inflammation of does not improve DC migration 
Based on data from mice studies (3, 4), we investigated whether pretreatment of the injection site to 
create a local inflammatory microenvironment, optimized DC migration. To this end, we pretreated 
the injection sites with TNF(n=3), imiquimod (n=4) or unloaded but activated DC 6 hours (n=3) or 24 
hours (n=3) prior to vaccination (Figure 1A,B). In patients pretreated with TNF or activated DC, the 
contralateral administration of 15×106 111In-labelled vaccine-DC served as intra-patient control. 
Although the migration from the pretreated site was higher than in the control site in the majority of 
those patients, it still did not exceeded 4% and did not significantly increase migration compared to 
unconditioned sites. Our previous studies have shown that vaccine-DC rapidly lose viability at the 
injection site after intranodal or intradermal delivery, which might contribute to defective migration 
to LN (15). Addition of GM-CSF as an adjuvant during DC vaccination might increase the survival of 
DC and thereby increase migration rates. Three patients were injected with 15106 DC in normal 
saline containing 14104 IU GM-SCF. Although the percentage of migrating cells after 48hours was 
higher than average in 2 of 3 patients, migration was still within the established range. Of note, the 
induration at the site of injection was markedly larger than after injection of DC alone, suggesting 
random migration into surrounding dermis. Lastly, we pretreated the injection site of 4 patients by 
imiquimod application every 12 hours for 2 days prior to vaccination. Again, no significant changes in 
migration rates were documented. Overall, the effects of pretreatment were limited and did not 
significantly improve subsequent migration of vaccine-DC to the draining LN.   
 
Local cell density is limiting factor 
We performed histological analysis of the pretreatment injection sites 48 hours post-injection in 
order to validate our imaging findings. Injection of DC consistently induced local inflammation, 
demonstrated by infiltrates of leukocytes around vessels in the dermis, mainly neutrophils and 
eosinophils. The number of lymphocytes in the dermis increased, compared to normal skin. 
Pretreatment of the injection site with either TNF (Figure 2A,B) or unloaded DC (Figure 2C); or co-
injection with GM-CSF (Figure 2D) induced some inflammation, as evidenced by the infiltration of 
leukocytes. However, this did not affect DC emigration.  
Histology showed that macrophages had infiltrated the dermis and subcutis around the injection site. 
In areas with SPIO+ cells were enlarged and exhibited pale pink nuclei, typical for necrotic cells. Thus, 
the histological evidence shows that DCs die at the site of injection and invariably induce an 
inflammatory response consisting of macrophages and neutrophils. As no apparent differences were 
noted after different pretreatment regimens, together with the notion that dying vaccine-DC were 
found at higher rates with larger numbers of injected cells; these data suggests that it must be the 
local cell density itself that hampers efficient emigration of the injection site.  
 
An in vitro assay to study migration of small numbers of DC  
To test this hypothesis, we adapted a novel assay we developed to mimic clinical vaccine conditions 
and which allows reliable quantification of reduced numbers of cells (8). The assay was modified to 
use a tissue sample instead of a gel scaffold, as done previously. DCs were cultured as used in patient 
vaccinations, with the addition of a labeling step for 19F detection. This labeling has previously been 
shown to have no effect on the DCs, including their migration (8), (Figure 3A). The grid overlay shows 
the voxels used in the 19F CSI scans. Imaging was carried out at hourly intervals without moving the 
sample, and the temperature was regulated. A control area under the cell injection was used to 
measure passive cell movement due to gravity. CCL21 was used to create a chemokine gradient for 
active CCR7-mediated migration. The percentage of total cells that migrated was calculated to 
represent the migratory cells. Figure 3B shows representative cell numbers at 1, 5 and 9 hours after 
injection of 5×106 DCs. The migratory and control regions are highlighted. 
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Figure 2. Immunohistochemical analyses of the injection site. We performed histological analysis of the pretreatment 
injection sites 48 hours post-injection in order to validate our imaging findings. (A-C) Pretreatment of the injection site with 
TNF, GM-CSF or unloaded DC, consistently induced local inflammation, demonstrated by infiltrates of leukocytes around 
vessels in the dermis, mainly neutrophils and eosinophils. Within areas with high cell density, especially at the injection 
sites, there is a high proportion of dying cells, including vaccine-DC. (D) Normal skin from patient in Figure 2C, for 
comparison.  
 
Reducing the cell density improves migration rates 
The following figure (Figure 4A) shows the migration over time for 5×106 DCs, for the migratory 
region (red) and the control region under the cell layer (blue). These data show that clear migration 
which is absent in the control region. The overall numbers of cells that migrated were 3×104 and 
4.5×105 with 5×105 and 5×106 cells, respectively, demonstrating the sensitivity of this assay. Figure 4B 
summarizes the results of three individual experiments with varying cell numbers in the gel scaffold. 
The data indicate that indeed increasing cell number suppresses migration. Thus, the percent of 
migratory cells is nearly 3% with 0.5 x106 and 0% with 15 x106 DC. Finally, histological analyses on the 
tissue samples, taken over and around the injection site, were analysed (Figure 4C). Extensive 
hypoxia was observed at the injection site (CAIX stain (brown); top panel). Furthermore, at the lower 
cells numbers, we observed trains of migratory cells (lower panels). These trains appear to be 
migrating along the muscle tissue, and were completely absent with samples with 15 and 10 x 106 
million DCs. 
 
 
 
Normal skin same patientTNF treated injection site
Injection site
A B
Injection site
GM-
CSF
Injection site
DC -
24hr
s
C D
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Planar scintigraphy not sufficient for imaging of low numbers of injected cells in vivo 
Finally, we compared the migration data obtained in vitro using our 19F MRI assay with the clinical 
data obtained using scintigraphy on 111In-labeled DCs (Figure 5a). Due to the difficulties of testing 
different conditions in patients, our clinical data only reflects migration with 105 and 106cells per 
injection. Five injections of 1×106 or 5 injections of 1×105 cells were injected intradermally, at 
different sites 1 centimeter apart. The average percentage of migratory cells was significantly 
increased to 5×106 cells compared to 1 injection with 15×106 cells; 1.9% (p<0.05), but not with 5×105 
cells; 0.5% (not significant) respectively. Thus, lowering the number of cells to 106 cells per injection 
improved migration by about 1.5-fold, in terms of percentage, relative to a single bolus injection of 
15×106 DC. So, trend in percentage of migratory cells is comparable with our in vitro data for 5 and 
10×106 cells, respectively. The percentage of migratory DC in patients would be expected to be 
highest with 0.5×106 cells, as predicted by the in vitro results. However, this apparent discordance is 
due to the sensitivity limits of scintigraphy (16), where the smaller numbers of migratory cells were 
probably simply not detected due to sensitivity issues. 
 
 
Figure 3. In vitro model to study migration of small numbers of cells. (A) Cell bolus position within the sample. Overlay of a 
1
H MRI image and 
19
F CSI cell map showing the position and the density of the cell bolus injection in the tissue sample.  The 
migration region is vertically above the cell pellet and the control region below. (B) The panels show representative data 
obtained at 1, 5 and 9 hrs after injection of 5×10
6
 DCs. The scale bar represents the number of cells. 
 
Discussion 
The interest in cellular therapy is increasing at fast pace, in particular research towards harnessing 
immune cells for anti-cancer therapy, which has been revived by recent key developments (17, 18). 
Owing to their unique immune stimulating properties, DCs have been the “hot” target for anti-cancer 
immunotherapy in the past decades. Endowed with knowledge of the crucial steps which underlie 
successful induction of tumor specific immune responses, various vaccination parameters have been 
optimized in previous studies (19). At this point, the paradigm shifts from small proof-of-principle 
studies to large randomized controlled trials. Accordingly, attention should be paid to the feasibility 
of cellular therapy at large scale. Intradermal injection of DC for immunotherapy is generally the 
easiest approach and therefore preferred in most clinical trials involving DC-based therapy (2). 
Unfortunately only limited numbers of DC will reach the draining lymph nodes. Improving the 
efficiency of DC migration might therefore increase the immunological response (20) and reduce 
costs while potentially improving patient response. In mice, immune responses were dose 
dependent (3, 21) and could be increased by conditioning of the injection site. We show here that 
migration rates of human monocyte-derived DC after intradermal injection in melanoma patients 
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could not be increased by pretreatment to induce a pro-inflammatory microenvironment at the 
injection site. Instead, by using a novel model, we demonstrate in vitro and in vivo that a reduction of 
cell numbers at the injection site is key to improved migration.  
 
Figure 4. Reducing the cell density improves 
migration rates in vitro.The change in time in 
the cell numbers within the migration and 
the control regions are plotted for 5×10
6
 DCs 
(n=3). (A) A clear trend is observed for the 
cell number time dependence in the 
migration region (left, in red); improved 
migration is observed for 5×10
6
 and 1×10
6
 
cells. No pattern is observed for the control 
region (right, in blue). (B) Summary of three 
individual experiments with varying cell 
numbers in the tissue assay. The data 
indicate that increasing cell number 
suppresses migration. Thus, the percent of 
migratory cells is nearly 3% 0.5 ×10
6
 and 0% 
with 15×10
6
 DCs. (C) Sections from the tissue 
used for the migration assay were cut and 
stained for hypoxia (brown); cell nuclei are 
purple. Note that nuclei are sparse in the 
surrounding muscle tissue. Representative 
images are shown for 10×10
6
 DC (top; low 
magnification), and 1×10
6 
DC (low and high 
magnification respectively). Migratory cells 
are evident in the lower panels. 
 
A number of factors might explain the discrepancy between our negative results and the positive 
effects of pretreatment of the injection site on migration in mice skin. First, closer analysis of the 
results in mouse models by Martin-Fontecha et al. revealed that migration rates were indeed 
dramatically increased by conditioning but even in their experiments never exceeded approximately 
2% (3). Conditioning of the skin was only effective in increasing the migration of suboptimal doses of 
DC from 0.01-0.1% to 1%. No increases in migration rates were observed when the migration rate of 
the untreated control was around 1-2%. Moreover, high doses of TNF have been demonstrated, to 
the contrary, to inhibit migration from the skin (22). Thirdly, the timing of pretreatment is critical. 
Clinical studies show that intradermal administration of TNF or IL1- induced the emigration of 
resident Langerhans cells to draining lymph nodes. In this setting, application of those pro-
inflammatory cytokines may act both directly on the DC and indirectly via the surrounding accessory 
cells. In our study, TNF is injected to the skin 8 hours prior to DC vaccination and will therefore 
exert its effect on the microenvironment and not directly on the DC. Given the burden for patients in 
terms of injections and logistics, we chose not to titrate the dose and timing of TNF to find the 
optimal. Moreover, Nair et al demonstrated that by conditioning the skin with the TLR-ligand 
Imiquimod, the migration of immature DC could be stimulated (21). However, even in this trial no 
improvement in migration rate was achieved as the injected DC had a mature, and thus highly 
migratory, phenotype. Finally, note that while several factors contribute to the migration of DC, 
these can be very difficult to study individually and even more so when considering the costs and 
logistics of a clinical study. Hence, such factors may best be studied in vitro before final optimization 
in vivo.  
The use of 19F MRI for quantitative cell tracking is a relatively new technique (12). Here we applied 
this technology to track migratory DC over 10 hours, in order to optimize the cell numbers used in DC 
vaccinations in the clinic. This technique allows us to use a wide range of cell numbers, up to the  
A
B
0 1 2 3 4 5 6 7 8 9 10
0
1x10
5
2x10
5
3x10
5
4x10
5
5x10
5
 
 
N
u
m
b
e
r 
o
f 
c
e
ll 
in
 t
h
e
 m
ig
ra
ti
o
n
 r
e
g
io
n
Time [h]
0 1 2 3 4 5 6 7 8 9 10
1.50x10
5
1.75x10
5
2.00x10
5
2.25x10
5
2.50x10
5
2.75x10
5
3.00x10
5
 
 
N
u
m
b
e
r 
o
f 
c
e
lls
 i
n
 t
h
e
 c
o
n
tr
o
l 
re
g
io
n
Time [h]
M
m
ig
ra
to
ry
c
e
lls
(%
 t
o
ta
l)
number of cells (x105)
C 10 x 106
1 x 106
1 x 106
123
Part 2, Chapter 7 
 
 
Figure 5. Reducing the cell density improves migration rates in vivo.Migration of DC to skin-draining lymph nodes was 
monitored after intradermal injection with reduced numbers of 
111
In-labeled DC vaccine and planar scintigraphy of injected 
region. (A) The percentage of migration with 15×10
6
 DC at 48 hrs post-injection (as a reference), 5×10
6
 (n=4), 5×10
5
 DC 
(n=4) or TNF pretreatment together with 5×10
6
 cells (n=2). The mean percentage of migration with 5×10
6
 DC was 2.6%, 
significantly higher than 15×10
6
 DC (p=0.0496, unpaired two-tailed t-test), whereas further reduction of cell number or 
pretreatment with TNF combined with reduced cell number, did not significantly improve migration rates (n.s. denotes 
not significant). (B) For each condition with reduced number of cells, the individual images are shown. Red arrows indicate 
the experimental site. 
 
millions of cells that are typical for current DC vaccination and to use opaque samples, such as tissue. 
Other migration assays require either small cell numbers or transparent samples (23). The 19F 
particles used to label the DC are not toxic to the cells and do not affect their migration, when 
compared to unlabeled cells (24). The expression of typical cell surface markers, used in chemotaxis 
and migration, is also unaffected. Although 19F MRI has not currently been applied to clinical cell 
tracking, the technique will be available for the clinic in the near future. The label we used here can 
also be adapted for clinical use. Furthermore, the assay conditions can easily be modified to include 
different cytokines or combinations of cytokines to study their effect on migration. Different cell 
types can also be used, as long as the cells can be labeled with a 19F agent. Some 19F labels may also 
be sensitive to oxygen partial pressures, and thus these can be measured during the experiments to 
indicate hypoxic regions. In this paper, we used bovine tissue instead of human tissue to avoid 
differences due to mismatched immune cells and the inflammatory condition of the tissue. However,  
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Supplementary Table 1. Patient characteristics 
   Primary tumor 
study 
code 
sex age Breslow 
thickness 
(mm) 
ulceration Clark 
level 
histological 
type 
origin N 
stage  
AJCC 
stage  
Site M 
stage  
prior 
therapy 
II-A-11 m 64 1,25 no 4 SSM skin N1a 3 inguinal M0  
II-C-03 m 60 9 yes 3 NM skin N1b 3 axilla M0  
II-C-14 f 65 n.a. n.a. n.a. n.a. skin N1b 3 inguinal M0  
II-D-01 m 51 1,2 n.a. n.a. n.a. skin N1a 3 inguinal M0  
II-D-02 f 58 2,5 no 3 NM skin N1a 3 inguinal M0  
II-D-03 m 65 2,5 yes 4 SSM skin N1a 3 inguinal M0  
II-D-04 f 53 0,73 no 4 SSM skin Nx 3 inguinal M0  
II-D-05 m 58 4,5 yes 4 NM skin N1b 3 inguinal M0  
II-D-06 m 58 2,55 no 4 SSM skin Nx 3 inguinal M0  
II-D-08 f 50 4,5 yes 5 SSM skin Nx 3 head/neck M0  
II-D-09 f 39 1,1 no 3 SSM skin N2a 3 axilla M0  
II-D-10 m 51 10 yes 5 SSM skin N3 3 axilla M0  
II-D-11 f 37 6 yes 4 NM skin N3 3 inguinal M0  
II-D-12 m 48 8 yes 4 NM skin Nx 3 axilla M0  
II-E-03 m 45 5,8 no 4 SSM skin N1a 3 axilla M0  
II-E-04 m 42 3,6 no 4 NM skin N2a 3 axilla M0  
II-E-06 m 49 3,2 n.a. n.a. SSM skin N2a 3 axilla + inguinal M0  
II-E-07 f 60 1,11 no 3 SSM skin Nx 3 axilla M0  
IV-B-11 m 66 n.a. n.a. n.a. n.a. uveal Nx 4 liver, lung, 
distant lymph 
nodes 
M1c DTIC, RTx 
IV-C-04 m 45 2,8 n.a. 4 n.a. skin Nx 3 head/neck M0  
IV-C-10 f 36 1,6 no 4 SSM skin N1a 3 axilla M0  
IV-D-09 m 51 1,4 no 4 SSM skin Nx 4 axilla or distant 
lymph nodes 
M1a no 
IV-D-11 m 45 n.a. n.a. n.a. n.a. mucosal N3 4 head/neck M0  
VI-A-04 f 67 1,6 n.a. 4 SSM skin Nx 4 distant lymph 
nodes 
M1a no 
VI-A-08 m 66 2,4 yes n.a. NM skin N0 4 liver, lung, 
distant lymph 
nodes 
M1c no 
n.a., not available; SSM, superficial spreading melanoma; NM, nodular melanoma; DTIC, Dacarbazine; RTx, irradiation 
 
the assay can readily be adapted to use other tissue types. Here we used CCL21 to provide a 
chemotactic gradient for DC migration. CCL21 is known to induce the active migration of DCs towards 
lymphatic vessels in vivo (25). 
One of the main issues with 19F MRI is its sensitivity in terms of detectable cells/voxel/unit imaging 
time. Under our conditions, we found the sensitivity to be higher than that of clinical scintigraphy 
(Figure 5A); the sensitivity in our set-up allows the detection of as little as 5000 cells/voxel, compared 
to 2×104 with scintigraphy (16). This is 4-fold higher than the sensitivity of scintigraphy in vivo. Note 
that the MRI was carried out on a clinical scanner using sequences that can be applied to humans; 
using a higher field research magnet and faster imaging sequences would improve sensitivity further. 
In our experiments, we chose to measure only migration in the vertical plane (i.e. along the 
chemokine gradient), as we felt this was the most relevant direction. However, it would certainly be 
feasible to measure migration in both planes or even in 3D in this setup. Furthermore, the relatively 
poor sensitivity of scintigraphy might be one reason why smaller numbers of migratory cells are not 
detected, and thus the percentage of migratory cells calculated is artificially low, especially when 
smaller cell numbers were injected initially. Although the spatial resolution has improved with more 
recent nuclear imaging modalities (SPECT, SPECT/CT) it is still far behind on MRI especially in soft 
tissues like lymph nodes. We previously demonstrated examination of intra-lymph node distribution 
of labeled DC at 7 Tesla MRI (16).  
The high density of cells at the injection site may prevent the access to sufficient oxygen and 
nutrients, and may therefore hamper cell movement and active migration. Indeed, hypoxia is evident 
at the injection site (Figure 4C). Hypoxia suppresses the production of matrix metallo-proteinasesand 
the migration of human monocyte derived-DC (3). After injection of a cell suspension in the dermis, 
the fluid will be readily drained into the afferent lymphatic vessels, due to elasticity of the skin. The 
cells however, will be caught in the extracellular matrix and will be packed together, devoid of 
nutrients and oxygen. The cells on the border of the injection depot may have the opportunity to 
move away from the depot.  
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The optimal numbers of DC per LN for adequate immune induction in clinical studies has not been 
established. Some studies report a dose-dependent relation with immune responses in human (26, 
27). Given the high immune stimulating potential of DC in vitro, it may not be surprising that even 
small numbers of DC, as in clinical studies, are sufficient. Indeed, we have shown previously that even 
small numbers of DC are capable of effective interacting with T cells (10, 15). Hypothetically, the 
unfavorable conditions at the site of delivery may select the most fit DC with high stimulatory 
potency, or simply those at the periphery of the bolus, which are then able to migrate to the LN and 
adequately induce immune responses. Combining this information with the current data, we suggest 
that multiple intradermal injections with small numbers of cells to target multiple lymph node basins 
would increase DC migration to LN, for example using a ‘tattoo’ delivery device (28). In particular, 
cells that appear to be actively migratory were only evident with the lower cell numbers (Figure 4C). 
It is possible that DC aggregation or chemotaxis could also be involved in reducing emigration with 
larger cell numbers, although these factors were not studied here.  
In conclusion, we have shown that pretreatment of the skin to create an inflammatory 
microenvironment at the injection site does not improve DC migration to LN after i.d. delivery. To the 
contrary, we demonstrate that reduction of cell density at the injection site is key to improved DC 
migration, both in vitro and in vivo. Since current imaging modalities for clinical in vivo tracking of DC 
are not sensitive enough to study migration of small numbers of DC, the in vitro model developed 
here facilitates further studies for improving migration rates.  
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Abstract 
We exploited dendritic cells (DC) to vaccinate melanoma patients. We recently demonstrated a 
statistical significant correlation between favorable clinical outcome and the presence of vaccine-
related tumor antigen specific T cells in delayed type hypersensitivity (DTH) skin biopsies. However, 
favorable clinical outcome is only observed in a minority of the treated patients. Therefore, it is 
obvious that current DC-based protocols need to be improved. For this reason, we study in small 
proof of principle trials the fate, interactions and effectiveness of the injected DC. 
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Antigen presenting dendritic cells 
DC are the professional antigen presenting cells (APC) of the immune system that instruct and 
control the activation of B and T lymphocytes, the mediators of specific immunity (1). DC are highly 
mobile cells and by their sequential migration from peripheral tissues to lymphoid organs they serve 
as sentinels of the immune system. Immature DC are very efficient in antigen uptake, mediated by 
high endocytotic activity and expression of an array of cell surface receptors capable of capturing 
antigens (2, 3). Inflammatory mediators and ‘danger signals’ promote maturation and re-routing of 
DC to the secondary lymphoid organs (1, 4). In the secondary lymphoid tissues, DC are mature and 
well equipped to attract, interact and activate naive T cells to initiate a primary immune response (1, 
5). DC are also able to directly activate NK cells (6) and can produce large amounts of interferon upon 
encounter with viral pathogens (7), thus providing a link between the adaptive and innate immune 
system. In murine tumor models protective immunity as well as regression of established tumors 
have been observed after vaccination with DC loaded with tumor antigens (8-10). Their unique 
capacity to initiate and modulate immune responses is currently exploited by many groups, including 
ours, to fight infectious diseases and cancer. One aspect of DC biology that is rapidly evolving is the 
apparent diversity of DC subsets (11). At least two distinct ontogenic pathways for DC development 
have been reported, the myeloid progenitor- and the lymphoid progenitor derived DC (12). Part of 
these different DC subsets may also be explained by differences in the maturation stage of DC and 
the local cytokine environment. The geographical localization of the DC-subsets in secondary 
lymphoid tissues is distinct, myeloid derived DC mainly migrate to or reside in the marginal zone (a 
primary entry point for blood-born antigens) whereas the lymphoid DC mainly reside in the T cell 
areas. This supports distinct functions for the DC-subsets, as been shown in murine studies (1, 12). It 
is now well appreciated that the DC subset, its maturation state and the microenvironment or type of 
pathogen a DC encounters in the periphery, determine the type of immune response that is induced, 
ranging from a TH1 or TH2 response to immune tolerance (12-14). Data are now accumulating that 
immature DC can induce tolerance and are able to induce regulatory T cells in vitro (15, 16) and in 
vivo (17). Regulatory T cells are involved in the control of peripheral tolerance (18) and the 
prevention of vigorous inflammatory reactions. These regulatory T cells affect immune responses at 
the level of antigen-presentation and during the effector phase of T cells at the site of the tumor. 
Although the exact mechanisms by which regulatory T cells exert their suppressive functions are not 
yet elucidated, direct cell-cell contact and cytokines like IL- o play a 
role. Our data on vaccination of melanoma patients also demonstrate that mature DC, but not 
immature DC, induce strong immune responses in vivo (19). Another aspect in the evolving field of 
immunotherapy is the re-acknowledgement of the role of the innate immune system. The 
eradication of a malignancy is the result of a concerted action of adaptive and innate immunity, in 
which natural killer (NK) cells and natural killer T (NKT) cells are important effector cells (20). Next to 
the direct cytotoxic effect on tumor cells, NK cells produce type I interferons that contribute to a 
great extent to a proinflammatory microenvironment. Clinical studies on adoptive NK-cell 
immunotherapy have shown that NK cells can target human tumors (21, 22).  
 
DC-based cancer vaccines: current status 
Over 60 different clinical studies have been carried out between 1996 and 2004, applying tumor 
antigen-loaded DC-based vaccines (23). The vast majority of these studies have been performed in 
melanoma patients (24, 25). In our studies, as well as in other groups, immunological and, notably 
long-lasting, clinical responses have consistently been observed following cellular therapy (24, 26, 
27). In several patients these clinical responses coincide with the induction of specific cytotoxic T cell 
responses. We have explored vaccination of cancer patients with monocyte-derived DC loaded with 
peptides derived from tumor-associated antigens. In our current culture protocol (28), we routinely 
generate large amounts of clinical grade mature and immature DC. DC maturation is induced using 
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MCM, TNF and PGE2. The first DC-trial at our institution has been initiated in 1998. Herein, the 
safety of DC based vaccines and the efficacy of immature DC versus mature DC was studied. HLA-
A2.1+, gp100+, tyrosinase+ metastatic melanoma patients were treated with peptide-pulsed 
immature or mature DC. As peptides we used two HLA-A2.1 restricted gp100 peptides (either native 
or modified peptides to improve their HLA-A2.1 binding affinity) (29, 30) and a tyrosinase peptide 
(31). All DC vaccines were co-loaded with the foreign protein KLH (Calbiochem, Darmstadt, Germany) 
that serves as a control for immune competence and stimulation of a T-helper response. 
Vaccinations were given 3 times with 2-week intervals, followed by injections with the peptides 
alone. Immune monitoring consisted of 1) DTH responses with pulsed- and unpulsed DC, 2) ELIspot-
assays (32, 33) and 3) tetramer assays (34-36). In addition to peripheral blood, immune monitoring 
was also performed using biopsies taken from DTH sites (see below). The results of the first clinical 
trial have been published (19), and unequivocally demonstrated that mature but not immature DC 
are capable of inducing potent anti-KLH specific T-cell, and B-cell responses (19). Clinical results 
demonstrated that 3/20 objective remissions were observed in stage IV melanoma patients 
vaccinated with mature DC. In this group 10 patients were vaccinated with mature DC, of these 
patients 1 was not evaluable because of detoriating condition and of the remaining 9 patients, 3 
showed stable disease >4 months (respectively 4.5, 7.5 and 22) 1 patient showed a mixed response 
and 1 patient achieved a partial response with complete remission after surgical intervention, that 
now lasts >7 years. All patients in this study were melanoma patients with metastatic disease (M1c, 1 
patient M1a) in WHO performance status 0. Moreover, clinical results correlated with the presence 
of vaccine-induced immune responses against the tumor-peptides (see below) (37). To date, >200 
melanoma patients have been vaccinated in our ongoing DC-trials, we observed no clinical benefit 
from vaccinations in patients with high tumor load (as judged by the clinician), elevated serum LDH, 
brain metastases or rapid progressive disease. Therefore, we excluded these patients, with a life 
expectancy less than 3 months, in ongoing studies. While on the down side the vaccine is not yet very 
effective, with an objective clinical response rate (i.e. > 1 year SD or better, stage IV melanoma 
patients) of approximately 10-15%, the positive message is that we clearly find T cell mediated 
immunological responses: 60% in patients with regional lymph node metastasis and 30% in patients 
with metastatic disease. Patients exhibiting these responses show an significantly improved 
progression free survival. Nevertheless, a number of variables need to be evaluated and controlled to 
further improve clinical outcome in cellular therapies, amongst these are generation of DC, use of 
different DC subsets, route of administration, optimal activation stimuli for DC (38), antigen-loading 
of dendritic cells, selection of tumor-derived antigens and so on (24). These variables are in ongoing 
debate, but one can conclude that the full potential of DC-based cellular therapy has not yet fully 
been exploited. However, the current consensus is to continue cellular therapy in well-designed small 
trials that meet a standardized list of quality criteria. This consensus list should at least describe 
quality-control criteria for ex vivo generated DC, patient characteristics, trial design including the 
different variables that are investigated, and tests for clinical and immunological responses (24, 39). 
Significant progress in cellular therapy against cancer, including DC vaccination, is only to be 
expected by careful immune monitoring studies in order to obtain detailed insight of the underlying 
(patho-) physiological processes that determine the success or failure of treatment. Different 
compartments and modalities are considered to monitor induced immune responses; e.g. accuracy 
of delivery, immune responses in peripheral blood, tumor and delayed type hypersensitivity (DTH) 
test biopsies, and clinical evaluation. Recently, it was shown that the modality of vaccination with a 
tumor-specific antigen influences the differentiation pathway of the anti-vaccine CD8 T cells, which 
may have an effect on their capacity to trigger a tumor rejection response (40). Palucka et al. 
observed that patients with a high baseline level of melanoma antigen-specific immunity more often 
show an immune response to the vaccine (41). Furthermore they show that patients who survived 
longer are those who showed immune response against two melanoma antigens presented on the 
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DC vaccine (42). Although sometimes correlations between tumor regression and T cell responses are 
observed (42, 43), the immunological studies performed so far are too diverse in their set-up to pool 
them in a meta-analysis (44). However, some lessons can be drawn from these studies. For example, 
an intact and proper functioning immune system seems to have a higher potential to react on 
immune therapy. From our immune monitoring data, mentioned below, we might not only conclude 
that the presence of tetramer specific T cells is correlated with an improved progression free survival. 
Another conclusion should be that in end-stage melanoma patients these tetramer specific T cells are 
less frequently induced (8 out of 26 patients) than in melanoma patients with regional lymph node 
metastasis (24 out of 31 patients). Secondly, upon induction of tumor antigen specific T cells, the 
next hurdle to take is the local immune suppressive environment created by the tumor. In end-stage 
melanoma patients, the misbalance is already in favor of the metastasizing tumor. In our ongoing 
studies we have seen that in some patients tetramer specific T cells are present after DC vaccination, 
but still experience progression. It became clear that these tetramer specific T cells did not produce 
interferon-
were not capable of breaking the local suppressive tumor-environment. We might take better 
advantage of the unique capacity of DC to direct the immune response by exploiting DC-based 
cellular therapy earlier in the disease course. It has been demonstrated that already in sentinel nodes 
melanoma-specific T cells are present, together with antigen-presenting cells. In this window 
between primary tumor and metastasis, immunological processes can be crucial. It might be at this 
turning point in the development of melanoma, that ex vivo generated DC can assist the immune 
system.  
 
DC migration in vivo 
For DC to induce potent immune responses their migration towards lymph nodes is essential. In 
mice, we have demonstrated that major differences can be found in numbers of migrating DC 
depending on the route of administration (subcutaneous gave the best results) and the maturation 
state (mature gave the best results) (45). With respect to the latter we were able to confirm these 
data in stage III melanoma patients with lymph node metastases who were scheduled for radical 
lymph node resection (46). During the first vaccination these patients received an injection of 111In-
labeled mature or immature DC to allow scintigraphic imaging to study in vivo migration (46). 
Regardless of the route of administration (intradermal or intranodal) mature DC were more efficient 
than immature DC in reaching the draining lymph node in vivo (46). The results described above were 
obtained by our developed method of radioactive labeling of DC (Figure 1) (45, 46). DC have 
therefore been labeled with radionuclides for scintigraphic imaging of cell trafficking, which is until to 
date the only FDA-approved clinical cellular imaging modality (46, 47). A major drawback of 
scintigraphy, however, is the lack of anatomical detail allowing only gross anatomical determination 
of migration between LNs without the ability to assess the intranodal distribution pattern of DC 
within each LN. Furthermore, due to its low spatial distribution, accurate delivery of cells which may 
be essential for subsequent migration into nearby lymph nodes cannot be properly evaluated using 
scintigrapy. In contrast, MR imaging is well suited to obtain three-dimensional whole body high-
resolution images and is widely used in clinical practice. The currently most sensitive markers to label 
cells for MR detection are (ultrasmall) superparamagnetic iron oxide ((U)SPIO) particles (48). We took 
advantage of the fact that DC naturally endocytose clinically applied, FDA-approved SPIO-labels in 
significant amounts, obviating these concerns. This provided us with the opportunity to label cells 
with high efficiency without affecting their function and use these cells in humans (49). We 
investigated the biodistribution of these SPIO-prelabeled DC applied as cancer vaccines in melanoma 
patients using MR imaging. In our DC vaccination protocols, in vitro generated DC loaded with tumor-
derived antigenic peptides were administered to stage III melanoma patients as outlined in Figure 1 
(46),(19). DC were labeled with 111In-oxine and SPIO (Endorem) separately and co-injected in a LN 
136
Part 3, Chapter 8 
 
in the lymph node basin to be resected. This provided the unique opportunity to not only obtain MR 
scans at 3 Tesla (T) before surgery, but also to generate high resolution MR images at 7T of individual 
 
Figure 1. Monitoring the accuracy of delivery of SPIO-labelled cells using MR imaging and scintigraphy. Monocytes are 
obtained by cytopheresis from stage III melanoma patients (A), they are cultured and labeled with SPIO particles and
 111
In 
(B). The cells are then injected intranodally into the lymph node basin that is to be resected and their biodistribution is 
monitored in vivo by scintigraphy (C) and MRI (D). The lymph node basin is resected (E) and separate lymph nodes are 
visualized with high resolution MRI at 7 Tesla (F) and histology (G) (Adapted from De Vries et al. Nat Biotechnol. 2005) 
 
resected LNs, and to correlate the results with scintigraphy and (immuno-) histopathology. 
Interestingly, we found that in only approximately 50% of the cases DC were correctly injected into 
the LN, despite ultrasound guidance of the injection needle by a highly experienced radiologist. 
Subsequent migration could be observed only when DCs were correctly injected into the lymph node, 
demonstrating not only the importance of accurate delivery, but also of careful monitoring of cell 
tracking in cellular therapy. Inadequate delivery may be an important reason why only a limited 
proportion of patients respond in ongoing clinical trials using DC vaccines. We found that the 
accuracy of MR imaging to visualize truly DC-positive LNs was significantly better than scintigraphy. 
These findings illustrate the power of additional anatomical information, which can also be of value 
for other fields of biomedical research. With Prussian blue staining we can visualize SPIO-labeled 
cells. We observed immunohistologically that the SPIO-labeled DC that do migrate enter the lymph 
nodes via the sinuses and reach the T cell areas where the actual DC-T cell interaction takes place. At 
this stage we were able to demonstrate that intranodally injected SPIO-labeled DC, electroporated 
with RNA encoding the tumor antigen gp100, express the gp100 protein. From resected lymph nodes 
rosettes, containing SPIO-labeled DC surrounded by enlarged and activated T cells, were isolated. So 
we disclosed the desired “functional unit” within a lymph node.   
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Immune monitoring in tissues 
Another aspect is monitoring the immune response that is thought to induce tumor regression. 
Immune monitoring is most straightforward after vaccination with defined antigens, however, 
responses have also been detected after lysate or total RNA loaded DC vaccines. Fortunately, many 
novel tools are now available to detect immune responses against known and unknown tumor 
antigens, including MHC-tetramers, Eli-spot- and cytokine release/catch assays (32-34, 36). No 
correlation was observed between the reactivity against KLH and the clinical outcome. We developed 
a novel approach to efficiently monitor DC vaccine related T cell responses in vaccinated patients 
using biopsies derived from delayed type hypersensitivity (DTH) sites (37). The results of this 
monitoring method correlated with the clinical outcome in stage III and IV melanoma patients. DTH 
challenges consisting of peptide-loaded DC plus or minus KLH, DC loaded with KLH, and unloaded DC 
revealed that essentially all patients mounted a positive DTH response with indurations up to 33 mm.  
 
Figure 3. Presence of tetramer specific T 
cells highly correlates with progression free 
survival in melanoma patients. Correlation 
between the presence of specific T cells 
and clinical outcome is shown in this plot 
comparing the progression free survival of 
stage IV melanoma patients with (closed 
line) and without (hatched line) tumor-
specific T cells in their DTH-infiltrated 
lymphocytes (For an updated version of 
this figure, see Chapter 11) 
 
 
 
 
 
 
 
 
 
As both unloaded DC and DC loaded with KLH and/or peptides were positive, indurations at the DTH 
site were not predictive of vaccine-related T cell responses in our setting. However, as no DTH was 
detected after the first intradermal injection of the vaccine, the occurrence of a positive DTH 
reaction should be directly related to the vaccination. The reason for the DTH response to unloaded 
DC is not clear but could be explained by the vast amount of chemokines produced by mature DC 
(28). Punch biopsies (6 mm) were taken from positive DTH sites and divided in half. One part was 
used for histochemistry and the other part was used to isolate DTH-infiltrating leukocytes (DIL). 
Immune staining showed clusters of CD2+CD3+ infiltrating cells of which 50-70% were CD4+ and 50-
30% were CD8+ T cells. No clusters of infiltrating cells were observed in unchallenged control skin 
biopsies. DIL were generated by cutting the biopsies in pieces and culturing of the outgrowing cells 
for 2 to 3 weeks in the presence of low dose IL-2 (100 U/ml) without restimulation. Interestingly, DIL 
specific for KLH could easily be found in biopsies from KLH-pulsed DC, not in DIL from peptide or 
unpulsed DTH biopsies. Moreover, in 11 (6 stage III, 5 stage IV) out of 22 patients tested, gp100/tyr 
tetramer positive T cell populations were readily detected. In 5 additional patients, antigen-specific 
cytotoxic T cells in DIL cultures were detected after additional vaccination cycles. 
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Figure 2. Specificity in DTH-infiltrated leukocyte (dil) cultures derived from patients vaccinated with peptide-loaded DC. In 
DIL cultured from a DTH performed with DC loaded with gp100 and KLH only T cells positive for the gp100 tetramers were 
observed. Tyrosinase tetramer positive cells were observed in the DIL derived from a DTH induced with tyrosinase peptide 
loaded DC.  The production of IFN corresponded with the observed tetramer positivity. 
  
No tetramer positive T cells were detected in DTH biopsies injected with unloaded DC or KLH loaded 
DC. Strikingly, in 6 of 7 patients in whom no tetramer positive cells were found in freshly isolated 
PBMC, significant numbers (up to 45%) of tetramer positive T cells were present in their cultured 
DTH biopsies taken at the same time point. Cytokine production and cytotoxicity of DIL upon co-
culture with the appropriate target cells were fully correlated with the specificity in the tetramer 
analysis. Moreover, DTH reactions induced with DC pulsed with the gp100 peptides accumulated 
gp100 specific T cells and not tyrosinase and vice versa (Figure 2). Finally, in situ tetramer staining on 
cryo-sections revealed that gp100/tyr specific tetramers-positive cells were specifically present in the 
infiltrating T cell clusters. Control tetramers against MART-1, HIV or EBV were negative (50). 
Collectively, these data not only indicate that significant numbers of tetramer positive T cells 
accumulate in the DTH site, but also demonstrated that these T cells specifically produced cytokines 
(Figure 2) and/or are cytotoxic for tumor antigen expressing target cells (data not shown)(37). Next, 
we compared the clinical and immunological data of 26 stage IV melanoma patients (figure 3). 
Inclusion criteria of patients are described previously (19). Patients had documented progressive 
disease within 2 months before study entry, serum lactate dehydrogenase  2x the upperlimit of 
normal, no prior chemotherapy or immunotherapy within 3 months before study entry, and no 
residual toxicity from prior treatments. Of these patients, 15 patients had progressive disease (PD), 9 
patients had stable disease with >4 months duration (SD), and 2 patients, one with multiple liver 
metastases at time of inclusion, are in complete remission (CR). No tumor-reactive DIL were found in 
13 of the 15 patients with PD. Of the 9 patients with SD, 4 patients with specific T cells had a 
progression free survival of >42, 22, 12, and 4.5 months (median 12 months). In the 5 patients with 
SD without tumor-reactive DIL the median progression free survival was 6 months (range 11-4.5). 
Both patients in CR (>60 and >42 months) had tumor-specific T cells. Although the number of 
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patients in this study is limited, a statistically significant (p=0,0012) correlation was observed 
between the presence of tumor-specific T cell reactivity and progression free survival (37). The 
results were confirmed in 31 stage III melanoma patients. 
 
Optimizing DC capabilities by RNA technology 
Besides the production of highly reproducible GMP quality controlled batches of DC vaccines, in vitro 
and in vivo tools to analyze B and T cell responses are developed and injected DC can now be 
visualized in the patient by advanced imaging technology. Another major breakthrough is the 
application of RNA transfected DC that express complete tumor antigens. This has now proven to be 
effective and safe in patients and, in comparison to gene therapy, RNA transfection is much more 
straight forward. Cellular therapy with dendritic cells is still in its infancy, but a number of variables 
are recognized that can contribute to exploit its full potential. In particular monocyte derived DC may 
not seem optimally equipped for their task in vivo. In this context, RNA technology is a promising 
new tool to achieve temporarily expression or suppression of specific proteins to optimize DC 
function . Recent findings have shown that DC transfected with RNA encoding the full length tumor 
antigens, express the corresponding protein in vivo for a prolonged period of time. Moreover, these 
RNA transfected DC are able to induce anti-tumor responses in patients. But one can think of a broad 
range of applications of this technology to improve the functional capabilities of monocyte derived 
dendritic cells. During our investigations we observed that the majority of injected DC die early by 
apoptosis and necrosis. After injection the cells encounter hypoxic conditions and it is known that 
hypoxia inhibits migration of DC, likely because it blocks the production of metalloproteases (51). 
Similarly, Decoy receptor 3 was shown to be upregulated by DC that propagates apoptotic signals 
(52). Inhibition of this and other death inducing pathways may significantly increase DC survival. 
Secondly, migration of current monocyte derived DC in vivo is poor, their migration may be impaired 
due to limited chemokine receptor and cell adhesion receptor functioning. By exploiting RNA 
technology we might enhance expression of the chemokine CCR7, crucial for lymph node migration. 
Similarly, induced production of GM-CSF and IL-15 (53) might directly or indirectly enhance DC 
migration. Next, RNA technology can be exploited to improve DC maturation and T cell stimulation. 
Toll like receptors have been shown to be of key importance in DC maturation and subsequent 
induction of immunity through the upregulation of cytokines/chemokines and co-stimulatory 
molecules. To enhance DC maturation DC might be transfected with RNA encoding  constitutively 
active TLRs or RNAs encoding co-stimulatory molecules, like CD70 and CD40L, can be introduced (K. 
Thielemans, personal communication). Expression of CD40L in DC has previously been reported to 
enhance the magnitude of CD4+ and CD8+ T cell responses in preclinical models (54, 55). Recently, 
CD70 has emerged as a key molecule for priming of CD8+ T cell responses (56). RNA interference to 
optimize T cell stimulation by ex vivo generated DC by another means is to induce expression of pro-
inflammatory cytokines like interleukin-12 and type I interferons. Aside expression of activatory 
molecules in DC, it is becoming more and more evident that down regulatory mechanisms are in 
place that limit the DC’s potential as a vaccine adjuvant. Recent murine data have demonstrated that 
SOCS1 (Suppressor of cytokine signaling 1) expression restricts the dendritic cells’ ability to break 
tolerance and induce antitumor immunity (57, 58). We have recently demonstrated that upon 
human DC maturation SOCS1 as well as SOCS3 are also rapidly upregulated. Therefore, silencing of 
inhibitory molecules like SOCS 1 and IL-10 by RNA interference might be another means improve 
human DC-based cancer vaccines. Furthermore, one of the most potent factors limiting vaccine 
efficacy is the immune suppressive activity of the regulatory T cell (Treg). Remarkably, several reports 
indicate the rapid expansion of Treg following immunotherapy, including following DC vaccination. 
ment of T regulatory T cells. Another Treg stimulatory 
molecule/pathway in DC as a candidate to silence concerns the enzyme indoleamine-2,3-dioxygenase 
(IDO). IDO1 appears most crucial for tryptophan catabolism and immune suppression (59, 60).  
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In vivo targeting of DC 
Direct targeting of antigens to DC surface receptors in vivo might replace laborious and expensive ex 
vivo culturing, and facilitate large-scale application of DC-based vaccination therapies. A major 
advantage of in vivo targeting strategies is that they can be produced in bulk quantities, whereas 
vaccines based on DC loaded with antigens ex vivo require tailor-made procedures for each 
individual. In addition, the opportunity to target natural DC subsets and at multiple sites in vivo might 
be preferable above loading more artificial ex vivo cultured DC. However, ex vivo culture conditions 
allow careful control of maturation and activation (61). Many of the receptors that are studied in 
targeting strategies belong to the C-type lectin receptor (CLR) family. The CLRs are a family of 
calcium-dependent lectins that share primary structural homology in their carbohydrate domain. 
Through this domain, CLRs bind to specific self or non-self sugar residues and are implicated in 
antigen capture and endocytosis. In our targeting studies we mainly investigated the targeting of DC-
SIGN. DC-SIGN is predominantly expressed on immature DC and at lower levels on mature DC and 
macrophages (62-64). By cloning the hypervariable domains of a mouse antibody specific for human 
DC-SIGN into human framework regions, we obtained a humanized antibody. We demonstrated that 
this antibody efficiently targets myeloid APC in vivo and reached saturation with one single dose. The 
binding of the humanized antibody to DC-SIGN showed high affinity and facilitated endocytosis. 
Furthermore, targeted delivery to human monocyte-derived DC of a model antigen conjugated to the 
humanized DC-SIGN specific antibody leads to presentation of the antigen by MHC class I and II 
molecules and elicits both naïve and memory T-cell responses in vitro (65). The CLR targeting 
strategies that are most likely to enter the clinic in the near future target DC-SIGN, CD205 (DEC205) 
and the mannose receptor. Of these, DC-SIGN seems the most DC/macrophage lineage-specific 
receptor, which might be advantageous since the targeting vector will not be scavenged by other cell 
types that could result in lower targeting efficiencies and undesirable side-effects. The expression of 
CD205 for example is in humans less restricted than in mice. Although human CD205 expression 
levels are highest in mature DC, CD205 is also expressed by B cells, T cells, monocytes, macrophages 
and NK cells (66). CD205 however seems to be more potent in mediating cross-presentation in vitro 
compared to the other two receptors. Furthermore, due lack of direct control in these targeting 
strategies, the duration and stability of the vaccine following administration will be difficult to 
determine. 
 
Conclusions and future prospects 
Dendritic cell immunotherapy has been introduced in the clinic. It has proven to be feasible, non-
toxic and effective in some cancer patients, particularly if the DC are appropriately matured and 
activated. However, many questions still remain. One of the concerns related to ex vivo generated 
DC is how to ensure effective migration to the T cell areas in the lymph node. In this context, we are 
pursuing the enhancement of migration of ex vivo generated DC by preconditioning the skin with 
inflammatory cytokines. The recent application of RNA technology in cellular therapy has paved the 
way to the next generation of dendritic cell based therapies. Different aspects of DC biology can now 
be optimized to enhance immunological and clinical responses. One can think of exploiting ex vivo 
generated DC equipped with enhanced expression of chemokine receptors to locate lymph nodes, 
silenced apoptotic pathways to increase longevity and upregulated production of pro-inflammatory 
cytokines to skew naïve T cells. These multiple approaches need to be investigated in small two-
armed principle of concept trials with thorough immune monitoring, in order to increase the clinical 
efficacy of DC-based cancer vaccines. A second promising approach that circumvents many of the 
posed hurdles with ex vivo loaded DC is in vivo targeting. Targeting studies using members of the CLR 
family have paved the way to clinical studies.  
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Abstract 
Cellular therapy promises to revolutionize medicine, by restoring tissue and organ function, and 
combating key disorders including cancer. As with all major developments, new tools must be 
introduced to allow optimization. For cell therapy, the key tool is in vivo imaging for real time 
assessment of parameters such as cell localization, numbers and viability. Such data is critical to 
modulate and tailor the therapy for each patient. In this review, we discuss recent work in the field of 
imaging cell therapies in the clinic, including preclinical work where clinical examples are not yet 
available. Clinical trials in which transferred cells were imaged using magnetic resonance imaging 
(MRI), nuclear scintigraphy, single photon emission computed tomography (SPECT), and positron 
emission tomography (PET) are evaluated from an imaging perspective. Preclinical cell tracking 
studies that focus on fluorescence and bioluminescence imaging are excluded, as these modalities 
are generally not applicable to clinical cell tracking. In this review, we assess the advantages and 
drawbacks of the various imaging techniques available, focusing on immune cells, particularly 
dendritic cells. Both strategies of prelabeling cells before transplant and the use of an injectable label 
to target cells in situ are covered. Finally, we discuss future developments, including the emergence 
of multimodal imaging technology for cell tracking from the preclinical to the clinical realm. 
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1. Introduction 
Cellular therapy is the use of transplanted cells, often autologous cells, to replace or renew damaged 
or diseased tissue. The idea of regulating the body’s own resources to regenerate diseased tissue or 
to fight disease is very compelling; this can potentially reduce unpleasant side-effects caused by 
harsher, non-targeted treatments such as chemotherapy while exerting a strong healing effect. The 
field of cellular therapeutics is blossoming and may in the near future become standard treatment 
for a wide range of conditions involving damaged tissue, such as stem cell transplants in post 
myocardial-infarction tissue or neurodegenerative disease, and in regulating the immune system, as 
in dendritic cell (DC) vaccinations or the transfer of antigen-specific T cells in cancer therapy. 
Currently, over 17,000 ongoing clinical trials involve some form of cell therapy 
(www.clinicaltrials.gov). Despite this major effort, translation from preclinical studies to humans has 
been difficult and largely disappointing. While the task itself is immensely complex, one key reason 
for this failure is the lack of tools to study transplanted cells by non-invasively and longitudinally in 
humans. In vivo imaging is the foremost contender, and therefore, to move forward we urgently 
need novel imaging tools for qualitative and quantitative monitoring of transplanted cells to 
determine the anatomical location, cell numbers, and functional lifespan in patients. 
Frequently, the function of the transplanted cells is measured by metabolic tests. Consider the 
example of cadaveric pancreatic islets transplanted to diabetic patients, generally in the hepatic 
portal vein (2): Transplant success is gauged by measuring blood glucose levels. However, since 
insulin levels are tightly regulated, loss of transplanted islets would simply upregulate insulin 
production by the remaining islets. In fact, type 1 diabetes itself results from a loss of both pancreatic 
islet mass and function to varying degrees. Thus, monitoring blood glucose levels alone does not 
provide an accurate picture of islet viability. This example clearly shows the need for assays to study 
the transferred islets directly, in terms of mass and function. For cell transplants in general, it is not 
sufficient to monitor cell numbers or cell function alone; both should be monitored simultaneously 
to accurately assess success of the therapy.  In clinical studies, multimodal in vivo imaging can offer 
tools for monitoring with minimal invasive procedures.  
The earliest in vivo imaging technique to study specific cells of interest in humans is leukocyte 
scintigraphy, which has now been used for about 30 years (3, 4). In this technique, leukocytes 
harvested from patient blood are labeled with radioactive tracers, commonly 111In agents, and re-
injected intravenously. The accumulation of these radiolabeled cells is used to locate foci of 
inflammation, for example in patients with fever of unknown origin (5). Imaging is done using a 
gamma camera or with single photon emission computed tomography (SPECT). Leukocyte 
scintigraphy is an example of diagnostic imaging, whereas the tracking of transplanted pancreatic 
islets is an example of therapeutic imaging. Diagnostic imaging has also been carried out exploiting 
other cell types including monocytes and macrophages (6).In this review we will focus on therapeutic 
imaging.  
Tracking of transplanted therapeutic cells using imaging is a relatively recent development, and 
currently no standard clinically-approved imaging technique exists for the quantitative, longitudinal 
monitoring of cells after transfer. Hence, here we discuss the different imaging modalities applicable 
to humans and their most promising applications so far, focusing on immune cells used as 
therapeutics. We also consider future possibilities, in particular the development of more sensitive 
cell tracers and multimodal imaging. Finally, we discuss some important issues related to cell tracking 
in vivo and data reporting standards. Fig. 1 shows examples images after DC vaccination in melanoma 
patients using MRI, PET and scintigraphy. 
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1.1 Clinical imaging and cell tracking modalities 
Several imaging modalities exist to track cells in animal models. However, only a few of these can be 
used in humans due to safety, technical and cost considerations. Table 1 lists common cell tracking 
modalities, their use in humans, their relative sensitivity using the most common imaging techniques 
and parameters and their application towards longitudinal use. 
The imaging techniques relevant to clinical cell tracking include scintigraphy with gamma cameras, 
positron emission tomography (PET), SPECT and magnetic resonance imaging (MRI). Computed 
tomography (CT) is frequently used in conjunction with SPECT and PET to give anatomic context. In 
general, techniques dependant on radioactive isotopes are limited by the half-lives of the isotopes, 
and are thus difficult to apply towards longitudinal imaging. However, an intriguing approach that 
might be a good compromise is to use an injectable label, for example a radiolabeled antibody to 
track specific cells i.e. in vivo labeling (7) (see graphical abstract). This can then be repeatedly 
injected for longitudinal cell tracking (8). However, non-specific label uptake or slow clearance can 
confound data interpretation. Furthermore, techniques using radioactive isotopes or ionizing 
radiation can be restricted by exposure limits in humans. The absence of radiation is therefore one of 
the reasons why MRI is an attractive alternative. Other reasons include its extremely high resolution, 
tomographic ability and inherent soft tissue contrast. On the downside, MRI can be several orders of 
magnitudes less sensitive and less quantitative than techniques using radioactive isotopes. Similar to 
scintigraphy, for MRI cells are labeled before transfer to the patient, although labels can be targeted 
in vivo (6) or cells can also be transduced to express reporter genes (9). 
Optical imaging techniques using fluorescence or bioluminescence, have proven invaluable in small 
animal models. These techniques are extremely fast and amenable to repeated sessions in the same 
animal. Existing markers such as green fluorescent protein (GFP) or luciferase expression can be 
exploited. In the case of bioluminescence imaging, a major advantage is the total absence of 
background allowing for data acquisition in a relatively quantitative manner. However, the limited 
depth penetration of these wavelengths of light currently restricts the techniques to small animals 
for non-invasive imaging. Accordingly, optical agents have not been applied to in vivo cell tracking in 
humans. Finally, the most widely-used imaging modality in the clinic does not exploit the visible light 
spectrum at all: Acoustic imaging, such as ultrasound imaging, is the most common structural 
imaging modality in the clinic. The technique gives real-time (4D) images with a limited field of view. 
Targeted labels have been developed for this technique (10), although human cell tracking has so far 
not been achieved. Due to resolution and penetration limits, ultrasound imaging is best-suited to 
gather structural data of superficial and echogenic structures, and appears less applicable to cell 
therapy.  
 
1.2 The role of imaging in optimizing cellular therapeutics 
The use of cell therapy brings us further into the realm of personalized medicine, as the therapeutic 
cells are often generated from the patients’ own cells. The complex process of isolating and 
producing therapeutic cells generates a myriad of variables, all of which may affect the clinical 
outcome. Some of these variables are listed in Table 2. In effect therapeutic cells function as “drugs” 
and therefore require the study of many of the same variables that need to be optimized for drug 
trials; these are discussed in further detail in a review on stem cell transfers to treat Parkinson’s 
disease  (11). This level of personalization, where the whole procedure is optimized for each 
individual, requires a system for monitoring the transferred cells in vivo. A longitudinal, and in many 
cases, also a quantitative technique to monitor cell numbers in vivo will allow optimization of the 
cellular therapy specifically for each patient, maximizing the chance of success of these costly 
therapies. Overall, the application of in vivo imaging can allow for the development of the optimal 
cellular therapeutic regimen for each patient. Current clinical cell therapy protocols will need to be 
modified to include a labeling step or to include infusions of label after cell transfer, along with the 
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addition of imaging sessions at relevant time points. Longitudinal cell tracking could allow 
adjustments of some of the many variables involved as necessary to maximize therapeutic effect. 
One important variable is the site of transfer. This plays a large role in cellular therapy. For example, 
the transfer site defines the local infrastructure including the availability of small blood vessels and 
lymphatics, and larger blood vessels with chemokine gradients that can influence the migration of 
transplanted cells. Any local inflammatory and immune response might lead to instant rejection of 
the cell graft. Moreover, the resident cells may direct maturation or differentiation of the transferred 
cells (12). For example, the local micro-environment is thought to contribute to a significant loss of 
pancreatic islets transplanted to the hepatic portal vein within the first few hours or days after 
transplant (2). From a more practical standpoint, certain transfer locations are more desirable simply 
because they are easy to access or easy to image, although not always both. For example, the liver is 
often the site of pancreatic islet transplants, but it can be difficult to image iron-labeled cells using 
MRI due to the large endogenous iron stores at the site (13). In the case of DC vaccinations, the role 
of the site of transfer was demonstrated in a study using ultrasound-guided injections of DC into a 
lymph node (LN); MR imaging of the injection site, revealed some misinjections which affected 
outcome (1). This study demonstrated both the importance of imaging in optimizing and validating 
cellular therapy, and the limitations of imaging modalities. 
Another key variable is the treatment schedule of cell therapies. This is dependent on the availability 
of equipment and technology, number of cells required, planned frequency of transfer, cost and level 
of discomfort to the patient, amongst others. Transfer sites that are readily accessible, such as 
subcutaneous injections, are utilized more frequently. Sites such as LN may become damaged by the 
injection and thus cannot be injected repeatedly. Other than accessibility, oxygenation at the 
transfer site also plays a role. It has been demonstrated that a large proportion of DC simply die at or 
near the injection site likely because hypoxic conditions hinder migration or stimulate apoptosis. The 
frequency of transfer can be limited by the numbers of cells that can be cultured or purified. In 
general, it is thought that injections of large numbers of cells especially in a small volume, can lead to 
cell death in the bolus due to nutrient deprivation or hypoxia. One solution is to inject the cells in 
smaller numbers, or in a scaffold or gel to improve nutrient access, or simply to maintain mechanical 
properties of the tissue (14). Imaging the migration of labeled cells from the injection site has been 
used as a measure of cell viability after transfer (15). In this example, the cells were labeled for 
imaging during their ex vivo maturation and culturing process (see graphical abstract). Thus, the 
addition of an ex vivo labeling step did not require significant modification of existing cell culture 
protocol. Imaging data was then used to optimize the site of transfer, for example by pretreating the 
site with cytokines (16). Another plausible example on how cell tracking could be implemented in the 
process of clinical decision making involves a multimodality approach to image transplanted stem 
cells and their effect on the function of damaged myocardium: After injection of a fixed number of 
pre-labeled stem cells and an exact estimation of the number of engrafted cells, their effect on 
myocardium can readily be imaged. Imaging of myocardiac motion by ultrasound, metabolic activity 
by 18F-FDG and myocardial perfusion by 201Tl scans is routinely performed. This detailed information 
on the delivery of transplanted cells can help in the considerations for subsequent treatment options 
when the expected improvement in cardiac function is not reached.  
Thus, the aim of in vivo imaging is to allow feedback on the success of the therapy in real time, so 
that the treatment schedule (i.e. variables such as the site of transfer and so on) can be modified to 
optimize the therapy in a patient. Table 2 lists several of the variables in cellular therapy that can be 
studied using imaging with relevant examples where available. In section 3 we discuss more specific 
examples of clinical cell tracking trials involving therapeutic immune cells.  
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2. Cell labeling 
Cells must be suitably labeled for detection via imaging, to distinguish them from the surrounding 
cellular milieu. In both preclinical and clinical situations, cells are typically labeled ex vivo, before 
transfer to the host for cell tracking studies. Another option is in vivo labeling, for instance by labeled 
antibodies specific for the transferred cells (see graphical abstract for a summary of both strategies). 
Both techniques have pros and cons, as discussed in the following sections. 
A recent review lists some general requirements for the use of novel agents for clinical cell tracking 
(17) namely that these cell labels must be shown to be non-toxic to cells in culture or animal models, 
that the labeled cells should be extensively characterized to determine any effect of labeling on cell 
functionality and that the label synthesis can be done in a reproducible manner in a GMP facility 
using compounds that are or can be approved for human use. They point out that the 
characterization of labeled cells in comparison to non-labeled controls must be repeated for each 
new cell type used. However, it is often difficult to study all the relevant features of cells in vivo using 
in vitro assays. One study on the effects of labeling human mesenchymal stem cells with a common 
MRI contrast agent found changes in the expression levels of several genes after labeling and 
exposure to a magnetic field (18). Such effects on cell function must be carefully investigated, 
especially in the case of long-lived cells that will persist and divide in the patient, such as stem cells. 
 
2.1 In vitro labeling 
Here, specific cell populations are purified from the patient and labeled for imaging before transfer 
(see graphical abstract). Advantages of this procedure include simplified removal of excess label and 
dead cells, and the possibility of conducting rigorous functional analyses on the labeled cells before 
transfer to the patient. Furthermore, non-specific labeling of irrelevant cells is greatly reduced if the 
relevant cell population is purified beforehand, and even cells that prove reluctant to take up label 
can be labeled using relatively harsh techniques such as electroporation or the use of transfection 
agents, especially positively charged peptides that can be used in the clinic. Many highly relevant 
therapeutic cells, such as stem cells, are not phagocytic and therefore need to be coaxed to take up 
imaging labels. One study on the biological effects of labeling mouse embryonic stem cells with three 
different transfection methods namely electroporation, protamine sulphate and poly-L-lysine, found 
that the transfection method used can affect factors such as cell differentiation and label uptake 
(19). Furthermore, transfection agents can result in non-specific uptake unless added to purified 
cells.  In vitro labeling allows detailed characterization of the labeled cells before transfer, in terms of 
viability, gene expression and functional status using standardized assays. For example, in DC 
vaccination studies, levels of antigen presenting molecules (MHC class I and II) and chemokine 
receptors (e.g. CCR7) are determined before injection (20), or with T cell therapy using tumor 
antigen-specific cytotoxic T cells,  cytotoxicity assays and intracellular IFN-gamma staining can be 
carried out (21). The homogeneity of label uptake within the population can also be determined.  
As cells are labeled before transfer, any cell division that occurs in vivo would dilute the label 
between daughter cells. This can result in errors in quantification of cell numbers or even loss of 
detectability (22). This holds especially for rapidly dividing cells. Label retention within the cell must 
also be characterized as imaging modalities typically detect just the label regardless of whether the 
label is contained in the relevant cells, lost to the extracellular matrix or transferred to other cells. 
Intracellular localization of label can also be important, particularly when using MR labels where it 
has been shown that clustering of MR labels in dense vacuoles yields better local contrast 
enhancement than cytosolic distribution (8). Furthermore, clearance of label from dead cells must 
also be studied. For example, 99Tc is not as suitable as 111In for labeling immune cells due to higher 
leakage from the cells and subsequent clearance by the kidneys (23). Finally, on a more practical 
note, ex vivo labeling and cell culture requires the use of a clinical clean room, which makes it a labor 
intensive and costly procedure.  
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The radiolabels typically used to label cells have half lives ranging from about 2 hours to over 2 days. 
This restricts the length of time that they can be detected in vivo, often to a length of time much 
shorter than the lifetime of the transferred cells. It also introduces logistical issues in planning such 
trials, as the label needs to be synthesized shortly before use, and the cell labeling procedure itself 
also needs to be performed in a short period of time. MRI is an exception, since these labels 
comprise of very stable compounds such as super paramagnetic iron oxide (SPIO) or gadolinium 
agents. These heavy metals are polymer-coated to reduce toxicity. Such MRI labels are called 
“contrast agents” because they are not detected directly but instead through their effect on the local 
contrast. MRI contrast agents have already been used in several clinical cell tracking trials (17), 
allowing for high resolution, longitudinal cell tracking. Cells have been extensively characterized after 
labeling for MRI. For example, labeling with iron oxide and poly-L-lysine was found not to affect 
overall long-term gene expression in neural stem cells (24). Another study on mesenchymal stem 
cells labeled with clinically approved iron oxide and a 3T MRI scanner found no effect on cell viability, 
proliferation rate, migration and differentiation capacity, albiet expression levels of some genes were 
affected (18). Finally, although MRI-based cell tracking is not restricted by half-life decay as with 
radiolabels, they are generally less suitable for quantification of cell numbers using current imaging 
protocols.  
  
2.2 In vivo labeling 
In this procedure, the label is generally injected systemically and either taken up non-specifically by 
the relevant (phagocytic) cells or targeted specifically to the relevant cell type (second strategy in 
graphical abstract). This process eliminates the ex vivo purification and labeling of cells and therefore 
is much easier to apply and, in general, only viable or functional cells will be able to take up the label 
effectively. Furthermore, the use of an injectable label allows the use of radiolabels for longitudinal 
studies, as the agent can be injected before each imaging session and therefore a short halflife is less 
of a restriction. A simple example of such a label would be a specific antibody bound to a radioactive 
isotope for SPECT (7). Similarly, ultrasmall superparamagnetic iron oxide (USPIO) particles have been 
administered intravenously and were taken up by macrophages and transported to LN. Subsequent 
MR images show abnormal accumulation patterns in the case of LN metastases, where there was no 
infiltration of labeled macrophages (6). Common problems faced with systemic transfer of label 
include restricting uptake to the relevant cell population, accumulation in non-relevant areas such as  
liver or bladder, the requirement for larger doses to allow sufficient signal in the relevant cells 
leading to increased background signal, clearance of label and clinical exposure limits if the agent is 
radioactive. On the other hand, the technique can be significantly cheaper as there is no requirement 
for cell handling and purification ex vivo. This also makes in vivo labeling is less labor intensive and 
therefore more amenable to large scale studies. Long and colleagues exploited in situ labeling 
through cell-to-cell transfer (25). In a mouse model they injected irradiated tumor cells labeled with 
SPIO and examined the migration to and accumulation in draining lymph nodes of APC which 
captured antigen from the injection site.  
An alternative labeling technique available to animal models is to transduce cells to express reporter 
genes, such as enzymes that trap tracers for PET; fluorescent proteins such as GFP for fluorescence 
imaging; luciferase for bioluminescence imaging; or iron transporters or  CEST proteins for MRI 
contrast (9). Such reporter gene expression is well-suited for the detection of proliferative cells, as 
the label does not dilute with cell division. Furthermore, continued expression over the cell’s lifetime 
allows longitudinal tracking, and can even be coupled to the expression of a particular gene of 
interest, or at the very least, to viability. However, the applicability of genetically modified cells to 
humans is not clear.  
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Figure 1. Examples of in vivo imaging of 
cellular therapy in clinical studies. Different 
modalities can be used to track pre-
labeled dendritic cells after injection, or to 
image their effect on the local immune 
system. For example, phagocytic DC can be 
labelled with 
111
Indium oxinate and 
visualized by scintigraphy directly after 
injection in the lymph node (A) and even 
48 hours later (B). Distribution or 
spreading over a number of secondary 
lymph nodes indicates active migration to 
secondary lymphoid organs and the 
number of dendritic cells per spot can be 
calculated as percentage of total injected 
cells. In contrast to scintigraphy, MRI has 
excellent soft tissue contrast with highly 
detailed anatomical information. Here, DC 
were labelled with SPIO and injected i.n. in 
the same patient as (B), following 
scintigraphy, MRI scanning was performed 
directly after injection (C) and 48 hours 
later (D). MRI allows determination of the 
exact location of injected cells, e.g. in a 
lymph node or fatty tissue, and to an exact 
number of lymph nodes (1). In another 
patient, the metabolic activity of the target 
lymph node before (E) and after (F) a 
series of i.n. DC vaccinations was 
investigated using 
18
F-FDG PET. An 
increase in glucose metabolism indicates 
activated lymphocytes, resulting from 
interaction with transplanted dendritic 
cells. 
 
 
 
 
3. Tracking immune cells 
Anti-cancer immunotherapy is an emerging approach to enhance endogenous tumor-directed 
immune responses. This strategy aims to avoid the harsh side effects that accompany chemotherapy 
by inducing toxicity to tumor cells in a highly selective manner. The immune system is designed to 
detect and eradicate pathogenic foreign and transformed body cells. Key players include professional 
antigen presenting cells (APC), e.g. DC and effector cells like CD8+ cytotoxic T cells, CD4+ helper T 
cells, CD4+CD25+ regulatory T cells and natural killer (NK) cells. Upon activation by pathogenic or 
abnormal cells, DC migrate to LN where they can activate effector cells, thus triggering an immune 
response (26). A long-term tumor-directed immune response is established upon concerted action of 
these diverse components of the immune system, and is the goal of clinical DV vaccination trials.  
Most clinical studies exploit either ex vivo generated tumor antigen-loaded autologous DC or 
adoptively transferred tumor-specific cytotoxic T cells, i.e. the initiators or the final executors of the 
anti-tumoral response cascade. Even though the field of immunotherapy is rather new and numerous 
variables need further investigation, it has consistently shown immunological and clinical responses, 
albeit in a subset of patients (27). Other cellular therapeutics which have been used in clinical trials 
include stem cells, particularly in cardiomyopathy and neurological conditions, although imaging has 
been less commonly carried out. Here, we will focus on the role of imaging in the development of 
DC-based vaccines and adoptively transferred tumor-specific T cells in melanoma and discuss the use 
of imaging in optimizing stem cell therapy.  
153
Part 3, Chapter 9 
 
 Table 1.        
Modality Used to track 
cells in 
humans 
Relative 
sensitivity 
Longitudinal 
cell tracking 
Quantification 
of cell numbers 
Assessment of 
cell viability or 
function 
Reference 
Nuclear medicine: Tracers, such as 
111
In, 
99
Tc or 
18
F, or ionizing radiation for imaging 
Scintigraphy Yes +++ + ++ No (4) 
SPECT Yes ++ + +++ No (4) 
PET Yes +++ + +++ Yes (28) 
Acoustic: Perfluorocarbon bubbles 
Ultrasound Possible + + + No (29) 
MRI: Contrast agents such as iron oxide or gadolium, or 
19
F cell tracers 
Metal-based 
contrast agents 
Yes +++ +++ + No (17) (30) 
19
F MRI Possible + +++ +++ No (31) 
Optical: Fluorescent dyes, proteins or quantum dots; bioluminescence detects luciferase activity 
Fluorescence No + +++ + Yes (32) 
Bioluminescence No ++ +++ ++ Yes (32) 
Two-photon No +++ ++ ++ Yes (33) 
 
3.1 Imaging DC therapy  
DC used in therapy are autologous cells, generally purified and differentiated from the monocyte 
fraction of peripheral blood mononuclear cells. Alternatively, immature DC can be obtained from 
circulating CD34+ progenitor cells. New techniques have become available to directly isolate specific 
DC populations from peripheral blood by positive selection using sorting beads. Immature DC can be 
activated by adding maturation stimuli like pro-inflammatory cytokines or pathogen-associated 
danger signals, resulting in upregulated expression of antigen-presenting molecules, co-stimulatory 
molecules and chemokine receptors (20, 26). Typically, DC are loaded with tumor antigens either by 
incubation or electroporation of encoding mRNA before transfer to induce antigen-specific 
responses. The influence of these parameters on the ensuing immune response is not fully 
understood. Other variables include those summarized in Table 2. In general, translocation to LN is 
considered an essential step in DC therapy and therefore in vivo imaging plays a key role in 
optimizing DC trials. Table 3 summarizes DC clinical studies, primarily with radioactively labeled DC.  
DC migration to LN is a key step in the activation of the immune system, and has been extensively 
studied using scintigraphy. Scintigraphic imaging allows quantification of low numbers of cells; in 
general, 2x104 labeled cells can be reliably tracked. However, scintigraphy alone does not show 
whether the DC actually interact with lymphocytes in the LN. In our studies, we were able to 
determine the exact location of the labeled DC within the LN by concurrently labeling DC with 111In 
for scintigraphy and iron oxide for MRI (1). High resolution MR on excised LN and immunohistological 
stainings further demonstrated interaction of these DC with T cells (34). The role of imaging in these 
studies has been critical- there is no other technique to monitor the efficacy of DC therapy in early 
stages, short of invasive tissue biopsies. 
 
Effect of the route and site of transfer on DC biodistribution 
DC have been administered by various routes in clinical trials: Intralymphatic (i.l.), intravenously (i.v.), 
intradermally (i.d.), subcutaneously (s.c.) or intranodally (i.n.), and combinations of these (Table 3). In 
i.l, i.n., i.d. and s.c. administration, specific LN are targeted (typically the draining LN), whereas in i.v. 
administration the DC are distributed over a large volume and available for entry to multiple LN.  
Intradermal vaccinations are the most common. The dermis is richly permeated with lymphatic 
vessels with loose endothelium accessible to DC. Scintigraphic data shows that i.d. transfers result in 
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Table 2.     
Variable Imaging modality Example References 
Delivery 
Route/site MRI SPIO-labeled DC monitored after i.v., s.c. or 
i.d. transfer 
(35) 
Real-time guided injections MRI Magnetocapsule-encapsulated islets, or with 
an MR-trackable injection cathether 
(36, 37) 
Number of cells Scintigraphy 
111
In-labeled DC monitored after intranodal 
or i.d. transfer 
(15) 
Pretreatment Scintigraphy  Pretreatment of host environment with 
cyclofosfamide 
(38) 
Scaffolds n/a Embedding transplanted cells in 
biodegradable polymeric matrices, for 
example to increase access to nutrients 
(39-44) 
Cells 
Purification/culturing 
protocol 
n/a Cytokines used to culture DC (45) 
Status Scintigraphy Mature and immature 
111
In-labeled DC (15) 
Cell treatment MRI, scintigraphy antigen loading of DC (45) (25) 
 
a reproducible delivery of up to 4% of the injected dose of mature DC to the LN, regardless of the 
maturation conditions or mode of antigen loading (Table 3). As discussed above, this relatively low 
number of emigration from the injection side is likely due to massive apoptosis from hypoxic 
conditions at the injection site and a high tissue density that prohibits migration. From the data in 
Table 3, it appears that more migration occurs when smaller numbers of cells are injected. As even 
these small numbers of cells that reach the LN are sufficient to induce tumor-directed immune 
responses (34), these DC are thought to display an optimal maturation phenotype. The results with 
s.c. administration are more variable, with only some studies detecting migration to LN, although 
always less than 4%. The subcutis consists of larger lymph vessels and has a different vasculature 
from the dermis, resulting in a less favorable milieu for DC. Variations in cell migration numbers upon 
s.c. injections might also be caused by differences in injection techniques.  
Next to i.d. transfer, i.n. administration is the most common in clinical studies. As the LN is the site of 
immune activation, delivery of DC directly into the LN obviates the need for specific and optimized 
migratory capacities and directly thrusts the entire dose of cells to the LN. The percentage of cells 
that migrate from the primary injected node to secondary nodes ranges from 0-84%.  This large 
variability cast doubt on the accuracy of i.n. injections, even when administered with ultrasound 
guidance. Therefore, we studied the migration and localization of a DC population dual-labeled with 
111In and iron oxide using scintigraphy and high resolution anatomic MRI (1). Surprisingly, in 4 out of 
8 vaccinations we observed no migration to adjacent LN due to misinjection of the DC, even with 
ultrasound-guided injections by an experienced radiologist. Intralymphatic delivery of DC vaccines 
may be an alternative to i.n. injections as it would not affect LN architecture. However, this is 
technically challenging and therefore less suitable for routine clinical use.  
Intravenous administration results in the same pattern of distribution in all clinical studies, starting 
with entrapment in the dense vasculature of the lungs. The lungs are the first network of small 
arterioles encountered after i.v. injection, and the entrapment may be caused by non-specific 
activation due to ex vivo handling of the cells. This is supported by the finding that mature DC are 
trapped in the lungs for a longer period than immature DC (46). In the next 24 hours, the DC 
redistribute mainly to the liver, spleen and bone marrow. No LN localization has been detected, as 
would have been expected based on studies using normal peripheral blood leukocytes (47). It is not 
clear whether DC actually do not reach the LN or whether SPECT or scintigraphy are not sensitive 
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enough to detect the small numbers of cells that might reach the LN. Hence, DC migration to LN 
upon i.v. transfer has not yet been demonstrated in humans.  
Taken together, these studies demonstrate that i.d. vaccination results in a reproducible delivery of a 
small, but potent, number of DC to the LN. It should be noted that localized transfers, such as i.d. or 
i.n. injections, are much easier to image than systemic transfers, due to the higher cell densities at 
the site of injection and a more restricted migration range relative to systemic transfers.  
 
DC dosage 
A dose of 10-15 x106 cells per injection is typical for localized transfers. For i.v. administration, the 
cell numbers are larger, as is their distribution volume. The low rates of active migration observed 
(generally <4%) suggest that the conditions at the site of transfer are not optimal for emigration as 
discussed above. Analysis of the injection site of i.n. and i.d. vaccination revealed that SPIO-labeled 
DC die within the first 48 hours and are scavenged by macrophages (34).  
Transferring larger numbers of cells increases the odds that the small percentage of migrating cells 
are detected, as the number of cells detected is limited by the sensitivity of the imaging technique. 
Ideally, the data should be confirmed by ex vivo analyses when tissue samples are available. Antigen 
capture by DC and subsequent migration to LN has been studied in animal models, where ex vivo 
isolation of in situ primed APC from the LN allowed validation and quantification of these cells (25).  
 
3.2 Imaging T cell therapy 
Another approach to actively enhance tumor-directed immune responses is to directly isolate 
endogenous tumor-specific immune cells (21). Malignancies are often infiltrated with tumor-specific 
cytotoxic T cells or NK cells which have been rendered impotent, likely due to the 
immunosuppressive tumor-microenvironment. Therefore, ex vivo expansion of purified tumor-
specific immune cells offers opportunities to manipulate their avidity, cytotoxicity and specificity. 
Another approach is to engineer normal lymphocytes into tumor-specific lymphocytes by 
transfection of specific T cell receptors. In both strategies, the enriched population is then 
transferred back into the patient. The host environment can also be preconditioned by lympho-
depletion with chemotherapy and/or irradiation. Several important issues need to be addressed 
when a new study like this is designed and imaging could help to optimize these variables. Most 
clinical studies that monitored transferred cells after direct labeling are over 20 years old as more 
recent work has focused on preclinical techniques to investigate indirect labeling of transferred cells.  
 
Tracking transferred cells to tumor sites 
Intravenous administration is the most widely used route, as the number of transferred tumor-
specific T cells is usually large (>109 cells). In some studies intratumoral administration is used, 
although no imaging studies have been carried out in these investigations. In one study activated 
killer monocytes were administered intraperitoneally in patients with ovarian cancer and 
intraperitoneal tumor patches (54). No activity outside the peritoneum was detected up to 9 days 
after injection using scintigraphy on 111In. However, this proves neither tumor specific localization of 
the transferred cells, nor their ability to evade the peritoneal cavity as ex vivo validation was not 
carried out. The distribution of T cells after i.v. administration follows a similar pattern to other 
immune cells; cells are first trapped in the lungs, after which they are distributed to the liver, spleen 
and bone marrow, as measured using scintigraphy (18, 55). However, activated tumor-specific T cells 
are expected to home to tumor cells to exert their action. 
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Table 3.  
ref source activatio
n status 
Culture 
conditions 
Antigen loading Radioisotope Route  No of cells 
(x10.6) 
No of 
pts 
Migration to 
LN, no pos/no 
total (range %) 
(48) monocyte immature  Pulsing tumor lysate 
111
In-oxine i.d. 6 1 0.42 
(48) monocyte immature  Pulsing tumor lysate 
99Tc-HMPAO i.d. 6 – 9  3 3/3, 0.05 – 0.22 
(49) monocyte immature  Electroporated RNA 
111
In-oxine i.d. 12.5 6 0 
(49) monocyte immature  Electroporated RNA 
111In-oxine i.d. 12.5 2 0.54 
(23) monocyte immature  Pulsing tumor antigen 
99
Tc-HMPAO i.d. 10 3 1/3, 0.07 
(15) monocyte immature  Pulsing tumor antigen 
111In-oxine i.d. 10 8 0.2 – 0.4 
(35) monocyte immature  Lipid transfected RNA 
111
In-oxyquinoline i.d. 1 4 Max 0.41 
(50) monocyte immature  Pulsing tumor antigen 
99Tc-HMPAO i.d. 1 – 7  5 “+” 
(46) monocyte immature  Pulsing tumor antigen 
111
In-oxine i.d. n/a 3 2/3, 0.48 
(23) monocyte immature  Pulsing tumor antigen 
111In-oxine i.d. 10 3 0/3 
(35) monocyte immature  Lipid transfected RNA 
111
In-oxyquinoline s.c. 1 4 0/4 
(46) monocyte immature  Pulsing tumor antigen 
111In-oxine s.c. n/a 3 1/3 
(23) monocyte immature  Pulsing tumor antigen 
111In-oxine s.c. 10 3 0/3 
(23) monocyte immature  Pulsing tumor antigen 
99Tc-HMPAO s.c. 10 3 0/3 
(15) monocyte immature  Pulsing tumor antigen 
111In-oxine i.n. 10 7 0.5 – 30 
(35) monocyte immature  Lipid transfected RNA 
111In-oxyquinoline i.v. 100 3 0/3 
(46) monocyte immature  Pulsing tumor antigen 
111In-oxine i.v. 33 – 180  3 0/3 
(46) monocyte immature  Pulsing tumor antigen 
18F-FDG i.v. 130 – 150  2 0/2 
(23) monocyte mature MPL Pulsing tumor antigen 
111In-oxine i.d. 10 3 1/3, 0.25 
(46) monocyte mature IFN-g, Imukin, FMKp Pulsing tumor antigen 
64Cu-PTSM i.d. 15.3 – 21.3  2 2/2, 0.06, 0.10 
(49) monocyte mature IL-1b, TNF-a, IL-6, 
PGE2 
Electroporated RNA  111In-oxine i.d. 12.5 8 0.5 – 2.0 
(46) monocyte mature IFN-g, Imukin, FMKp Pulsing tumor antigen 
111In-oxine i.d. n/a/ 3 2/3, 1.08, 1.29 
(23) monocyte mature MPL Pulsing tumor antigen 
99Tc-HMPAO i.d. 10 3 0/3 
(15) monocyte mature IL-1b, IL-6, TNF-a, 
PGE2 
Pulsing tumor antigen 111In-oxine i.d. 10 10 10/10, 0.5 – 3.9 
(34) monocyte mature IL-1b, IL-6, TNF-a, 
PGE2 
Pulsing tumor antigen 111In-oxine i.d. 15 12 12/12, 0.1 – 3.7 
(51) monocyte mature IFNg, Ribomunyl Pulsing tumor antigen 
111In-oxine i.d. 8 – 34  6 2/6, 0 – 1.8  
 monocyte mature IL-1b, IL-6, TNF-a, 
PGE2 
Pulsing tumor lysate 111In-oxine i.d. 6.7 – 7  2 2/2, 0.95 – 3.14 
 monocyte mature IL-1b, IL-6, TNF-a, 
PGE2 
Pulsing tumor lysate 99Tc-HMPAO i.d. 4 – 12  5 5/5, 0.39 – 1.75 
(46) monocyte mature IFN-g, Imukin, FMKp Pulsing tumor antigen 
111In-oxine s.c. n/a 3 3/3, 1.3, 0.73 
(23) monocyte mature MPL Pulsing tumor antigen 
111In-oxine s.c. 10 3 1/3, 0.25 
(46) monocyte mature IFN-g, Imukin, FMKp Pulsing tumor antigen 
64Cu-PTSM s.c. 17.6 2 1/2, 0.04 
(23) monocyte mature MPL Pulsing tumor antigen 
99Tc-HMPAO s.c. 10 3 0/3 
(46) monocyte mature IFN-g, Imukin, FMKp Pulsing tumor antigen 
64Cu-PTSM i.n. n/a 2 0/2 
(1) monocyte mature IL-1b, IL-6, TNF-a, 
PGE2 
Pulsing tumor antigen 111In-oxine i.n. 15 9 4/9, 1.7 – 17 
(46) monocyte mature IFN-g, Imukin, FMKp Pulsing tumor antigen 
111
In-oxine i.n. n/a 3 1/3 
(15) monocyte mature IL-1b, IL-6, TNF-a, 
PGE2 
Pulsing tumor antigen 
111
In-oxine i.n. 10 7 0.4 – 84  
(34) monocyte mature IL-1b, IL-6, TNF-a, 
PGE2 
Pulsing tumor antigen 111In-oxine i.n. 15 15 9/15, 0 – 56  
(52) monocyte mature IL-1b, IL-6, TNF-a, 
PGE2 
RNA electroporated 111In-oxine i.n. 15 8 6/8, 0 – 65  
(51) monocyte mature IFNg, Ribomunyl Pulsing tumor antigen  i.n. 7 – 25  5 2/5, 0 – 26  
(53) CD34+ 
proge 
mature TNF-a Pulsing tumor antigen 
111In-oxine i.v. 16 – 17  2 0/2 
(46) monocyte mature IFN-g, Imukin, FMKp Pulsing tumor antigen 
64Cu-PTSM i.v. 140 – 160  2 0/2 
(46) monocyte mature IFN-g, Imukin, FMKp Pulsing tumor antigen 
111
In-oxine i.v. 110 – 250  3 0/3 
(53) CD34+ 
proge 
mature TNF-a Pulsing tumor antigen 
99
Tc-HMPAO i.l.  10 – 13  3 “+” 
(51) monocyte mature IFNg, Ribomunyl Pulsing tumor antigen 
111In-oxine i.l. 33 – 50  4 4/4, “80” 
 
Early imaging studies using 111In-oxine labeled ex vivo expanded T cells and NK cells (56) indeed 
showed that tumor-specific T cells do traffic to tumor sites, (57-61) whereas normal lymphocytes do 
not. In a recent study using whole body SPECT in breast cancer patients, it was shown however that 
ex vivo 111In-labeled tumor-specific T cells do not penetrate solid tumor masses, although they will 
attack loose tumor cells circulating in bone marrow (55). This observation might indicate either that 
not all tumors are susceptible to this treatment or that this treatment might be less effective in 
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patients with high tumor burden. Hence, combining this treatment with therapies that target tumor 
stromal cells, such as angiogenesis inhibitors, may probe beneficial. Another explanation is that the 
transferred cells lack specific homing receptors for effective localization to the tumor. Regardless, 
relocation to tumor sites is correlated with clinical response (60). In this respect, it would be 
tempting to investigate whether transferred cells can cross the blood brain barrier, since adoptive 
cell transfer can induce regression of brain metastasis (21). To conclude, active relocation of 
transferred immune cells to tumor sites is crucial for their therapeutic effect and incorrect delivery is 
one factor that hampers clinical efficacy. Imaging is well-suited to study cell distribution in vivo. 
However, molecular studies of adhesion and chemotactic factors are warranted to define a minimal 
set of homing receptors for immune cells in clinical adoptive cell transfer studies (57).  
 
Pre-treatment 
In the previous section, we concluded that therapeutic effect of adoptive cell transfer in cancer 
patients at least partly depends on the capacity of transferred T cells to home to the tumor. Different 
cell populations might have different intrinsic homing properties, which can be enhanced during ex 
vivo expansion. Another approach to improve clinical responses by improving homing to tumor site is 
demonstrated by the finding that pretreatment with cyclophosphamide increased the tumor 
localization of transferred cells (60). Furthermore, the concomitant administration of Interleukin-2 is 
known to induce homing of T cells to LN. Although this has not been demonstrated in imaging 
studies, it is likely that these pretreatments might explain the improved results of the combined 
treatment. Thus, one should consider using imaging techniques to support new combinations of 
adoptive cell transfer with immune modulating agents.  
 
Optimizing dose and frequency 
Thus far, the focus has been mainly on the quality and characteristics of transferred cells. However, 
dosage and frequency are important variables in immunotherapy. By using 111In-labeled tumor-
specific T cells, Pockaj et al. demonstrated an association between homing to the tumor site and the 
number of cells administered per transfer (60). As tumor destruction causes the release of 
inflammatory cytokines which attract immune cells, it is likely that this correlation is more complex 
than simple dose dependency.  
To determine the optimal frequency of adoptive cell transfer, one should be informed about the 
persistence of transferred cells. This has mostly been done by using PCR to detect specific antigen 
receptors on cells purified from blood. PCR  allows sensitive quantification of the number of 
circulating transferred cell, although not in vivo.  Furthermore, isolated cells can be tested for 
phenotype and function ex vivo. However, as discussed above, homing to tumor sites of transferred 
cytotoxic and NK cells or homing to LN for DC is crucial, and these cells are not available for PCR 
detection, as tissue samples are not generally available. A recent preclinical study used quantitative 
in vivo 19F MRI to longitudinally follow the increase and subsequent decrease of the number of 
antigen-specific T cells homing to a specific LN, over a period of 3 weeks in mice (62). This technique 
may be useful to track cell migration clinically in the near future. Currently, cells are labeled with 
radioisotopes, where the absence of excreted radioactivity suggests that the transferred cells have 
remained intact and survived in the host. It has been shown that 111In-labeled allogeneic NK cells 
remain detectable in blood for as long as 6 days after transfer, with some accumulation in tumor 
tissue using whole body scintigraphy in humans (56). For tumor-specific cytotoxic T cells, transferred 
cells circulated up to two weeks after transfer, with unimpaired effector function for at least 24 
hours (61). The next step in these developments is the use of transferred cells that express tumor-
homing molecules or specific enzymes to trap imaging probes. The first report of this novel approach 
imaged a patient with glioblastoma multiforme who received cytotoxic T cells transduced with a 
tumor-homing, chimeric T cell receptor and the PET-reporter gene HSV1tk, which phosphorylates 
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and traps an 18F PET probe (63). By combining MRI and PET, the authors showed specific localization 
of the transferred cells to the tumor lesion.   
 
3.3 Imaging in the other cellular therapies 
Another emerging application of cellular therapy is the transfer of stem cells to replace damaged 
cells in tissues that have a limited capacity to regenerate. Typically, these are cardiac myocytes in 
ischaemic myocardium, neuronal cells in ischaemic brain injury or degenerative diseases like 
Alzheimers’ disease, and donor pancreatic islets in type I (autoimmune) diabetes. In this section we 
will discuss imaging in cardiac disease and the transplantation of pancreatic islets. Cardiac diseases 
like acute myocardial infarction and congestive heart failure are increasingly prevalent and current 
therapies aim to reduce stress on the remaining cardiomyocytes, although, no definitive therapeutic 
treatment is available. The engraftment of stem and progenitor cells has been extensively 
investigated in the recent years, with modest benefit in clinical outcome. Table 4 summarizes the 
clinical trials using radiolabeled cells to investigate their fate upon transfer. Intravenous transfer does 
not result in any accumulation of transferred cells to the myocardium (64), probably due to the lack 
of active homing and the poor perfusion of the injured sites. Furthermore, regardless of the type of 
cell that is used, transfer of cells into the coronary artery leads to only very low cell engraftment; 
maximum 39% after 1 hour and then decreasing in the next 24 hours. Optimizing the route of 
delivery, type of cell, timing after injury will improve results as revealed by these imaging studies.  
The role of MRI in tracking progenitor cells in cardiac diseases is limited, although it obviates the use 
of radioisotopes in cells with high proliferative potential and long life span. Animal studies have 
shown that apart from the continuous motion of the heart, recent hemorrhages and nonspecific 
uptake of SPIO label by macrophages interferes with the SPIO-induced signal hypointensity of 
transferred cells (65).   
However, in other cases, MRI does play an important role in the search for the optimal site of 
transfer, for example in the case of pancreatic islets (66, 67). Requirements for the site include a rich 
supply of oxygenated and nutrient-rich blood since islets are highly sensitive to hypoxia, drainage to 
the liver where the insulin acts, and local immune protection as type 1 diabetes is an autoimmune 
disorder. To the best of our knowledge, only one clinical study has been published using MRI to study 
transplanted islets longitudinally (13). In this study, iron-labeled allogeneic pancreatic islets were 
transplanted in the hepatic portal vein. It was shown in vitro that labeling with ferucarbotran did not 
affect cell function and this was supported by the in vivo finding that all patients became insulin 
independent. However, the naturally high iron load in the liver interfered with detection of 
transplanted islets and the number of hypointense spots in the liver did not correlate with the 
number of transplanted cells. Validation using tissue biopsies was not possible, as it would damage 
the remaining functional islets. A second clinical study on tracking iron-labeled pancreatic islets is 
currently ongoing. In succession of their in vitro and animal work (67, 68), Jirak and colleagues have 
initiated a clinical study in which 8 patients were enrolled at the time of writing (personal 
communication).  
 
4. Concerns and future perspectives  
Clinical imaging is far behind preclinical animal studies in terms of the resolution, sensitivity and label 
availability. The same is true for the scanners themselves, for example animal MRI scanners can 
reach 16T or higher, while 7T is considered “high field” for human scanner, with most clinical 
scanners being less than 3T. Thus, most of the cutting-edge development occurs in animal models. 
Hence, in this section we examine current preclinical work that is potentially applicable to clinical cell 
tracking, as well as discuss some general concerns about in vivo clinical cell tracking.  
 
 
159
Part 3, Chapter 9 
 
Table 4 
Ref Disease stage Source of cells label Site of transfer # of 
patients 
Distribution in 
myocardium, 
<2 hour (%) 
Distribution in 
myocardium, 24 
hours (%) 
(69) 5 – 10 days after stent 
for AMI 
Bone marrow cells, 
unselected 
18F-FDG Intracoronary, 
infarct related 
artery 
6 1.3 – 5.3  n/a 
(69) 5 – 10 days after stent 
for AMI 
CD34+ bone marrow cells 18F-FDG Intracoronary, 
infarct related 
artery 
3 14 – 39  n/a 
(70) 3 – 300 days after AMI  Peripheral HSC 18F-FDG Intracoronary 
artery 
17 0.2 – 3.3 1 patient 
“present” 
(71) Congestive heart failure Bone marrow MNC 99Tc Intracoronary 
artery 
6 5.4 ± 1.7 2.3 ± 0.6 
(72) 18 – 22 months after 
AMI 
CD34+ 18F-FDG Intracoronary 
artery 
7 1.2 – 5  n/a 
(73) AMI Bone marrow MNC 99Tc-HMPAO Intracoronary 
artery 
12 16.14 ± 7.06 10.29 ± 6.88 
(74) 5 days to 17 years after 
AMI 
Proangiogenic progenitor 111In-oxine Intracoronary  17 1 – 19 1 – 3  
(75) >12 months after AMI CD133+ peripheral blood 
stem cells 
111In-oxine intracoronary 2 6.9 – 8 2 2.3 – 3.2  
(76) 9 – 81 months after 
AMI 
CD133+ / CD34+ bone 
marrow progenitor cells 
99Tc-HMPAO Intracoronary, 
infarct related 
artery 
8 9.2 ± 3.6 6.8 ± 2.4 
(77) 7 – 21 days after AMI Peripheral blood CD34+ 18F-FDG intracoronary 6 4 – 7  n/a 
(73) AMI Bone marrow MNC 99Tc-HMPAO Intracoronary 
vein 
6 4.62 ± 1.40 3.13 ± 0.99 
(70) 3 – 300 days after AMI Peripheral HSC 18F-FDG intravenous 3 0 n/a 
(69) 5 – 10 days after stent 
for AMI 
Bone marrow cells, 
unselected 
18F-FDG Intravenous 3 0 n/a 
 
4.1 Developments on the horizon 
Several promising new technologies have been developed in preclinical studies. Here, we discuss 
some techniques that might translate to clinical use in the near future.  
Optical imaging techniques have not been applied to humans for cell tracking both because of light 
penetration limitations and the lack of FDA-approved agents specifically for cell labeling. However, 
preliminary ex vivo labeling has been done. For example, human embryonic stem cell-derived 
cardiomyocytes were labeled with an FDA-approved contrast agent ex vivo. The dye used, 
indocyanine green, is currently used to determine cardiac output, hepatic function and other factors 
via blood tests. The labeled stem cells remained fluorescent up to 48 hours after labeling, without 
any observed effect on viability or cell function (78). Dyes and microscopy are also commonly used in 
surgery, for example to locate LN. These clinical trials are reviewed elsewhere (79). It is conceivable 
that these techniques can be adapted to allow cell tracking, perhaps in conjunction with surgery. In 
all cases, the effects of labeling on cell function, especially in the case of long-lived cells must be fully 
characterized before clinical use. 
One exciting development that might soon make the jump to clinical use is the application of non-
proton MRI for cell tracking, primarily using 19F MRI for quantitative, longitudinal cell tracking in vivo 
(80). The use of a tracer based on 19F, instead of metal-based contrast agents such as iron oxides, 
allows for quantification of cell numbers directly from the image data. The use of such “hot-spot” 
imaging would also overcome the difficulty in positive identification of labeled cells using 
conventional metal-based contrast agents in MRI. Another recent development is the advent of 
imaging using chemical exchange saturation transfer (CEST) labels. These agents work by locally 
modifying the 1H resonance frequency in a very specific manner, and can be made sensitive to 
factors such as temperature, pH or metabolite concentrations, thus possibly allowing detection of 
cell function in vivo (81, 82). CEST imaging has also been applied to reporter genes (9, 83). The recent 
interest in hyperpolarization, which results in a short-lived signal increase of several orders of 
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magnitude, has been used to study such elusive factors as the real time metabolism of substrates 
using MRI (84, 85). This technology may also allow the development of injectable agents for cell 
tracking, analogous to injectable agents used in SPECT or PET imaging- but without the radioactivity. 
Another recent study used labeled cells with iron for MRI contrast and also used the magnetic 
gradients in the scanner to direct the cells in a vascular bifurcation phantom (86). This opens the 
possibility of interactive manipulation of the labeled cells, perhaps using real time imaging and 
scanners without a closed bore that allow access to surgeons during imaging. Thus, the field offers 
great promise for in vivo imaging in the near future. 
 
4.2 Multimodal imaging 
Multimodal imaging is the use of different, complementary imaging modalities to study the same 
subject. These images might be of the same label or the same cells with different labels. Furthermore 
all imaging may occur in the same scanner or in different scanners with subsequent image 
registration. The main draw of multimodal imaging is the use of the strengths of one imaging 
modality to overcome the weaknesses of another. For example, tracer-specific SPECT or PET scans 
are commonly combined with CT to provide functional information with anatomic context.  
The translation of this technology to the clinic is challenging. Technical challenges include the design 
and construction of safe, reliable multi-modal imaging scanners and the development of image 
registration algorithms when different scanners are used requiring patient repositioning. However, 
dual modality imaging has already become established in the diagnosis, staging and monitoring of 
response to treatment, especially with cancer patients, primarily using SPECT/CT and, more recently 
with PET/CT (87). Dual PET/CT imaging is relatively well-established in animal models, and has begun 
to be used in humans. A recent study demonstrated the clinical value of this technology in patients 
with thyroid carcinoma (88); after comparing the accuracy of diagnoses with PET, CT or PET/CT scan 
data, they found PET/CT data was far superior and allowed an accurate diagnosis of both the 
localization and characterization of lesions in all 18 of the patients imaged. Similarly, SPECT/CT 
scanners are used to provide functional data via SPECT and anatomic data via CT, generally in cancer 
and neurology (89). Although these techniques have not yet been applied to cellular therapies, 
further development of such technology will allow it in the future. Finally, it should be noted the use 
of techniques using injectable radioactive tracers for PET or SPECT will also require the identification 
of suitable (highly-specific) targets on the transplanted therapeutic cells.  
Designing a dual functional scanner combining MRI with either PET or SPECT has proved more 
difficult due to the strong magnetic fields required for MRI. A prototype human PET/MRI scanner was 
tested to acquire images of the human brain in volunteers and patients (90). In this prototype 
scanner, PET acquisition did indeed interfere with the MR imaging, but further development may 
allow the simultaneous acquisition of morphologic (MRI) and functional (PET) data from the same 
scan. The development of PET/MR scanners is discussed elsewhere (91). One of the first clinical 
studies to use MRI to track injected DC in melanoma patients combined MRI with scintigraphy (1), 
although not in the same scanner. The injected cells were labeled with both iron oxide for MRI 
contrast and 111In for quantitative scintigraphy. This was the first study that assessed both the 
localization of the transplanted cells (MRI) and quantified the percentage of migratory cells 
(scintigraphy). In addition, the cells were injected in the LN using ultrasound guidance. 
In preclinical studies, in vivo cell tracking has been carried out with cells labeled with nanoparticles 
detectable by no less than four imaging modalities- MRI, PET, bioluminescence and fluorescence 
(92). Dual-modality probes are now increasingly common in preclinical models. 
 
4.3 Are we imaging labeled cells or just label? 
This is a vital question that must be considered. It is especially important in longer-lived, dividing and 
migratory cells that are pre-labeled before transfer. In vivo imaging modalities, in many cases, detect 
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only the presence of the contrast agent or the label, without being sensitive to whether the label is 
still associated with the relevant cells. In general, label retention in transferred cells is not a problem 
soon after transplant. The problem arises when labeled cells begin to divide, migrate or die. Label 
can also be transferred to neighboring cells or to the extracellular matrix. Thus, it is necessary that 
the clearance pathways and timelines of labels are well-studied beforehand.  When bone marrow 
stromal cells were labeled with an MRI contrast agent, a fluorescent dye or with GFP and transferred 
to areas of inflammation or angiogenesis in a mouse model, it was found that the resident 
macrophages took up as much as 15% of these labels, regardless of the number of cells transferred 
or their viability  (93). A similar study where iron-labeled cells were implanted in the ischemic 
myocardium in mice, found that there was no change in the signal voids observed in MRI scans in 
terms of their number, size or location regardless of whether the transferred cells were alive or dead 
at the time of transplant (94). Movement of label in the images suggests that the cells are alive and 
actively migrating, although it could be an artifact of bystander uptake of the label or of dead labeled 
cells by resident phagocytes, and reflect their movement. These studies show that the fate of label 
must be carefully characterized, generally using conventional histological techniques or flow 
cytometry, before conclusions can be made about cell numbers or even localization from in vivo 
image data alone. 
Many cell therapy approaches utilize transfers of externally cultured cells, which may originate from 
the patient. This external phase is ideal for cell labeling with imaging agents, and it is the most 
common approach in both clinical and preclinical models. It also allows more effective label uptake in 
non-phagocytic cells, such as stem cells or T cells, which often do not take up imaging label 
effectively. In preclinical models, this low uptake can be countered through the use of transfection 
agents, which are generally not an option for clinical studies. Thus techniques such as 
electroporation or the use of positively charged peptides have been tested to improve cell loading 
(95, 96). Specific antibodies can also be used in vitro to increase cell loading (97).  Regardless of the 
loading technique, cell loading needs to be reproducible and precise, such that the average amount 
of label per cell can be accurately quantified. This is vital for quantifying cell numbers from the in vivo 
image data. However, difficulties occur when the cells are transferred in vivo and the cell loading can 
then no longer be monitored. This is especially problematic with dividing cells where the label can 
either be lost or distributed between daughter cells. Cell division can also dilute the label down to 
undetectable levels. Often, these processes cannot be studied in vitro as many cell types cannot be 
cultured for long periods of time, for example pancreatic islets. However, quantitative cell tracking 
has been carried out for up for 3 weeks in actively dividing T cells using 19F MRI “in vivo cytometry” in 
mice (62). In this case, the error due to the rate of cell division was considered tolerable. 
 
4.4 Single cell imaging 
Imaging single cells in vivo would allow quantitative and qualitative assessment of the success of the 
treatment, as each transferred cell could be monitored. Imaging a single cell in vivo using any 
technique other than microscopic approaches is a challenge even in preclinical models. Currently, 
MRI has the highest resolution for imaging soft tissue, and accordingly, single cells have been 
detected using MRI using clinical imaging parameters: Cells were labeled with low amounts of iron 
and imaged in a 1.5 T clinical MRI scanner with a voxel size of 60 µm3 (98). Single cell in vivo imaging 
has thus far not been carried out in humans and will likely require significant further development of 
clinical MRI scanners, imaging techniques and cell labels. 
From a more practical standpoint, it would be beneficial to be able to monitor small numbers of cells, 
or larger numbers of cells with lower label loading. For example, several studies have shown that 
only up to 4% of injected DC reached the LN, and that this migration is better when smaller numbers 
of cells are injected (see Table 3). This would mean much even lower cell numbers reaching the LN, 
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despite a higher percentage of migration, straining current detection limits with techniques such as 
scintigraphy. 
 
4.5 Towards standardized reporting 
Another key problem, that is perhaps simpler to solve, is the lack of a standardized reporting 
protocol for imaging and cell quantification studies. Thus, comparison and meta-analysis between 
studies is somewhat unnecessarily complicated, as illustrated by the incomplete data in Table 3. We 
suggest that in future imaging studies involving quantitative cell imaging it would be useful to include 
a minimal set of parameters, outlined in Table 5. This list is not exhaustive, but it includes some of 
the more common variables that need to be defined to allow inter-study analyses. 
 
5 Conclusions 
Medical imaging technology is already allowing the study of transplanted cells in vivo. One major 
hurdle that must be overcome is the cost of expensive imaging scanners - often multi-million dollar 
investments. Multimodal scanners are even more expensive. It would be ideal if the cheaper imaging 
techniques, such as ultrasound or fluorescence-based approaches, could be adapted to clinical cell 
tracking. For example, dyes are already used in more invasive procedures to identify LN or demarcate 
tumors (99, 100). Ultrasound has also been used with targeted imaging labels, particularly 
perfluorocarbon microbubbles (101).  Such targeted contrast agents might allow the monitoring of 
transplanted cells noninvasively and in an extremely cost-efficient manner (101). However, much 
development is needed for these techniques to be adapted to cell tracking. Furthermore, the imaging 
modality or modalities selected must be carefully tailored to the model, in particular their detection 
thresholds must be considered.The incorporation of imaging in the clinical protocol is illustrated 
briefly in the graphical abstract. As described in the text, this would require both a labeling step 
(either ex vivo or in vivo), and one or more imaging steps at relevant time points after cell transfer. A 
control “before” image may also be necessary for background signal. The development of successful 
cell therapy is intricately coupled to the development of medical imaging technology that can allow 
non-invasive, longitudinal and quantitative monitoring of the transferred cells. This new technology 
might validate the old adage “seeing is believing”. 
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Abstract  
Keyhole limpet hemocyanin (KLH) attracts biomedical interest because of its remarkable 
immunostimulatory properties. Currently, KLH is used as vaccine adjuvant, carrier-protein for 
haptens and as local treatment for bladder-cancer. Since a quantitative human anti-KLH assay is 
lacking, it has not been possible to monitor the dynamics of KLH-specific antibody (Ab) responses 
after in vivo KLH-exposure. We designed a quantitative assay to measure KLH-specific Abs in humans 
and retrospectively studied the relation between vaccination parameters and the vaccine-induced 
anti-KLH Ab responses. Anti-KLH Abs were purified from pooled serum of melanoma patients who 
have responded to KLH as a vaccine adjuvant. Standard isotype-specific calibration curves were 
generated to measure KLH-specific Ab-responses in individual serum samples using ELISA. 
KLH-specific IgM, IgA, IgG and all IgG-subclasses were accurately measured at concentrations as low 
as 20 µg/ml. The intra- and inter-assay coefficients of variation of this ELISA were below 6.7% and 
9.9%, respectively. Analyses of 128 patients demonstrated that mature DC induced higher levels of 
KLH-specific IgG compared to immature DC, prior infusion with anti-CD25 abolished IgG and IgM 
production and patients with locoregional disease developed more robust IgG responses than 
advanced metastatic melanoma patients.  
We present the first quantitative assay to measure KLH-specific Abs in human serum, which now 
enables monitoring both the dynamics and absolute concentrations of humoral immune responses in 
individuals exposed to KLH. This assay may provide a valuable biomarker for the immunogenicity and 
clinical effectiveness of KLH-containing vaccines and therapies.  
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Introduction 
Keyhole limpet hemocyanin (KLH) is a high-molecular-weight glycoprotein, purified from a marine 
snail species called Megathura crenulata, which induces both cell-mediated and humoral responses 
in animals and humans. Because of its high immunogenicity and low toxicity, KLH is used for a variety 
of basic research and clinical applications (1). KLH was introduced into the clinic in 1967 to assess 
immunocompetence of individuals (2). Later, KLH became a standard carrier for the production of 
antibodies (Abs) to small molecule haptens such as peptides and oligosaccharides (1). Besides this, 
KLH is used as a local treatment for patients with bladder cancer (3). Finally, KLH has progressed into 
clinical trials as either adjuvant- or immunomonitoring tool in a variety of vaccines directed against 
cancer (4, 5) or infectious diseases (6). Dendritic cells (DCs) are potent antigen presenting cells and 
play a central role in the induction and maintenance of antigen-specific immunity. Antigen-specific 
immune responses in cancer patients can be induced by exploiting autologous DCs (7). In our 
institute, autologous DCs are activated ex vivo and loaded with tumor antigens. KLH is added to the 
vaccine both as a non-specific T helper cell stimulus and to facilitate monitoring of the vaccine-
induced immune-responses (8-10). After DC injection, the cells migrate towards the lymph nodes 
where they present their processed antigens to the adaptive arm of the immune system, inducing 
antigen-specific T and B cell responses (11). In the last decade, several parameters of DC based 
therapy have been optimized to improve vaccine-induced immunological responses, particularly in 
melanoma patients (12). For example, it is well-accepted that the use of mature DC is superior to 
immature DC (13) and pretreatment with anti-CD25 antibodies does not improve immunological 
responses (14). The route of administration largely dictates the failure or success of the induced 
immunological responses (15, 16). Similarly, evidence is accumulating that the use of non-specific 
helper epitopes, such as KLH, is critical to the induction of effective anti-tumor responses (17). In 
these clinical trials, much effort has been put in the detection of tumor-antigen specific immune 
responses, e.g. ELIspots (18, 19), T cell receptor (TCR) frequency assessment (20) and analyses of skin 
test biopsies (21, 22).  These assays have multiple disadvantages; the assays are laborious, have 
limited sensitivity, often lack association with clinical outcome and are difficult to standardize (23, 
24). Strikingly, not much attention has been paid to the dynamics, levels and patterns of the vaccine-
induced anti-KLH humoral responses in clinical trials, which could provide a simple and direct method 
for evaluation of vaccine-induced immune responses. Assays to monitor cellular (25, 26) and humoral 
(27-29) immune responses against KLH have been developed to facilitate optimal use of biomedical 
KLH applications. The enzyme-linked immunosorbent assay (ELISA) proved a simple and sensitive 
assay to measure serological Abs and in 1979 the first quantitative assay to detect KLH-specific Ab in 
mice was published (27). Five years later the first ELISA was developed to detect KLH-specific Ab in 
human serum (28). Currently, all published human anti-KLH ELISA’s report Ab-responses in arbitrary 
units based on optical density-values, which yields relative units/values only. Because of the lack of a 
quantitative human anti-KLH assay, so far it has not been possible to monitor the dynamics of KLH-
specific Ab-responses after in vivo KLH-exposure. It was neither possible to link the concentration of 
induced KLH-Abs to either the immunocompetence of an individual or to the immunogenicity of KLH-
containing vaccines. In this study we present the first quantitative ELISA to measure KLH-specific Abs 
in human serum, measuring both IgG, IgA, IgM and all IgG-subclasses. We demonstrate that it is now 
possible to monitor the dynamics of both KLH specific Ab-levels and Ab class-switching in individuals 
that are repeatedly exposed to KLH. Furthermore, we retrospectively analyzed the humoral anti-KLH 
responses of melanoma patients enrolled in our clinical trials investigating dendritic cell based 
vaccinations. Our data confirm that individuals exposed to KLH react to it as a primary immunogen, 
inducing a characteristic primary immune response. Moreover, analyses of our clinical DC based 
vaccination protocols demonstrated that variations in the vaccination parameters dramatically 
influence both the quantity and the quality of the induced humoral response. 
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Materials and Methods 
Preparation of serum-pool containing anti-KLH antibodies. 
Serum was pooled from HLA-A*02:01 melanoma patients and colorectal cancer patients who were 
previously vaccinated with KLH-pulsed dendritic cells (DCs). To generate a serum pool with a broad 
spectrum of KLH-specific Abs, sera were obtained from 28 patients enrolled in different clinical trials 
within our institute in which the maturation status of the DCs and the route of vaccine administration 
varied per clinical trial (13-15, 30, 31). For the exact details regarding the vaccination protocols and 
the patient inclusion we refer to these individual studies. In all studies, KLH was added at day 3 of the 
DC culture at a concentration of 10 µg/ml and patients received maximum three vaccination cycles of 
3 bi-weekly vaccinations at a 6 months interval. Informed consent was obtained from all patients and 
the study was approved by our Institutional Review Board.   
 
Purification of KLH-specific antibodies 
Using a KLH-coated column (Alpha Diagnostic International, San Antonio, Texas), 18 ml starting 
serum-pool of KLH-specific Abs was isolated from the above-mentioned trials. Prior to use, the 
column was extensively washed with elution buffer (0.1 M glycine HCl pH 2.5) to dissociate 
multimeric KLH and remove monomers that were not covalently linked to the sepharose bed. 
Subsequently, the column was equilibrated with PBS, followed by application of the pooled serum, 
washing with PBS and elution of the KLH-specific Abs with elution buffer and neutralized with 
Tris/HCL pH 9.0. The KLH-specific IgM-, IgA- and IgG-Abs in the eluate with a volume of 1380 µl were 
quantified using nephelometry on an Immage apparatus (Beckman Coulter, Brea, Ca), IgG subclasses 
were measured on a BNII (Siemens, Münich, Germany) using reagents of The Binding Site 
(Birmingham, UK) all according to the manufacturers protocol. Following this approach, a 1.4 ml 
polyclonal anti-KLH stock was obtained in which all major immunoglobulin isotypes and IgG 
subclasses were represented (Supplementary Table 1). This stock of purified and quantified KLH-
specific Abs was stored at -80 °C and used to generate standard curves for the quantitative ELISA. All 
experiments in this manuscript were performed with one single calibrated work standard of 34 ml 
created from 28 different patients. 
 
Quantitative anti-KLH ELISA 
96-well plates were coated for 18 hours at 4°C with 5 μg/mL KLH (Biosyn, Carlsbad, CA) in PBS in a 
total volume of 120 μL per well and wells were subsequently blocked with skimmed milk powder. 
After washing the plates different concentrations of patient serum were added for 1 hour at room 
temperature. To prepare suitable standard curves for the anti-KLH ELISA’s, the work-standard was 
serially diluted to establish a 7-point standard curve for each Ab-isotype (Supplementary Figure 1, 
available online). For analysis of individual patient samples, a standard curve was added to each 
plate. After washing, specific Abs against either human IgM or IgA or total IgG or IgG1 or IgG2 or IgG3 
or IgG4 labeled with horseradish peroxidase (Invitrogen, San Diego, CA) at 1:500 were added to the 
wells as 100 μL aliquots. The isotype-specific secondary Abs allows quantification of both human IgM, 
IgA, total IgG, IgG1, IgG2, IgG3 and IgG4 KLH-specific Abs. After a further incubation for 1 hour at 
room temperature and a final washing with buffer, peroxidase activity was revealed using 3,3′ 5,5-
tetramethyl-benzide as substrate. The reaction was stopped with sulfuric acid and samples were 
measured in a microtiter plate reader at 450 nm. A uniform detection limit of the anti-KLH ELISA’s 
was arbitrarily determined at 20 μg/ml. This detection limit falls within the lower linear part of all 
anti-KLH calibration curves. Precision and linearity were determined according to the Clinical and 
Laboratoy Standards Institute protocols EP5 and EP6, respectively.   
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Statistical analysis 
Precision and linearity was analyzed using EP Evaluator 9 software, all other statistical analyses were 
performed by Graphpad Prism 5.0. For the comparison of different vaccination protocols, patients 
were grouped based on similar protocol characteristics, such as stage of disease on entry, route of 
administration, pretreatment with anti-CD25 antibodies, additional treatment with interleukin-2 (IL-
2) or the method of tumorantigen loading. For the comparison of 2 groups all the above mentioned 
protocol characteristics should be similar, except for the single parameter under investigation. 
Maximum KLH-specific Ab responses, out of at least 3 samples obtained at standard time points 
during the first cycle, were compared, as this reflects the individual’s competence to generate a 
humoral response. Nonparametric Mann-Whitney test was performed to compare the KLH-specific 
Ab-responses of similar isotypes in two groups of melanoma patients exposed to KLH. A two-tailed p-
value <0.05 was considered significant. 
 
Results 
Assay performance and validation 
To evaluate the precision of the assay, pooled serum samples were measured in 2 replicates per run, 
1 run per day for a minimum of 20 runs. The resulting anti-KLH ELISA’s have an intra-assay 
imprecision, denoted by the coefficient of variation (CV), that ranged from 4.3% to 6.7%. The inter-
assay CV varied from 6.4% to 9.9% (Table 1). To test for assay-linearity we serially diluted 2 individual 
patient serum samples per KLH-assay isotype at a minimum of 5 levels, assayed in quadruplicate. The 
results yielded slopes ranging from 0.918 to 1.036 and the coefficients of determination (R2) ranged 
from 0.991 to 0.998 (Figure 1). A method-comparison analysis was not possible, as there is no golden 
standard quantitative human anti-KLH available. 
 
Monitoring the dynamics of humoral anti-KLH responses in individual patients 
Repetitive serum sampling of individual patients enrolled in clinical trials on dendritic cell based 
vaccinations allows in-depth monitoring of the kinetics of the KLH-specific Ab-responses during 
therapy. In the majority of patients, we detected the first KLH-specific Abs after the 2nd or 3rd 
vaccination. We show one representative melanoma patient who had detectable levels of KLH-
specific IgM Abs after the second vaccination (Figure 2a). The IgM response was followed by KLH-
specific IgG Abs and after four vaccinations also by IgA Abs. Ab titers were drastically decreased  
 
Table 1 Performance assessment of the anti-KLH ELISA assays 
 IgGtotal IgG1 IgG2 IgG3 IgG4 IgAtotal IgMtotal 
Mean 
(mg/L
) 
478.0 282.0 80.4 5.0 76.3 22.8 719.7 
Variat
ion 
Intra Inter Intra Inter Intra Inter Intra Inter Intra Inter Intra Inter Intra Inter 
Std. 
Dev. 
22.1 30.5 13.6 25.1 5.4 7.1 0.22 0.40 4.1 5.1 1.1 2.2 44.4 71.6 
CV 
(%) 
4.6 6.4 4.8 8.9 6.7 7.1 4.3 7.9 5.4 6.7 5.0 9.7 6.2 9.9 
Abbreviations: CV, coefficient of variation; intra, intra-assay imprecision; inter, inter-assay imprecision 
 
between vaccination cycles and after the last vaccination. IgG subclass analysis showed that IgG1 
predominantly contributed to the KLH-specific IgG response in this patient (Figure 2b). This example 
demonstrates that the KLH Ab-response strongly depends on the schedule of KLH exposure and the 
time point of serum sampling. One vaccinated patient received 9 vaccinations that did not contain 
KLH, because of a severe shellfish allergy. We detected no KLH-specific Abs in this specific patient (Fig 
2c,d), demonstrating that KLH-specific Ab-responses are caused specifically by the KLH added to the 
vaccine and not by the vaccine itself. The high specificity of the anti-KLH ELISA is further illustrated by 
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the fact that none of the 57 tested patients had detectable KLH-specific Abs prior to vaccination 
(Figure 3a, bars indicated by ‘before’).  
 
 
Figure 1. Serial dilution linearity of the anti-KLH ELISA. Serum samples of patients exposed to KLH were serially diluted with 
assay buffer and measured in quadruplicate. The results for linearity of the ELISA for the anti-KLH isotypes IgG (A) IgA (B) 
and IgM (C) are shown. Calculated concentrations are based on stock-concentration and dilution factor. Slopes and 
coefficients of determination (R2) are indicated in each panel. The line of identity is indicated by the dashed line. 
 
Variations in vaccination parameters have major influence on the levels and patterns of humoral anti-
KLH responses 
Another application of this novel assay is that it allows the comparison of the humoral 
immunogenicity of different KLH-containing interventions. To demonstrate this, we performed 
subgroup analyses in a total of 118 melanoma patients, 43 stage III and 85 stage IV, who received 
dendritic cell based vaccinations according to different protocols (Table 2). Pretreatment with a 
single dose of intravenous humanized monoclonal anti-CD25 antibody (Daclizumab) significantly 
reduced the overall anti-KLH Ig responses (Figure 3a). The mean level of anti-KLH IgG without 
pretreatment (protocol 5, n=22) was 142 mg/L compared to 18 mg/L after pretreatment (protocol 4, 
n=13, p=0.0267). With regard to anti-KLH IgA, the mean levels were 5 mg/L with no pretreatment 
and 2 mg/L with pretreatment; for anti-KLH IgM this was 157 mg/L compared to 7 mg/L, respectively 
(p=0.0275). Vaccination with immature DC (protocol 1, n=9) barely induced anti-KLH antibodies 
compared to vaccination with mature DC (protocol 5, n=22)(Figure 3b). Anti-KLH IgG antibodies were 
detected in 2/9 patients upon immature DC vaccination and in 12/22 patients after vaccination with 
mature DC, mean 9 mg/L and 142 mg/L, respectively (p=0.0600). Anti-KLH IgM antibodies were 
induced in the same patients, 2/9 patients after immature DC vaccination and 9/22 patients after 
mature DC vaccination, to similar extend, 147 mean mg/L and 157 mg/L respectively (p=0.4157). As 
expected, the method of loading the tumor-antigens onto the dendritic cells, either pulsing with 
defined peptides (protocol 3, n=24) or electroporation with mRNA encoding the tumor antigens 
(protocol 2, n=17), did not affect the concentration or the pattern of vaccine-induced anti-KLH 
humoral responses (Figure 3c). Combined intravenous/intradermal vaccination (protocol 5, n=22) 
induced significantly more anti-KLH IgM antibodies as compared to intranodal vaccination (protocol 2 
and 3, n=41), mean 157 mg/L and 27 mg/L respectively (p=0.0222), but no differences in IgG or IgA 
levels were noted (Figure 3d).  We observed significantly higher anti-KLH IgG titers in melanoma 
patients who were vaccinated adjuvant to radical lymph node dissection (stage III) compared to 
melanoma patients with irresectable locoregional disease or distant metastatic disease (stage IV). 
Mean concentrations of all isotypes were at least two times higher in stage III patients compared to 
stage IV melanoma patients (Figure 3e). However, the most prominent was anti-KLH IgG, mean 310 
mg/L in stage III patients (protocol 6, n=43) compared to 94 mg/L in stage IV patients (protocol 2 and 
3, n=41), p=0.0002. 
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Figure 2. A detailed characterization of KLH-specific antibody responses in individual patients; two examples. Two patients 
who received 9 vaccinations of KLH loaded dendritic cells over a period of 18 months are characterized in detail for KLH-
specific antibody responses. Each vaccination is indicated by a black arrow. One patient had a robust humoral response, the 
kinetics of the KLH-specific IgG, IgA and IgM responses are shown in (A). In (B) the IgG immune response is subdivided into 
the four IgG subclasses, demonstrating that IgG1 predominantly contributes to the KLH-specific immune response in this 
patient. The second patient received vaccinations with DC not loaded with KLH. In this patient KLH-specific antibody-
responses were completely absent (C,D). 
 
Discussion 
KLH is widely used for biomedical applications because of its remarkable immunogenic properties. In 
the current study, we describe a novel, highly sensitive and quantitative, sandwich ELISA 
standardized to measure IgM, IgA and IgG Abs specific for KLH. We demonstrate that it is now 
possible to monitor the dynamics and concentrations of humoral KLH specific immune-responses in 
individuals exposed to KLH and in clinical trials. Importantly, we show that vaccine-induced KLH 
specific humoral responses largely depend on variations in vaccination parameters in DC based 
clinical trials. Using our novel anti-KLH ELISA we found that melanoma patients exposed to KLH 
loaded DCs often initially develop KLH specific IgM Abs, which is associated with a primary immune 
response as was expected from literature (32). After subsequent vaccinations in our patients, this is 
usually followed by class-switching and production of KLH specific IgG Abs, suggestive for a secondary 
immune response. This secondary immune response is accompanied by KLH specific IgA Abs in a 
minority of patients. In general, Ab isotype switching and the identity of the immunoglobulin 
subclasses is regulated by cytokines and B-cell activators (33). In this respect, Ab-responses in terms 
of isotype and subclass will be influenced by the route and conditions under which KLH is 
administered. In our studies, in which all individuals were exposed to KLH-loaded cytokine-matured 
DCs, IgG1 was the predominant subclass produced. We hypothesize that the method of KLH 
exposure and/or individual patient characteristics can result in significant skewing of the IgG subclass 
response. We further demonstrate that, using this novel assay, it is now possible to link the 
concentration of induced KLH specific Abs to the humoral immunogenicity of the KLH-containing DC 
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Figure 3. Variations in vaccination parameters induce different humoral anti-KLH responses. In total 128 melanoma patients 
were exposed to KLH by 3 bi-weekly vaccinations containing KLH loaded DC. None of the 35 patients tested (protocols 4 and 
5) had KLH-specific antibodies prior to vaccination (a). KLH-specific Ab responses compared between (a) patients treated 
with or without daclizumab prior to the KLH exposure; (b) patients vaccinated with immature or mature KLH-loaded DC; (c) 
peptide-loaded or mRNA-transfected KLH-loaded DC; (d) intranodal or intravenous/intradermal routes of administration 
and (e) patients with locoregional metastatic disease or distant metastatic disease at inclusion. Mean levels of KLH-specific 
IgG (white bars), IgA (grey bars) and IgM (black bars) antibodies are shown in mg/L. Error bars indicate standard error of the 
mean; n.d., not detected.  
 
based vaccines used in our institute. In our cohort of patients with metastatic melanoma we have 
found that adjustments in the vaccination protocol can significantly affect the humoral responses 
against KLH. We show for example that a single dose of daclizumab, a humanized monoclonal anti-
CD25 Ab, prior to injection of KLH loaded DCs almost completely abolishes the KLH-specific humoral 
response. Blocking CD25 on activated T cells and regulatory T cells greatly reduces the capacity of the 
immune system to respond to de novo antigens. The in vivo effects of daclizumab on T cells are well 
documented (34), but the effects of daclizumab on humoral immune-responses were largely 
unexplored. Although injected prior to vaccination, circulating daclizumab may bind to CD25-
expressing vaccinated DC, providing yet another possible explanation for the strongly reduced 
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vaccine-induced humoral responses to KLH. The maturation status of the DCs is another parameter 
that strongly affects humoral immunogenicity of the vaccine. We previously demonstrated that more 
effective cellular immune responses are induced with mature DCs compared to immature DCs (35). 
Now we demonstrate that mature DC also generate stronger humoral immune responses and are 
essential for efficient immunoglobulin class switching. In addition, we show that there is no 
significant difference in the KLH-specific IgG and IgA responses when the KLH-vaccine is administered 
intravenously/intradermally or intranodally in melanoma patients. However, intravenous/ 
intradermal injections tend to result in increased KLH-specific IgM responses compared to intranodal 
injection. In case of differential tumor-antigen loading onto the DC, we would not expect different 
KLH responses since in all protocols the DC are pulsed with KLH at day 3 after isolation, and loading 
with tumor-antigen occurs just before administration. Indeed, with regard to different methods of 
tumor-antigen loading we did not detect differences in levels or specificity of anti-KLH humoral 
reponses. Several lines of evidence demonstrate that tumor cells actively create a local and systemic 
immune suppressive environment (36-38). The level of tumorload may therefore negatively correlate 
with the competence of a patients’ immune system to respond to antigens such as KLH (39). We 
investigated the humoral KLH responses in patients treated with DC based vaccinations adjuvant to 
radical lymph node dissection, and thus without macroscopic disease (stage III), and in patients with 
distant metastatic and measurable disease, stage IV melanoma. We indeed confirm that anti-KLH Ab 
production was higher in stage III patients compared to patients with stage IV melanoma, which 
argues in favour of applying immunotherapy at earlier stages of disease. Further analysis is 
warranted to investigate if the KLH-specific Ab-response in the context of anti-cancer vaccines can be 
used as a surrogate biomarker for tumor-specific immune-responses. The standardized ELISA 
presented here can facilitate in this effort as it allows inter-institutional comparisons of the humoral 
immunogenicity of KLH-containing vaccines. Although we initially developed the quantitative anti-
KLH ELISA to monitor vaccine-induced immune responses, the assay allows quantification of humoral 
responsiveness as a measure of immunocompetence in individuals exposed to KLH. Since KLH elicits a 
primary immune response, intramuscular injection of KLH is the method of choice to investigate the 
capacity of an individual to respond to novel antigens, overcoming the confounding influence of 
previous exposure history (40). Finally, because of its capacity as a nonspecific immune stimulator, 
KLH has been investigated as an intravesical agent to treat superficial bladder cancer (3). Previously, 
it has been reported that the presence of anti-KLH antibodies was associated with treatment 
response (41). In this respect it is interesting to investigate whether in-depth analysis of the KLH-
specific Ab-responses in these patients can be an early predictor of therapy outcome.  In conclusion, 
we here present a sensitive and specific quantitative assay to measure KLH-specific Abs in human 
serum. We demonstrate that with this assay it is now possible to monitor both the dynamics and 
absolute concentrations of KLH-specific humoral responses in individuals exposed to KLH, for 
example to evaluate humoral immune competence. In addition, it may provide a valuable biomarker 
for the immunogenicity and clinical effectiveness of KLH-containing vaccines and therapies.  
 
Table 2 Patients and protocol characteristics 
Protocol nr. Stage   Nr of 
patients 
Maturation 
status 
Route of 
administration 
Anti-CD25 
pretreatment 
Method of Ag-loading 
 
1 IV 9 immature i.v./i.d. no peptide pulsing 
2 IV 17 mature i.n. no mRNA electroporation 
3 IV 24 mature i.n. no peptide pulsing 
4 IV 13 mature i.v./i.d. yes peptide pulsing 
5 IV 22 mature i.v./i.d. no peptide pulsing 
 total 85     
6 III 43 mature i.n. no peptide pulsing or mRNA electroporation 
 total 43     
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Abstract 
The identification of responding patients early during treatment would improve the capability to 
develop effective new immunotherapies more rapidly. Here we describe a bioassay that may link 
early T cell-mediated immune responses to later clinical benefits. This bioassay rests upon the tenet 
of immunotherapy that tumor-specific effector T cells capable of invading peripheral tissue can 
recognize tumor-antigens and exert cytotoxic functions there. To demonstrate its utility, we 
conducted a retrospective study of a large cohort of metastatic melanoma patients (n=91) enrolled in 
dendritic cell (DC)-based vaccination protocols to examine an hypothesized correlation of post-
treatment skin-infiltrating lymphocytes (SKILs) with overall survival (OS). Stringent immunological 
criteria were defined to identify long-term survivors. The presence of TAA-specific CD8+ T cell 
populations within SKILs (criterion I) was highly predictive for long-term survival. Further restriction 
by selecting for the presence of TAA-specific CD8+ T cells specifically recognizing tumor peptide 
(criterion II) were also associated with improved OS. Recognition of naturally processed antigen 
(criterion III), maximized the accuracy of the test, with a median OS of 24.1 versus 9.9 months 
(p=0.001). Our results show that detailed characterization of SKILs can permit an accurate selection 
of metastatic melanoma patients who benefit most from DC-based vaccination. This simple and 
robust bioassay integrates multiple aspects of cellular functions that mediate effective immune 
responses, thereby offering an effective tool to rapidly identify patients who are responding to 
immunotherapy at an early stage of treatment.   
180
Part 3, Chapter 11 
 
Introduction  
The focus of treatment for metastatic cancer patients is shifting from a generalized approach based 
on population markers, to a personalized approach based on individual tumor and host 
characteristics (1). Immunotherapy is intrinsically a personalized treatment modality, as it acts via the 
patients’ own immune system to induce anti-cancer immunity. Recent trials have underscored the 
potential of immunotherapy in metastatic cancers, especially in melanoma (2). Owing to their unique 
immune stimulatory properties, dendritic cells (DC) are an essential target for anti-cancer 
immunotherapy. We and others have explored DC-based therapy to induce tumor associated antigen 
(TAA)-specific immune responses in this population (3, 4). Interestingly, the reported rates of long-
lasting responses in immunotherapy trials are generally low, but remarkably constant, regardless of 
the chosen regimen (5). This long-standing observation hints at a subgroup of ‘immune reactive’ 
patients. Identification of responding patients early during treatment would therefore greatly 
improve clinical efficacy of these novel and costly therapies. Thus, bioassays which accurately link 
immune responses to clinical outcome are warranted (1).  
The mainstay of immunotherapy is to induce, enhance or sustain TAA-specific effector T cell 
immunity. Consequently, currently used bioassays focus on cellular immune responses at different 
time-points after immunotherapeutic intervention. For example, most vaccination studies include a 
control antigen like keyhole limpet hemocyanin (KLH) or tetanus toxoid (TT) as a surrogate marker 
for immune competence (6). However, the high immunogenicity of these control antigens often 
induce profound cellular and humoral responses, which do not accurately model the less abundant, 
and often self-antigens, TAA-specific cellular responses. Another widely used approach is ELIspot, 
which determines the production of a single cytokine upon antigenic stimulation, e.g. IFN ELIspots. 
Typically, ELIspots are performed on cell-samples obtained from peripheral blood, whereas anti-
tumor effects can only be expected from immune cells capable of leaving the circulation and invading 
peripheral tissues. Although ELIspots are rather sensitive, they need careful standardization (7, 8).  
Moreover, they evaluate a single cytokine, whereas cytokine profiles better reveal the functional 
programming of effector cells. Imaging results from previous trials using adoptive cell transfer show 
that the migratory capacity of effector cells is positively correlated to clinical outcome (9), suggesting 
that this functionality should be incorporated in bioassays as well (10). Novel techniques have 
recently been developed that allow high throughput assessment of individual variations in many 
functional processes, e.g. differences in signaling pathways in immune cells (11). However, as of now 
these techniques lack validation and are not yet applicable in the evaluation for therapy-induced 
immune responses.  
Previously, we reported that screening cultures from delayed type hypersensitivity (DTH) skin test 
biopsies, by using tetrameric MHC-peptide complexes, provides a valuable tool to link immune 
responses to clinical outcome in metastatic melanoma patients who underwent DC-based 
vaccinations (12). In this study, we extend these findings in a large cohort and demonstrate that 
detailed analysis of skin-test infiltrating lymphocyte (SKIL) cultures is a solid bioassay to predict 
survival in metastatic melanoma patients. This bioassay is simple, feasible and integrates multiple 
aspects of effector cell functions needed for effective immune responses. 
 
Materials and methods 
Patient characteristics 
We retrospectively analyzed a cohort of 91 patients with irresectable locoregional or distant 
metastatic melanoma, who were enrolled in our vaccination studies between June 1999 and June 
2008 (Table 1). Eligibility criteria included melanoma patients with irresectable locoregional or 
distant metastatic disease, according to the 2001 American Joint Committee on Cancer Staging 
criteria (13). Other inclusion criteria include HLA-A*02:01 phenotype, known HLA-DRB*01*04 status, 
melanoma expressing the melanoma-associated antigens gp100 and tyrosinase and World Health 
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Organization performance status 0 or 1. Patients with symptomatic brain metastases, serious 
concomitant disease or a history of second malignancy were excluded. The studies were approved by 
our Institutional Review Board and written informed consent was obtained from all patients. 
 
Treatment schedule 
All patients were vaccinated with cytokine-matured monocyte-derived autologous DCs loaded with 
tumor associated antigens (TAA) of gp100 and tyrosinase according to a schedule of 3 biweekly 
vaccinations followed in week 7-8 by delayed type hypersensitivity (DTH) skin test (Supplementary 
Figure 1). Differences in protocols included the route of administration (intranodal, intradermal or 
combined intradermal/intraveneously), method of antigen loading (detailed information below) and 
pretreatment with anti-CD25 antibody; described in Table 1. Unless progressive disease was 
documented, patients received a maximum of 3 vaccination cycles, each with a 6 month interval. For 
the exact details regarding the vaccination protocols we refer to these individual studies (14-18). 
 
 
Supplementary Figure 1. Schedule of treatment and monitoring. Patients received 3 vaccinations a biweekly interval, 
followed a delayed type hypersensitivity (DTH) skin test. After completing one cycle and if no progression of disease was 
confirmed on CT-scan, patients were eligible to receive a maximum of two more cycles and were followed up to 5 years. 
Abbreviations: Vx = visit x; M = month, D = day, W = week, Y = year, vacx = vaccination x; FU = follow-up; * follow-up visits 
were planned every 3 months; # CT-scans were planned every 6 months. 
 
 
Dendritic cell vaccine 
Monocytes were enriched from leukapheresis products by counterflow centrifugation using Elutra-
cell separator (Gambro BCT, Inc, Lakewood, CO) and single-use, functionally sealed disposable Elutra 
sets, as described before (19) and according to the manufacturer. Monocytes were cultured in the 
presence of interleukin (IL)-4 (500 U/ml) GM-CSF (800 U/ml) (both Cellgenix, Freiburg, Germany) and 
KLH (10 μg/ml, Calbiochem, Darmstadt, Germany). DC were matured with autologous monocyte-
conditioned medium (30%, v/v) supplemented with prostaglandin E2 (10 μg/ml, Pharmacia & Upjohn, 
Puurs, Belgium) and 10 ng/ml tumor necrosis factor-α (Cellgenix, Freiburg, Germany) for 48 hours as 
described previously (20). This procedure gave rise to mature DC meeting the release criteria 
described previously (3). DC were pulsed with the HLA class I gp100-derived peptides gp100:154-162, 
gp100:280-288 and the tyrosinase-derived peptide tyrosinase:369-377. DC from HLA-DRB*01*04–
positive patients were also pulsed with HLA-DRB*01*04–binding peptides of both gp100 and 
tyrosinase (gp100:44-59 and tyro:448-462 analog (21, 22). Peptide-pulsing was performed as 
described previously (16). In the other protocols mature DC were electroporated with mRNA 
encoding gp100 or tyrosinase as described previously (23) and cells were resuspended in 0.1 mL for 
injection. 
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KLH-specific proliferation and IFN production 
PBMC were isolated from heparinized blood by Ficoll-Paque density centrifugation, stimulated with 
KLH (4 µg/2×105 PBMC) in X-VIVO with 2% HS. After 3 days, cells were incubated with 3H-thymidine 
for 8 hours, incorporation was measured with a -counter. Experiments were performed in triplicate, 
non-specific proliferation upon stimulation with OVA was used as control. IFN production was 
measured in the supernatants after 24 hours by ELISA. Human IFN monoclonal antibody 2G1 was 
used for coating (0.75 g/mL), human IFN biotin-labeled mAb M701B (0.05 mg/mL) was used for 
detection (all Thermo Scientific Inc). Recombinant human IFN RIFNG100 was used as standard. At 
least a two-fold increase compared to OVA was considered positive.  
 
Skin-test infiltrating lymphocyte (SKIL) analyses 
Skin tests were performed within 1-2 weeks after each vaccination cycle (Supplementary Figure 1) 
(24).  Briefly, 2 to 10×105 DC pulsed with either gp100, tyrosinase or both epitopes or transfected 
with mRNA encoding either gp100 or tyrosinase or both (specifically indicated in the relevant text 
and figures) were injected intradermally in the skin of the back of the patient at different sites, 4 cm 
apart from each other. After 48 hours, the maximum diameter of induration was measured by 
palpation and punch biopsies (6 mm) were taken. Half of the biopsy was cryopreserved by snap 
freezing and the other part was manually cut and cultured or 2 to 4 weeks in RPMI-1640 containing 
7% HS and IL-2 (100 U/ml), every 7 days half of the medium was replaced by fresh IL-2 containing 
RPMI-1640 7%HS.  
 
Tetramer staining of SKILs 
SKIL cultures were stained with tetrameric-MHC complexes containing the MHC-I epitopes 
gp100:154-162, gp100:280-288 or tyrosinase:369-377 (Sanquin, Amsterdam, The Netherlands) as 
described previously (12). Tetrameric-MHC complexes recognizing HIV were used as correction for 
background binding. Tetramer positivity was defined as at least two-fold increase in the double 
positive population.  
 
Cytotoxic Acitivity of SKILs 
Cytotoxic activity by SKILs in response to T2 cells pulsed with the indicated peptides or BLM (a 
melanoma cell line expressing HLA-A*02:01 and no endogenous expression of gp100 and tyrosinase), 
transfected with control antigen G250, or with gp100 or with tyrosinase, or an allogenic HLA-
A*02:01-positive, gp100-positive, and tyrosinase-positive tumor cell line (Mel624) were measured. 
Target cells were incubated with 100 Ci Na2[
51Cr]O4 (Amersham, Bucks, UK) and, after washing, 
added to SKILs (1×105 cells) and unlabeled K562 cells (1×104 cells) in triplicate wells of a round 
bottom microtiter plate (E/T ratio 10/1). After 4 hours, supernatants were harvested and 
radioactivity was measured. The specific percentage of cytotoxicity was defined by the following 
formula:  
 
                      
                                                        
                                                   
      
 
Positive and specific cytotoxic activity was defined as a two-fold increase compared to stimulation 
with the same cell-lines pulsed with an irrelevant peptide.  
 
Cytokine production profiles by SKILs 
The production of IFN, TNF, IL-10, IL-5, IL-4, IL-2 by SKILs was measured in supernatants after 16 
hours of co-culture with different target cells to obtain a cytokine profile of post-vaccination SKILs. 
Target cells include T2 cells pulsed with the indicated peptides or BLM (a melanoma cell line 
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expressing HLA-A*02:01 and no endogenous expression of gp100 and tyrosinase), transfected with 
control antigen G250, or with gp100 or with tyrosinase, or an allogenic HLA-A*02:01-positive, gp100-
positive, and tyrosinase-positive tumor cell line (Mel624) with SKILs, using the cytometric bead array 
(Th1/Th2 Cytokine CBA 1; BD Pharmingen), according to the manufacturer instructions. Positive and 
specific cytotoxic activity was defined as a two-fold increase compared to stimulation with the same 
cell-lines pulsed with an irrelevant peptide.  
 
 
Supplementary Figure 2. Definition of criteria for SKIL culture evaluation. Three examples are shown to illustrate the 
definition of SKIL culture criteria. (A) Criterion III, one patient (IV-B-16-St) with a clear population of TAA-specific CD8
+
 T 
cells in SKIL cultures, which produce high levels of IFN upon encounter of both the defined gp100 peptides and naturally 
processed gp100 presented by a HLA-A*02:01 positive melanoma cell line (Mel624). Moderate amounts of IL-2 are 
produced and minimal production of IL-5, representing a clear IFN dominant cytokine profile.  (B) Criterion II, a patient (IV-
B-11-Ro) with TAA-specific CD8
+
 T cells in SKIL cultures which produce high levels of IFN and IL-2 upon encounter of the 
gp100 peptide, but fail to recognize the naturally processed gp100. (C) Criterion I, a patient (IV-A-07-Th) with a population 
of TAA-specific CD8
+
 T cells in SKIL cultures, recognizing the g100-154 peptide, but not the naturally processed gp100. 
Furthermore, those TAA-specific CD8
+
 T cells do not produce IFN but produce elevated levels of IL-5 instead, indicating that 
the immune system is skewed towards tumor tolerance. 
 
Skin-test infiltrating lymphocyte culture evaluation 
SKILs were evaluated according to increasingly stringent criteria; the presence of TAA-specific CD8+ T 
cells by tetrameric MHC-peptide complexes (criterion I); peptide-recognition by specific production 
of Thelper 1 (Th1) cytokines (e.g. IFN and/or IL-2) or cytotoxicity and no Thelper 2 (Th2) cytokines 
(criterion II); or tumor-recognition of naturally processed TAA by specific production of Th1 cytokines 
or cytotoxicity and no Th2 cytokines (criterion III), an example is provided in Supplementary Figure 2. 
The best overall TAA-specific responses wasused for analyses, regardless of the time point at which 
the SKILs were obtained within the study, as this reflects the individual competence to generate a 
specific immune response.  
 
Statistical analysis 
Overall survival (OS) was calculated from the date of apheresis to date of death and analyzed by 
Kaplan-Meier estimation using SPSS19.0 (SPSS Inc, Chicago, IL). Statistical significance was evaluated 
using the log-rank test. Cox proportional hazard model was used to calculate hazard ratios (HR) for 
survival. 
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Table 1. Vaccination protocols and characteristics of SKIL cultures. 
Protocol  Number of 
evaluable 
patients  
(total) 
Method of 
antigen    loading            
Route of 
administration  
Anti-CD25 
mAb**  
Number of 
cultures with 
outgrowth 
pos/total (%)  
Mean 
      
(x10
6
)  
Range  
             
(x10
6
)  
1  1  (1)  Class I wt  i.d.  no  4/4 (100)  0.15  0.09 – 0.2  
2  13 (17)  Class I wt  i.n.  no  48/48 (100)  0.50  0.03 – 5.6  
3  17 (22)  RNA ¥  i.n.  no  115/126 (86)  0.53  0.01 – 7.0  
4  13 (15)  Class I wt  i.v./i.d.  no  44/63 (70)  0.59  0.01 – 1.8  
5  9 (10)  Class I mod †  i.v./i.d.  no  21/48 (44)  0.16  0.01 – 1.3  
6  11 (11)  Class I/II wt ‡  i.n.  no  65/73 (89)  0.53  0.01 – 3.1  
7  13 (15)  Class I wt  i.v./i.d.  yes  42/54 (78)  0.44  0.01 – 3.3  
total  77 (91)     339/416  (82)    
Abbreviations: mAb, monoclonal antibody; wt, wild type; mod, modified, i.d., intradermal,; i.n., intranodal; i.v., intravenous  
** Four or eight days prior to first vaccination, anti-CD25 antibody 0.5 mg/kg was administered intravenously  
$ Class I wt; HLA class I-restricted wild-type gp100-derived peptides 154-162 and 280-288 and HLA class I-restricted 
tyrosinase-derived peptide 369-377  
¥ mRNA; messenger RNA encoding full length gp100 and tyrosinase 
† Class I mod; HLA class I-restricted modified gp100-derived peptides 154-162 Q→A and 280-288 A→V and HLA class I-
restricted tyrosinase-derived peptide 
 
Results  
Vaccination protocols and SKIL cultures 
Seventy-seven patients completed at least 1 scheduled cycle and were thus evaluable for 
immunological response (Table 1). Fourteen patients did not complete 1 scheduled cycle due to rapid 
progressive disease. The patients were vaccinated according to the various vaccination protocols, 
including intranodal, intradermal, intravenous/intradermal vaccinations; mode of antigen loading of 
DC was either pulsing with MHC Class I or MHC Class I and II defined epitopes derived from gp100 
and tyrosinase, or electroporation with mRNA encoding these tumor associated antigens (25). In one 
protocol, patients received a single infusion of anti-CD25 antibody therapy prior to the first 
vaccination (14). To demonstrate that this procedure is feasible for large scale clinical studies, we 
determined the rate of successful SKIL cultures and their yield (Table 1). 329 out of 410 (80%) 
cultures yielded sufficient numbers of cells to allow further analysis, which results appear to be 
independent of the vaccination protocol (Table 1). On average, 4 successful cultures with different 
specificities were obtained per patient during complete course of 3 vaccination cycles. 
 
KLH-specific T cell responses do not predict overall survival 
Peripheral blood samples during and after completion of each vaccination cycle were available for 70 
patients for testing of KLH-specific CD4+ T cell proliferation. The maximum standard index (SI) 
compared to ovalbumin (OVA) was recorded and designated ‘strong’ if more than 40. No significant 
difference in median OS was observed for patients with or without strong KLH-specific CD4+ T cell 
response; being 6.9 and 9.0 months respectively (p=0.95, Figure 1a, Table 2). We analyzed the 
cytokines produced upon KLH encounter and 9 out of 40 tested patients showed a clear IFN 
dominant response. However, this parameter did not significantly discriminate between patients 
with good and poor prognosis; median OS 16.7 and 11.0 months respectively, p=0.40 (Figure 1b, 
Table 2).  
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Induration at the injection site is not predictive for clinical outcome  
After completing the first cycle of three vaccinations, the induration in 70 evaluable patients upon 
intradermal challenge with DC expressing gp100 or tyrosinase was median 13mm (range 0 – 36mm) 
and 13mm (0 – 34mm) respectively. The degree of induration was not predictive for clinical outcome 
with a maximum induration >15mm corresponding with a median OS of 9.8 months and a maximum 
induration ≤15mm corresponding with 13.0 months, p=0.675 (Figure 1c). 
 
SKIL procedure does not require the presence of defined epitopes  
In some protocols we exploited DC transfected with mRNA encoding gp100 and tyrosinase, thus 
expressing multiple undefined epitopes. To investigate whether the results of tetramer screening of 
SKIL cultures depend on the presence of defined TAA epitopes, we performed parallel skin-test 
challenges within individual patients. In one cohort (n=17) we performed the delayed type 
hypersensitivity (DTH) procedure with intradermal injections of DC pulsed with defined epitopes 
(gp100:154-168, gp100:280-288 and tyrosinase:369-377) and DC transfected with mRNA encoding 
the same tumor antigens (full length gp100 and tyrosinase) within individual patients, who were 
vaccinated with mRNA-transfected DC. Cultures from SKILs obtained from DTH sites containing DC 
loaded with defined epitopes or mRNA-transfected DC, yielded equal numbers of cells and successful 
cultures. In total, 126 DTH challenges were performed in parallel, of these, 59 out of 63 mRNA-DC-
challenged and 54 out of 63 peptide-DC-challenged skin-test biopsies yielded successful cultures. 
Comparable average yields per culture were obtained, 0.53 (range 0.01 – 7.0) x106 cells with mRNA-
transfected DC and 0.40 (range 0.01 – 2.8) x106 cells for peptide pulsed DC. Furthermore, tetramer 
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Figure 1. KLH-specific T cell responses do not predict 
clinical outcome. Kaplan-Meier analyses of overall 
survival (OS) according to KLH-specific T cell responses 
during DC-based vaccination in melanoma patients. (A) 
The levels of KLH-specific proliferation, expressed as 
standard index (SI) compared to proliferative responses 
to the irrelevant protein, were not predictive for OS. (B) 
The production of significant levels of IFN upon KLH-
stimulation was not associated with improved OS. (C) 
The maximum diameter of induration of the skin test 
was not associated with OS.  
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screening for TAA-specific T cells showed that challenge with DC pulsed with defined epitopes or DC 
transfected with mRNA have similar sensitivity and specificity (data not shown). TAA-specific CD8+ T 
cells directed against all 3 defined epitopes were detected in single SKIL cultures obtained from 
intradermal challenge with DC transfected with mRNA encoding both gp100 and tyrosinase (data not 
shown).  
 
 
NOTE: A graphical representation of the hazard ratios associated with different response criteria were estimated using Cox 
proportional-hazard models. Hazard ratio <1 defines a positive correlation with overall survival if the criterion is met. 
Horizontal lines represent 95% confidence intervals. Abbreviations: KLH, keyhole limpet hemocyanin; IFN, interferon-
gamma; SI, standard index compared to stimulation with Ovalbumin. 
 
SKIL culture evaluation accurately predicts clinical outcome 
To investigate the role of the breadth of response, we analyzed the clinical outcome in relation to the 
number of epitopes that were recognized. The presence of one TAA-specific CD8+ T cell population in 
SKIL cultures was demonstrated in 14 patients, who had a median OS of 9.8 months (95%CI 7.3 – 
12.3) compared to 10.9 months (95%CI 5.7 – 16.0) in 52 patients in whom no TAA-specific CD8+ T cell 
populations were detected (Figure 2a). Two or 3 TAA-specific CD8+ T cell populations were detected 
in 8 and 3 patients, respectively, corresponding with a median OS of 14.2 months (95%CI 0.4 – 30.7) 
and median not reached, respectively (Figure 2a). Overall, the presence of TAA-specific CD8+ T cells in 
SKIL cultures (criterion I) was demonstrated in 25 patients and was associated with improved 
survival; median OS 14.1 months compared to 10.9 months in patients without TAA-specific CD8+ T 
cells (Figure 2b) and HR 0.60 (95%CI 0.42 – 0.86, p=0.005, Table 2). Since patients were vaccinated 
with DC loaded with either multiple melanoma peptides or mRNA-transfected DC presenting multiple 
undefined antigens, T cell populations with different specificities could have been induced. In 18 
patients with TAA-specific CD8+ T cells we also demonstrated vaccine-specific peptide-recognition 
(criterion II), which was strongly associated with improved survival (median OS 14.2 months versus 
10.2 months in patients without vaccine-specific peptide-recognition, Figure 2c and HR 0.42 (95%CI 
0.23 – 0.77, p=0.005, Table 2). To even better identify immune responsive patients, we selected for 
SKILs responding to naturally processed antigen by producing Th1 cytokines, predominantly IFN. 
This was observed in 12 of these 18 patients who had a median OS of 24.1 versus 9.9 months in 
patients without SKILs responding to naturally processed antigen (Figure 2d) and HR 0.30 (0.14 – 
0.65), p=0.002 (Table 2). As multiple cytokines were measured in SKIL cultures, we were able to 
identify functionally different cytokine profiles. As mentioned above and Supplementary Figure 2, in 
the majority of cases we detected IFN dominated cytokine production. However, in 2 patients we 
detected predominantly IL-5 production by SKILs responding to peptide-pulsed target cells, indicative 
Table 2. Hazard Ratios associated with criteria for response
Response criterium Hazard Ratio 
(95%CI)
P-value
Criterium III 0.30 (0.14 – 0.65) 0.002
Criterium II 0.42 (0.23 – 0.77) 0.005
Criterium I 0.60 (0.42 – 0.86) 0.005
Nr of epitopes (0, 1, 2 or 3) 0.60 (0.42 – 0.85) 0.004
KLH proliferation (SI >40) 0.93 (0.73 – 1.20) 0.583
0.0 0.5 1.0 1.5
better prognosis worse prognosis
2.0
Table 2
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of Th2 skewing of the immune response. The detection of this response coincided with rapid 
progressive disease in both patients (Figure 3).  
 
Figure 2. Analyses of SKIL cultures predict clinical outcome of DC-based therapy in metastatic melanoma patients. Kaplan-
Meier analyses of overall survival (OS) according to different criteria for immune response in skin-test infiltrating 
lymphocyte (SKIL) cultures obtained during DC-based vaccination in melanoma patients. (A) The breadth of the vaccine-
specific immune responses, measured as the number of vaccine-specific tetramer-positive populations in SKIL cultures, 
correlates with OS. (B) SKIL cultures were sampled with tetrameric MHC-peptide complexes for the presence of TAA-specific 
CD8
+
 T cells (criterion I). (C) Next, SKIL cultures were evaluated for recognition of tumor-peptides by the production of IFN 
or cytotoxicity, but no IL-5 production (criterion II); improving the accuracy of this bioassay to select patients with a 
favourable clinical outcome. (D) Lastly, SKIL cultures were evaluated according to the most stringent criterion III, specific 
-5 production upon recognition of naturally processed tumor antigen; which was 
highly associated with improved OS. 
 
Discussion 
Although the presence of tumor-specific cytotoxic T cells in cancer patients has been reported to 
associate with favourable clinical outcome (26), bioassays that accurately link vaccine-specific 
immune responses to survival are lacking. Although tetramer analysis or ELIspot assays of TAA-
specific responses in peripheral blood are available, the low prevalence of TAA-specific T cells in 
peripheral blood makes this procedure less suitable for routine monitoring. Moreover, besides 
antigen specificity and effector activity, anti-tumor CD8+ T cells must be able to extravasate and 
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migrate into peripheral target tissues. We addressed this issue by evaluating SKIL cultures. This 
bioassay integrates multiple facets of an effective immune response. First, it serves as a ‘fitness test’; 
the in vivo intradermal challenge selects TAA-specific T cells that possess the migratory capacities to 
leave the circulation and penetrate peripheral tissue. Secondly, tetrameric MHC-peptide complexes 
allow sampling of different specificities (criterion I) within the SKIL population. Since SKILs are 
expanded in vitro in the absence of antigen, the composition of different specificities closely parallels 
the in vivo situation. Thirdly, more stringent recognition can be assessed by challenging SKILs either 
with target cells loaded with defined antigenic peptides (criterion II) or by target cells that express 
naturally processed TAA (criterion III). Finally, measuring cytokine profiles upon antigenic challenge 
reflects the in vivo programming of TAA-specific T cells either towards Th1 or Th2 immune responses. 
The latter is of crucial importance to interpret anti-tumor responses and eventual clinical outcome.  
 
Figure 3. Immunological response closely relates to the individual clinical course of disease. Two patients are shown in 
whom the immunological evaluation predicted the course of their disease. (A) Data of IV-A-01 is depicted in whom TAA-
specific CD8
+
 T cell with specific cytotoxic capacity were detected after the first cycle of vaccinations. (B) After completing 
the third cycle of vaccinations, IFN-producing TAA-specific CD8
+
 T cells were detected in SKIL cultures and no IL-5 was 
produced. As of May 2012, this patient survived 120+ months from start of vaccinations. (C) Data of IV-A-05 is shown in 
whom no TAA-specific CD8
+
 T cells were detected after the first cycle of vaccinations.  (D) However, SKIL culture evaluation 
upon the third cycle of vaccinations revealed TAA-specific CD8
+
 T that produced high levels of IL-5 upon antigen encounter. 
Planned evaluation showed rapid progression of disease; the patient died shortly after the third vaccination series, 20 
months after start of vaccination.  
 
In most clinical studies a highly immunogenic non-tumor antigen is included in the vaccine, such as 
keyhole limpet hemocyanin (KLH) or tetanus toxoid (TT). The rationale for this approach is two-fold; 
it is used as a surrogate marker to which excessive humoral and proliferative responses will be 
induced, in that respect is serves to evaluate immune competence per individual. Secondly, these 
immunogenic proteins contain a multitude of predominantly T helper cell epitopes; ergo, it functions 
as a non-tumor specific adjuvant. We have previously investigated the magnitude and dynamics of 
humoral responses in this cohort of metastatic melanoma patients who underwent DC-based 
therapy (27). Our findings show that humoral anti-KLH responses are dictated by different 
vaccination parameters, such as route of administration and anti-CD25 mAb pretreatment. CD8+ 
cytotoxic T cells (CTLs), as the endpoint effectors, represent a critical population for anti-cancer 
immunity. However, cellular responses to KLH are invariantly induced in the vast majority of patients, 
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regardless of the vaccination protocol (14-18, 28). In this study we show that neither the magnitude 
of KLH-specific T cell responses, nor the quality of the KLH-
production is predictive for clinical outcome. This demonstrates that loading ex vivo generated DC 
with KLH does not provide adequate means to assess anti-tumor cellular immune competence. This 
notion is further supported by the lack of correlation between the quality of vaccine-specific immune 
responses, as determined by the above mentioned SKIL criteria, and the magnitude of KLH-specific 
cellular responses (Supplementary Figure 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 3 and 4. KLH-specific T cell responses and levels of induration according to SKIL classification. 
Regardless of the number of epitopes or the increasingly stringent criteria for TAA-specific immune responses; the levels of 
KLH-specific T cell responses were similar and highly variable between individuals. One-way ANOVA was used for 
comparison of KLH-specific T cell responses in groups of patients with increasing breadth of TAA-specific CD8
+
 T cell 
responses. Student t-test was used for comparison of KLH-specific T cell responses in groups of patients as defined by 
different SKIL criteria. Regardless of the number of epitopes or the increasingly stringent criteria for TAA-specific immune 
responses; the maximum induration at the injection site was similar in all groups. One-way ANOVA was used for 
comparison of induration in groups of patients with increasing breadth of TAA-specific CD8
+
 T cell responses. Student t-test 
was used for comparison of induration in groups of patients as defined by different SKIL criteria.  
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It has been reported in some studies that the degree of induration at the injection site would reflect 
the individual capacity to mount a vaccine-specific immune response, and therefore correlate to 
therapy response. If so, the degree of induration would provide an easy and accessible measure for 
therapy evaluation. In general, induration is regarded as a typical CD4+ T cell reaction. On the 
contrary, others have shown that intradermal injection site can be briskly infiltrated by CD8+ T cells, 
suggesting that the level of induration would in fact show Th1 type immune induction. Our data 
clearly illustrate that induration is not associated with overall survival or with TAA-specific CD8+ T cell 
responses (Supplementary Figure 3). Furthermore, the measurement of induration is subject to high 
inter-test variability which complicates standardization. Our increasing understanding of the complex 
interaction of an individuals’ immune system and cancer and the development of 
immunotherapeutic interventions with clinical benefit, have drastically influenced the way we design 
and perform clinical studies on immunotherapy (29). From small proof-of-principal studies focussing 
on a single parameter (3), we now focus on large randomized prospective studies with adjusted 
endpoints, designed to evaluate potential biomarkers and specific clinical response patterns (1, 30).  
 
Supplementary Figure 5. Patient selection based on SKIL criteria. SKIL criteria are applied to select patients with immune 
responses meeting increasingly stringent criteria. 
 
In this respect, we evaluated SKIL culture analyses for its feasibility in large studies. With notion of its 
invasive nature, this procedure is relatively easy to perform, does not need specialized personnel and 
is not labour intensive and is acceptable to the large majority of patients. Importantly, this procedure 
consistently yields sufficient numbers of SKILs to address the vaccine-specific immune response, 
which is independent of the vaccination protocol or intradermal challenge conditions. Even in 
patients vaccinated with DC loaded with modified tumor peptides to enhance MHC-binding efficacy, 
we detected CD8+ SKILs directed against the tumor to similar extend as in other vaccination 
protocols. This is in line with our previous observation that modified peptides efficiently elicit 
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responses to wildtype peptides (31), resulting in comparable immunological responses in vivo as 
vaccination with wildtype peptide loaded DC (15). 
The development of tools to monitor immune responses during immunotherapy is complicated by 
the evoluation of different effector T cell populations over time in response to vaccination and tumor 
changes. So far, it is not clear which time window after start of treatment reflects the vaccine-
induced responses best and might be predictive of clinical outcome.  Furthermore, the relevant 
effector populations are distributed over several body compartments, like draining lymph nodes, 
tumor tissue, bone marrow and peripheral blood; and it is debatable what compartment is best 
suitable to monitor vaccine-specific immune responses.  The patients displayed in Figure 3 illustrate 
that the evaluation of both the kinetics and functional status of vaccine-specific responses is critical 
for correct correlation with clinical outcome. In the first patient, if only the percentage of vaccine-
specific SKILs would have been assessed, it would have been a decline in vaccine-specific SKILs, 
However, the specific Th1 type responses after 1 and 3 cycles classifies this response as ‘favourable’. 
In the second patient, the appearance of vaccine-specific SKILs could have been interpreted as a 
favourable response. However, since we measured a typical Th2 skewed functional status, this 
response was correctly classified as non-favourable. We acknowledge that further studies, 
incorporating multiple facets of tumor-specific immune responses at multiple time points after 
treatment, are warranted to elucidate the optimal time window to perform immune monitoring.  
In conclusion, by evaluating the migratory-, antigen recognition-, as well as the effector function of 
SKILs, we are able to select for multifunctional CD8+ T cells with high tumor recognition efficacy. We 
demonstrated that analyzing SKILs is a simple and robust, bioassay to predict overall survival in 
metastatic melanoma patients. Therefore, it represents an ideal candidate for immune monitoring in 
upcoming immunotherapy trials.  
  
  
192
Part 3, Chapter 11 
 
References 
1. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent 
successes and next steps. Nat Rev Cancer. 2011;11:805-12. 
2. Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy - revisited. Nat Rev Drug Discov.10:591-600. 
3. Figdor CG, De Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med. 
2004;10:475-80. 
4. Palucka K, Ueno H, Banchereau J. Recent developments in cancer vaccines. J Immunol. 2011;186:1325-31. 
5. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in 
melanoma: current status and future prospects. Oncologist. 2011;16:5-24. 
6. Schumacher K. Keyhole limpet hemocyanin (KLH) conjugate vaccines as novel therapeutic tools in malignant 
disorders. J Cancer Res Clin Oncol. 2001;127 Suppl 2:R1-2. 
7. Britten CM, Janetzki S, Ben-Porat L, Clay TM, Kalos M, Maecker H, et al. Harmonization guidelines for HLA-peptide 
multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine 
Consortium. Cancer Immunol Immunother. 2009;58:1701-13. 
8. Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, et al. Results and harmonization guidelines 
from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium 
(CVC/SVI). Cancer Immunol Immunother. 2008;57:303-15. 
9. Pockaj BA, Sherry RM, Wei JP, Yannelli JR, Carter CS, Leitman SF, et al. Localization of 111indium-labeled tumor 
infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with 
cyclophosphamide and correlation with response. Cancer. 1994;73:1731-7. 
10. Mauro C, Fu H, Marelli-Berg F. T cell trafficking and metabolism: novel mechanisms and targets for 
immunomodulation. Currt Opin Pharmacol. 2012.[Epub ahead of print] 
11. Wang E, Panelli MC, Marincola FM. Gene profiling of immune responses against tumors. Curr Opin Immunol. 
2005;17:423-7. 
12. De Vries IJ, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen MJ, et al. Immunomonitoring tumor-
specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical 
outcome. J Clin Oncol. 2005;23:5779-87. 
13. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint 
Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-48. 
14. Jacobs JF, Punt CJ, Lesterhuis WJ, Sutmuller RP, Brouwer HM, Scharenborg NM, et al. Dendritic cell vaccination in 
combination with anti-CD25 monoclonal antibody treatment, a phase I/II study in metastatic melanoma patients. 
Clin Cancer Res. 2011;16(20):5067-78 
15. Lesterhuis WJ, Schreibelt G, Scharenborg NM, Brouwer HM, Gerritsen MJ, Croockewit S, et al. Wild-type and 
modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term 
clinical responses independent of the peptide used. Cancer Immunol Immunother. 2011;60:249-60. 
16. De Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, et al. Maturation of dendritic 
cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res. 
2003;9:5091-100. 
17. Verdijk P, Aarntzen EH, Lesterhuis WJ, Boullart AC, Kok E, van Rossum MM, et al. Limited amounts of dendritic 
cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. 
Clin Cancer Res. 2009;15:2531-40. 
18. Lesterhuis WJ, De Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, et al. Route of administration 
modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. 
Clin Cancer Res. 2011;17:5725-35. 
19. Berger TG, Feuerstein B, Strasser E, Hirsch U, Schreiner D, Schuler G, et al. Large-scale generation of mature 
monocyte-derived dendritic cells for clinical application in cell factories. J Immunol Methods. 2002;268:131-40. 
20. De Vries IJ, Adema GJ, Punt CJ, Figdor CG. Phenotypical and functional characterization of clinical-grade dendritic 
cells. Methods Mol Med. 2005;109:113-26. 
21. Topalian SL, Gonzales MI, Parkhurst M, Li YF, Southwood S, Sette A, et al. Melanoma-specific CD4+ T cells 
recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med. 1996;183:1965-71. 
22. Li K, Adibzadeh M, Halder T, Kalbacher H, Heinzel S, Muller C, et al. Tumour-specific MHC-class-II-restricted 
responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from 
melanoma cells. Cancer Immunol Immunother. 1998;47:32-8. 
23. Schuurhuis DH, Verdijk P, Schreibelt G, Aarntzen EH, Scharenborg N, de Boer A, et al. In situ expression of tumor 
antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients. Cancer Res. 
2009;69:2927-34. 
24.  Labtube.tv [internet], Sudbury (United Kingdom) Technology Networks Ltd, available from www.labtube.tv 
25.  Aarntzen EH, Schreibelt G, Bol K, Lesterhuis WJ, Croockewit AJ, de Wilt JH, et al. Vaccination with mRNA-
electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III 
and IV melanoma patients. Clin Cancer Res. 2012 [Epub ahead of print] 
26. Coulie PG, van der Bruggen P. T-cell responses of vaccinated cancer patients. Curr Opin Immunol. 2003;15:131-7. 
27. Aarntzen EH, de Vries IJ, Goertz JH, Beldhuis-Valkis M, Brouwers HM, van de Rakt MW, et al. Humoral anti-KLH 
responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different 
vaccination parameters. Cancer Immunol Immunother. 2012.[Epub ahead of print] 
28. Lesterhuis WJ, De Vries IJ, Schreibelt G, Schuurhuis DH, Aarntzen EH, De Boer A, et al. Immunogenicity of dendritic 
cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. 
Anticancer Res. 2010;30:5091-7. 
29. Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol. 2011;29:4828-36. 
193
Part 3, Chapter 11 
 
30. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy 
activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412-20. 
31.  Bakker ABH, van der Burg SH, Huijbens RJF, Drijfhout JW, Melief CJM, Adema GJ, et al. Analogues of CTL epitopes 
with improved MHC class-I binding capacity elicit antimelanoma CTL recognizing the wild-type epitope. Int J 
Cancer. 1997;70:302–309. 
 
  
194
Chapter 12 
 
 
Early identification of antigen-specific immune responses in vivo by 
18F-FLT PET imaging 
 
 
 
Aarntzen EH 
Srinivas M* 
De Wilt JHW* 
Jacobs JF 
Lesterhuis WJ 
Windhorst AD 
Troost EG 
Bonenkamp JJ 
Van Rossum MM 
Blokx WA 
Mus RD 
Boerman OC 
Punt CJ 
 Figdor CG 
Oyen WJ 
De Vries IJ 
* contributed equally 
 
 
 
Proc Natl Acad Sci U S A. 2011;108(45):18396-9. 
195
 196
Part 3, Chapter 12 
 
Abstract 
Current biomarkers are unable to adequately predict vaccine-induced immune protection in humans 
with infectious disease or cancer. However, timely and adequate assessment of antigen-specific 
immune responses is critical for successful vaccine development. Therefore, we have developed a 
method for the direct assessment of immune responses in vivo in a clinical setting. Melanoma 
patients with lymph node (LN) metastases received dendritic cell (DC) vaccine therapy, injected 
intranodally, followed by 18F-labeled 3’-fluoro-3’-deoxy-thymidine (18F-FLT) PET at varying time points 
after vaccination. Control LNs received saline or DCs without antigen.  De novo immune responses 
were readily visualized in treated LNs early after the prime vaccination, and these persisted for up to 
three weeks. This selective 18F-FLT uptake was markedly absent in control LNs, although tracer 
uptake in treated LNs increased profoundly with as little as 4.5×105 DCs. Immunohistochemical 
staining confirmed injected DC dispersion to T cell areas and resultant activation of CD4+ and CD8+ T 
cells. The level of LN tracer uptake significantly correlates to the level of circulating antigen-specific 
IgG antibodies and antigen-specific proliferation of T cells in peripheral blood. Furthermore, this 
correlation was not observed with 18F-FDG. Therefore, 18F-FLT PET offers a sensitive tool to study the 
kinetics, localization and involvement of lymphocyte subsets in response to vaccination. This allows 
for early discrimination of responding from non-responding patients in anti-cancer vaccination and 
aid physicians in individualized decision-making. 
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Introduction 
The field of vaccination has expanded over the last few years to include the development of 
therapeutic vaccines against infectious diseases such as AIDS (1,2) and tuberculosis (3); as well as 
conditions such as cancer (4,5). In particular, antigen-specific immunotherapy has recently 
progressed through the development of effective therapeutic vaccinations in advanced melanoma 
(6-8) and prostate cancer (5). Antigen-specific immune responses in cancer patients can also be 
induced by exploiting autologous dendritic cells (DCs) that are “educated” ex vivo i.e. DCs that are 
appropriately activated and loaded with tumor antigens (9). DCs are the most potent antigen 
presenting cells of the immune system and play a central role in the induction and maintenance of 
antigen-specific immunity (10). These cells capture and process antigen and migrate to the lymph 
nodes (LNs) where they present the antigen to the adaptive arm of the immune system, inducing 
antigen-specific T and B cell responses. This vaccine-induced immune protection cannot be 
adequately detected in humans, as most therapeutic vaccines have been characterized only in animal 
models (3, 11). The detection of vaccine-inducted immune responses in vivo using a clinically-
applicable means is critical for the optimization of novel immunotherapies.  Thus, we developed a 
technique for the direct assessment of immune responses in vivo during therapeutic vaccination. 
Positron emission tomography (PET) is a widely available, highly sensitive imaging modality for the in 
vivo visualization and quantification of molecular processes at a cellular level. Furthermore, whole 
body imaging allows localization in a longitudinal fashion. These features are necessary to measure 
immune responses by quantification of the low numbers of proliferating T and B cells early after 
vaccination in relevant LNs. Thus far, investigators have mainly exploited 18F-labeled fluoro-2-deoxy-
2-D-glucose (18F-FDG) for PET imaging of proliferating cells, based on the increased glucose 
metabolism of these cells. Recently, novel tracers have been developed that facilitate imaging of 
other cellular processes: 18F-labeled 3’-fluoro-3’-deoxy-thymidine (18F-FLT) was designed as a tracer 
for cell proliferation (12) and is increasingly being applied in oncology. However, it has been 
recognized that enhanced nucleoside demand is not restricted to tumor cells (13). Indeed, a 
successful vaccination results in the proliferation of activated lymphocytes in a highly controlled 
manner within LNs. This proliferation is accompanied by a large metabolic switch in lymphocytes 
(14), and could serve as a marker of immune responsiveness. We hypothesized that PET imaging, 
exploiting 18F-FLT, can specifically detect highly proliferative immune cell responses in proximal LNs 
upon vaccination and thus would allow in vivo assessment of vaccine-induced antigen-specific T and 
B cell responses. Such a ‘detection system’ would allow early discrimination of responding patients 
and therefore aid physicians in individualized decision-making.  
 
Methods 
Patients and treatment schedule 
The presented data result from side-studies in two clinical trials in melanoma patients with regional 
lymph node metastases who are scheduled for radical lymph node dissection (ClinicalTrials.gov 
number NCT00243594 and NCT00243529). Eligibility criteria included stage III melanoma according 
to the 2001 American Joint Committee on Cancer Staging criteria (15), planned regional lymph node 
dissection (RLND) for lymph node metastases or interval <2 months after RLND, HLA-A*02:01 
phenotype, melanoma expressing gp100 and tyrosinase, and World Health Organization 
performance status 0 or 1. Additional eligibility criteria have been described previously (16). The 
study was approved by our Regional Review Board, and written informed consent was obtained from 
all patients. In total, 14 patients were included for additional imaging studies. The vaccine consisted 
of autologous mature DCs, pulsed with tumor associated antigens and keyhole limpet hemocyanin 
(KLH). KLH is a highly immunogenic antigen that serves as a surrogate marker for immune 
competence and as a non-specific T helper cell stimulus. Similar DCs, but not loaded with KLH or 
tumor antigen, or sterile saline served as control vaccination. All injections were directly to the LN 
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(intranodally) by a highly experienced radiologist under ultra-sound guidance. All patients received 
three intranodal vaccinations at a biweekly interval; patients who remained free of disease 
progression were eligible for two maintenance cycles at 6 month intervals with the same schedule.  
One or two days prior to RLND, patients received one extra vaccination with DCs labeled with 111In-
oxine and superparamagnetic iron oxide (SPIO) for cell tracking studies in the region that was to be 
resected (17).  
 
Dendritic cell vaccine 
Monocytes were enriched from leukapheresis, as described previously (18) and cultured in the 
presence of interleukin (IL)-4, GM-CSF to induce differentiation to DC phenotype. DCs were matured 
with a cocktail of pro-inflammatory cytokines consisting of IL-1, IL-6, TNF supplemented with 
prostaglandin E2 for 48 hours. This procedure gave rise to mature DCs meeting the release criteria 
(19). DCs were pulsed with the HLA class I gp100-derived peptides gp100:154-167, gp100:280-288 
and the tyrosinase-derived peptide tyrosinase:369-376 directly after harvesting or thawing. 
Alternatively, mature DCs were electroporated with mRNA encoding gp100 or tyrosinase (20). 
Peptide pulsing or mRNA electroporation was performed under good manufacturing practice (GMP) 
conditions. More detailed description of the ex vivo culture methods are provided in Supplementary 
Text S1. Cells were resuspended in 0,1 mL saline for intranodal injection. 
 
Positron emission tomography imaging 
PET/CT scans were performed at varying time points after vaccination (Supplementary Table S1). 
Patients were instructed to drink 1 L of water, and received 10mg furosemide intraveneously to 
stimulate urinary tracer excretion. Emission images were acquired 1 hour after intravenous injection 
of 250 MBq 18F-FLT. The images were corrected for attenuation using low-dose CT and reconstructed 
using the ordered-subsets expectation maximization (OSEM) algorithm. Low-dose CT scan was used 
for anatomical correlation. The image sets were reviewed in consensus by two observers. Three-
dimensional regions of interest were placed manually over LNs by using a dedicated software 
program. Maximum standardized uptake values (SUVmax) were calculated for visible LNs of interest, 
according to the following formula: SUV = radioactivity concentration in tissue (Bq/kg)/(injected dose 
(Bq)/patient weight (kg)). Bone marrow SUVmax in the proximal part of the femoral bone served as 
internal positive control.  
 
In vitro immune monitoring 
Antibodies against KLH were measured in the serum of vaccinated patients using enzyme-linked 
immunosorbent assays (ELISA) (16). Microtiter plates were coated with KLH and different 
concentrations of patient serum were allowed to bind. After extensive washing, patient antibodies 
were detected with mouse antihuman IgG, IgA or IgM antibodies labeled with horseradish 
peroxidase; 3,3’-5,5-tetramethyl-benzidine was used as a substrate and plates were measured in a 
microtiter plate reader. An isotype-specific calibration curve for the KLH response was included in 
each microtiter plate. Cellular responses against KLH were measured in a proliferation assay; 1 x105 
peripheral blood mononuclear cells taken at time points of scanning, were plated per well either in 
the presence of KLH or without. After 4 days of culture, 1 Ci/well of (3H)thymidine was added and 
incorporation was measured in a -counter.  
 
111In labeling and scintigraphy 
DC were incubated with 111In-oxine for 15 minutes at room temperature. In vivo planar scintigraphic 
images were acquired with a gamma camera equipped with medium energy collimators, at day 0 and 
48 hours later. Migration was quantified by region-of-interest analysis of the individual nodes 
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visualized on the images and expressed as the relative fraction of 111In-labeled DC that had migrated 
from the injection depot. 
 
SPIO labeling and immunohistochemistry 
Superparamagnetic iron oxide (SPIO) was added 3 days after onset of DCs culturing. The iron-content 
was previously determined to be 10-30pg of iron per cell in this standardized procedure (21) without 
affecting the viability. Sections (10 m) of the resected LNs were stained with 2% potassium 
hexacyanoferrate (II)-trihydrate in 0.2 M HCl for 15 min and counterstained with 0.05% nuclear fast 
red in 5% aluminium sulphate. Immunohistochemistry was performed using antibodies against CD4, 
CD8, CD25. The slides were stained with Prussian Blue to detect SPIO-labeled cells.  
 
Statistical analysis 
The two-tailed paired t-test was applied for comparison of pre and post vaccination PET signals of 
LNs and bone marrow. Correlations between SUVmax of PET signal in LN and KLH specific in vitro 
monitoring were calculated using linear regression. All statistical analyses were calculated using 
GraphPad Prism (version 4.0). p<0.05 was regarded as statistically significant. 
 
Results 
18F-FLT PET visualizes the immune response early after vaccination 
To evaluate whether the 18F-FLT PET signal of proliferating T and B cells co-localized with antigen-
loaded DCs, we labeled the cells ex vivo with 111In-oxine and SPIO. Planar scintigraphy was performed 
immediately following PET/CT scanning to localize and quantify the 111In-labeled DCs. Three days 
after vaccination, up to four LN were revealed with retention of 18F-FLT (Figure 1a). The scintigraphic 
images demonstrated that the PET signal intensity increased only in those LNs that contained 
antigen-loaded 111In-labeled DCs (Figure 1b). Profound18F-FLT uptake was observed even when very 
low numbers (4.5×105 cells) of antigen-loaded DCs were present. Immunohistochemical staining of 
the LNs revealed the presence of SPIO-labeled DC in the T cell areas and the activation of CD4+ and 
CD8+ T cells (Figure 1c-d). 
 
18F-FLT PET signal requires antigen-loaded dendritic cells 
We observed a significant increase in 18F-FLT signal early after the very first vaccination (Figure 1e,f), 
indicating that de novo immune responses are readily visualized. Vaccinated LNs remained positive 
up to 3 weeks after the last vaccination (Figure 1g,h). Bone marrow uptake served as internal positive 
control. Four patients underwent sequential scanning after vaccination. We observed a pronounced 
increase in18F-FLT signal exclusively in vaccinated LNs from day 3 to 6 post-vaccination in 3 out of 4 
patients (Figure 1i-l). We observed a further increase in 18F-FLT accumulation  (p<0.05) in LNs of who 
received three subsequent intranodal vaccinations, but not in control LNs which were either not 
injected, injected with saline or injected with DC not loaded with antigen (Figure 2a-c). This indicates 
that the observed increase in PET signal upon vaccination cannot be attributed solely to the effect of 
tissue damage by intranodal injection or to the presence of DCs alone, but that it requires the 
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Figure 1. 
18
F-FLT PET visualizes the immune response following vaccination.  (A) Three days after intranodal delivery of the 
111
In/SPIO-labeled and antigen-loaded DC, 
18
F-FLT PET/CT scan was performed which showed tracer retention in the 
injected and three draining LNs. (B) Immediately prior to the PET/CT scan, the same LNs were visualized by scintigraphy, 
containing 4%, 3% and 22% of the injected radioactivity. (C,D) The same day a radical LN dissection was performed and 
111
In-DC containing LNs were identified with a gamma probe. Immunohistochemical analyses of these LNs demonstrated a 
close interaction between injected SPIO-labeled DC and CD8
+
 T cells, resulting in increased expression of activation marker 
CD25. (E,F) To show that de novo immune responses can also be imaged with 
18
F-FLT we performed 
18
F-FLT PET scans in one 
patient after the prime vaccination (pt 2). At day 5 post vaccination, 
18
F-FLT signal had increased from SUVmax 1.7 to 2.5, 
whereas the control lymph node that received vaccination with DC not loaded with antigen did not show an increase in 
18
F-
FLT signal (SUVmax 0.9 to 0.8). (G,H) In patient 6, who received multiple vaccinations, a sustained 
18
F-FLT signal was 
detected up to three weeks after the last vaccination, but not in the non-vaccinated control LN. (I-L) In order to find the 
optimal time point for 
18
F-FLT PET imaging, sequential 
18
F-FLT PET/CT scans were performed in 4 patients. We observed a 
profound increase in 
18
F-FLT signal in vaccinated LNs (filled squares) but not in control LNs (open squares) between day 3 to 
6 post injection with antigen-loaded DC. However, patient 3 received vaccination with DC loaded with tumor-antigen but 
not the control-antigen KLH. All patients received no other vaccinations 6 months prior to imaging. 
 
presence of antigen. Interestingly, in one patient who did not detect PET signal in LN upon 
vaccination, the vaccine did include the melanoma-associated antigens but not KLH. Thus, these data 
support the notion that the measured 18F-FLT signal is indeed antigen-specific. 
 
 18F-FLT PET signal correlates with in vitro monitoring assays 
To validate our findings, we compared tracer retention in the LNs with the presence of antigen-
specific T and B cell responses in peripheral blood samples taken at the time of imaging. We 
observed a significant correlation between 18F-FLT accumulation and the level of circulating KLH-
specific IgG antibodies as well as KLH-specific proliferation of T cells (Figure 2d,e). In one patient 
(circle) we observed high 18F-FLT uptake without apparent KLH-specific T cell proliferation. This 
patient not only showed exceptionally high KLH-specific IgG antibodies in the serum, but also 
profound levels of IgA and IgM antibodies, indicating that in this case the 18F-FLT signal most likely 
reflects vigorous B cell proliferation. Vice versa, another patient, (triangle) exhibited modest B cell 
responses but pronounced T cell proliferation against KLH. Together, from these observations we 
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conclude that accumulation of 18F-FLT in the vaccinated LNs reflects the sum of both antigen-specific 
T and antigen-specific B cell responses. This correlation is specific to the FLT tracer as it was not 
observed with 18F-FDG. 
 
 
Figure 2. Increased 
18
F-FLT PET signal directly correlates to antigen-specific immune responses. (A) A significant increase in 
18
F-FLT signal (p<0.05) was detected in LNs after 3 intranodal vaccinations, except in one patient (pt 3). (B) In contrast, in 
control LNs no increase in tracer retention was observed. (C) Control LNs consisted of LNs at the contralateral side, either 
non-vaccinated LN or LN vaccinated with saline or DCs not loaded with antigen. An increase of 
18
F-FLT signal was not 
observed in any of these cases. (D) Peripheral blood samples at the time point of the scan showed a significant correlation 
between the level of KLH-specific IgG antibodies and the intensity of 
18
F-FLT uptake in the LNs, p<0.05. (E) Proliferation of 
peripheral blood mononuclear cells upon stimulation with KLH demonstrated a clear correlation between the intensity of 
18
F-FLT signal and the KLH specific proliferation in vitro, p<0.05. One patient (square) showed high 
18
F-FLT uptake (SUVmax 
7.8) without accompanying KLH specific proliferation (403 ± 76 cpm), but showed pronounced humoral response to KLH 
(KLH IgG 918 mg/L), involving also KLH-specific IgA and IgM. In a second patient (circle), the observed 
18
F-FLT PET signal 
(SUVmax 6.6) resulted from a modest KLH-specific IgG response (KLH IgG 118 mg/L) and a pronounced KLH-specific 
proliferation (45030 ± 12996 cpm). 
 
Discussion 
We here demonstrate that 18F-FLT PET can be used to directly monitor antigen-specific immune 
responses in vivo shortly after therapeutic vaccination, as it offers a sensitive tool to study the 
kinetics, localization of induction of antigen-specific lymphocyte activation upon vaccination with 
antigen-loaded autologous DCs. For vaccination strategies in preventive settings, the established in 
vitro assays for proliferative and humoral responses are sufficient to predict adequate immunity. 
However, for a number of novel vaccination strategies that are designed as therapeutic intervention, 
no such established assays exist. To the contrary, for therapeutic vaccines that target major 
infectious diseases such as HIV, tuberculosis and malaria, or malignancies, the lack of tools to predict 
adequate immunity hampers translation of these vaccines to the clinic. We took the opportunity of 
our vaccination protocols that provide an unique setting in which we can control all elements 
required for a successful immune response; the antigen presenting cell is labeled and tracked in vivo, 
loaded with known antigens and delivered at the specific immune reactive site. Furthermore, the 
induced lymphocyte responses can be measured with established and well-validated assays. We used 
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this system as a model to systematically investigate the application of non-invasive in vivo nuclear 
imaging modality to evaluate antigen-specific immune responses upon therapeutic vaccination.  
 
Supplementary Figure 3. 
18
F-FDG PET does not target antigen-specific immune responses. (A-C) 
18
F-FDG and 
18
F-FLT PET 
were compared within individual patients for their imaging properties, at day 5 and 7 after last vaccination respectively. 
Both tracers target specifically vaccinated LN, but not control LNs, to equal extent. Bone marrow retention was higher for 
18
F-FLT compared to 
18
F-FDG, which is consistent with the known distribution pattern for both tracers. (D) Contralateral LNs 
served as negative controls within individual patients, no increase in 
18
F-FDG PET signal was detected in non-vaccinated 
LNs, vaccinated with saline or DC not loaded with antigen. Notably, the 
18
F-FDG signal intensity did not exceed SUVmax 3.3 
even in LN vaccinated with antigen-loaded DC. (E,F) Consequently, no correlation was detected between 
18
F-FDG signal 
intensity and KLH-specific IgG antibody production or proliferation response measured simultaneously in vitro. 
 
In recently published large phase III trials, it has been demonstrated that immunotherapies can be 
effective even in advanced cancer patients. Both antigen-specific (5,7) and non-antigen specific 
agents (6) have now been approved by the FDA. Considering the amount of effort poured into the 
development of these novel agents, PET-based monitoring will advance our knowledge of the 
immunological processes that precede the failure or success of novel immunotherapies. 
Furthermore, it should vastly improve efficient application by aiding in individualized decision 
making. Most anti-cancer vaccines aim at inducing tumor-specific cytotoxic CD8+ T cell responses. 
However, tumor-specific CD8+ T cell responses occur at low precursor frequencies and might 
therefore contribute less to LN reactivity than vigorous KLH-specific responses8. To this end, we 
injected 3 patients with DCs loaded with KLH, but not with tumor-antigen. Interestingly, we 
measured markedly increased 18F-FLT signals which cannot solely be attributed to KLH, since control 
vaccination with KLH-loaded DC in contralateral LNs induced only a modest 18F-FLT signal (Figure  S2). 
The challenge we now face is to further improve immune response imaging in vivo, and find tracers 
that are specific for different lymphocyte populations. Recently, in a preclinical model of mice 
challenged with an immunogenic sarcoma, 18F-FDG accumulated mainly in cells of the innate immune 
system, whereas 2-fluoro-D-(arabinofuranosyl)-cytosine accumulated predominantly in CD8+ T cells 
(22). Our findings that 18F-FDG signal intensity does not correlated with immune reactivity (Figure  
S3), indicates that targeting glucose metabolism is not specific for antigen-specific immune 
activation. Hence, we have shown that 18F-FLT is a sensitive and specific PET tracer for monitoring 
lymphocyte activation after DC vaccine therapy in a clinical setting. 
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Supplementary Table 1 
Patient 
code  
Method of antigen 
loading  
Nr of 
vaccinations 
received total  
Time of scan  
(day post 
vaccination)  
Tracer  Control vaccination  
1  mRNA electroporated  7   +2, +6, +10  (18F)FLT  saline  
2  mRNA electroporated  1   +5  (18F)FLT  unpulsed DC  
2  mRNA electroporated  6   +7  (18F)FLT  unpulsed DC  
3  mRNA electroporated *  4   +2, +7, +9  (18F)FLT  unpulsed DC  
4  mRNA electroporated  4   +4, +6, +11  (18F)FLT  KLH pulsed DC  
4  mRNA electroporated  9   +7  (18F)FLT  unpulsed DC  
9  mRNA electroporated  7   +3, +5, +10  (18F)FLT  KLH pulsed DC  
5  mRNA electroporated  7   +7  (18F)FLT  non-vaccinated  
6  mRNA electroporated  8   +5  (18F)FLT  non-vaccinated  
7  mRNA electroporated  6   +7  (18F)FLT  saline  
8  peptide pulsed  1   +3  (18F)FLT  non-vaccinated  
10  peptide pulsed  6   +21  (18F)FDG  non-vaccinated  
11  peptide pulsed  1   +6  (18F)FDG  non-vaccinated  
12  peptide pulsed  7   +6  (18F)FDG  non-vaccinated  
13  peptide pulsed  7   +5  (18F)FDG  non-vaccinated  
14  peptide pulsed  7   +5  (18F)FDG  non-vaccinated  
7  mRNA electroporated  6   +5  (18F)FDG  saline  
4  mRNA electroporated  9   +5  (18F)FDG  unpulsed DC  
2  mRNA electroporated  6   +5  (18F)FDG  unpulsed DC  
Supplementary Figure 1. Study design for multimodality imaging in DC-based cellular therapy. In our DC-based cellular 
therapy studies in melanoma patients, monocytes are obtained by apheresis and differentiated into immature dendritic cells 
(DC) by addition of interleukin-4 and GM-CSF. The control antigen KLH is added to the culture, which is spontaneously 
phagocytosed by immature DC. After six days, KLH-loaded immature DC are activated for two days by a cocktail of 
proinflammatory cytokines; interleukin-1b, interleukin-6, prostaglandin E2 and tumor-necrosis-factor alpha, to induce a 
mature phenotype. Mature DC are either pulsed with peptides derived from melanoma-associated antigens gp100 and 
tyrosinase or electroporated with mRNA encoding these antigens. At this stage, SPIO particles are added for cell tracking by 
immunohistochemistry (IH) and (
111
Indium) is added for tracking and quantification by scintigraphy. Upon intranodal delivery 
of the vaccine, immune responses are monitored in peripheral blood for KLH-specific responses, PET imaging for lymph node 
reactivity, scintigraphy for DC localization and immunohistrochemistry for in vitro assessment of interaction DC with 
lymphocytes. 
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Supplementary Figure 2.  
18
F-FLT PET signal increased in tumor-specific T cell responses. (A) To investigate whether the 
observed increase in 
18
F-FLT signal was attributable to tumor-specific immune responses, we analyzed three patients in 
detail. Patient 3 received vaccination with DC loaded with tumor antigen, but not loaded with KLH. No increase in 
18
F-FLT 
signal intensity was observed. (B,C) Since the vaccinations did not include KLH, no KLH-specific responses were detected 
upon vaccination in peripheral blood. (D) However, also no tumor-specific T cell responses were induced, explaining the 
absence of increase in 
18
F-FLT signal intensity. In two patients, control vaccinations consisted of dendritic cells loaded with 
KLH but not with melanoma-associated antigen. (E) In patient 4 no increase in the control LN was observed, whereas the LN 
vaccinated with DC loaded with both KLH and melanoma-associated antigens showed an enhanced 
18
F-FLT signal, SUVmax 
3.9. (F,G) In this patient no significant concurrent KLH-specific proliferative or IgG responses were detected, which is 
consistent with the absent 
18
F-FLT signal in the control lymph nodes. (H) After completion of vaccination, tumor-specific 
CD8
+
 T cells were detected in cultures from delayed type hypersensitivity skin test biopsies, indicating that a tumor-specific 
immune response was indeed induced. (J) Similar investigations were performed in patient 9. The control LN vaccinated 
with DC loaded with KLH (but not melanoma-associated antigens) showed enhanced 
18
F-FLT signal, SUVmax 3.1, albeit at a 
lesser extent than observed in the LN vaccinated with DC loaded with both KLH and melanoma-associated antigen. (J,K) We 
measured a profound proliferative response to KLH and an increased humoral response to KLH in concurrent blood 
samples, consistent with the induced 
18
F-FLT signal in the lymph node vaccinated with KLH loaded DCs. (L) After completion 
of vaccinations, tumor-specific CD4
+
 T cells were detected in delayed type hypersensitivity skin test biopsies. From this we 
conclude that the measured 
18
F-FLT signal intensity did not only result from KLH specific T and B cell responses, but can to a 
certain extent be attributed to tumor-specific T cells. 
  
205
Part 3, Chapter 12 
 
References 
1. Buchbinder, S.P., et al., Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-
blind, randomised, placebo-controlled, test-of-concept trial. Lancet, 2008. 372(9653): p. 1881-93. 
2. Rerks-Ngarm, S., et al., Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med, 
2009. 361(23): p. 2209-20. 
3. Wallis, R.S., et al., Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. 
Lancet. 375(9729): p. 1920-37. 
4. Kenter, G.G., et al., Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med, 
2009. 361(19): p. 1838-47. 
5. Kantoff, P.W., et al., Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 363(5): p. 
411-22. 
6. Hodi, F.S., et al., Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 363(8): 
p. 711-23. 
7. Schwartzentruber, D.J., et al., gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N 
Engl J Med. 364(22): p. 2119-27. 
8. Lesterhuis, W.J., J.B. Haanen, and C.J. Punt, Cancer immunotherapy - revisited. Nat Rev Drug Discov. 10(8): p. 591-
600. 
9. Lesterhuis, W.J., et al., Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol, 2008. 
66(2): p. 118-34. 
10. Banchereau, J. and A.K. Palucka, Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol, 2005. 
5(4): p. 296-306. 
11. Appay, V., D.C. Douek, and D.A. Price, CD8+ T cell efficacy in vaccination and disease. Nat Med, 2008. 14(6): p. 
623-8. 
12. Shields, A.F., et al., Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med, 1998. 
4(11): p. 1334-6. 
13. Troost, E.G., et al., 18F-FLT PET Does Not Discriminate Between Reactive and Metastatic Lymph Nodes in Primary 
Head and Neck Cancer Patients. J Nucl Med, 2007. 48(5): p. 726-735. 
14. Fox, C.J., P.S. Hammerman, and C.B. Thompson, Fuel feeds function: energy metabolism and the T-cell response. 
Nat Rev Immunol, 2005. 5(11): p. 844-52. 
15. Balch, C.M., et al., Final version of the American Joint Committee on Cancer staging system for cutaneous 
melanoma. J Clin Oncol, 2001. 19(16): p. 3635-48. 
16. de Vries, I.J., et al., Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after 
dendritic cell vaccination correlates with clinical outcome. J Clin Oncol, 2005. 23(24): p. 5779-87. 
17. de Vries, I.J., et al., Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular 
therapy. Nat Biotechnol, 2005. 23(11): p. 1407-13. 
18. de Vries, I.J., et al., Phenotypical and functional characterization of clinical-grade dendritic cells. Methods Mol 
Med, 2005. 109: p. 113-26. 
19. Figdor, C.G., et al., Dendritic cell immunotherapy: mapping the way. Nat Med, 2004. 10(5): p. 475-80. 
20. Schuurhuis, D.H., et al., In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in 
lymph nodes of melanoma patients. Cancer Res, 2009. 69(7): p. 2927-34. 
21. Verdijk, P., et al., Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer 
vaccines. Int J Cancer, 2007. 120(5): p. 978-84. 
22. Nair-Gill, E., et al., PET probes for distinct metabolic pathways have different cell specificities during immune 
responses in mice. J Clin Invest. 120(6): p. 2005-15. 
 
 
206
Chapter 13 
 
 
In vivo imaging of therapy-induced anti-cancer immune responses 
in humans 
 
 
 
Aarntzen EH 
Srinivas M 
Radu CG 
Punt CJ 
Boerman OC 
Figdor CG 
Oyen WJ 
De Vries IJ 
 
 
 
 
 
 
 
 
 
 
 
 
Cell Mol Life Sci. 2012 Oct 5th (accepted)
207
 208
Part 3, Chapter 13 
 
Abstract  
Immunotherapy aims to re-engage and revitalize the immune system in the fight against cancer. 
Research in the past decades has shown that the relationship between the immune system and 
human cancer is complex, highly dynamic and variable between individuals. Considering the 
complexity, enormous effort and costs involved optimizing immunotherapeutic approaches clinically 
applicable tool to monitor therapy-induced immune responses in vivo is most warranted. However, 
development of such a tool is complicated by the fact that a developing immune response 
encompasses several body compartments, e.g. peripheral tissues, lymph nodes (LN), lymphatic and 
vascular systems, as well as the tumour site itself. Moreover, the cells that comprise the immune 
system are not static but constantly circulate through the vascular and lymphatic system. Molecular 
imaging is considered the favourite candidate to fulfil this task. The progress in imaging technologies 
and modalities has provided a versatile toolbox to address these issues. This review focuses on the 
detection of therapy-induced anti-cancer immune responses in vivo and provides a comprehensive 
overview of clinically available imaging techniques as well as perspectives on future developments. In 
the discussion we will focus on issues that specifically relate to imaging of the immune system and 
we will discuss the strengths and limitations of the current clinical imaging techniques. The last 
section provides future directions that we envision to be crucial for further development.   
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1. Introduction  
Immunotherapy aims to re-engage and revitalize the immune system in the fight against cancer. A 
recent series of successes has indicated the broad potential of this approach and has led to the 
approval of several novel immunotherapies (1-3). Although the recent progress is exciting, the 
underlying mechanisms are only partly understood (4). Considering the enormous effort and costs 
involved in developing, optimizing and applying an effective immunotherapeutic approach it is 
remarkable that a monitoring tool that accurately identifies a responding patient early during 
immunotherapeutic treatment is lacking. Research in the past decades has shown that the 
relationship between the immune system and human cancer is complex, highly dynamic and variable 
between individuals (5). Given the diversity in immune responses among individual patients to a 
single immunotherapeutic intervention, every clinical case potentially provides a unique opportunity 
to understand the crucial processes that precede the failure or success of immune responses. In this 
respect, individualized medicine is not only a goal in itself but rather a tool to develop successful 
therapy. Therefore, further progress can only be expected only if we manage to take this opportunity 
and learn how to guide therapy based on individual responses. The development of a clinically 
applicable tool to monitor therapy-induced immune responses in vivo is thus most warranted. 
However, development of such a tool is complicated by the fact that a developing immune response 
encompasses several body compartments, e.g. peripheral tissues, lymph nodes (LN), lymphatic and 
vascular systems, as well as the tumour site itself. Moreover, the cells that comprise the immune 
system are not static but constantly circulate through the vascular and lymphatic system. Current 
attempts to find such a monitoring tool often use surrogate markers, such as control antigens, or 
focus on a single functionality of immune effector cells, e.g. interferon gamma (IFN enzyme-linked 
immunosorbent spots (ELIspots). In both cases, the results do not accurately link immune responses 
to clinical outcome. Furthermore, current immune monitoring assays are based on peripheral blood 
cells or tissue and are therefore invasive. Novel techniques allow high throughput assessment of 
individual variations in functional processes, e.g. differences in signalling pathways in immune cells 
(6). As of now, these techniques lack validation and are not yet applicable in the evaluation of 
therapy-induced responses. In general, the assays currently available provide only snapshots of a 
continuous and dynamic process. Moreover, most assays attempt to either extrapolate the findings 
in individual subjects to the general treated population, or to interpret findings in individual patients 
based on previous findings in the general population. Thus, in order development of a more 
complete picture, we require new tools;  the ideal monitoring tool should be non-invasive, allow 
longitudinal data acquisition and reveal critical immunological processes that occur early during a 
treatment course on an individual basis. Quantification would be a further asset. Molecular imaging 
is considered the favourite candidate to fulfil this task. The progress in imaging technologies and 
modalities has provided a versatile toolbox (Figure 1) to address the issues mentioned above. 
Imaging modalities are available to image functional processes from a molecular scale to whole body 
levels. This review focuses on the detection of therapy-induced anti-cancer immune responses in vivo 
and provides a comprehensive overview of clinically available imaging techniques as well as 
perspectives on future developments. We begin with an overview of the de novo immune response 
and the current therapeutic approaches that intervene at a given phase of the response. Next, we 
describe the possible target processes and the imaging techniques available within each phase of the 
developing immune response. In the discussion we will focus on issues that specifically relate to 
imaging of the immune system and we will discuss the strengths and limitations of the current 
clinical imaging techniques. The last section provides future directions that we envision to be crucial 
for further development.   
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2. Current immunotherapy approaches 
The immune system is a highly organized multi-cellular system designed to protect the host from 
invading pathogens and malignantly transformed cells (7). As such, the immune system acts with 
enormous specificity and great sensitivity, in concert with regulatory mechanisms, to avoid 
destructive self-reactivity. Many cell types from both innate (e.g. natural killer (NK) cells and 
macrophages) and adaptive (e.g. dendritic cells (DC), B cells and T cells) immunity contribute to 
immune competency. T cells are often considered to be the most critical effector cells in anti-cancer 
responses, since these cells are capable of developing antigen-specific memory responses. There are 
two major subsets of T cells, defined by the expression of the CD4 and CD8 surface markers. CD4+ T 
cells are subdivided to T helper 1 (Th1) cells, which activate macrophages, antigen-presenting cells 
and cytotoxic CD8+ T cells to promote cellular immunity. T helper 2 (Th2) cells promote antibody 
production by activating B cells. Within the CD4+ T cell repertoire, a subset of T cells has the plasticity 
to become regulatory T cells (Treg), which mediate peripheral tolerance in physiological conditions. 
Although CD8+ cytotoxic T cells (CTLs), as the endpoint effectors, represent a critical population for 
anti-cancer immunity, it has become clear that only a concerted action involving other cell types such 
as T helper cells and NK cells, can result in an effective anti-cancer clinical response. In that respect, 
the secretion of small molecules like cytokines and chemokines is an important means of short and 
long-distant communication between cells. Developing tumours are often infiltrated by lymphocytes 
that specifically recognize tumour associated antigens (TAA), but apparently are incapable of tumour 
eradication. However, these tumour-infiltrating lymphocytes can exert specific effector functions 
when disconnected from the suppressive tumour milieu. Based on this long-standing observation, 
the mainstay of immunotherapy is to induce, enhance or sustain such tumour-specific cellular 
immune responses in order to overcome the suppressive environment at the tumour site. To achieve 
this, a plethora of strategies have been tested in preclinical models. Current immunotherapy 
approaches which have been tested in clinical trials intervene at different phases of a developing 
immune response. The next sections provide an overview of a developing anti-cancer immune 
response, divided in phases, and the current immunotherapeutic strategies that intervene at these 
phases (Figure 2).  
 
2.1. Phase I: Antigen encounter 
The development of human tumours is a multistep process that occurs over an extended length of 
time (8). Since tumour cells originate from a normal cell and evade the immune system; human 
tumours express self-antigens that are poorly immunogenic, and lack pathogen associated molecular 
patterns (PAMPs). As such, they rarely trigger robust inflammatory responses, especially when 
compared to the response to invading pathogens. Peripheral tissues are constantly screened by 
specialized antigen presenting cells (APC) such as Langerhans cells and DC, which act as the sentinels 
of the immune system (7). These immature APC are phagocytic and capture antigens. Small numbers 
of APC migrate to draining LNs (LN) and present the processed TAA in major histocompatibility (MHC) 
complexes to effector cells. In the absence of inflammation, these APC remain in an immature state 
and ineffectively activate T cells. This absence of co-stimulatory signals and inflammatory cytokines 
leads to a tolerogenic T cell response. However, immature APC that encounter antigens under 
inflammatory conditions undergo a transformation to mature APC, which are highly migratory and 
potent orchestrators of adaptive immune responses.  
 
2.1.1. Tumour antigen containing vaccines 
Following the identification of several TAA, a series of clinical trials has evaluated cancer vaccines 
that deliver TAA to neutral sites like skin or muscle, similar to preventive vaccines, in order to be 
recognized and phagocytosed by endogenous APC. These vaccines can consist of TAA peptides alone, 
in combination with immune stimulatory adjuvants like TLR-agonists and chemical agents (e.g. 
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complete Freund’s adjuvant (CFA) or Montanide) (9), or complexed with immunogenic viral particles. 
A recent single-arm clinical study demonstrated that vaccination with long-peptides derived from 
human papilloma virus (HPV)-16 E6 and E7 antigens induced complete tumour regressions in HPV-
associated preneoplastic lesions (10). In order to use the full repertoire of possible immunogenic 
epitopes; autologous or allogeneic tumour cells can be modified to provide immunostimulatory 
signals together with TAA (11).  
 
Figure 1: Overview of the developing immune response and possible targets for therapeutic strategies and imagin.g 
 
2.1.2. Cellular vaccines 
The isolation of specialized APC for ex vivo loading with antigen and activation, provides a more 
easily controlled setting (12). A recent phase III trial involving antigen-loaded antigen-presenting cells 
in patients with advanced prostate cancer, demonstrated improved overall survival with vaccinations 
compared to placebo (13). We have extensively studied the immunological responses to autologous 
antigen-loaded DC (14, 15). A highly interesting approach is the in vivo targeting of APC, which would 
replace laborious and expensive ex vivo culturing and facilitate large-scale application of DC-based 
vaccination therapies (16).  
 
2.2. Phase II: Expansion of immune effector cells 
2.2.1. Cytokine-based immunotherapy 
Soluble signalling molecules, e.g. cytokines, play an important role in the induction of inflammatory 
responses, since they allow recruitment of lymphocytes and APC to the LN (LN). Next, in the 
interaction of APC with lymphocytes in LN, cytokines provide a directive signal to the immune 
effector cells to skew their differentiation. Lastly, cytokines may have a direct anti-tumour effect or 
at least induce inflammatory responses at the site of the tumour. The important role of cytokines 
prompted the administration of cytokines as anti-cancer immunotherapy. Interleukin-2 (IL-2), first 
described in 1976 as a T-cell growth factor (17), plays a central role in immune regulation and T-cell 
proliferation (18). IL-2 was approved by the US Food and Drug Administration (FDA) in 1998 for 
treatment of advanced metastatic melanoma and in 2005 for the treatment of metastatic renal cell 
cancer. High-dose bolus intravenous IL-2 injections demonstrated antitumour effects (19, 20). Long-
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term follow-up of these studies demonstrated durable responses in 4% of the patients (21) 
suggesting the establishment of a memory T-cell response. However, the side effects associated with 
this treatment regimen are severe and often require hospitalization (22). Interferon alfa (IFN-) was 
the first exogenous cytokine to demonstrate antitumour activity in advanced melanoma. Interferon 
-2b, a type I IFN, is a highly pleiotropic cytokine with immunoregulatory, as well as direct 
antitumour properties in multiple malignancies (23). In 1995, interferon--2b became the first 
immunotherapy approved by the FDA for the adjuvant treatment of high-risk primary melanoma and 
objective responses were observed in approximately 15% of patients with metastatic melanoma. 
However, due to its multiple effects, tolerability is an issue with this regimen and has hampered 
widespread use. Moreover, both IL-2 and IFN have not shown a clear benefit in overall survival, 
neither in the adjuvant setting nor in metastatic disease.  
 
2.2.2. Adoptive T cell transfer 
Other than strategies to prime TAA-specific T cells in vivo, by cellular vaccines or cytokines, TAA-
specific T cells can be isolated from tumour tissue or peripheral blood and primed in vitro to enhance 
their effector function. Adoptive cell transfer (ACT) involves the administration of tumour-specific T 
cells. The earliest form of ACT that demonstrated effective anti-tumour immunity was allogeneic 
bone marrow transplantation for chronic myeloid leukemia (24, 25). Later studies have revealed that 
after T cells, alloreactive NK cells play a pivotal role in the graft versus leukemia effect (26). Following 
the finding that T cells isolated from tumour or tumour draining LNs can elicit specific anti-tumour 
effect in vitro, this approach has been investigated in solid tumours. Transferred TAA-specific T cells 
are either isolated from patient tumour biopsies and expanded in vitro under immune stimulating 
conditions, or peripheral blood T cells are endowed with antigen specific T cell receptors (TCRs) or 
fusion proteins termed chimeric activation receptors (CARs) (27, 28). The expanded numbers of TAA-
specific T cells in ACT should break immune tolerance at the tumour level and regenerate a broad 
tumour-specific immune response. Clinical trials show that critical issues for further improvement of 
this approach are the ex vivo re-programming of TILs towards a pro-inflammatory phenotype, 
sufficient T cell homing to the tumour and the avidity of T cells involved for in vivo expressed TAA 
(29, 30).  
 
2.3. Phase III: Targeting the tumour and its microenvironment 
2.3.1. Monoclonal antibodies 
Several immunotherapeutic strategies exploit direct anti-tumour effects, instead of indirectly by 
enhancing cellular immunity as mentioned above. The most prominent are monoclonal antibodies 
(mAbs) which can be divided in different classes according to their target (reviewed in (31)). First, 
mAbs are designed to activate the immune system by both antibody dependent cellular cytotoxicity 
(ADCC), such as anti-CD20 mAb (rituximab) and complement dependent cytotoxicity (CDC). Other 
mAbs inhibit cellular signalling pathways, such as the anti-Her2neu antibody trastuzumab, the anti-
VEGF antibody bevacizumab and the anti-EGFR antibodies cetuximab and panitumumab. A novel 
promising antibody-based strategy is the use of bi-specific antibodies, which combine two different 
binding sites in order to bring specific effector cells in close proximity to specific target cells. For 
example, blinatomumab has a binding site for CD3, part of the TCR, and CD19, abundantly expressed 
on B cells. In a recent phase II study, has shown high response rates in patients with relapsed or 
refractory B-precursor acute lymphatic lymphoma (32).  
 
2.3.2. Chemotherapy-induced immunogenic cell death 
Evidence is accumulating that the immune system makes a crucial contribution to the antitumour 
effects of conventional chemotherapy-based and radiotherapy-based cancer treatments (33). It has 
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become clear that cell death induced by cytotoxic agents can be immunogenic and as such can 
trigger effective immune responses, reviewed in (34). 
 
2.3.3. Overcoming tolerance 
Strategies to neutralize immune suppressor mechanisms include chemotherapy (for example, low-
dose cyclophosphamide), the use of antibodies (for example, CD25-targeted antibodies) in an 
attempt to deplete regulatory T cells and the use of antibodies against immune-checkpoint 
molecules (for example, cytotoxic T lymphocyte-associated protein 4 (CTLA4)-targeted antibodies 
and programmed cell death 1 (PD1)-targeted antibodies). Many of these strategies were recently 
reviewed (35, 36). Ipilimumab, a mAb that blocks the inhibitory signalling by CTLA-4 which is 
expressed on activated T cells has demonstrated significant clinical efficacy in two recent large phase 
III trials (37, 38). Based on these trials, ipilimumab has been approved by the FDA for metastatic 
melanoma (1, 39). 
 
3. General issues in clinical imaging 
The recent development of novel immunotherapies warrants monitoring tools that allow accurate 
and early prediction of therapy response and disclose the critical preceding immunological 
mechanisms of action. In order to address these needs in clinical immunotherapy trials, the ideal 
monitoring tool is an imaging modality that allows whole-body, non-invasive, quantitative and 
longitudinal visualization of functional processes on a molecular level. However, in practice, myriad 
factors affect the choice of label and imaging modality for a specific application. Matching the right 
imaging system, including modality and probe, to an application is essential to its success. 
Multimodality imaging can maximize the strengths of each imaging modality while minimizing its 
weaknesses (Table 1), and is therefore being extensively explored. The next section describes the 
basic properties of clinically applicable imaging modalities.  
 
3.1 Scintigraphy 
Planar scintigraphy is based on the detection of gamma radiation emitting radionuclides, yielding 2D 
images. Most cell-tracking studies use scintigraphy because of the ability to quantificatify signal, 
lower cost and wider availability. Scintigraphic imaging allows quantification of roughly greater than 
104 labeled cells, dependent on the amount of activity that can be loaded per cell (40). However, 
scintigraphy lacks anatomic detail and is therefore increasingly being replaced by SPECT/CT. with a 
key issue that arises when using radionuclides is the half life of the label in relation to the life span of 
the transferred cells. The radiolabels that are typically used are 111In and 99mTc, with half-lives of 2.8 
days and 6 h, respectively, or 18F with a half-life of 2 hours. This restricts the length of time that they 
can be detected in vivo (2-3 half-lives), often much shorter than the lifetime of the transferred cells. 
It also introduces logistic issues in planning such trials, as the entire process, from label synthesis to 
the final imaging, must be performed in a short period of time. Furthermore, label retention within 
cellular compartments must also be characterized, as imaging modalities typically detect just the 
label regardless of whether the label is contained in the relevant cells, lost to the extracellular matrix 
or transferred to other cells. For example, 99mTc is not as suitable as 111In for labeling immune cells 
due to higher leakage of the 99mTc label from the cells (41) and subsequent accumulation in the 
intestine. 18F-FDG has proven to be of little value in labeling transferred cells for in vivo tracking due 
to massive release from the cells (42), besides its short half-life.   
 
3.2 Magnetic Resonance Imaging 
MRI uses powerful magnets to polarize and excite single protons in water molecules, producing a 
detectable signal. It is a promising solution to the lack of anatomical detail in nuclear imaging 
modalities, since MRI provides excellent intrinsic contrast and high spatial resolution, even in soft 
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tissues. MRI labels comprise of very stable compounds such as superparamagnetic iron oxide (SPIO) 
or Gd agents. These heavy metals are chelated to reduce toxicity. Such labels are called “contrast 
agents” because they are not detected directly but instead through their effect on local contrast of 
mobile water in tissues. In this case, intracellular localization of label can also be important, 
particularly when using MRI labels where it has been shown that clustering of MRI labels in dense 
vacuoles yields better local contrast enhancement than cytosolic distribution (43). Contrast agents 
have already been used in several clinical cell tracking trials (44), allowing for high resolution, 
longitudinal cell tracking. Finally, although MRI-based cell tracking is not restricted by radioactive 
decay as with radiolabels, this method is less suitable for quantification of cell numbers using current 
imaging protocols. Furthermore, the effect of these metals on the cells must be considered. 
Therefore, a novel class of 19F-based MRI contrast agents has been developed (45) with no 
physiological background and direct detection, which is suitable for quantification. The development 
of novel imaging protocols and pulse sequences has led to the functional assessment of the tissue 
using techniques such as dynamic contrast-enhanced MRI (DCE-MRI) and diffusion weighted imaging, 
which is dicussed in later sections. The combination of anatomical information and functional 
information using a single imaging modality is very powerful and therefore increasingly being 
investigated to monitor tumour responses to treatment.  
 
Table 1. Characterization of clinically available imaging technologies for imaging immune responses.  
modality spatial resolution temporal 
resolution 
sensitivity Label lifetime functional 
information 
cell tracking anatomical 
information 
MRI 50 micron – cm  s – min  
variable, generally 
medium to low 
variable yes 
ex vivo labeled 
cells 
yes 
PET mm – cm  min – hr  
extreme high 
(picomolar) 
hr – days  yes in vivo no 
SPECT mm – cm  min – hr  extreme high hr – days  yes ex vivo no 
Planar 
Scintigraphy 
mm – cm  min – hr  high hr- days yes ex vivo no 
 
3.3 Positron Emission Tomography 
PET reveals a three-dimensional image of functional processes as the system detects pairs of gamma 
rays emitted by a positron-emitting radionuclide. An advantage of PET tracers is that they are 
injected systemically, and then taken up by the relevant cells, as opposed to ex vivo labels as typically 
occurs with MRI, SPECT and scintigraphy. Thus the procedure can be carried out longitudinally 
(repeatedly), within the limits of radiation exposure. For example, patients were imaged with 18F-FLT 
PET at various time points to determine the peak of the DC-induced response (46). However, in situ 
labeling requires high sensitivity detection, typically through PET (47). Another problem with 
systemic administration of tracer is the nonspecific accumulation in organs such as the kidneys or 
bladder, as well as uptake by irrelevant cell types, such as macrophages. 18F-FDG for example 
accumulates in the myocardium and in the brain and 18F-FLT accumulation is typically in the bone 
marrow. It is important to consider the dosage and penetration of these injectable tracers, 
particularly given their short lifetime. Furthermore, tumours or other lesions can be susceptible to 
permeability changes from vascular disruption or leakage and this can affect the perceived signal 
intensity. 
 
3.4 Computed Tomography 
CT scans generate a three-dimensional image from a large series of two-dimensional X-ray images 
taken around a single axis of a subject. Its use has dramatically increased in the past decades due to 
increased availability and the circumvention of superimposition compared to planar X-ray images. 
The use of contrast agents has increased its diagnostic accuracy even further. For monitoring 
therapy-induced responses, CT scans provide accurate assessment of tumour volumes. X-ray beams 
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are attenuated to different degrees by different tissue, resulting in image contrast. Based on the 
different attenuation of X-rays passing different tissues, a CT scan could provide information on the 
composition of tumours. Although, changes in tumour composition are often observed on CT scans 
after initiation of treatment, this is not standard used to evaluate treatment during clinical practice.  
 
3.5 Ultrasound 
Ultrasonography uses high frequency sound waves in the megahertz range that are reflected by 
tissue to varying degrees. While it may provide less anatomical detail than techniques such as CT or 
MRI, it has several advantages, in particular that it studies the function of moving structures in real-
time, emits no ionizing radiation and is widely available, and relatively cheap. On the other hand, its 
short penetration depth (centimeter range) and poor reproducibility are drawbacks for studying 
deep structures and its use in clinical trials. Doppler capabilities on modern scanners allow the blood 
flow in arteries and veins to be assessed, which can be further enhanced by the use of intravenous 
contrast agents, such as gas microbubbles. 
 
 4. Immunological targets for imaging in humans 
Given the enormous task of the immune system to maintain tolerance to self-antigens and yet 
induce immunity to potential harmful pathogens and malignantly transformed cells, it is obvious that 
immune responses are tightly regulated by intensive crosstalk between different immune cells. 
However, for the purpose of this overview, we have simplified this multistep process into a linear tri-
phase sequel. The next section provides a description of immunological processes that have been 
used or potentially can be used as target for clinical imaging of developing immune responses. Each 
subsection highlights the specific contributions of the use of imaging to optimize therapy-induce 
immune responses.  
 
4.1. Phase I: Antigen encounter  
The recognition and phagocytosis of antigens that are expressed by tumour cells represents the first 
step to induce an immune response (Figure 2a). APC, e.g. DC, are specifically designed to fulfil this 
role. As such, APC are the main target for immunotherapeutic strategies exploiting TAA, either by in 
vivo loading or cellular therapy, using ex vivo generated antigen-loaded APC.  
 
4.1.1 Labeling antigen presenting cells in vitro 
DC used in vaccination therapy are autologous cells, generally purified and differentiated from 
monocytes or from bone marrow. These DC are typically activated in vitro by adding pro-
inflammatory cytokines or pathogen-associated danger signals, resulting in a phenotype with 
enhanced immune stimulatory properties (12, 14). The therapeutic DC are loaded with tumour 
antigens before transfer back into the patient to induce antigen-specific responses. The ex vivo 
isolation of the DC allows convenient access for labeling before transfer, most clinical studies have 
used 99mTc or 111In to label the therapeutic cells for tracking in vivo, reviewed in (48). Preclinical 
models have shown that the site of delivery greatly influences the subpopulation of DC that is 
targeted (49). Moreover, the site of activation of lymphocytes dictates their preferential homing 
characteristics; skin-draining LNs induce skin-homing phenotypes in contrast to organ-draining LNs, 
which are involved in visceral homing lymphocytes (50, 51). Lastly, the route of administration is 
important for the in vivo biodistribution of the transferred cells. The dermis is richly permeated with 
lymphatic vessels with loose endothelium accessible to DC. The subcutis consists of larger lymphatic 
vessels and has a different vasculature from the dermis, resulting in a less favourable milieu for DC to 
migrate. Imaging the therapeutic DC upon vaccination has revealed important clues on how to 
optimize vaccination protocols.  
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Optimizing the route of administration 
Therapeutic DC have been administered by various routes in clinical trials: Intralymphatic (i.l.), 
intravenously (i.v.), intradermally (i.d.), subcutaneously (s.c.) or intranodally (i.n.), and combinations 
of these. Intradermal vaccinations have been used commonly. Scintigraphic imaging of 111In-labeled 
DC shows that i.d. transfers result in a reproducible delivery of up to 4% of the injected dose of 
mature DC to the LN, regardless of the maturation conditions or mode of antigen loading. These 
small numbers of cells that reach the LN are sufficient to induce TAA-specific immune responses (52). 
The results with s.c. administration are more variable, with only some studies detecting migration to 
LN, and always less than 4%. Variations upon s.c. injections might be explained due to differences in 
injection techniques and the less favourable lymphatic structure of the subcutis. Intravenous 
administration results in a constant pattern of distribution in clinical studies, starting with 
entrapment in the capillaries of the lungs, which is most likely caused by non-specific activation and 
subsequent transient stiffening of cell membrane due to ex vivo handling of the cells. This is 
supported by the finding that mature DC are trapped in the lungs for a longer period of time than 
immature DC (53). Thereafter the DC redistribute mainly to the liver, spleen and bone marrow. No LN 
localization has been detected, as expected based on studies using normal peripheral blood 
leukocytes (54). It is not clear whether DC actually completely fail to reach the LNs or whether the 
techniques used are not sufficiently sensitive to detect the small numbers of cells that do reach the 
LNs. Hence, DC migration to LN upon i.v. transfer has not yet been demonstrated in humans. These 
studies demonstrate that i.d. injections result in a reproducible delivery of a small, but potent, 
number of DC to the LN. It should be noted that localized transfers, such as i.d. or i.n. injections, are 
much easier to image than systemic transfers, due to the higher local cell densities, at least at the 
injection site.  
 
 
Figure 3. Example PET/CT scan of the dynamics of 
18
F-FLT uptake in LN after vaccination 
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Confirming accurate delivery of the vaccine 
Intranodal administration is the most common in clinical studies, after i.d. injections. As the LN is the 
site of immune activation, delivery of DC directly into the LN obviates the need for specific and 
optimized migratory capacities and directly thrusts the entire dose of cells to the optimal location. 
The percentage of cells that migrate from the primary injected node to secondary nodes ranges from 
0-84%. This large variability cast doubts on the accuracy of i.n. injections, even when administered 
under ultrasound guidance. Therefore, we studied the migration and localization of a DC population 
dual-labeled with 111In and iron oxide using scintigraphy and high resolution anatomic MRI (55). 
Surprisingly, in 4 out of 8 vaccinations we observed no migration to secondary LN, due to extranodal 
injection of the DC (confirmed using high resolution MRI).  
 
4.1.2. Labeling antigen-presenting cells in vivo 
More challenging is in vivo labeling of antigen presenting cells. Tagging DC in vivo through the use of 
labeled antigen is a convenient trick (56, 57). For example, a nasal vaccine consisting of 18F-labeled 
botulinum neurotoxin was imaged in real-time and in a quantitative manner using PET in primates 
(58). In this study the investigators demonstrated that nasal administration is safe with respect to 
spreading antigens to the central nervous system. Furthermore, whole-body PET allowed detection 
of the degradation of the vaccine over a period of 4 hours. Long and colleagues exploited in situ 
labeling through cell-to-cell transfer. In a mouse model they injected irradiated tumour cells labeled 
with superparamagnetic iron oxide (SPIO), and tracked the subsequent migration of APCs, which had 
taken up the label to draining LNs (59). The cells could even be magnetically recovered ex vivo, 
allowing the investigators to study the phenotype and functionality of the transplanted cells after 
injection. In humans, this can be done using 111In-labeled tumour antigen peptides and scintigraphy 
(60). In another approach, the label is injected systemically and either taken up non-specifically by 
the relevant (phagocytic) cells or specifically by the relevant cell type. This approach circumvents the 
ex vivo purification and labeling of cells and therefore is much easier to apply and more amenable to 
use in large scale studies. A simple example of such a label would be the use of a radiolabeled 
specific antibody bound to a radioactive isotope for SPECT (61). Preclinically, this can be done using 
several techniques including MRI (62) and multimodal nanoparticles (48, 63). However, in clinical 
practice it has been proven difficult to achieve sufficient signal in the relevant cells, which has so far 
hampered its use in human studies. 
 
4.2. Second phase: expansion of immune effector cells 
The LN are the key organ site in the interplay with DC for initiation of the ensuing immune response 
and remodelling of the LN infrastructure is an early event of this process (64, 65). Murine studies 
showed that this occurs via endothelial cell (EC) activation and proliferation (Figure 2b). VEGF is 
known to induce EC activation and is expressed on EC, DC, B cells and T cells, in response to 
inflammatory cytokines (66-71). Expansion of the LN infrastructure, e.g. lymphangiogenesis and 
angiogenesis, facilitates the recruitment of immune cells and their proliferation. Enhanced influx and 
entry of DC enhances the immune response by ensuring ample antigen presentation. Next, increased 
influx and screening by naïve T cells for specific antigens results in more potent responses (72-74). 
Thus lymphangiogenesis, APC – lymphocyte interaction and lymphocyte proliferation can serve as 
markers for immune responsiveness. 
 
4.2.1. Remodelling of the LN vasculature 
It has been shown that LN volume can change nearly 5-fold with induction of an immune response 
(75). Direct imaging for LN volume is relatively straightforward, and can be done using various 
techniques visualising the anatomy including MRI, CT and ultrasound (76). Recent data have shown 
that ultrasound imaging using targeted microbubbles improves the evaluation of the 
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microvasculature, even in 3 dimensions (77). The availability of Gadolinium (Gd) or (ultrasmall) SPIO 
based contrast agents, allows the use of dynamic contrast enhanced (DCE)-MRI to monitor 
angiogenesis on a functional level (78-81). DCE-MRI allows assessment of properties of LN 
vasculature such as expansion of LN size, total blood flow and blood volume, permeability of 
perfused capillaries and total surface of perfused capillaries. To date, the main application of 
diffusion weighted (DW)-MRI in imaging LNs is to detect metastatic LNs, for which it has proven high 
sensitivity. Accordingly, imaging reactive LNs in immune responses is logically the next application 
(75). It has recently been shown that MRI measures of vascularity using an injected iron based 
contrast agent, are comparable to those obtained from traditional histology, which has long been the 
gold standard to study angiogenesis (82), thus validating the technique. 
 
Indirect imaging of LN vasculature 
Alternatively, lymphangiogenesis can be measured by targeted imaging of molecular markers (83). 
The dominant events in the remodelling of newly formed blood- and lymph vessels, reviewed in (84), 
are coordinated by the expression of VEGF, and sprouting v
integrin. PET tracers have been developed to probe these specific targets. In our Institute, the anti-
VEGF antibody bevacizumab, labeled with 111In, is used for the scintigraphic detection of VEGF in 
tumours (85), but could easily be applied to image LN revascularisation. More recently, a new 
generation of protein-targeted contrast agents for multimodal imaging of the cell-surface receptor 
for VEGF was described (86). These probes are based on recombinant VEGF with a cysteine-
containing tag that allows site-specific labeling with contrast agents for near-infrared fluorescence 
imaging, single-photon emission computed tomography (SPECT) or PET, reviewed in (87). It is 
expected that an integrin targeting probe for PET will be available for clinical use in the next few 
years. Importantly, integrin-targeted PET probes have already been tested for safety in humans (88), 
(89). v3 integrin has also been targeted by radiolabeled RGD-peptides which specifically bind the 
integrin, an example of which is 18F-FPPRGD2 (89), 18F-galactoRGD (90) or 18F-Fluciclatide (91). In 
mice, similar PET probes have been shown to be sensitive to antiangiogenic therapy (91). Using a 124I-
labeled antibody against the lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1), 
Mumprecht et al imaged inflammation-induced expansion and regression of lymphatic networks in 
vivo in mice with PET (92). MRI is also being explored in preclinical models to specifically target 
molecular markers such as v3 integrin (93, 94). In clinical practice, enlargement of regional LN in 
response to preventive or therapeutic vaccination is a well-known phenomenon. Surprisingly, it has 
not yet been systemically investigated as a marker of immune responsiveness by using imaging 
modalities.  
 
4.2.2. Imaging lymphocyte activation in LNs 
In order to stimulate lymphocyte proliferation, antigen-bearing mature DC must come into direct 
contact with the lymphocytes. This cell-cell interaction is best imaged using microscopic techniques, 
including intravital microscopy, which allow direct viewing. Imaging such specific cell-cell interactions 
in vivo has not yet been performed in clinical studies. However, preclinical studies have revealed 
important information on the dynamics and kinetics of critical interactions and have paved the way 
for clinical applications.  
 
Imaging chemotaxis 
Aimed at facilitating influx of both APC and effector cells, reactive LN express and secrete 
chemokines in order for immune cells to relocate to the reactive LN (73, 95). Amongst others (96, 
97), the presentation of chemokine CCR7 is dominant (98, 99) and provides a rational target for 
imaging. Chemotactic agents, which play a key role in directing trafficking, are also suitable imaging 
targets. CXCL12 is a key chemotaxis factor for lymphocytes, and is detected by CXCR4 on their cell 
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membrane. CXCR4 overexpression is thought to play a role in cancer (100). Thus, it has been 
explored as a potential imaging target. Imaging of surface receptors allows for in situ labeling of the 
lymphocytes, given that detection is highly specific and sensitive. Hence, PET is the most suitable 
approach, together with well-designed radioactive probes (101). CXCR4 expression has been assayed 
in vivo in a dynamic manner using tagged ligands (102, 103), showing that CXCR4 can reliably and 
specifically be targeted in a manner that correlates with cellular composition shown by 
immunohistochemistry. 
 
APC – lymphocyte interaction 
The in situ dynamics of DC/T cell interactions have been studied extensively using advanced 
microscopy methods which make it possible to study the kinetics of DC/T cell interactions (for 
example, (104)). Techniques such as intravital microscopy have enabled the study of immune cells in 
their native environment, with minimal external interference (105-109) . Single molecule techniques 
now facilitate direct study of the relevant receptors and cell components at the T cell synapse (110). 
It is now even possible to measure the forces generated by these molecular interactions ex vivo (98). 
From these studies, it became clear that DC/T cell interactions are highly complex and precisely 
regulated events that govern immune responses. Such findings contribute to the concept that 
immune activation occurs in separate stages (static, dynamic), emphasizing the importance of 
motility (e.g. CCR7 expression) and chemokine secretion by LN stroma/cells and DC. With respect to 
DC-based immune therapy, these studies show that the life-span of DC, prolonged antigen 
presentation and the migratory capacity are crucial for efficient immune induction. These extremely 
high-resolution techniques are obviously restricted to ex vivo use.  
 
Lymphocyte proliferation 
Efficient stimulation by APC should result in lymphocyte activation and the subsequent release of 
cytokines, such as IL-2, together with extensive proliferation, is an energy-consuming process. 
Activated, antigen-specific lymphocytes then emigrate from the LNs to antigen depots. In terms of 
detection of the immune response, these changes in cell metabolism are a candidate for imaging. In 
particular PET has been employed to study immune activation in vivo, as it allows the use of 
radiolabeled, injectable analogues of relevant metabolites, particularly glucose and nucleotides. 
Increased glucose uptake can be measured using 18F-labeled fluoro-2-deoxy-2-D-glucose (18F-FDG) 
PET, which is by far the most commonly used PET tracer. In hematolymphoid tissues however, 
increased levels of deoxycytidine (DCK) expression is found; DCK is the rate-limiting step in the 
deoxcycytidine salvage pathway. The tissue-specific expression of this enzyme allows more specific 
targeting by appropriate PET tracers (111). For example, 18F–2-fluoro-d-(arabinofuranosyl)cytosine 
(18F-FAC), a fluorinated deoxycytidine analog, has been  shown in animal models to accumulate 
preferentially in CD8+ T cells in mice studies. In contrast to 18F-FDG, this preferentially accumulated in 
innate immune cells (112). The accumulation of nucleotide analogues, required for increased DNA 
synthesis during cell division, is another sensitive marker for antigen-specific lymphocytes, at least in 
melanoma patients vaccinated with antigen-loaded DC. 18F-FLT is trapped intracellularly after 
phosphorylation by thymidine kinase 1 (TK-1). 18F-FLT-phosphate is not incorporated into DNA since 
18F-FLT-monophosphate is a very poor substrate for the second kinase, thymidylate kinase (TMPK), 
and thus hampers procession to 18F-FLT-triphosphate, which can be incorporated into the DNA. The 
accumulation of nucleotide analogues has also been studied using other radiolabels in humans. In 
one study, an 11C-tagged thymidine analogue used for PET was compared to 18F-FDG-PET in lung 
cancer (113). This study confirmed our results that nucleotide analogue 18F-FLT, is more specific for 
detecting proliferation than 18F-FDG. In our study, we directly compared the properties of 18F-FDG 
and 18F-labeled 3’-fluoro-3’-deoxy-thymidine (18F-FLT) within individual patients and demonstrated 
that in terms of sensitivity and specificity, both tracers perform similarly (46). However, for 18F-FDG 
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there was no correlation with the in vitro monitoring assays measuring concurrent antigen-specific T 
and B cell responses. Furthermore, 18F-FDG uptake can be attributed to other factors, including other 
treatments such as vaccinations (114). In contrast, 18F-FLT retention in the LNs of vaccinated patients 
only increased in the presence of antigen-loaded DC. Moreover, the degree of increase directly 
correlated to the magnitude of the induced antigen-specific T and B cell responses. This was the first 
clinical demonstration in that antigen-specific therapy-induced immune responses can be imaged in 
vivo early after treatment initiation (Figure 3. Example of a time course of 18F-FLT uptake in 
vaccinated LN).  
 
4.2.3. Imaging trafficking of immune effector cells 
Activated lymphocytes must leave the LNs and migrate to sites where their cognate antigen is 
present. Imaging of lymphocyte trafficking is most easily achieved with ex vivo labeled cells, as in 
cases of ACT, but some clinical studies have explored in vivo labeling of effector cells as well.  
 
Ex vivo labeling of transferred cells 
Imaging of cells after ACT has recently been reviewed (115). Transfused cells often traffic initially to 
the lungs, bone marrow, liver and spleen (61), a process that is regulated by small molecules, 
primarily cytokines and chemokines. It has been demonstrated in early clinical trials that 
pretreatment with cyclophosphamide augments the trafficking of transferred cell to the tumor sites 
(116). In a similar way, IL-2 co-administration might positively contribute to the vaccination effect 
(117). The use of reporter gene expression, as another way to study small molecule expression, is 
particularly exciting. It detects the actual synthesis of the molecule and is independent of factors 
such as lifetime and distribution of the molecule itself. Furthermore, the use of an enzymatic 
reporter allows for amplification of a weak signal. Hence, mice have been transfected with luciferase 
linked to interferon- (118). In this study, the 
plasmids were injected directly in the liver. Such technology can readily be adapted to other 
molecules of interest. For example, antigen specific T cells expressing a viral TK gene were tracked in 
recipient mice over a period of three weeks, using an 18F-tagged probe specific to this variant of TK 
(119). Quantitative detection of the labeled T cells was possible, with a sensitivity limit in the order of 
104 T cells – low enough to detect the milder immune response triggered by non-mutated self-
antigens in cancer. However, nonspecific probe accumulation in the tumour complicated image 
interpretation.  
 
In vivo imaging of effector cells  
Imaging of lymphocytes, particularly T cells, has been carried out in vivo in preclinical models using 
several imaging modalities (120). Lymphocyte imaging requires a suitable target for the imaging 
probe, such as cell surface markers. For example, 99mTc-labeled IL-2 can be used to detect 
lymphocytes associated lesions in melanoma patients (121). This probe detects tumour-infiltrating 
lymphocytes, and such imaging can be used to study the effect of therapy. The technique can also be 
modified to target other immune cells, provided for example, with non-depleting 111In-labeled anti-
CD4 antibodies to track CD4+ T cells, as in a murine model of colitis (122). The signal measured by 
SPECT in this model was found to correlate with standard pathologic measures, although unlike 
standard pathology, the SPECT/CT measurements are noninvasive and can be applied in humans. A 
recent example is the use of in vivo 19F MRI to longitudinally and quantitatively track T cell homing to 
draining LN (123). Here, the numbers of antigen specific T cells in a relevant LN were quantified over 
a period of 3 weeks, in the same animal. Quantification errors arising from dilution of label due to 
cell division are unavoidable in such systems (124). A unique situation arises for in vivo clinical 
imaging of the immune system in humans in the cornea, where advanced microscopy techniques 
such as confocal and dual photon microscopy have been carried out on endogenous DC and 
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lymphocyte infiltration (125). The transparency and favourable optical properties of the eye makes 
this possible. However, the functionality of the immune system in the eye may not be directly 
comparable to that in other regions - it was long thought that the eye was “immune privileged” and 
lacked an immune system. In vivo imaging in the eye is more advanced in preclinical settings, which 
allows more manipulation and the use of pre-labeled cells (126). 
 
4.3. Third phase: targeting the tumour and its microenvironment 
Traditionally, measuring the change in tumour volumes according to the response evaluation criteria 
for solid tumours (RECIST) has been the key criterion upon the therapy effect is judged (127). The use 
of volume as a measure for response to treatment is based on a large body of evidence involving 
chemotherapy. Indeed, the direct cytotoxic mode of action of chemotherapy often translates into 
tumour shrinkage weeks to months after the start of treatment. This initial volume response is often 
correlated to clinical outcome and thus justifies its use in clinical decision-making. However, now that 
immunotherapeutic strategies have entered clinical practice, it has become clear that the traditional 
RECIST criteria are challenged by the advance of immunotherapy (128). In general, several factors 
need to be considered for the development and optimization of a clinical imaging protocol. For 
example, there are often no solid data to plan the optimal label or contrast dosage, timing and 
frequency of imaging and interaction with drugs or other interventions. Frequently there are not 
enough subjects to obtain results with statistical significance, especially given the high variability that 
can occur between patients. Thus, trials that incorporate novel imaging for response evaluation must 
be scrupulously planned beforehand, but can also yield valuable information on the mechanism of 
action of the applied therapy and on the early identification of responding subjects. The next sections 
describe several imaging strategies to dissect the relative contributions of tumour progression and 
on-site immune action.  
 
4.3.1. Evaluation of tumour volume 
Tumour shrinkage results from a complex interplay of various components of the immune system in 
different body compartments. In general, this takes weeks to months to develop and in this time 
frame the tumour will continue its expansive growth, giving misleading results when tumour size 
alone is measured. Secondly, in order to eliminate tumour cells, immune cells need to penetrate the 
tumour and its microenvironment to achieve cell-cell contact. This implies increased cellularity of the 
tumour and is, in terms of tumour volume, indicative for tumour progression. Wolchok et al (129) 
proposed a new response paradigm that addresses these issues, while using volume-based criteria. 
They evaluated a novel set of response criteria in a large series of patients with advanced melanoma 
who received ipilimumab, a fully human monoclonal antibody that blocks CTLA-4 (129). These 
immune-related response criteria now more accurately characterize new response patterns, 
especially those with delayed tumour shrinkage or initial tumour growth followed by tumour 
shrinkage. However, these novel criteria are designed to avoid preliminary termination of a possible 
effective immunotherapeutic treatment, but they fail to reveal cellular and molecular processes that 
precede a clinically meaningful response. Furthermore, as a result from the delayed volume 
responses that are associated with the indirect mode of action of immunotherapy, this information 
becomes available rather late after initiation of treatment. 
 
4.3.2. Imaging tumour cellular composition 
One rational approach to circumvent the above-mentioned issues is to measure the relative number 
of tumour cells in a suspected tumour-containing volume before and after start of treatment. Such 
an approach requires a highly sensitive and quantifiable tumour-specific marker, e.g. by using PET 
tracers. The developments in melanoma-specific markers is recently reviewed in (130). In this 
respect, novel compounds that target melanin biosynthesis and metallopeptides binding to 
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melanocortin type 1 receptor, which are overexpressed in melanoma, are promising agents (131-
133). Changes that occur in the tumour due to an increased immune response can be imaged using 
MRI, for example through changes in relaxation times, contrast or apparent diffusion coefficient. 
These changes have been shown to correlate with conventional histological measure in mice (134). In 
this study, the immune response was induced by transferred cytotoxic T cells that expressed a 
modified TCR specific for a tumour antigen. However, to date there is no experience with the 
evaluation of responses to immunotherapy in particular.  
 
4.3.2. Imaging tumour metabolic activity 
Currently, 18F-FDG is the most commonly used radiopharmaceutical for imaging tumour metabolism 
in clinical practice. Its use is based on the increased glycolytic rate in tumours compared to 
physiologic cells, known as the Warburg effect. Without doubt, imaging changes occurring in tumour 
metabolism early after treatment initiation by PET, has contributed to the optimization of clinical 
decision making in the management of patients with various types of cancer. However, the 
infiltration of effector immune cells, which are metabolically active as well, can be a confounder in 
the interpretation of tumour responses, leading to 18F-FDG-positive tumour lesions due to activated 
immune cells rather than tumor cells  (135). However, other studies have demonstrated otherwise, 
immunohistochemical staining showed highly 18F-FDG avid lesions that were not regression showed 
indeed a high proliferative rate of tumor cells, whereas low 18F-FDG avid lesions were massively 
infiltrated by activated immune cells. There is increasing attention for the development of tracers 
which are more tumour-specific, in order to discriminate tumour metabolism from inflammatory 
responses.  Potential candidates are amino acids, nucleotides, choline and -receptor ligands. In a 
preclinical model, Van Waarde et al.compared 2 -receptor ligands, 11C-methionine and 11C-choline 
with 18F-FDG and found that one of the 18F-labeled -receptor ligands selectively targeted glioma 
metabolism; 30-fold tracer uptake compared to sterile inflammation (136). Further in vitro studies in 
this models showed that increased sigma-ligand binding and 11C-choline uptake reflected active 
membrane repair upon chemotherapy-induced cell damage. Along the same lines, imaging 
nucleotide metabolism by 18F-FLT, as a tracer for tumour cell proliferation in humans, has extensively 
been evaluated to show proliferation specifically. Effector immune cells that infiltrate tumours are 
mostly of a differentiated phenotype and show no proliferative activity on the spot. However, no 
comparative studies in humans have been performed to study the relative selectivity of 18F-FLT for 
tumour cells compared to inflammation (137). 
 
5. Discussion and future directions 
Direct visualization is a powerful tool to push forward the understanding of complex processes, 
which has intrigued researchers for ages (Figure 1 Timeline). In the next section we describe 
particular issues concerning the application of imaging immune responses in clinical practice. 
Understanding those issues in the imaging of therapy-induced immune responses will hopefully 
improve the usage of these powerful tool in future clinical trials and thus contribute to the 
optimization of anti-cancer treatment.  
 
5.1 General issues in imaging the immune system  
Germain et al.eloquently stated that the imaging of the immune system is the biological equivalent 
of Heisenberg’s principle, which implies that it is not possible to study the system without perturbing 
it (105). Indeed, the function of the immune system is to maintain cellular integrity and homeostasis; 
hence how can you label and probe it without affecting the system? Therefore, extra caution must be 
taken in the development of probes and labels for imaging. The highly mobile and rapidly changing 
nature of the immune system further complicates imaging studies. We have previously suggested 
two basic strategies for in vivo cell tracking (48). Briefly, cells can be pre-labeled before transfer or a 
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targeted label can be used to label the relevant cells in situ. Typically, the first strategy is used for 
MRI (pre-labeling with contrast agents), and the second for PET. This is a reflection of both the 
detectable lifetime of the labels and the sensitivity of the detection technique.  
 
Ex vivo labeling of cells 
From an imaging perspective, there are several advantages to this approach. First, the ex vivo 
isolation of the DC allows convenient access for labeling before transfer, and for detailed 
characterization of the labeled cells in terms of viability, gene expression and functional status (27, 
48). Secondly, the homogeneity of label uptake within the population can also be determined and 
removal of excess label and dead cells is simpler. Furthermore, non-specific labeling of irrelevant 
cells is greatly reduced if the relevant cell population is purified beforehand. However, it can be an 
expensive and laborious process to purify, culture and label cells ex vivo before transfer. The effect of 
an imaging label on cells must be carefully considered. For example, radioactive probes can become 
highly concentrated locally and affect the labeled cells directly (138). This can be particularly 
deleterious for long-lived or highly proliferating cells, such as stem cells or activated T cells. MRI 
labels, such as those based on iron oxide have also been shown to impact cell migration (139) (140)  
and induce oxidative stress due to the catalytic iron moiety (141). The fate of the label, particularly 
its ability to stay with the relevant cell is crucial. It is known that cells can transfer their intracellular 
label to neighbouring cells, particularly when under stress leading to “secondarily labeled cells” 
which can confound imaging data (142). Hence, one always should ask – and answer – the question 
“What am I imaging?” These cellular effects must be considered in addition to any systemic side 
effects of the label, for example nausea or rashes; nephrogenic systemic fibrosis is a concern with 
Gd-based contrast agents for MRI.  
 
In vivo labeling of cells  
The alternatives to ex vivo labeling, using long-lived agents, are in situ labeling or genetic 
modification of the cells to express an imaging reporter gene. In situ labeling typically uses short-
lived labels, as with injectable PET tracers. These tracers can even be generated from clinical 
applicable antibodies, for example 89Zr-labeled Fresolimumab for PET detection of tumor necrosis 
factor (TNF)- expression in mice (143). However, antibodies can neutralize or otherwise affect 
activity of the target molecule and/or cell. While that is often the purpose in antibody therapy, it is 
not necessarily desirable when imaging functionality or expression. In general, only viable or 
functional cells will be able to take up the label effectively, so non-specific labeling will not restrict its 
use. Furthermore, the use of an injectable label allows the use of radiolabels for longitudinal studies, 
as the agent can be injected (or re-injected) before each imaging session. However, the general 
problems faced with systemic transfer of label include limited uptake in the relevant cell population, 
accumulation in non-relevant tissues such as the liver or bladder, the requirement for higher activity 
doses to allow sufficient signal in the relevant cells, clearance of label and clinical radiation exposure 
limits for radioactive agents. The use of reporter genes is a powerful approach. This technique is 
well-suited for the detection of proliferative cells, as the label does not dilute with cell division. 
Furthermore, continued expression over the cell’s lifetime allows longitudinal tracking, and can even 
be coupled to the expression of a particular gene of interest, or at the very least, to viable cells. 
Moreover, intrinsically labeled cells are attractive due to the absence of background from nonspecific 
uptake (56). However, the applicability of genetically modified cells to humans is not yet clear (144). 
Finally, it is always necessary to consider whether images are really specific to the relevant cells i.e. 
the specificity of detection. While this is typically more of a problem with injected labels or targeted 
agents that are injected systemically, it can also affect prelabeled cells through nonspecific transfer 
or loss of label from the transferred cells. The actual physical location of the label should be 
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confirmed using histology on tissue sections during the development and validation of such 
monitoring tools.  
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Figure 2: Timeline of development of immunotherapies and development of imaging tools.  
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5.2 Future directions: How can imaging contribute?  
The greatest challenge is to find a target process that is critical to successful immune activation, so 
that imaging this process accurately predicts response to intervention. Crucially, this must be done 
without disturbing the targeted process. Moreover, the imaging results should deliver important 
information as early after start of treatment as possible, to allow timely adjustment of treatment per 
individual. In this section we describe three possible solutions, using novel imaging tools fulfilling the 
needs described above.  
 
Imaging specific functionalities 
PET reporter gene (PRG)/probe (PRP) systems, recently reviewed in (145, 146) have proven their use 
in many preclinical models (119). PRG encodes a protein that mediates the accumulation of a specific 
reporter probe, labeled with positron-emitting radionuclide. These systems allow long-term whole-
body visualization of the functional status of the transduced and transplanted cells, and can thus 
provide valuable information on the localization, the kinetics and the magnitude of transgene 
expression over time. The application in patients has long been hampered by safety concerns; the 
most commonly used transgenes are from viral origin and can trigger an immune attack against the 
transfected cells in humans (147). However, strategies to circumvent the safety concerns are being 
developed, paving the way to application in clinical trials. For example, therapeutic cells have 
genetically been modified to implement a suicide gene in ACT as a safety precaution. Another 
possibility to circumvent this immunogenicity is customizing the reporter gene, as has been done 
with thymidine kinase (TK) (144). TK gene therapy has been applied in small clinical trials (148, 149) 
and the cells used in ACT are frequently genetically modified (for example (150, 151)). Recently, 
humanized transgenes were described (144, 152, 153), based on a mutated form of the human 
thymidine kinase 2 (TK2). By using this PRG and a thymidine analog L-18F-FMAU as PRP, the 
investigators could efficiently target and visualize nucleotide metabolism in proliferating cells, 
without perturbing the endogenous enzymes. In this study, the biodistribution of the used PRP and 
another probe, 18F-FHBG, were studied in patients, as a first step towards clinical application. This 
promising technique can easily be adjusted to target other functional processes; from the monitoring 
of cell-based therapies to anti-angiogenic treatment. In animal models, the relevant cells can be 
transduced to express reporter genes, such as enzymes that trap tracers for PET, fluorescent proteins 
such as green fluorescence protein (GFP) for fluorescence imaging, luciferase for bioluminescence 
imaging, or iron transporters or CEST proteins (154) for MRI contrast, and even for multimodality 
imaging using a triple reporter gene construct for fluorescence (eGFP), 18F-FLT PET (TK 1 and 2) and 
luminescence (luciferase) (155). 
 
Novel tracers that target specific effector cell populations 
The activation and proliferation of immune effector cells is accompanied by an enormous metabolic 
switch. In a resting state the immune system maintains the existence of a diverse population of cells. 
Once danger is detected, specific populations need to shift to a highly activated state that runs 
specific transcriptional and translational programmes, within a time frame of hours, reviewed in 
(156, 157). In order to respond to these increased energy demands, T cells must actively acquire 
metabolites from their environment. For example, ligation of T cell receptor initiates cellular 
proliferation, whereas triggering of co-stimulatory molecules enables the uptake and usage of 
metabolites. Circulating growth factors, like cytokines and hormones, contribute to the ability of 
effector cells to switch between resting and activated states. Since the immune system comprises a 
multitude of different cell types and effector functions, it is of no surprise that in this tightly 
regulated process, specific effector functions are supported by specific metabolic pathways (157). In 
a preclinical study, Nair-Gill et al.investigated the immune cell specificity of PET probes for two 
different metabolic pathways: 18F-FDG for glycolysis and 18F-labeled 2-fluoro-d-
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(arabinofuranosyl)cytosine (18F-FAC) for deoxycytidine salvage; in response to a retrovirus-induced 
sarcoma (112). They demonstrated that the two probes had distinct patterns of accumulation: 18F-
FDG accumulated to the highest levels in innate immune cells, while 18F-FAC accumulated 
predominantly in CD8+ T cells in a manner that correlated with cellular proliferation. Thus, innate and 
adaptive cell types differ in glycolytic and deoxycytidine salvage demands during an immune 
response, and this can be targeted with specific PET probes. In a similar fashion, Shu et al (158) 
develop PET probes with improved metabolic stability and specificity for rate-limiting enzyme in the 
deoxyribonucleoside salvage pathway: deoxycytidine kinase (dCK). Given the increased body of 
knowledge on the metabolic fates of different cell populations, it is just a matter of time before this 
will be translated to monitor immune responses in clinical trials.  
 
Targeting on-site immune responses in tumour tissue 
The transfer of technology from tumour and preclinical imaging holds great promise. One example of 
such technology transfer is in the detection of apoptosis in vivo. This might also be considered in 
non-immunotherapeutic regimen, since it has now been demonstrated that tumour regression at 
least partly results from chemotherapy-induced programmed cell death and the subsequent influx 
and activation of immune cells (34). The induction of tumour cell apoptosis by infiltrating immune 
cells precedes detectable tumour volume shrinkage (reviewed in (159)). Effective treatment should 
result in cell lysis, loss of membrane integrity and increased extracellular space. These physical 
changes can be detected and measured using MRI. MRI is already available in the clinic and could be 
applied to monitoring immune responses in vivo. Amongst others, Annexin-V, hydrophobic cations 
and caspase inhibitors have been tested as potential probes for imaging apoptosis in preclinical 
models. 99mTc-labeled Annexin-V has been tested in clinical trials (160). Indeed, the authors found 
that increased Annexin-V uptake in the tumour site early after start of platinum-based chemotherapy 
in non-small cell lung cancer (NSCLC) was associated with improved clinical response. Another 
apoptosis marker that has been tested in humans is 18F-labeled 2-(5-fluoropentyhl)-2-methyl malonic 
acid (18F-ML10) (161, 162). It is interesting to note that just 10 years ago, the field of in vivo imaging 
of the immune system was virtually non-existent. Five years ago, a review article covering imaging for 
cell tracking focused on the same techniques that we are still developing - SPIO labels for MRI, 
scintigraphy and PET visualizing TK activity (163). More recently, we have seen the preliminary 
introduction of these techniques in humans, the introduction of quantitative in vivo 19F MRI, and the 
distinct possibility of imminent TK-based PET in humans. We have also learned that all these probes 
and imaging modalities are likely to perturb the cells we are imaging. Thus, although in vivo imaging 
is a new field, we are already beginning to see its applications in imaging the immune system. 
Together with improvements in labels and imaging hardware, and the advent of multimodal imaging 
scanners, the future of in vivo imaging of the immune system looks bright. 
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Concluding Remarks 
 
 
 
The incidence of cancer is rising at fast pace; it is estimated that in the year 2030 22.2 million people 
will experience cancer, representing a 75% increase from the year 2008 (1). Anti-cancer treatments 
have evolved accordingly and at this point, surgery, radiotherapy and chemotherapy offer 
considerable response rates in many types of cancer, even in metastatic stage of disease. However, 
for some cancers, these classical treatment modalities have reached their potential. Metastatic or 
irresectable melanoma is one of them. By summing up 20 trials from 2002 to 2010 on chemotherapy 
and combinations of chemotherapy with novel biological or immunotherapies in metastatic 
melanoma, Garbe et al brutely demonstrate this notion; median overall survival still does not exceed 
10 months regardless of the regimen (2). 
 
“If there is anything I (first person singular) could do...” is a recurrent thought of many metastatic 
melanoma patients who enter the stage of ‘no standard systemic treatment with proven benefit’.  
“Imagine your own immune cells harnessed in a vaccine to fight cancer” is a thought that has 
probably crossed the mind of Ralph Steinman many times when he performed his early experiments.  
Notwithstanding other important contributions to the development of anti-cancer immunotherapy 
by others, Ralph Steinman discovered dendritic cells as the orchestrators of immune responses. He 
has pursued the role of dendritic cells since their discovery in 1973, leading to the first vaccination of 
a B-cell lymphoma patient in 1996 (3). As of June 2012, 151 clinical trials on dendritic cell vaccination 
are open for inclusion worldwide (www.clinicaltrials.gov). The rapid development from discovery to 
clinical application is unprecedented in medical history. Apart from his tenacious drive, he 
exemplifies the ‘from bed to benchside’ paradigm by demonstrating that translation of experimental 
data to clinical cases and careful clinical observation for validation of experimental data is an 
inexhaustible source of motivation. Lastly, the story of dendritic cell based vaccination seems to 
answer to the hope of many patients who face the limits of standard medical care that there must be 
a reasonable option beyond ‘standard’. 
 
Have dendritic cell based vaccination saved many lives? No. In line with the reported responses rates 
in literature, our studies demonstrate that only a small minority of patients survive >24 months and 
in most cases we could show an active role for the immune system. However, it has provided a 
unique platform to study interventions in a complex organ that encompasses several body 
compartments, e.g. peripheral tissues, lymph nodes, lymphatic and vascular systems and the tumour 
site. Moreover, the cells that comprise the immune system are not static but constantly circulate 
through the vascular and lymphatic system while they undergo many stages of differentiation during 
their life span. 
 
The lesson from the latter is that every clinical case potentially provides a unique opportunity to 
learn about the critical processes that precede the failure or successful induction of an immune 
response. Progress of anti-cancer immunotherapy is only to be expected only if we manage to take 
this opportunity and learn how to guide therapy based on individual characteristics. The 
acknowledgement of the lack of biomarkers as the major hurdle for improved efficacy of 
immunotherapy has drastically influenced the way we design and perform clinical studies. Instead of 
performing small proof-of-principal studies in academic centres, focussing on a single parameter; 
large sponsor-driven randomized prospective studies are designed to find potential biomarkers. 
However, the approach of finding biomarkers for personalized medicine based on statistical analyses 
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of a general population has one demerit; it has lost its link to the individual case. Functional in vivo 
multimodal imaging is an ideal candidate to fulfill this thrilling task. It allows longitudinal assessment 
of the presence, specificity, phenotype, localization and multiple functionalities of immune cells in 
real-time in an individual case, linking therapeutic interventions to clinical outcome. In this respect 
the old adagium ‘seeing is believing’, is an undeniable truth.  
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Het afweersysteem 
Ons afweersysteem is een goed georganiseerd systeem dat bestaat uit een grote verscheidenheid 
van cellen, met elk een unieke functie. Het is zó ontworpen dat het bij uitstek geschikt is om ons 
lichaam te beschermen tegen indringers van buitenaf, zoals virussen en bacteriën, of tegen 
ontregelde cellen uit ons lichaam zelf, zoals kankercellen. Om deze ingewikkelde maar uiterst 
belangrijke taak te kunnen verrichten werkt ons afweersysteem met een enorme precisie; alleen 
gevaarlijke cellen worden aangepakt, óók als dat maar een enkele cel is. In het geval dat gevaarlijke 
cellen van buitenaf ons willen indringen, zoals een virus bij een fikse keelverkoudheid, reageert ons 
afweersysteem vaak heel adequaat; we worden er een beetje ziek van, maar het levert geen echt 
gevaar op. Hoe gaat een dergelijke afweerreactie in zijn werk? Het begint met het herkennen van 
virusdeeltjes als ‘gevaar’, hiervoor zijn dendritische cellen heel geschikt. Dendritische cellen zijn 
uitgerust met speciale herkenningsmoleculen (receptoren) op de buitenkant van hun celwand, 
bedoelt om unieke stukjes eiwit (antigenen) te herkennen. Daarnaast zijn dendritische cellen 
gelokaliseerd op strategische plaatsen, waar er contact is met de buitenwereld, zoals slijmvliezen en 
de huid. Deze dendritische cellen zijn continu op zoek naar alles wat niet in het lichaam thuishoort, 
en wat dus misschien wel gevaarlijk kan zijn. Wanneer zij iets herkennen als vreemd, en hierdoor 
gealarmeerd worden, zullen ze naar de lymfeklieren bewegen en de informatie die zij ergens 
opgepikt hebben zullen ze dan meenemen. De lymfklieren zijn een ontmoetingsplaats voor 
afweercellen; doorlopend komen dendritische cellen binnen met informatie over indringers die 
mogelijk een gevaar vormen. In de lymfeklier zijn ook andere afweercellen te vinden, dit zijn de 
cellen die het eigenlijke opruimwerk moeten doen, de T cellen. Deze afweercellen herkennen elk één 
specifiek uniek stukje eiwit (antigeen), en wanneer hun dit unieke stukje eiwit aangeboden wordt 
door een gealarmeerde dendritische cel, zullen zij in actie komen. Dat betekent dat zij zich zullen 
gaan vermenigvuldigen en de lymfeklier verlaten, om in grote getallen door het lichaam te zwerven, 
op zoek naar dat unieke 
stukje eiwit, …om het 
vervolgens op te ruimen. Dit 
proces werkt 24 uur per dag, 
7 dagen per week. In het 
geval van een 
keelverkoudheid herkennen 
we deze stappen; ons 
slijmvlies van de keel wordt 
binnengedrongen, we 
krijgen keelpijn; vervolgens 
komen onze dendritische 
cellen in actie en nemen 
stukjes eiwitten mee naar de 
lymfeklieren. Gelukkig zijn er 
genoeg T cellen die deze 
antigenen herkennen en er 
begint een afweerreactie op 
gang te komen, onze 
lymfeklieren in de hals 
235
 zwellen dan ook op om ruimte te maken voor deze grote aantallen afweercellen. Na een paar dagen 
is ons afweersysteem op volle sterkte en wordt het virus opgeruimd. Ons afweersysteem kent ook 
een aantal regelsystemen, waardoor de afweerreactie weer wordt geremd wanneer het gevaar 
geweken is en er geen onnodige schade wordt aangedaan aan de gezonde weefsels.  
 
Het afweersysteem en kanker 
Wanneer bij iemand kanker wordt vastgesteld, is de afweerreactie niet adequaat genoeg geweest. 
Ons afweersysteem is blijkbaar onvoldoende in staat geweest om de kankercellen te herkennen als 
‘gevaar’ en onze gezondheid is ernstig bedreigd. De kankercellen zijn op sommige punten in het 
voordeel; zij zijn van oorsprong lichaamseigen cellen en worden dus veel minder snel als ‘gevaarlijk’ 
herkend. Daarnaast maken kankercellen slim gebruik van de normale regelmechanismen om de 
afweercellen af te remmen in hun aanval op de kankercellen. Het ontwikkelen van kanker is een kat- 
en-muis spel tussen kankercellen en het afweersysteem. En op het moment dat bij patiënten kanker 
wordt ontdekt is vaak de kanker aan de winnende hand. Hoewel we ons goed moeten realiseren dat 
het hebben van kanker verre van kinderspel is, laat het onderwerp van dit proefschrift zich wel goed 
uitleggen door een vergelijking te maken met een strategisch spel.  
 
 
 
 
Het spel 
In dit strategisch spel zijn kanker en het afweersysteem elkaars tegenspelers, en het doel is de 
controle over het lichaam te veroveren. Beide spelers hebben de beschikking over een set 
speelkaarten; mogelijkheden die zij op elk gewenst moment in kunnen zetten om de tegenspeler te 
slim af te zijn.   
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 De speelkaarten 
Aan de kant van het afweersysteem zijn dit de belangrijkste speelkaarten.  
Dendritische cellen. Zoals hierboven beschreven hebben dendritische cellen een tweeledige rol, zij 
zijn in eerste instantie ‘verkenners’, continu op zoek naar gevaar. Maar wanneer zij ‘gevaar’ ontdekt 
hebben, ondergaan dendritische cellen een verandering; zij worden enorm goed in het activeren van 
juist die afweercellen die voor dàt specifieke gevaar op dàt moment in actie moeten komen. Het 
worden zogenaamde professionele antigeen-presenterende cellen, oftewel de ‘generaals’ van ons 
afweersysteem.  
 
 
 
T cellen. Er zijn ook afweercellen die het opruimwerk moeten doen, deze zou je de ‘soldaatcellen’ 
kunnen noemen. Zij kunnen elk 1 stukje eiwit herkennen, maar vervolgens zich meer dan een 
duizendvoud vermenigvuldigen. Er zijn veel verschillende klassen en soorten T cellen, maar voor het 
opruimen van kanker zijn CD8+ en CD4+ T cellen het belangrijkst.  
Andere soldaatcellen. Ons afweersysteem bestaat uit veel meer ‘soldaatcellen’, sommigen komen 
pas in actie wanneer ze door dendritische cellen geactiveerd worden, omdat zij hun de bijbehorende 
unieke stukjes eiwit presenteren, bijvoorbeeld B cellen. Andere ‘soldaatcellen’ komen ook zonder 
tussenkomst van dendritische cellen in actie en herkennen minder unieke stukjes eiwit, zoals NK 
cellen of macrofagen. Deze ‘soldaatcellen’ vallen buiten het onderwerp van dit proefschrift.  
 
De tegenspeler, kanker, heeft een ander set speelkaarten. Kankercellen zijn kwaadaardig ontregelde 
lichaamseigen cellen, ze lijken dus in veel opzichten nog op de normale cellen binnen een bepaald 
weefsel. Het belangrijkste verschil is dat zij zich continu vermenigvuldigen, zonder zich iets aan te 
trekken van de terugkoppeling uit het weefsel. Daarnaast houden kankercellen zich niet aan de 
natuurlijke grenzen, en zullen zij zich dus door het lichaam willen verspreiden (metastaseren).  
Maskering. Kankercellen lijken weliswaar voor het grootste deel op normale cellen, echter door hun 
mutaties kunnen er unieke stukjes eiwit ontstaan (antigen), waardoor ze te herkennen zijn door het 
afweersysteem. Door deze unieke stukjes eiwit niet te laten zien, kan de kankercel zich voor het 
afweersysteem onzichtbaar maken.  
Remmende cellen. Onderdeel van een normaal werkend afweersysteem zijn de remmende cellen, 
regulatoire T cellen genoemd. Zij zijn één van de regelmechanismen die het afweersysteem kent om 
geen schade aan gezonde weefsels toe te brengen. Kankercellen trekken bij voorkeur deze 
remmende cellen aan en creëren op die manier een barrière voor soldaatcellen.  
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Signaalstoffen. Al die verschillende cellen van het afweersysteem moeten met elkaar communiceren, 
dit doen ze niet alleen door fysiek met elkaar contact te maken, zij scheiden ook signaalstoffen af 
(cytokinen). Sommige van deze signalen zullen activerend werken, andere juist remmend. 
Kankercellen gebruiken juist de remmende signaalstoffen om een aanval van soldaatcellen te 
weerstaan.  
 
Het spelbord 
De huid. Dit proefschrift gaat over de behandeling van kanker, dat is ontstaan uit de 
pigmenthoudende cellen (melanoom). In principe kan deze vorm van kanker overal ontstaan, maar 
het gebeurt veruit het vaakst vanuit de pigmenthoudende cellen van de huid; een moedervlek. 
Vandaar uit kan het zich uitspreiden door het hele lichaam. Melanoom is een vorm van kanker dat 
zich al in een vroeg stadium via het bloed door het lichaam kan verspreiden, mede hierom noemen 
we dit een ‘agressieve’ vorm van kanker.  
Lymfeklieren. Boven zijn lymfeklieren beschreven als de ontmoetingsplaats tussen afweercellen; 
vooral dendritische cellen en T cellen. Om die reden zijn ook lymfeklieren strategisch gelegen en 
hebben we er veel van; hun aantal wordt geschat tussen 500 en 600. Een normale lymfeklier is 
slechts 8 tot 10mm groot.  
Andere organen. Ons lichaam bestaat uit veel verschillende weefsels en organen, sommige hiervan 
zijn van essentieel belang. Van het melanoom weten we dat er verschil in ernst bestaat wanneer het 
zich heeft verspreidt naar verschillende organen; de overleving van patiënten is slechter wanneer het 
melanoom zich niet alleen in de huid of in de lymfeklieren heeft verspreid, maar ook naar de longen. 
Uitzaaiingen naar de lever of andere organen maakt de overleving van deze patiënten opnieuw nog 
slechter.  
 
De troefkaarten; immunotherapie  
De rol van het afweersysteem bij het herkennen en het opruimen van kankercellen, heeft ertoe 
geleid dat onderzoekers en artsen het gebruik van het afweersysteem als behandeling tegen kanker 
zijn gaan onderzoeken. Een behandeling waarin gebruik wordt gemaakt van ons afweersysteem 
noemen we immunotherapie; en dat kan aangrijpen op verschillende afweercellen. De studies die in 
dit proefschrift worden beschreven richten zich op vaccinaties met dendritische cellen, vanwege hun 
centrale rol in het opstarten van een afweerreactie. De dendritische cellen van een patiënt worden 
meestal verzameld uit afweercellen die veel voorkomen in het bloed, zogenaamde monocyten. Van 
deze cellen worden dendritische cellen gekweekt, deze worden in het Tumor Immunologisch 
Laboratorium geactiveerd door toevoeging van alarmsignalen en ze worden opgeladen met unieke 
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 stukjes eiwit van een melanoom (antigenen) 
waarvan bij de patiënt is getest of deze 
inderdaad ook op zijn of haar melanoom 
voorkomen. Vervolgens wordt dit vaccin, de 
geactiveerde en met melanoom antigenen 
beladen lichaamseigen dendritische cellen, 
geïnjecteerd in de patiënt, vaak direct in de 
lymfeklier. Van daaruit zouden deze dendritische 
cellen hun natuurlijke rol weer op moeten 
pakken; ze zouden opzoek moeten gaan naar de 
‘soldaatcellen’ die dit specifieke melanoom 
herkennen. Op deze manier wordt het 
afweersysteem wakker geschud en getraind op 
het herkennen en opruimen van kankercellen. Er 
zijn meer soorten troefkaarten, allemaal vormen 
van immunotherapie die buiten het onderwerp 
van dit proefschrift vallen. Maar het belangrijkst 
is dat met deze kaarten het afweersysteem een 
troef in handen heeft die de kankercellen niet 
hebben. We moeten er dus ons voordeel mee 
doen! Het nadeel echter, is dat de troefkaarten 
‘immunotherapie’ moeten worden uitgespeeld 
zonder dat de behandelaar een goed zicht heeft 
op het spelbeloop.  
 
De tactiek kaarten; immuno monitoring 
Als je je troefkaarten blind moet uitspelen, is de kans groot dat je ze niet optimaal in kunt zetten. En 
zoals eerder gezegd, als kanker je tegenstander is, dan is het cruciaal om zo effectief mogelijk te 
spelen. Het onderwerp van dit proefschrift is het vinden van manieren om tòch zicht te krijgen op het 
spelbeloop; dit noemen we ‘immuno monitoring’. In sommige gevallen is dat letterlijk ‘zicht krijgen 
op’, want met behulp van scantechnieken kunnen belangrijke processen in een afweerreactie 
gevolgd worden, zonder dat dit proces verstoord hoeft te worden. Andere technieken bestaan uit het 
verkrijgen van informatie over de afweerreactie door afweercellen af te nemen van strategische 
plaatsen, zoals lymfeklieren, bloed of de huid. Deze ‘tactiek’ kaarten worden hier kort uitgelegd.  
Scintigrafie. De eerste stap in een succesvolle dendritische cel vaccinatie is het bereiken van de 
lymfeklier. In de studies in dit proefschrift wordt het vaccin via de huid ingespoten en zullen de 
dendritische cellen zelf hun weg naar de lymfeklier moeten vinden; slechts weinig cellen zullen de 
lymfeklier daadwerkelijk bereiken. Het vaccin kan ook direct in een lymfeklier worden geïnjecteerd, 
wat gezien de grootte van een lymfeklier technisch erg moeilijk is. Tijdens het maken van het vaccin 
kunnen de dendritische cellen een radioactief label meekrijgen, dat door middel van een gamma-
camera gevolgd kan worden, dit heet scintigrafie. De scans zijn niet gedetailleerd, maar zijn wel erg 
gevoelig en in staat om te berekenen hoeveel dendritische cellen er daadwerkelijk in de lymfeklieren 
zijn aangekomen.   
MRI scan. Een MRI scan staat voor Magnetic Resonance Imaging, en maakt in tegenstelling tot 
radioactieve scans gebruik van minuscule verstoringen in magnetische velden. Wanneer dendritische 
cellen met een ijzer-label of een 19F-label gemerkt worden, kunnen ze met een MRI scan gevolgd 
worden. Het voordeel boven scintigrafie is dat deze scan veel gedetailleerder is. Als nadeel geldt 
echter, dat ijzer-labels niet geteld kunnen worden, en dus het aantal dendritische cellen niet 
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 berekend kan worden. 19F is een nieuw label, waarmee dit wel kan en daarmee kan dit nadeel 
omzeild worden. In dit proefschrift demonstreren wij dat op deze manier onderzocht kan worden 
wat de meest effectieve manier is om het vaccin toe te dienen. 
Bloedtesten. Behalve dat het belangrijk is om te weten of het vaccin goed in de lymfeklieren aan is 
gekomen, is het van cruciaal belang dat je in kunt schatten wat het effect is op de afweercellen. 
Afweercellen die in een lymfeklier geactiveerd zijn, zullen de lymfeklier verlaten en via het bloed in 
de rest van het lichaam opzoek gaan naar de kankercellen waarop ze getraind zijn. De afweercellen in 
het bloed kunnen dus een blauwdruk zijn van wat er in een lymfeklier gebeurd is. In de praktijk is het 
echter vaak zo dat er in ons bloed enorm veel afweercellen zijn, en het aandeel van afweercellen die 
door de dendritische cel vaccinaties geactiveerd zijn is dan ook erg klein. Het kan dus erg moeilijk zijn 
om naar een paar specifieke afweercellen te zoeken. Daarnaast wil je eigenlijk niet alleen weten dat 
deze afweercellen er zijn, maar vooral wat ze tegen de kanker kunnen uitrichten. Er zijn tot op heden 
geen testen die je op grote schaal kunt toepassen om naast de aanwezigheid van deze melanoom 
herkennende afweercellen, ook hun functie te bepalen.  
 
 
 
Huidtest. Met deze test wordt eigenlijk een oefensituatie opgezet; dendritische cellen die met unieke 
stukjes eiwit van het melanoom (antigenen) zijn beladen worden in de huid gespoten. Als alles goed 
is gegaan, zullen na de vaccinaties afweercellen door het lichaam zwerven die deze antigenen 
kunnen herkennen. Om deze antigenen te vinden, zullen de afweercellen de bloedbaan moeten 
verlaten en de huid binnen dringen. Na het afnemen van zo’n stukje huid (biopt) kunnen deze 
afweercellen in het laboratorium aan testen van verschillende moeilijkheidsgraad worden 
onderworpen. Zo kan heel gedetailleerd in kaart worden gebracht hoe functioneel de afweercellen 
zijn. In dit proefschrift tonen wij aan dat deze test goed kan voorspellen hoe de afweercellen in het 
lichaam hun werk doen.  
PET/CT scan. Een PET/CT scan staat voor Positron Emitting Tomography/Computed Tomography, een 
combinatie van scans waarbij enerzijds radioactieve straling wordt gemeten en anderzijds een 
anatomische afbeelding wordt gemaakt. Met behulp van chemische technieken kunnen veel stofjes 
een radioactief label krijgen en zo zichtbaar worden voor een PET scan. Als je deze stofjes slim kiest, 
kun je heel precies naar functionele lichaamsprocessen kijken. In dit proefschrift worden twee van 
die stofjes gebruikt; 18F-gelabeld FDG en 18F-gelabeld FLT. FDG is een suiker, dat door heel actieve 
cellen gebruikt wordt als brandstof om energie uit vrij te maken. Zowel kankercellen als afweercellen 
zijn heel actieve cellen en zullen dus veel suiker opnemen. Met behulp van een PET scan kun je deze 
actieve cellen dan ook opsporen. FLT is een bouwsteen van ons genetisch materiaal (DNA), cellen die 
zich vermenigvuldigen moeten de helft van hun DNA meegeven aan hun nakomelingen en zelf weer 
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 aanvullen. Vermenigvuldigende cellen zullen dus veel DNA-bouwstenen nodig hebben. Opnieuw kun 
je met een PET scan dan ook zien waar cellen zich bevinden die snel aan het vermenigvuldigen zijn. In 
dit proefschrift hebben wij uitgezocht of je door FDG of FLT te gebruiken met een PET scan kunt zien 
of er in de lymfeklieren daadwerkelijk activatie en/of vermenigvuldiging van afweercellen plaatsvindt 
na vaccinatie met dendritische cellen. Het blijkt dat dit wel met FLT, maar niet met FDG, kan en dat 
dit ook overeenkomt met andere manieren om de effecten na vaccinatie te meten.  
 
De afloop 
Hoe de afloop van de strijd tussen het afweersysteem en de kanker zal zijn, is niet te voorspellen. In 
het geval van patiënten met een uitgezaaide vorm van melanoom is de kans op overleving erg klein. 
Helaas hebben tot op heden dendritische celvaccinatie, of andere vormen van immunotherapie, 
hierop nog weinig invloed gehad. De afgelopen jaren hebben echter wel laten zien dat door het 
vaccin te verbeteren, we steeds beter in staat zijn om het afweersysteem ook goed te activeren; we 
hebben dus betere troefkaarten in handen. Daarnaast hebben we nu, door gebruik te maken van 
tactiek kaarten, ook de mogelijkheid gekregen om al in een vroeg stadium inzicht te krijgen in de 
effecten van vaccinaties. Op deze manier zouden we de vaccinaties zo efficiënt mogelijk in kunnen 
zetten, en belangrijker, zo zouden we de behandeling per patiënt aan kunnen passen om zijn of haar 
kansen zo groot mogelijk te maken.  
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 Dankwoord 
 
Dit proefschrift zou niet zijn geworden wat het nu is, zonder de inzet van de patiënten die deel 
hebben genomen aan de vaccinatie studies. Het contact met hen tijdens de vaccinatie poli was vaak 
intensief en persoonlijk. Er zijn veel momenten die me als dierbare herinneringen bij zullen blijven en 
me nog lang zullen motiveren om onderzoek te doen binnen de oncologie. Keer op keer, hebben zij 
mij versteld doen staan van de veerkracht van mensen, een les waarvoor ik ze heel dankbaar ben.  
Een tweede groot woord van dank gaat uit naar mijn promotoren en co-promotor, die elk op zijn of 
haar eigen wijze een kritische bijdrage heeft geleverd aan dit proefschrift. Professor Punt, beste 
Kees, je hebt een enorm scherp inzicht in het doen van klinische studies. Jouw rechtlijnigheid en 
vastberaden manier van onderzoek doen heb ik erg gewaardeerd, al was het voor een over-
enthousiaste jongeling zoals ik niet altijd goed in te voelen. Daarnaast heb je me doen inzien dat wij 
allemaal eens de Nachttrein naar Lissabon zouden moeten nemen. Professor Figdor, beste Carl, je 
hebt me laten zien dat goed onderzoek een team effort is. Als geen ander weet je mensen te 
motiveren en over grenzen heen te kijken, om vervolgens je eigen creatieve lijn te volgen. Een goed 
voorbeeld doet goed volgen? Jouw feedback is direct en altijd raak. Professor De Vries, beste 
Jolanda, ik ken niemand die zo snel kan schakelen en zoveel ballen tegelijk in de lucht kan houden als 
jij. Voor ik het in de gaten heb, denk jij al tien stappen vooruit. Je hebt me veel vrijheid gegeven om 
mijn eigen ideeën uit te voeren en tegelijkertijd kon ik altijd binnen lopen om de meest 
uiteenlopende zaken te bespreken. Doctor Jacobs, beste Hans, sinds mijn eerste kennismaking met 
het TIL hebben onze wegen spontaan vaak parallel gelopen. Al zijn de gekke gezichten bij de 
flowkasten alweer even geleden, de momenten op het werk of privé zijn nog altijd even inspirerend! 
Je rol als co-promotor heb je dubbel en dwars verdiend.  
De ‘klinische club’ en oudgedienden; Nicole, Mandy, Annemiek, Gerty, Jurjen, Kalijn, Tjitske, 
Jeanette, Michel, Danita, Pauline, Mangala, Eric, Marieke, Joost, Daniël, Mary-lène, jullie zijn de 
motor achter deze studies. Het was fantastisch om met jullie samen te werken! Ik heb veel van jullie 
geleerd: van pipetteren en dendritische cellen kweken, tot het opvoeden van kinderen. Het zou goed 
zijn om af en toe te beseffen hoe uniek het is om met zoveel verschillende individuen zo’n goed team 
te vormen.  
Gerty en Kalijn, met jullie als paranimfen hoef ik geen nacht wakker te liggen om mijn promotie, 
jullie zijn veel nauwkeuriger in het plannen en voorbereiden dan ik! Gerty, bedankt voor alle 
‘puntjes-op-de-i’, en het was een eer om met de winnaar van de abstract-prijs terug te vliegen uit 
Budapest… Kalijn, bij jou is de vaccinatiepoli in goede handen, volgens mij zie je onderzoek als 
topsport!  
Mangala, vanaf het begin ben je de perfecte sparring-partner geweest; je denkt standaard out-of-the 
box. Als we samen aan een artikel werken is het af binnen 2 weken… of binnen 2 jaar! 
Daarnaast had ik het voorrecht om met nog heel veel anderen samen te werken, elk van hen maakte 
dat ik dit proefschrift met heel veel plezier heb geschreven. Zo waren er de Tillers, die zulke 
ongelooflijk goede afdelingsfeesten kunnen vieren, dat ik ze, voor zover ik me kan herinneren, nooit 
meer zal vergeten! Een speciale knipoog naar de TIL-band Under DC, die meer belachelijke foto’s 
hebben opgeleverd dan me lief is… Ook wil ik de dames van Poli Rood bedanken, in het bijzonder 
Christel, Maritha, Maartje, Michiel, Mirjam, Iris en Karin, die er voor zorgden dat de vaccinatie poli 
ook in roerige tijden altijd soepel bleef lopen. De aferese-dames, Gaby, Corry, Mariëtte en Monique, 
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 die in ruil voor een zak drop altijd wel een gaatje wisten te vinden in het afereseprogramma. De 
dames van het Onco secretariaat, Carola, Jolanda, Tonnie, Brechje die creatief meedachten zodat we 
de logistiek van de vaccinaties altijd weer rond kregen en die stapels met statussen gezocht hebben. 
De (oud-)bewoners van De Villa, die van een gehorige, koude, of juist snikhete, oude barak toch een 
gezellige plek wisten te maken. De vaccinatie studies hebben bij uitstek een multidisciplinair 
karakter, en zonder de inzet van de afdeling Heelkunde, Han, Hans, Annelies, de afdeling Pathologie, 
Willeke, Han, Arie, Peter, de afdeling Dermatologie, Michelle, Rianne, Wilmy, de afdeling 
Hematologie, Sandra, de afdeling Radiologie, Roel, Simon en de echo-laboranten, de afdeling 
Nucleaire Geneeskunde, Peter, Eddy, Maichel, Miranda, Michel, Martin, en de apotheek, Marieke, 
zou het resultaat zijn echte glans nooit gekregen hebben.  
De afdeling Nucleaire Geneeskunde verdient hier een speciale plaats. Allereerst Wim en Fee, 
bedankt voor het vertrouwen dat jullie in mij stellen om te mogen beginnen aan de opleiding terwijl 
er nog een proefschrift af te ronden viel en voor de ruimte die jullie hebben gegeven om dit goed te 
doen. Volgens mij bevat dit proefschrift genoeg potentie om binnen de Nucleaire Geneeskunde het 
onderzoek een vervolg te kunnen geven; maar nu eerst op volle kracht vooruit! Daarnaast aan mijn 
collega-aios, Ben, Rick, Michelle, Elske, Jeroen, Dennis, Sabine L. en Sabine H. ook een groot 
dankjewel voor jullie geduld en gezelligheid. Mede door jullie zit ik nu op een goede plek!  
Ook buiten het werk zijn er veel mensen die op meer of minder zichtbare manier hun bijdrage 
hebben gehad aan dit proefschrift. Vanaf De Intro van de studie Geneeskunde en soms al eerder zijn 
er ‘De Jongens’, inmiddels aangevuld met wederhelften. Op één of andere manier weten we elkaar 
toch elke keer weer te vinden, hoever we soms ook uitwaaieren. De spelletjesavonden, de jam-
sessies op krappe Vosseveld kamertjes, de optredens, de wandeltochten, de discussies en de 
biertjes; ik hoop ze nooit te hoeven missen. Anthony, Jurrian, Esther, Michiel, Ilker, Ivar, Leonoor, 
Anil, Jenny, Johan, super jongens! Ook ‘de volleybal club’, dat nu eigenlijk alleen nog maar een 
dekmantel is voor het doen van spelletjes, het voeren van politieke discussie en tegenwoordig ook 
het bespreken van de obstakels die jonge ouders tegen komen. Joost, Nienke, Remco, Maaike, 
Rianne en Christian, bedankt voor jullie gezelligheid en interesse! Ook het thuisfront, Koen, 
Monique, Bram, Lizan, maar ook Hans en Bertha, Mirjam, Tom, Arjan en Lieke, en eigenlijk ook 
Lotte, Wessel, Len en Fenna, horen hier. Jullie zijn al bij veel mooie momenten geweest en ik ben 
heel blij dat jullie er nu ook weer bij zijn. Als we als ‘family’ wat ondernemen en voelt dat altijd als 
‘thuis’, bedankt daarvoor.  
Pa en ma, jullie onvoorwaardelijke steun heeft mij het zelfvertrouwen gegeven om dit proefschrift 
tot een goed eind te brengen. ‘Volg je eigen kop’ en ‘pratende mensen zijn te helpen’, hebben jullie 
ooit gezegd, en dat blijken telkens weer wijze lessen te zijn. Van de trein naar Eindhoven waar het 
ooit begon, tot het oppassen op de jongens in de laatste maanden, jullie staan altijd voor me klaar en 
daar kan ik jullie niet genoeg voor bedanken.  
Duuk en Tibbe en ons derde kleine wonder, jullie hebben mij de mooiste titel gegeven van allemaal! 
Lieve Sabrina, jou ontmoeten is het beste wat mij ooit is overkomen, we overlappen, we vullen 
elkaar aan, je stuurt me, je remt me en je motiveert me, je bedenkt wat ik nooit had kunnen 
bedenken en je zegt de goeie dingen op het goede moment; en in alles geldt ‘better together’. 
Zonder jou zou ik niet zijn wie ik nu ben, bedankt lief, ik hou van je! 
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